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SUMMARY
Mechanical and thermal stimuli were used to determine threshold responses in normal 
experimental sheep which were familiar with both test procedures. The average control 
response threshold to noxious thermal and mechanical stimulation was 54.5°C and 3.2 
Newtons (N), respectively. The effects of 2 non-steroidal anti-inflammatory drugs 
(NSAIDs), flunixin meglumine and carprofen, were investigated using the 2 test systems. 
Neither drug was shown to influence thresholds to noxious stimulation over a 6 hour 
period in normal sheep.
Thresholds to noxious mechanical stimulation were .recorded from normal farm sheep 
which were unfamiliar with the testing procedure. The average response threshold in 
these sheep was significantly greater than that recorded from experimental sheep (mean, 
4.9N), but fell over a period of 3 days to a similar level recorded from experimental sheep 
(mean, 3 .IN). Thresholds to noxious mechanical stimulation in farm sheep which were 
unfamiliar with the testing procedure, and which had been suffering from footrot for a 
period of not less than 1 week, were not significantly different from normal farm sheep 
(mean, 4.7N). In addition, when these sheep were tested over a period of 3 days, 
thresholds did not fall in the manner described for normal sheep (mean, 4.6N). However, 
administration of flunixin meglumine, 1.0 mg/kg, IV, once daily for 3 days in sheep 
suffering from footrot caused a significant reduction in thresholds to noxious mechanical 
stimulation in sheep suffering from footrot on the third and fourth days after treatment 
had been initiated.
Thresholds to noxious mechanical and thermal stimulation were assessed in sheep 
undergoing anaesthesia and abdominal surgery, and the effects of flunixin meglumine, 
carprofen and buprenorphine, a partial opioid agonist, on thresholds investigated. 
Induction of anaesthesia was achieved by injection of thiopentone or ketamine, IV, and 
anaesthesia was maintained by administration of halothane in oxygen and nitrous oxide. 
After thiopentone induction, thermal and mechanical thresholds were not shown to 
change after a 20 minute period of general anaesthesia alone, and similarly, thresholds to 
noxious mechanical stimulation were not significantly different from control values after 
induction of anaesthesia with either thiopentone or ketamine in sheep which underwent 
abdominal surgery. However, after thiopentone induction, thresholds to noxious thermal 
stimulation were significantly lower than control values 45, 60 and 120 minutes post- 
operatively. Intra-operative injection of flunixin meglumine (1.0 mg/kg, IV) and 
buprenorphine (10 |ig/kg, IV) prevented the development of post-operative thermal
vii
hyperalgesia, while carprofen (4.0 mg/kg, IV), not only prevented the development of 
hyperalgesia in the immediate post-operative period, but also caused a significant increase 
in thresholds to noxious thermal stimulation 60 minutes post-operatively. Thresholds to 
noxious thermal stimulation were unchanged in the post-operative period in sheep 
anaesthetised with ketamine which subsequently had undergone abdominal surgery under 
halothane anaesthesia.
Thresholds to noxious mechanical stimulation were investigated during peripheral limb 
ischaemia, induced by application of a pneumatic tourniquet to the forelimb of sheep. 
During limb ischaemia, mechanical thresholds fell to below control values, and 
immediately prior to tourniquet deflation, were significantly lower than those recorded 
pre-inflation (3 .IN vs 1.7N). Injection of flunixin meglumine (1.0 mg/kg, IV) and 
carprofen (0.7 mg/kg, IV) 1 hour prior to tourniquet inflation attenuated the fall in 
mechanical thresholds recorded after injection of saline (5 ml (0.9 %), IV) 1 hour before 
inflation. Similarly, administration of fentanyl (5 jLig/kg, IV), a fi-opioid agonist, 
prevented the reduction in thresholds observed during tourniquet inflation.
Thresholds to noxious mechanical and thermal stimulation were assessed for a period of 
120 minutes after intradermal injection of saline (0.9 %, 100 fil) or the irritant 
carrageenan (0.0625 %, 100 p.1). Flunixin meglumine (2.0 mg/kg, IV), carprofen (4.0 
mg/kg, IV) or saline (5 ml (0.9 %), IV) was administered at 120 minutes, and 
subsequently, thresholds to noxious stimulation were investigated for a further 4 hours. 
Intradermal injection of carrageenan did not cause a clearly defined change in thresholds 
to noxious mechanical stimulation, but thresholds to thermal stimulation were 
significantly lower than control values 120 minutes after injection of the irritant (group 
mean, 52.4°C vs 49.3°C). Thresholds to noxious thermal stimulation remained 
significantly lower than control values after administration of saline, IV, for a further 60 
minutes. However, after administration of either NSAID, thresholds were no longer 
significantly different from control values.
Pharmacokinetic analyses of plasma levels of flunixin meglumine and carprofen (0.7 and
4.0 mg/kg) following intravenous injection in sheep was carried out. The decline of 
flunixin meglumine in plasma was best described by a tri-exponential equation, after 
injection of both 1.0 and 2.0 mg/kg, with elimination half-lives o f 221.7 and 205.8 
minutes, respectively. The decline of carprofen in plasma was best described by a bi­
exponential equation, after injection of both 0.7 and 4.0 mg/kg, with elimination half- 
lives of 25.8 and 32.3 hours, respectively.
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A comparison of 2 subjective rating scales, an numerical rating scale (NRS) and a visual 
analogue scale (VAS), for rating lameness in sheep was made. Both scales were shown 
to be reproducible and repeatable, but the VAS was more sensitive than the NRS and did 
not force observers to group unlike data. It was dem onstrated that although 
reproducibility of both the VAS and NRS was poor when an untrained observer was 
compared with a trained observer, the repeatability of both scales was good for untrained 
as well as trained observers. The VAS was used to score a group of sheep for lameness 
and to assess the response to flunixin meglumine (1.0 or 2.0 mg/kg, IV) over a 6 hour 
period after injection. No significant differences were shown between the 2 different dose 
rates used in the study, nor were there any significant differences within either group. 
However, injection of flunixin meglumine caused a reduction in lameness in >80% of 
sheep administered the lower dose at some time after injection, while >70 % of sheep 
administered the higher dose rate showed a similar reduction.
ix
LIST OF FIGURES
Figure 1.1. Simplified representation of the biosynthesis of prostaglandins (PG) and 
thromboxanes (TX) from arachidonic acid.
Figure 1.2. Simplified representation of the metabolism of arachidonic acid by the 
lipoxygenase group of enzymes.
Figure 2.1. Photograph of a pneumatic tourniquet (T) and the sphygmomanometer 
used to inflate the tourniquet.
Figure 2.2. Photograph of apparatus for the production of mechanical nociceptive 
stimuli.
Figure 2.3. Schematic representation of apparatus for the production of mechanical 
nociceptive stimuli.
Figure 2.4. Photograph of apparatus for the production of thermal nociceptive stimuli.
Figure 3.1. Control mechanical threshold responses in sheep recorded over a 6 hour 
(hr) time course.
Figure 3.2. Changes in mechanical threshold responses after administration of xylazine 
hydrochloride (50 Jig/kg, IV) in sheep.
r.
Figure 3.3. Changes in mechanical threshold responses after the administration of 
saline (5 ml, IV) in 8 sheep.
Figure 3.4. Changes in mechanical threshold responses after the administration of 
flunixin meglumine, 1.0 (Flu 1) and 2.0 (Flu 2) mg/kg, IV, in sheep.
Figure 3.5. Changes in mechanical threshold responses after the administration of 
carprofen, 0.7 (Carp 0.7) and 4.0 (Carp 4) mg/kg, IV, in sheep.
Figure 3.6. Control thermal threshold responses in sheep recorded over a 6 hour (hr) 
time course.
Figure 3.7. Changes in thermal threshold responses after administration of xylazine 
hydrochloride (50 |ig/kg, IV) in sheep.
Figure 3.8. Changes in thermal threshold responses after administration of saline (5 ml,
XIV) in sheep.
Figure 3.9. Changes in thermal threshold responses after administration of flunixin 
meglumine 1.0 (Flu 1) and 2.0 (Flu 2) mg/kg, IV, in sheep.
Figure 3.10. Changes in thermal threshold responses after administration of carprofen
0.7 (Carp 0.7) and 4.0 (Carp 4) mg/kg, IV, in sheep.
F igure  3.11. Changes in mechanical threshold responses after administration of 
flunixin meglumine, 1.0 (Flu 1) and 2.0 (Flu 2) mg/kg, IV, in sheep suffering footrot.
Figure 3.12. Thresholds to noxious mechanical stimulation for sheep either post- 
operatively and post-anaesthesia, and the effect of various intra-operative treatments.
F igure 3.13. Changes in thermal threshold responses in 1 group of sheep post- 
operatively (n=7) (No Tx) and a second group of sheep (n=4) after general anaesthesia 
(GA).
F igure 3.14. Post-operative changes in thermal threshold responses in 3 groups of 
sheep, 2 of which received different intra-operative treatments.
F igure 3.15. Post-operative changes in thermal threshold responses in 2 groups of 
sheep, 1 of which received buprenorphine hydrochloride intra-operatively.
F igure 3.16. Post-operative changes in thermal threshold responses in 2 groups of 
sheep after induction of general anaesthesia using different agents.
F igure 4.1. Thresholds to noxious mechanical stimulation before, during and after 
inflation of a pneumatic tourniquet on the forelimb of sheep.
F igure 4.2. Response to injection of saline (0.9 %) (sal), 100 p.1, and carrageenan 
(carra), 100 p.1 of 0.0625 %, intradermally on the lateral aspect of a forelimb in sheep.
F igure  4.3. Response to injection of carrageenan (carra), 100 p.1 o f 0.0625 %, 
intradermally on the lateral aspect of a forelimb in a group of 6 sheep on 3 occasions, 7 to 
14 days, apart.
Figure 5.1. Typical chromatogram of flunixin meglumine in ovine plasma.
Figure 5.2. A semilogarithmic plot of the decline of mean concentration of flunixin 
meglumine in plasma (±SEM) of sheep plotted against time in minutes (min) after the IV
administration of either 1.0 mg/kg or 2.0 mg/kg of drug.
Figure 5.3. Typical chromatogram of carprofen in ovine plasma.
F igure  5.4. A semilogarithmic plot of the decline of mean plasma concentration 
(±SEM) of carprofen racemate, in sheep, with time in hours (hr), after the IV 
administration of either 0.7 mg/kg or 4.0 mg/kg of drug.
F igure 6.1. Format of the visual analogue scale (VAS) used in the assessment of 
lameness.
Figure 6.2a . The scores awarded to 45 sheep for lameness by observer 1 using the 
visual analogue scale (VAS), plotted against the scores awarded to the same 45 sheep 
using the numerical rating scale (NRS).
Figure 6.2b . The scores awarded to 45 sheep for lameness by observer 2 using the 
visual analogue scale (VAS), plotted against the scores awarded to the same 45 sheep 
using the numerical rating scale (NRS).
Figure 6.3. The scores awarded to 25 sheep by observer 3 using the visual analogue 
scale (VAS), plotted against the score awarded to the same 25 sheep using the numerical 
rating scale (NRS).
xii
LIST OF TABLES
T able 3.1. Individual, mean and standard error of the mean (SEM), for thresholds to 
noxious mechanical (Newtons) and thermal (°C) stimulation in a group of 8 normal sheep 
over a period of 6 hours (hr).
T ab le  3.2: Thresholds to noxious mechanical and thermal stimulation in sheep 
administered xylazine hydrochloride.
Table 3.3. Thresholds to noxious mechanical and thermal stimulation in normal sheep 
over 6 hours, after administration of saline, IV.
Table 3.4. Thresholds to noxious mechanical and thermal stimulation in normal sheep 
over 6 hours, after administration of flunixin meglumine, 1.0 mg/kg, IV.
Table 3.5. Thresholds to noxious mechanical and thermal stimulation in normal sheep 
over 6 hours, after administration of flunixin meglumine, 2.0 mg/kg, IV.
Table 3.6. Thresholds to noxious mechanical and thermal stimulation in normal sheep 
over 6 hours, after administration of carprofen, 0.7 mg/kg, IV.
Table 3.7. Thresholds to noxious mechanical and thermal stimulation in normal sheep 
over 6 hours, after administration of carprofen, 4.0 mg/kg, IV.
Table 3.8. Thresholds to noxious mechanical stimulation in farm sheep unaccustomed 
to the testing procedure.
Table 3.9. Thresholds to noxious mechanical stimulation in farm sheep unaccustomed 
to the testing procedure, over a period of 3 days.
Table 3.10: Thresholds to noxious mechanical stimulation in farm sheep suffering from 
footrot and unaccustomed to the testing procedure.
T ab le  3.11. Lameness and foot lesion scores in a group of sheep suffering from 
footrot.
Table 3.12. Thresholds to noxious mechanical stimulation in farm sheep suffering from 
footrot and unaccustomed to the testing procedure, over a period of 3 days.
Table 3.13a. Thresholds to noxious mechanical stimulation in sheep suffering footrot
xiii
after injection of flunixin meglumine, 1.0 mg/kg, IV.
Table 3.13b. Thresholds to noxious mechanical stimulation in sheep suffering footrot 
after injection of flunixin meglumine, 2.0 mg/kg, IV.
Table 3.14. Thresholds to noxious mechanical stimulation in a group of sheep suffering 
footrot. Response to injection of flunixin meglumine (1.0 mg/kg), IV, over a period of 4 
days.
Table 3.15a. Demographic and anaesthetic details of a group of sheep undergoing 
general anaesthesia with or without ventral midline laparotomy.
Table 3.15b. Demographic and anaesthetic details of a group of sheep undergoing 
general anaesthesia with or without ventral midline laparotomy.
Table 3.16. Thresholds to noxious mechanical and thermal stimulation post- 
operatively, for sheep administered buprenorphine (10 M-g/kg, IV) intra-operatively.
Table 3.17. Thresholds to noxious mechanical and thermal stimulation post- 
operatively, for sheep administered flunixin meglumine (1.0 mg/kg, IV) intra-operatively.
Table 3.18. Thresholds to noxious mechanical and thermal stimulation post- 
operatively, for sheep administered carprofen (4.0 mg/kg, IV) intra-operatively.
Table 3.19. Thresholds to noxious mechanical and thermal stimulation for sheep post- 
operatively.
Table 3.20. Thresholds to noxious mechanical and thermal stimulation for sheep post­
general anaesthesia.
Table 3.21. Thresholds to noxious mechanical and thermal stimulation for sheep post- 
operatively.
Table 4.1. Thresholds to noxious mechanical stimulation before, during and after 
inflation of a pneumatic tourniquet on the ipsilateral forelimb of sheep.
Table 4.2. Thresholds to noxious mechanical stimulation before, during and after 
inflation of a pneumatic tourniquet on the contralateral forelimb of sheep.
Table 4.3. The effect of saline, IV, on thresholds to noxious mechanical stimulation 
during and after inflation of a pneumatic tourniquet on the ipsilateral forelimb of sheep.
x iv
Table 4.4. The effect of fentanyl, IV, on thresholds to noxious mechanical stimulation 
during and after inflation of a pneumatic tourniquet on the ipsilateral forelimb of sheep.
Table 4.5. The effect of flunixin meglumine, IV, on thresholds to noxious mechanical 
stimulation during and after inflation of a pneumatic tourniquet on the ipsilateral forelimb 
of sheep.
Table 4.6. The effect of carprofen, IV, on thresholds to noxious mechanical stimulation 
during and after inflation of a pneumatic tourniquet on the ipsilateral forelimb of sheep.
Table 4.7. The effect of intradermal injection of saline on thresholds to noxious 
mechanical and thermal stimulation in sheep.
Table 4.8. The effect of intradermal injection of carrageenan on thresholds to noxious 
mechanical and thermal stimulation in sheep, and the response to injection of flunixin 
meglumine intravenously.
Table 4.9. The effect of intradermal injection of carrageenan on thresholds to noxious 
mechanical and thermal stimulation in sheep, and the response to injection of carprofen 
intravenously.
Table 4.10. The effect of intradermal injection of carrageenan on thresholds to noxious 
mechanical and thermal stimulation in sheep, and the response to injection of saline, 
intravenously.
Table 4.11. Changes in thresholds to noxious thermal stimulation after intradermal 
injection of carrageenan, on 3 different occasions in sheep.
Table 5.1. Mean recovery and coefficient of variation (%) of flunixin meglumine in 
ovine plasma (n=14).
Table 5.2. Individual and mean pharmacokinetic constants, ± standard error of the 
mean (SEM), for 9 sheep determined after injection of flunixin meglumine, 1.0 mg/kg, 
IV.
Table 5.3. The individual and mean plasma pharmacokinetic parameters, ±  standard 
error of the mean (SEM), for 9 sheep given flunixin meglumine, 1.0 mg/kg, IV.
Table 5.4. The individual and mean, mean residence time for observed values 
(MRT(0bs)), ± standard error of the mean (SEM), for sheep given flunixin meglumine,
X V
LO or 2.0 mg/kg, IV.
T ab le  5.5. Individual and mean pharmacokinetic constants, ± standard error of the 
mean (SEM), for 5 sheep determined after injection of flunixin meglumine, 2.0 mg/kg, 
IV.
T able  5.6. The individual and mean plasma pharmacokinetic parameters, ± standard 
error of the mean (SEM), for 5 sheep given flunixin meglumine, 2.0 mg/kg, IV.
Table 5.7: Mean recovery and coefficient of variation (%) of carprofen in ovine plasma 
(n=10).
Table 5.8. Individual and mean, ± standard error of the mean'(SEM), pharmacokinetic 
constants for 5 sheep determined after IV injection of carprofen, 0.7 mg/kg.
T able 5.9. The individual and mean, ± standard error of the mean (SEM), plasma 
pharmacokinetic parameters for 5 sheep given carprofen, 0.7 mg/kg IV.
Table 5.10. The individual, mean, ± standard error of the mean (SEM) mean residence 
times for observed values (MRT(obs)) for sheep given carprofen, 0.7 or 4.0 mg/kg, IV.
Table 5.11. Individual and mean, ± standard error of the mean (SEM), pharmacokinetic 
constants for 5 sheep determined after injection of carprofen, 4.0 mg/kg, IV.
T able 5.12. The individual and mean, ± standard error of the mean (SEM), plasma 
pharmacokinetic parameters for 5 sheep given carprofen, 4.0 mg/kg, IV.
Table 6.1. Scores assigned by observers 1 and 2 when a group of 45 sheep were rated 
for lameness, using a continuous scoring system (visual analogue scale; VAS) and a 
discrete scoring system (numerical rating scale; NRS) on the same occasion.
Table 6.2. Scores assigned by observers 1 and 2 when a group of 17 sheep were rated 
for lameness, using the visual analogue scale (VAS) and the numerical rating scale 
(NRS), on 2 occasions (T1 and T2), 1 hour apart.
Table 6.3. Scores assigned by 2 observers (Obs), 1 and 2, familiar with the use of a 
visual analogue rating scale (VAS) and an numerical rating scale (NRS), and 1 untrained 
observer, observer 3 where 25 sheep were rated for lameness on 1 occasion.
Table 6.4. Scores assigned by observers (obs) 1, 2 and 3 when a group of 10 sheep 
were rated for lameness, using a visual analogue scale (VAS) and an numerical rating
xv i
scale (NRS) on 2 occasions (T1 and T2), 1 hour apart.
Table 6.5a. Scores assigned by observers (Obs) 1 and 2 when a group of 8 sheep were 
rated for lameness using a visual analogue scale before and after the administration of 
flunixin meglumine, 1.0 mg/kg, IV, at time 0.
Table 6.5b. Scores assigned by observers (Obs) 1 and 2 when a group of 17 sheep 
were rated for lameness using a visual analogue scale (VAS) before and after the 
administration of flunixin meglumine, 2.0 mg/kg, IV, at time 0.
Table 6.6a. The decrease in the level of lameness, recorded as a percentage of the pre- 
treatment visual analogue scores awarded to 6 sheep by observers (Obs) 1 and 2. 
Flunixin meglumine was administered at 1.0 mg/kg, IV, at time 0.
Table 6.6b. The decrease in the level of lameness, recorded as a percentage of the pre- 
treatment visual analogue scores awarded to 15 sheep by observers (Obs) 1 and 2. 
Flunixin meglumine was administered at 2.0 mg/kg, IV, at time 0.
xv i i
ABBREVIATIONS
aufs absorbance units full scale
CNS central nervous system
5 delta
e. g. for example
et al. and others
etc. et cetera
F ig .  f ig u re
g  gravity, 10*11 N.m/s2
Hg mercury
HPLC high performance liquid chromatography
hr hours
i . e . that is
ICV intracerebroventricular
ID intradermal
IM intramuscular
iu international units
IV intravenous
kg kilograms
kPa kiloPascal
1 litres
X wavelength
XV111
M molar
p, mu
p.g micrograms
mg milligrams
min minutes
p.1 microlitres
mm millimeters
mV millivolts
ng nanograms
nm nanometers
No. number
obs observed values
p probability
pH negative logarithm of hydrogen ion concentration
PMNL polymorphonuclear leucocytes
R rectus
r Pearson linear correlation coefficient
S sinister
SEM standard error of the mean
spp. bacterial species
uv ultraviolet
vide infra see below
vide supra 
vs
°-C/°C
see above 
versus
degrees centigrade
CH A PTER 1 
G EN ERA L IN TRO D U CTIO N
2Pain is a subjective experience, the definition and description of which is unique to the 
individual that experiences the painful stimulus, and it should be accepted that pain is what 
the subject says is painful (Beecher, 1957). Humans have the luxury of language and can 
attempt to convey to a second party the temporal, spatial and affective aspects of the 
sensation which they perceive as painful. An observer of human pain also may notice 
alterations in the normal physiological responses such as an increase in blood pressure, heart 
rate, respiratory rate or guarding of the painful area. The evaluation of pain in animals 
becomes more challenging where assessments of pain rely exclusively on observation of 
animal behaviour and of physiological changes.
The ability to quantify and qualify pain is a pre-requisite to the assessment of the analgesic 
efficacy of drugs both experimentally and clinically, and requires a knowledge of the 
neurophysiological and neuroanatomical events which occur during nociception.
1.1 Mechanisms of noxious information processing
The anatomical pathways and physiological mechanisms of transmission of noxious 
information from the periphery to the central nervous system (CNS) have been reviewed in 
detail by Zimmerman (1976) and Yaksh and Hammond (1982). Briefly, sensory information 
is received by a variety of end organs, and it is generally accepted that those responsible for 
the sensation of pain are free nerve endings which are located widely throughout the tissues 
of the body. The free nerve endings subserving detection of pain are referred to as 
nociceptors, and respond to a variety of noxious stimuli including high intensity mechanical 
and thermal stimuli and also to noxious chemical stimulation by either endogenous or 
exogenous substances. Noxious stimulation causes impulses in one of 2 main types of 
primary afferent nerve fibre i. e. non-myelinated C-fibres or A8-fibres, which are the 
slowest conducting myelinated fibres. The cell bodies of the primary afferent fibres are 
located in the dorsal root ganglia and the fibres enter the dorsal hom of the spinal cord within 
the dorsal roots. The grey matter of the spinal cord is divided into a series of numbered 
laminae (Rexed, 1952). Within the cord the primary afferent fibres synapse with the 
neurones of the cord. The faster conducting A8-fibres synapse mainly in laminae I and V, 
whereas the slower conducting C-fibres synapse primarily in lamina II, or the substantia 
gelatinosa. Conscious perception of pain requires the onward transmission o f noxious 
information from the spinal cord to the higher centres, although the response to the noxious 
stimulus may involve activation of a local spinal reflex. Fibres carrying nociceptive 
information ascend from the dorsal horn of the spinal cord, both contra- and ipsilaterally, in 
the ventrolateral columns of the spinal cord, to 3 main areas of the brain, the reticular 
formation (spinoreticular fibres or anterolateral tract), periaqueductal grey matter (PAG) 
(spinomesencephalic or spinobulbar fibres) and to the medial and ventrobasal thalamus
3(spinothalamic fibres). The sensory nucleus of the spinal tract of the trigeminal nerve, is the 
most caudal segment of the sensory nucleus of the trigeminal nerve, and is continuous with 
the dorsal horn of the spinal cord. It receives the central projections of all neurones carrying 
nociceptive and thermal information from the head region, which travel to the reticular 
formation and the ventroposterior thalamus.
Stimulation of various supraspinal structures in the medulla and pons, including the nucleus 
raphe magnus, nucleus reticularis paragigantocellularis and locus coeruleus, in the midbrain 
e. g. the PAG, and also in the fore brain e. g. lateral hypothalamus and ventrobasal 
thalamus, can cause analgesia and inhibit transmission in nociceptive neurones (Carstens, 
1983). These actions are mediated by activation of serotonergic and noradrenergic pathways 
which have a mainly depressant action on spinal cord neurones (Belcher et al. , 1978), 
although endogenous opioid systems have been implicated (Finley eta l. , 1981; W oolf and 
Wall, 1983). The descending pathways are one of the important mechanisms in the 'Gate 
Theory of Pain' proposed by Melzack and Wall (1965), where they suggested that 
descending efferents from supraspinal centres modulated transmission of noxious 
information. Moreover, it was suggested that lamina II neurones acted to regulate 
transmission between primary afferent fibres and ascending tracts, via a network of 
interneurones. Within this network, inhibitory interneurones are activated by both 
descending inhibitory influences and non-noxious primary afferent input e. g. from 
mechanoreceptors via large diameter A (3-fibres, whereas nociceptive afferent fibres activated 
facilitatory interneurones. Finally, the somatosensory cortex receives input from the 3 main 
ascending tracts already mentioned, and presumably mediates the sensory-discriminative 
aspects of pain.
1.2 Production and assessment of nociceptive stimuli
The pain threshold is the intensity of stimulation which is first perceived as pain and 
generally is considered to be approximately the same in humans and animals (Vierck, 1976). 
The intensity of stimulation at which the subject can no longer tolerate the pain is known as 
the pain tolerance threshold (Vierck, 1976). There are 4 main stimulus types used to induce 
experimental pain, mechanical, thermal, chemical and electrical. These stimuli may be used 
in 2 main ways to elicit these responses, either fixed stimulation intensity with different 
stimulation duration, or fixed stimulation duration with variable stimulus intensity. When 
these tests are applied in the normal animal they elicit physiological pain i. e. they result in a 
transient, localized and stimulus specific reaction (Woolf, 1989), but they may also be used 
to induce pathological pain e. g. thermal, chemical or electrical 'bums', adjuvant-induced 
arthritis or experimental surgery after which stimulation results in a diffuse and persistent 
reaction with spatial spread of pain to uninjured tissues. In addition, reduction of thresholds
4to painful stimuli (allodynia) and an increase in response to the stimulus (hyperalgesia) may 
be observed (Woolf, 1989; 1991). However, it is important to note that the latter 2 terms 
frequently are used interchangeably. Clinical pain is found to have many of the features of 
pathological pain. The source of clinical pain is not always apparent, although direct trauma, 
and many disease states, result in the development of acute or chronic pain.
Although recent developments in cell culture have aided investigation of cellular mechanisms 
of pain and hyperalgesia (Ortmann and Perkins, 1977; Baccaglini and Hogan, 1983; 
McGuirk and Dolphin, 1992; Nicol et al. , 1992), experimental pain allows evaluation of 
new analgesic agents and is used extensively in the investigation of the mechanisms involved 
in the induction of hyperalgesia and persistent pain. However, it is important that every 
effort is made to minimise distress to experimental animals and to operate within ethical 
guidelines. Beecher (1957) recommended that the following points should be taken into 
consideration when inducing experimental pain: the chosen stimulus should be applied to a 
part of the body where measured responses are associated with pain; the stimulus should 
result in little tissue damage at the pain threshold level, and the hazard to the subject be small 
at highest intensity; there should be a relationship between the intensity of stimulus and the 
intensity of pain experienced; repeated determinations using the same stimulus should not 
affect the quantifiable response; the stimulus should result in a clear end point; the stimulus 
should allow for small alterations in threshold to be detected and should allow for detection 
of different doses of analgesic, and finally, it should be applicable in both man and animals. 
Since these recommendations were made, the subject has been reviewed extensively and 
further recommendations added, specifically with reference to induction of chronic pain 
(Zimmerman, 1983; Dubner, 1987; Loew, 1987).
1.2.1 Mechanical methods
Von Frey (1897) first described the use of hairs of varying diameter and length to bend the 
cutaneous epithelium in man to evoke pain. Horse hairs were attached to a lever, and the 
weight required to bend the hair and evoke a painful response was evaluated. The method 
was limited after the administration of analgesics because the operational weight range was 
narrow. Various modifications of the original system have been tried in an attempt to 
increase the effective range of the system e. g. by applying the stimulus to more sensitive 
skin regions (Seevers and Pfeiffer, 1936). Pressure applied to the tail of animals was used in 
the 1920s (Eddy, 1928; Franklin and Abbott, 1989), and attempted escape or vocalization 
were used as the end-points. However, this method was not found to be reliable in all 
species (Smith, 1938), and occasionally, tissue damage was evident after repeated use 
(Friend and Harris, 1948), which influenced thresholds determined subsequently.
5Green and Young (1951) described apparatus which applied a steadily increasing pressure to 
the tail of the rat and which was quantifiable. They showed that application of a pressure 4 
times greater than threshold pressure did not result in tissue damage, and recommended such 
a pressure as maximal. A modification of this system, where pain threshold in an inflamed 
rat paw is assessed (Randall and Selitto, 1957), currently is used widely in analgesic drug 
testing. In the domestic species, various systems of assessment of thresholds to noxious 
mechanical stimulation have been described (Pippi and Lumb, 1979; Nolan et al. , 1987a; 
Hamlin et al. , 1988). Pressure also may be used to produce visceral pain, and distension of 
the oesophagus, common bile duct and intestine have been investigated in humans 
(Chapman et al. , 1949). Similarly, in the domestic species distension of the caecum or 
colon has been used as a method of investigating thresholds to noxious stimuli (Pippi et al, 
1979; Sawyer and Rech, 1987). Ischaemic muscle pain also has been induced by applying 
pressure around an extremity to occlude blood flow (Hewer and Keele, 1948).
1.2.2 Thermal Methods
Radiant Heat
Heat applied to the skin, initially by contact through hot water or hot objects, was used for 
many years, but was limited by the concurrent sensations of touch and pressure evoked at 
the same time (Beecher, 1957). Oppel and Hardy (1937) demonstrated that radiant heat 
could be used to allow quantification of response temperature in man and in 1940, Hardy 
and colleagues used fixed duration, variable intensity radiant heat to measure thresholds to 
noxious thermal stimulation in man. In the latter study, the radiant energy from a 500 or 
1000 watt projection lamp was focused for a defined period of time onto an area of skin 
which had been blackened. An electrically timed shutter was used to control exposure, and a 
rheostat to control the current delivered to the lamp which varied the intensity of radiation. In 
an attempt to limit experimental variation resulting from the degree of skin blackening 
achieved, a colour filter was employed by Flodmark and Rammer (1945). Variations from 
the original method described by Hardy et al. (1940) in humans, including fixed intensity 
variable duration, has been used in many different species, including rats (D'Amour and 
Smith, 1941), dogs (Andrews and Workman, 1941), guinea pigs (Winder et al. , 1946), 
cats (Booth, 1954) and horses (Pippi et al. , 1979; Kamerling et al. , 1985; Schatzmann et 
al. , 1990).
6Conducted heat
The 2 most widely used alternatives to the radiant heat method of Hardy et al. (1940) are the 
hot-plate test (Woolfe and McDonald, 1944) and the tail immersion test (Janssen et al. , 
1963) which employ conduction of heat. In the hot-plate test (Woolfe and McDonald, 1944), 
a metal plate is heated to a pre-determined level and mice dropped onto the plate. The latency 
to response is measured and responses included shaking and licking the paws and kicking. 
The use of hot-plates which increase in temperature over time also has been described, 
where threshold temperature rather than response latency is recorded (Oden and Oden, 1982; 
Hunskaar et al. , 1986a). The second test using conducted heat is the tail immersion test 
(Janssen et al. , 1963), where the rat's tail is submerged in water heated to a pre-set 
temperature and response latency measured. Thresholds to noxious thermal stimulation also 
have been tested using conducted heat in the larger domestic species, where a heating 
element is placed in contact with the animals skin and either the response temperature, or 
time to response is measured (Nolan et al. , 1987a; Schatzmann et al. , 1990).
Threshold to noxious thermal stimulation also may be assessed by investigating the response 
to cooling (Kunkle, 1949), although currently this method is not frequently employed in 
assessments of analgesic efficacy.
1.2.3 Electrical methods
Many tests using electric impulses to activate nociceptors have been described, but currently 
there are only a limited number of methods used for the evaluation of nociceptive responses. 
The tooth-pulp stimulation test relies upon the reflexive action of opening the jaw, observed 
after electrical stimulation of the tooth, or recording the electromyographic response from the 
jaw muscles (Chapman e ta l . , 1985). Chewing and licking, and gross escape behaviour also 
have been noted (Ha et al. , 1978; Mason et al. , 1985). This test has been described in 
many species, including humans, rats, monkeys, dogs, cats, rabbits, guinea pigs (Franklin 
and Abbott, 1989) and horses (Brunson e ta l . , 1985).
The flinch-jump test was first described by Evans (1961), and measures the threshold to an 
electrical shock transmitted through the floor of a test chamber at which the rat either flinches 
or jumps, characterised by elevation of 1 or more paws from the floor. Electrical shocks also 
may be used to induce vocalization in mice, as well as other rodents (Nilsen, 1961). 
Electrical shocks are administered via cutaneous electrodes or clips positioned at the base of 
the tail, and the threshold is the lowest shock intensity that elicits a squeak.
71.2.4 Chemical methods
Noxious stimulation resulting from the injection or application of chemical substances differs 
from those methods already mentioned, because the animal cannot limit the extent of the 
aggravation once induced. In 1951, Armstrong and colleagues described the production of a 
blister base, by removing the epidermis from a blister induced by cantharidin, and assessed 
the response to application of chemicals to the base by asking subjects to squeeze a pressure 
bulb. Chemical methods commonly used in the assessment of nociceptive responses 
currently, include the writhing response observed in rodents after intraperitoneal 
administration of irritants, first described by Vander Wende and Margolin (1956), the 
formalin test (Dubuisson and Dennis, 1977) and the Randall-Selitto test (Randall and Selitto, 
1957), which combines chemically-induced inflammation and evaluation of thresholds to 
noxious mechanical stimulation. Chemically-induced arthritis also is used in the assessment 
of potential analgesics (for review see Otterness and Bliven, 1985). These methods are 
discussed in more detail in chapter 4.
1.3 Responses to noxious stimuli
Responses to noxious stimulation in nature have a protective role aimed at avoiding or 
limiting tissue damage, and may be classified into the following categories: simple reflexes 
such as limb withdrawal; unlearned behaviour such as vocalization and learned behaviour 
such as escape detection (Bonica, 1992).
1.3.1 Animals
In animals, the simple reflex behaviours are assessed either by measuring the response 
latency or the intensity at which the response occurs e. g . the tail flick reflex in the rat, 
(D'Amour and Smith, 1941), where the end point is when the tail is flicked. Further simple 
reflex behaviours include limb withdrawal tests (Randall and Selitto, 1957; Pippi and Lumb, 
1979; Nolan et al. , 1987a; Hamlin e ta l . , 1988), skin flinch (Evans, 1961; Kamerling etal.
, 1985) and jaw opening reflexes (Mitchell, 1964). Interpretation of data from simple reflex 
behaviours can be complicated by alterations in motor function as well as sensory 
processing, and do not consider the affective component of pain. Organized unlearned 
behaviour includes paw licking or face rubbing (Woolfe and MacDonald, 1944; Chapman et 
al. , 1985), writhing responses (Siegmund et al. , 1957) and vocalization (Eddy, 1928), and 
probably involves affective responses. Learned responses also may be used in threshold 
assessment i. e. shock-titration. These responses require the animal to exhibit learned 
behaviour to avoid noxious stimuli and escape latency is recorded (Chapman et al. , 1985).
81.3.2 Man
Many of the simple reflex behaviours which are exhibited by animals in response to noxious 
stimuli are not demonstrated in humans. However, in psychophysical experiments, the 
human subject may be asked to convey their impression of the intensity of the applied 
stimulus verbally or using rating scales. Thus, the end-point of many test systems in humans 
is taken when the subject reports that the pain threshold, or tolerance, has been reached e. g. 
radiant thermal stimulation of the forehead (Hardy et al. , 1952) and cold water stimulation 
(W olf and Hardy, 1941). Using rating scales the subject is asked to complete a structured 
categorized scale according to the severity of pain they are experiencing. The scales used 
include unidimensional scales e. g. visual analogue scale, numerical rating scale (see chapter 
6), and multidimensional scales e. g. McGill Pain Questionnaire (Melzack, 1975). However, 
it should be noted that these systems can be sensitive to placebo effects, expectancy and 
other psychological variables (Chapman et al. , 1985). Various other psychophysical and 
physiological methods have been employed in human pain estimation, and are reviewed by 
Chapman etal. (1985).
1.4 Analgesics
There are many drugs which have been shown to exert analgesic effects, both experimentally 
and clinically, and some of them will be reviewed briefly. Those used most commonly 
include the non-steroidal anti-inflammatory drugs (NSAIDs), opioids and a 2-adrenoreceptor 
agonists. Various other agents have also been shown to provide analgesia but will not be 
considered here. These include the local anaesthetic agents, ketamine, benzodiazepines and 
muscarinic agonists such as acetylcholine (de Jong and Wagman, 1963; Owen et al. , 1987; 
Sawynok, 1987; M aurse te ra /., 1989; Bartolini e ta l . , 1992).
1.4.1 Opioids
Opioid drugs exert their analgesic actions by binding to specific opioid receptors, including 
mu (p.), delta (5) and kappa (k), in the brain and spinal cord, and there are a variety of 
endogenous ligands which act at these receptors (Martin et al. , 1976; Lord et al. , 1977; 
Dubner and Bennett, 1983). Opioid receptors also have been identified in the periphery and 
opioid drugs have been shown to have peripheral analgesic effects (Ferreira and Nakamura, 
1979a; Fields et al. , 1980; Joris et al. , 1987). Opioid drugs, which may be full agonists, 
antagonists, have partial agonist activity or act as agonists at one receptor while exerting 
antagonistic effects at another (mixed agonists/antagonists), have different binding 
selectivities on different receptor subtypes. The opioids are used widely for the control of 
moderate to severe pain, particularly in the peri-operative period (Mitchell and Smith, 1989).
9Unfortunately, there are a variety of side-effects associated with the use of these drugs, 
including tolerance, dependence, respiratory depression and cardiovascular effects (see 
Martin, 1984).
1.4.2 (X2-adrenoreceptor agonists
The oc2-adrenoreceptor agonists e. g. clonidine, xylazine and detomidine, have been shown 
to be potent analgesic agents in a variety of species (Schmitt et al. , 1974; Fielding et al. , 
1978; Nolan et al. , 1987a; 1987b; Chambers et al. , 1993a; Kyles et al. , 1993), and the 
analgesic actions of these drugs is mediated, at least partially, at the level of the spinal cord 
(Kyles et al. , 1993). Injection of the oc2-adrenoreceptor agonists can cause various side- 
effects, as described for the opioids, including cardiovascular and respiratory depression 
(see Greene and Thurmon, 1988).
1.4.3 Non-steroidal anti-inflammatory drugs
Non-steroidal anti-inflammatory drugs are those substances, other than steroids, which 
suppress one or more components of the inflammatory response (Lees and Higgins, 1985). 
This definition encompasses many non-specific agents and consequently, in this thesis, the 
term NSAID will be used to refer to those drugs which inhibit some component of the 
enzyme systems involved in the metabolism of arachidonic acid. The NSAIDs used clinically 
are generally weak organic acids and possess analgesic and anti-pyretic properties in addition 
to their anti-inflammatory actions.
Approximately 8 % of people in the United States of America have a rheumatic symptom at 
any one time (Brooks and Day, 1991), and this is reflected in the number of prescriptions 
written for NSAIDs in human medicine. More recently, these dmgs have been used for the 
control of post-operative pain, either on their own or in conjunction with more traditional 
therapy (Mitchell and Smith, 1989). In veterinary medicine, the NSAIDs are widely used for 
a variety of conditions, and in many species the NSAIDs are the only drugs licensed for use 
which possess analgesic properties.
The NSAIDs used clinically are weak organic acids and may be further subdivided into 2 
groups, the carboxylic acids and the enolic acids. The salicylates (e. g. acetylsalicylic acid, 
sodium salicylate), indolines (e. g. indomethacin, zomepirac, diclofenac), propionic acids 
(e. g. ibuprofen, naproxen, ketoprofen, carprofen), quinolines (e. g. cinchophen), 
aminonicotinic acids (e . g. flunixin meglumine) and anthranilic acids (meclofenamic acid, 
tolfenamic acid) are all carboxylic acids, while the pyrazolones (e. g. phenylbutazone, 
dipyrone) and oxicams (e. g. piroxicam and miloxicam) may be classified as enolic acids. A
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comprehensive review of the acidic NSAIDs has been made (Lombardino, 1985), and only 
flunixin meglumine and carprofen will be considered in greater detail.
Flunixin meglumine is a methyl homologue of niflumic acid, and relatively little has been 
published in the human literature relating to this drug (Ciofalo et a l . , 1975; 1977; Zederfeldt 
et al. , 1977; Sunshine et al. , 1984). However, flunixin is licensed for use in dogs, horses 
and cattle in the United Kingdom, and many experimental and clinical studies have reported 
the use of this agent. The pharmacokinetics of flunixin have been investigated in several of 
the domestic species (see chapter 5), and it is a potent inhibitor of the generation of 
metabolites of arachidonic acid metabolism (Semrad et al. , 1985; Higgins e ta l.  , 1986; 
McKellar e ta l . , 1989; Lees and Taylor, 1991; McKellar et a l . , 1991a; Soma et a l . , 1992). 
Its use has been described for the control of pain and inflammation associated with 
musculoskeletal disorders (Houdeshell and Hennessey, 1977; McKellar et al. , 1991b), 
respiratory conditions (Selman e ta l . , 1986), mastitis (Anderson e ta l . , 1986; Lohuis e ta l . , 
1989), colic (Vemimb and Hennessey, 1977), post-operative pain (Reid and Nolan, 1991) 
and endotoxic shock (Moore et al. , 1981; Hardie et al. , 1983; Hardie et al. , 1985a) in the 
domestic species.
Carprofen, a propionic acid derivative, has more recently been launched onto the veterinary 
market in the United Kingdom, although it has been available for humans in other European 
countries for some time. Carprofen is presented in solution as a racemic mixture, and the 
pharmacokinetics of the racemate, and also of the enantiomers have been investigated in 
several of the domestic species (see chapter 5). Unlike flunixin, carprofen is a poor inhibitor 
of cyclooxygenase, an important enzyme for the metabolism of arachidonic acid, although it 
is a potent anti-inflammatory agent (Randall and Baruth, 1976; Strub et al. , 1982). In 
addition, carprofen has no activity against another important enzyme for the metabolism of 
arachidonic acid, lipoxygenase, but it has been shown to have an effect on one of the 
enzymes regulating the release of arachidonic acid from its membrane bound site (Hope and 
Welton, 1983). Clinical studies investigating the use of carprofen are limited, but McKellar 
etal. (1991b) reported that carprofen was a useful anti-inflammatory and analgesic agent in 
degenerative joint disease in dogs. Moreover, it has been used successfully in the treatment 
of a variety of rheumatic complaints, and for the control of acute pain in man (Feldmeier, 
1982; Klein, 1982; Standel, 1982).
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1.4.3.1 The pharmacology of the NSAIDs with reference to their anti­
nociceptive actions
The pharmacology of the NSAIDs cannot be discussed without a knowledge of the 
metabolic pathways at which this group of drugs have been shown to act. Consequently, the 
metabolism of the polyunsaturated fatty acid, arachidonic acid, will be reviewed.
1.4.3.1.1 Arachidonic acid metabolism
Ulf von Euler (1936) reported the isolation of an acidic polar lipid from human semen which 
he called prostaglandin, and which later was shown to be a combination of several different 
lipids, including prostaglandin El and prostaglandin Floe (Bergstrom and Sjovall, I960).
Bergstrom and colleagues (1963). later reported the isolation of several other stable 
prostaglandins, and shortly afterwards, it was demonstrated that the mono-, bis- and tri- 
enoic prostaglandins were formed from the polyunsaturated fatty acids, dihomo-y-linolenic 
acid (8, 11, 14-eicosatrienoic acid), arachidonic acid (5, 8, 11, 14-eicosatetraenoic acid) and 
timnodonic acid (5, 8, 11, 14, 17-eicosapentaenoic acid), respectively (Bergstrom et al. , 
1964; Van Dorp et al. , 1964). Piper and Vane (1969) detected the release of a labile 
substance during anaphylaxis in isolated perfused guinea pig lungs, half-life of 
approximately 2 minutes, which they called rabbit aorta contracting substance (RCS), and 
they reported that its release was inhibited by the aspirin-like drugs. Although release of 
RCS from lungs in in vitro preparations could be demonstrated after challenge with a variety 
of endogenous and exogenous substances, including arachidonic acid (Palmer e ta l . , 1973), 
this substance did not match any of the known prostaglandins. Vane (1971) suggested that 
RCS was an unstable intermediate in the biosynthesis of prostaglandins, the possibility of 
which had been suggested previously by Samuelsson (1965). The presence of an unstable 
intermediate product was confirmed, and identified as PGH2 (15-hydroperoxy-9, 11- 
endoperoxide) by Hamberg and Samuelsson (1973), and other workers reported the 
presence of a second intermediate in the same year, referred to as PGG2 (15-hydroxy-9,11- 
endoperoxide) (Nugteren and Hazelhoff, 1973), and they suggested that these unstable 
products were the same substances which had been referred to previously as RCS.
The unstable intermediate products, PGG2 and PGH2, or the cyclic endoperoxides, are the 
precursors for a wide variety of prostanoid products, including PGD, PGE and PGF (Fig. 
1.1). Hamberg and co-workers (1975) reported the presence of an unstable non-prostanoid 
substance generated from the cyclic endoperoxides during platelet aggregation, which was 
iden tified  as throm boxane A 2 (T X A 2 ). Thus, this product also had been
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partly responsible for the activity of RCS. Shortly afterwards, a novel prostanoid, 
prostacyclin, or PGI2 , was described, which was again unstable (Moncada et al. , 1976),
and which was later shown to be the intermediate product in the formation of the stable 
prostanoid product, 6-keto-PGFia (Johnson et al. , 1976). These discoveries, coupled with
the earlier characterisation of a second metabolic pathway for arachidonic acid leading to the 
production of 12-hydroperoxyeicosatetraenoic acid (12-HPETE), an unstable intermediate, 
and 12-hydroxyeicosatetraenoic acid (12-HETE), indicated that the generation of 
prostaglandins was only part of the story of arachidonic acid metabolism (Hamberg and 
Samuelsson, 1974) (Fig. 1.2). Moreover, in 1976, Borgeat and colleagues described the 
production of 5-hydroperoxyeicosatetraenoic acid (5-HPETE), an unstable intermediate 
product, and 3 years later, 5-hydroxyeicosatetraenoic acid (5-HETE) was discovered 
(Borgeat and Samuelsson, 1979), the metabolic product of which was an unstable epoxide 
of arachidonic acid, later named leukotriene A4 (LTA4 ) (Samuelsson et al. , 1979). 
Leukotriene A4 also was unstable, and was transformed into LTB4 by the action of LTA 
hydrolase, or alternatively was conjugated with glutathione to form LTC4 (Murphy e ta l . , 
1979; Samuelsson et al. , 1979). Finally, it was demonstrated that the formation of the 
remaining leukotrienes, LTD4 , LTE4 and LTF4 , occured in sequence from LTC4 (see 
Piper, 1984; Samuelsson et al. , 1987) (Fig. 1.2). Leukotriene C4 , D 4 and E4 now are 
considered to represent the 'slow reacting substances of anaphylaxis', initially described in 
1938 by Feldberg and Kellaway. The prostaglandins, thromboxanes and leukotrienes, are 
collectively referred to as the eicosanoids, 20 carbon derivatives of polyunsaturated fatty 
acids such as arachidonic acid.
Arachidonic acid, the most common precursor of the naturally occurring prostaglandins, 
thromboxanes and leukotrienes, may be obtained directly from the diet or by anabolic 
desaturation and chain elongation from dietary linoleic acid (Moncada and Vane, 1979). 
Within the body, it is transported bound to albumin, and is incorporated into the 
phospholipids of cell membranes, as well as other subcellular structures, of all tissues 
(Moncada and Vane, 1979). Arachidonic acid is found mainly in esterified form in the sn-2 
position of membrane phospholipids, which suggests that phospholipase A2 (PLA2) is 
probably responsible for the hydrolization and release of arachidonate, forming the rate 
limiting step in the production of the eicosanoids (Flower and Blackwell, 1976). Burch and 
Axelrod (1987) demonstrated that bradykinin, by interacting with plasma membrane-bound 
receptors coupled to guanine nucleotide-binding regulatory proteins, caused direct activation 
of PLA2, leading to the production of PGE2. Phospholipase C also may be involved in the 
generation of free arachidonate within the body (Lapetina, 1982), as may
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the diacyglycerol lipase enzymes (Okazaki et al. , 1981). A variety of stimuli have been 
shown to result in increased prostaglandin production, and thus activation of the 
phospholipase enzymes, including mechanical, physical, hormonal, nervous and 
immunological stimuli (Granstrom, 1983). There are 2 main forms of PLA2, extracellular 
and intracellular forms, and the regulation and inhibition of PLA2 enzymes was recently 
reviewed (G lasere ta l . , 1993).
Once liberated from cell membrane phospholipid, free arachidonate is either immediately re- 
incorporated into the cell membrane or metabolized by one of 2 enzyme pathways, either via 
the prostaglandin endoperoxide synthetase system, or via the lipoxygenase system (Higgins, 
1985; Toh e ta l . , 1992). Prostaglandin endoperoxide synthetase, hereafter referred to as the 
cyclooxygenase enzyme system (PGH synthase), is a bifunctional enzyme with both fatty 
acid cyclooxygenase activity (arachidonic acid to PGG2 ), and prostaglandin 
hydroperoxidase activity (PGG2 to PGH2) (vide supra). Immunocytochemical studies have 
located these enzymes to the endoplasmic reticulum and nuclear membrane within cultured 
fibroblasts (Rollins and Smith, 1980), and recently it was demonstrated that the 
cyclooxygenase enzyme is encoded by at least 2 genes that are expressed, and differentially 
regulated, in a variety of cell types (Hla and Neilson, 1992), supporting previous proposals 
that isoenzymes of cyclooxygenase existed (Smith and Lands, 1972; Flower and Vane, 
1973; Lin e ta l . , 1989). The lipoxygenase system is comprised of a series of lipoxygenases, 
that peroxidize arachidonic acid, by incorporation of one oxygen molecule, at different 
carbon atoms e. g. 5-, 12- and 15-lipoxygenase resulting in the formation of the unstable 
hydroperoxides described above.
1.4.3.1.2 Inhibition of eicosanoid biosynthesis by NSAIDs
Several mechanisms of action of the NSAIDs have been suggested including a direct effect at 
the prostaglandin receptor (Collier and Sweatmen, 1968; Rees et al. , 1988; Rees and Lopez- 
Bemal, 1989), and inhibition of histamine and bradykinin release (Lewis and Whittle, 1977; 
Harris and Vavra, 1985). However, although both peripheral and central mechanisms of 
NSAID-induced anti nociception have been proposed (vide infra), it is accepted generally that 
the mode of action of the NSAIDs, regardless of site, is the inhibition of the formation of the 
prostaglandins and other endogenous pro-inflammatory mediators (Ferreira et al. , 1971; 
Smith and Willis, 1971; Vane, 1971). Smith and Willis (1971) demonstrated that while 
prostaglandin production was inhibited in the presence of NSAIDs, the release and activity 
of PLA2 was unaffected. Thus, the NSAIDs did not act to prevent the release of arachidonic 
acid, but instead acted further down the metabolic pathway, but it was not until 1976 that it 
was proposed that the NSAIDs were acting by inhibiting the action of the enzyme 
cyclooxygenase (Vane, 1976). The non-steroidal inhibitors of cyclooxygenase may be
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classified according to the method by which they inhibit the enzyme: rapid reversible 
competitive inhibition e. g. aryl propionate derivatives such as ibuprofen; irreversible, time- 
dependent inactivation e. g. aspirin, and reversible non-competitive e. g. paracetamol 
(Lands, 1981; Higgs and Vane, 1983). However, it has been suggested that other 
mechanisms of action must play a role, because NSAIDs which are weak inhibitors of 
cyclooxygenase e. g. carprofen, appear to be as effective clinically as more potent inhibitors 
of the enzyme (Randall and Baruth, 1976; Strub et al. , 1982; Preston et al. , 1989). Some 
of the products of the lipoxygenase pathway have been shown to cause hyperalgesia 
experimentally (see chapter 3), and a number of NSAIDs including aspirin, diclofenac, 
indomethacin and ketoprofen, have been reported to inhibit the various lipoxygenase 
enzymes (Dawson e ta l . ,  1982; Paajanen et al. , 1982; O'Neill and Lewis, 1989). However, 
to date, this mechanism of action has not been shown to contribute to the antinociceptive 
properties of the NSAIDs. Various other actions of the NSAIDs have been proposed to 
account for the potent anti-inflammatory effects of these drugs, and have been reviewed 
briefly by Brooks and Day (1991).
1.4.3.2 Antinociceptive actions of the NSAIDs
Salicylic acid was proposed as an analgesic agent by Vulpian in 1880, and towards the end 
of the 19th century, Dreser suggested the use of aspirin for the same purpose (Lim e ta l . , 
1964; Vane and Botting, 1992). For many years it was believed that the analgesic activity of 
these agents, and other aspirin-like drugs, or non-steroidal anti-inflammatory drugs 
(NSAIDs), was caused by an effect on the CNS. However, the observations of Randall and 
Selitto (1957), amongst others (Seigmund et al. , 1957; Winder, 1959), suggested that the 
anti-inflammatory actions of these drugs may have had a peripheral component, and some 
suggested that the analgesic effects of these agents occurred as a result o f the anti­
inflammatory actions (Randall and Selitto, 1957). In 1962, Guzman and colleagues showed 
that the analgesic actions of the NSAIDs did not rely completely on the anti-inflammatory 
effects of the drugs, by demonstrating that the injection of NSAIDs attenuated the 
physiological responses indicative of pain after intra-arterial injection of bradykinin in 
healthy anaesthetised dogs. Moreover, later studies showed that the NSAIDs were effective 
analgesics at doses which were not anti-inflammatory (Gilfoil et al. , 1963; Winter and 
Flataker, 1965).
Peripheral actions
One of the first major clues to whether the NSAIDs exerted their analgesic effects centrally 
or peripherally came from the paper published by Lim et al. (1964). Using the cross- 
perfused spleen preparation, the authors observed that bradykinin injected into the 
vasoisolated, but neurally intact, spleen of a recipient dog caused a physiological pain
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response. The response was diminished after administration of morphine systemically to the 
recipient dog, but not after similar administration to the donor dog. In contrast, injection of 
NSAIDs in the recipient dog did not reduced the pain response, suggesting that the agents 
administered did not exert any analgesic effects centrally, whereas injection of the same 
agents to the donor dog did attenuate the pain response. Consequently, the authors 
concluded that the NSAIDs exerted their analgesic effects by a peripheral mechanism of 
action. This proposal was supported by the findings of several other authors subsequently 
(Guzman et al. , 1964; Whittle, 1964; Scott, 1968). It was suggested that the NSAIDs 
perhaps were acting as antagonists at a peripheral receptor, preventing binding of algesic 
agents (Lim et al. , 1964), however, there also was evidence that the NSAIDs exerted their 
analgesic actions only in the presence of tissue damage or inflammation (Winder, 1959).
The breakthrough in'the investigation of the analgesic activity of the NSAIDs came with 2 
important discoveries. In 1969, Willis demonstrated the presence of prostaglandins in 
inflammatory exudate, and 2 years later Vane (1971) proposed that the NSAIDs acted by 
inhibiting the formation of the prostaglandins. This suggestion was supported by further 
work published in the same year (Smith and Willis, 1971; Ferreira et al. , 1971). Although 
Vane's discovery (1971) explained both the anti-inflammatory and anti-pyretic actions of the 
NSAIDs, it did not appear immediately to provide an explanation for the analgesic effects of 
this group of drugs.
The prostaglandins had not been shown to be algesic agents, causing instead a hyperalgesia 
(Horton, 1963; Crunkhorn and Willis, 1969; 1971; Juhlin and Michaelsson, 1969; Willis, 
1969; Karim, 1971). The peripheral and central mechanisms of prostaglandin-evoked 
hyperalgesia are reviewed in chapter 3. Ferreira (1972) demonstrated that aspirin did not 
attenuate the hyperalgesia caused by subdermal infusion of PG Ei, but suggested that the 
analgesic action of the NSAIDs could be explained by inhibition o f prostaglandin 
production, thus preventing sensitization of peripheral pain receptors. In the same year, 
Collier and Schneider (1972) demonstrated that although NSAIDs did not block 
prostaglandin-induced writhing responses in mice, they did block the writhing responses 
induced by the intraperitoneal injection of bradykinin and other algesic agents, and they 
suggested that prostaglandins might be released by such noxious stimuli. In addition, 
Ferreira et al. (1973) showed that bradykinin injected intra-arterially in isolated dog spleen, 
released prostaglandin-like material, and moreover, they demonstrated that the release of this 
substance, or substances, was blocked by administration of a NSAID. These findings 
suggested that the NSAIDs exerted their analgesic actions by preventing the formation of the 
prostaglandins peripherally, thus inhibiting the sensitization of peripheral nociceptors. These 
authors also demonstrated that the pseudoaffective responses of increased blood pressure 
aid respiratory rate, evoked after bradykinin was injected into the splenic artery of dogs,
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were attenuated by pre-treatment with NSAIDs. Similarly, Moncada et al. (1975) 
demonstrated that the rise in blood pressure recorded after intra-articular injection of 
bradykinin was attenuated by local injection of NSAIDs, and that the beneficial effects of 
NSAID injection were lost when exogenous prostaglandin was injected into the joint. 
Moreover, the authors of the latter study demonstrated that pre-treatment with indomethacin, 
a NSAID, prevented the increase in locally produced PGE2 in the dog knee joint induced by 
carrageenan injection. The findings of the previous studies were reinforced by Ferreira et al. 
(1978a), who demonstrated that local intraplantar injection of NSAIDs attenuated the 
hyperalgesic response observed after administration of carrageenan. Inhibition of the 
formation of the prostaglandins in the periphery, thereby preventing sensitization of 
peripheral nociceptors to the effects of both endogenous and exogenous algesic influences, 
has remained the most popular explanation of the antinociceptive activity of the NSAIDs 
(Menasse e ta l. , 1978; Milne and Twomey, l9$0; Schweizer and Brom, 1985; Haubrich et 
al. , 1990). However, despite the weight of evidence supporting a peripheral site of 
antinociceptive action of the NSAIDs, it is possible that antinociception is mediated, at least 
in part via a central mode of action.
Central actions
Towards the end of the last century, a central mode of action for the NSAIDs was claimed 
by Dreser (vide supra), and this suggestion was maintained until challenged by the work of 
Lim et al. (1964) and Guzman etal. (1964). In 1978, Ferreira and colleagues (1978a) again 
proposed a central component to the analgesic effects observed after administration of the 
NSAIDs. In the latter study the authors observed that both intracerebroventricular (ICV) and 
intraplantar injection of NSAIDs diminished the hyperalgesia recorded in the rat paw after 
intraplantar injection of carrageenan. Interestingly, they discovered that previous treatment of 
one paw with carrageenan reduced the oedema caused by a second injection of carrageenan 
in the contralateral paw. However, although the intensity of the subsequent hyperalgesia was 
not reduced, the time to plateau of effect was shorter. These workers also demonstrated that 
SC-19220, a prostaglandin antagonist, injected either ICV or intraplantar, inhibited the 
hyperalgesia evoked by injection of carrageenan. Moreover, they showed that ICV injection 
of prostaglandin enhanced the hyperalgesic response observed after intraplantar injection of 
prostaglandin. The authors concluded that previous inflammation triggered a central 
mechanism which accelerated the response to any subsequent inflammatory stimulus, and 
that this mechanism involved the release of prostaglandins within the CNS. It is interesting 
to note that later work supported the suggestion that changes within the CNS occur after 
inflammation, although different mechanisms were proposed (Woolf, 1983; also see chapter 
3), and also that spinal administration of prostaglandins has been shown to cause peripheral 
hyperalgesia (Uda e ta l . , 1990).
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Shyu et al. (1984) demonstrated that both systemic and central administration of aspirin 
caused analgesia in monkeys after tooth pulp stimulation, and they showed that to achieve 
the same level of analgesia a 200 fold increase in dose was required after systemic 
administration. Moreover, they observed that aspirin-induced analgesia was antagonised by 
depletion of 5-hydroxytryptamine (5-HT), and enhanced by pre-treatment with either 5-HT 
or a 5-HT precursor. In a second study, metamizol, a pyrazolone derivative with NSAID 
activity, increased the response latency to noxious thermal stimulation in rats after both 
intrathecal and systemic injection, although intrathecal administration in spinal rats was 
ineffective (Carlsson et al. , 1986). The latter workers also demonstrated that metamizol 
exerted a central analgesic effect involving activation of descending inhibitory systems 
originating in the periaqueductal grey matter. Intrathecal administration of aspirin and 
indomethacin in rats also caused analgesia, demonstrated by an increase in latency to 
response after noxious thermal and mechanical stimulation, although a similar response was 
not observed after systemic administration of indomethacin (Taiwo and Levine, 1988a), 
while intrathecal administration of PGE2 resulted in hyperalgesia to mechanical and thermal 
stimuli. M oreover, thermal and mechanical analgesia observed after intrathecal 
administration of morphine was both prevented and reversed by intrathecal injection of 
PGE2- Interestingly, the authors demonstrated a synergistic effect between morphine and the 
NSAIDs administered intrathecally. In the same study, it was shown that PGE2 
administered centrally, blocked analgesia induced by electrical stimulation of the nucleus 
reticularis paragigantocellularis, while indomethacin reduced the current required to evoke a 
similar level of analgesia. Furthermore, blocking or destroying spinal noradrenergic 
synapses prevented the development of the effects observed after spinal administration of 
PGE2 or NSAIDs. More recently, Bjorkman et al. (1990) demonstrated that diclofenac 
exerted a central, naloxone-reversible antinociceptive action in rat writhing and colo-rectal 
distension models after both central and systemic administration. It is interesting to note that 
injection of diclofenac had previously been shown to be linked to an increase in 
hypothalamic, and a decrease in pituitary (3-endorphin, in association with increased 
circulating levels of the opioid peptide (Sacerdote et al. , 1985). Moreover, it was 
demonstrated recently that administration of flunixin meglumine to sheep caused a naloxone- 
reversible analgesia, and the authors proposed the involvment of a descending opioidergic 
system in NSAID-induced analgesia (Chambers e ta l. , 1993b).
Electrophysiological studies also have suggested a central component to NSAID-induced 
analgesia (Guilbaud e ta l . , 1982; Yezierski e ta l . , 1983; Carlsson et al. , 1988; Groppetti et 
al. , 1988; Jurna and Brune, 1990; Jurna et al. , 1992). Guilbaud et al. (1982) investigated 
the activity of ventrobasal thalamic neurones in rats with experimentally-induced arthritis, 
and showed that systemically administered aspirin depressed neuronal responses to joint
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manipulation. Further studies have investigated the effects of the NSAIDs on evoked activity 
of thalamic neurones in the normal animal, and shown that these agents dose-dependently 
inhibit evoked responses in a naloxone irreversible manner, and that unlike morphine the 
NSAIDs do not completely block evoked activity (Carlsson et al. , 1988; Groppetti etal.. , 
1988; Jurna and Brune, 1990; Jurna et al. , 1992). In addition, Groppetti et al. (1988) 
reported that lysine acetylsalicylate decreased the concentration of met-enkephalin immuno- 
reactive derivatives in several areas of the brain, although concentrations of 5-hydroxy indole 
acetic acid, a metabolite of 5-HT, increased. Moreover, pre-treatment with a 5-HT receptor 
antagonist attenuated the antinociceptive activity of the NSAID, and administration of both 
tryptophan or 5-hydroxytryptophan mimicked the effects of the NSAID i. e. increased 
turnover of 5-HT and reduced evoked neuronal activity.
Several central sites of action of the NSAIDs have been proposed: preoptic anterior 
hypothalamus (Shyu eta l. , 1984; Shyu and Lin, 1985); lateral hypothalamus (Dubas and 
Parker, 1971); periaqueductal grey matter (Carlsson et al. , 1986) and the thalamus 
(Carlsson et al. , 1988). Moreover, several mechanisms for the central analgesic action of 
the NSAIDs have been suggested (vide supra) (Shyu et al. , 1984; Shyu and Lin, 1985; 
Groppetti et al. , 1988; Taiwo and Levine, 1988a). Recently, Malmberg and Yaksh (1992a) 
demonstrated that spinal administration of NSAIDs attenuated the hyperalgesic response 
observed after spinal injection of both substance P and N-methyl-D-aspartate agonists, and 
pre- and post-treatment with the NSAIDs were shown to be equally effective at limiting 
hyperalgesia. In a second study, the same authors investigated the central effects of various 
NSAIDs from several different chemical groups including, acetylsalicylic acid, ketorolac, 
indomethacin, acetaminophen, zomepirac, flurbiprofen and ibuprofen (racemate and S(+)- 
isomer and R(-)-isomer) (Malmberg and Yaksh, 1992b). This was an important 
investigation because, although a large number of studies had been conducted into the central 
mechanisms of NSAID-induced antinociception, only a limited number of agents had been 
investigated, primarily indomethacin and aspirin. The authors of the latter study described a 
dose-dependent, stereospecific, submaximal suppression of the second phase of the 
response to injection of formalin into the rat paw, after both spinal and systemic 
administration of the NSAIDs previously mentioned. It is of interest that the drugs were 100 
to 1000 times more potent after spinal injection, were effective both pre- and post-formalin 
injection and that when administered intrathecally, they had little effect on the escape 
response generated by the hot-plate test.
Experimental evidence supporting a central site of antinociceptive action of the NSAIDs is 
accumulating, but presently, only a limited number of clinical studies have been reported. 
Intrathecal administration of lysine acetylsalicylic acid has been shown to provide relief from 
pain in patients with cancer (Devoghel, 1983), and more recently, Wilier etal. (1989), using
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the threshold of the nociceptive flexion reflex from the biceps femoris muscle, elicited by 
electrical stimulation of the sural nerve, demonstrated a supraspinal mode of action for 
ketoprofen. Obviously, there is a need for further clinical studies to be conducted, not only 
in humans, but also in the domestic species.
1.4.3.3 Other actions of the NSAIDs
In addition to their antinociceptive effects, the NSAIDs exert 2 other main pharmacological 
actions, anti-inflammatory effects and anti-pyretic effects. While the anti-inflammatory 
actions of the NSAIDs are very important, and these drugs are prescribed widely for the 
control of many inflammatory conditions, including both acute and chronic inflammatory 
musculoskeletal conditions, only a brief review of the anti-inflammatory effects will be 
given. Many of the products of arachidonic acid metabolism are important mediators of the 
inflammatory response, characterised by the signs of swelling, erythema, heat, pain and loss 
of function (Higgins and Lees, 1984). These signs may be explained in part by the action of 
the eicosanoids, in combination with other chemical and cellular responses e. g. many of the 
prostaglandins, and some of the products of the lipoxygenase pathways mediate 
hyperalgesia in association with other endogenous chemical mediators (see chapter 3); PGE2 
and PGI2 mediate vasodilation; the hydroxyeicosatetraenoic acids are potent chemotaxins; 
LTB4 is a potent chemotaxin for polymorphonuclear leukocytes and affects vascular 
permeability and TXB2 promotes platelet aggregation and vasoconstriction (Higgins and 
Lees, 1984; Lees and Higgins 1985; Lees et al. , 1991a). In the treatment of inflammatory 
conditions, removal, or treatment directed at the initiating factor, is of primary importance, 
however drugs which directly or indirectly modulate the activity of the chemical mediators of 
inflammation, such as the NSAIDs, also play an important role in limiting the effects of 
inflammation. It is interesting to note that the dose of many NSAIDs required for 
antinociception is frequently less than that required for anti-inflammatory effect (Dawson and 
Willoughby, 1985).
A comprehensive review of the role of the eicosanoids in pyresis is given by Milton (1992). 
Briefly, pyresis occurs as part of the host acute phase response in response to infection, 
inflammation and tissue damage, and is mediated by interleukin- 1 which activates PLA2, 
thus stimulating arachidonic acid metabolism and increasing production of prostaglandins 
(see D inarello , 1984). M ilton and W endlandt (1970) dem onstrated  that 
intracerebroventricular injection of a variety of prostaglandins caused symptoms similar to 
those observed after injection of bacterial endotoxin, but which in contrast, were not 
controlled by administration of paracetamol. Consequently, the authors proposed that PGEi 
acted as a modulator of temperature regulation. Since the latter report, the area has been 
researched extensively, and the role of prostaglandins in the induction and maintenance of
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fever is well established (see Milton, 1992). The Reverend Stone (1763) described the use 
of an extract of willow bark in the treatment of fever, and since that account, salicylates and 
other NSAIDs have been used to control pyresis, acting to prevent the production of 
prostaglandins by inhibiting fatty acid cyclooxygenase.
The prostaglandins and leukotrienes, especially LTB4, may act to contract or relax smooth 
muscle in the vascular system (Bergstrom et al. , 1968; Piper, 1984; Bhagwat et al. , 1985), 
but in addition, the eicosanoids can cause similar effects on bronchial and tracheal smooth 
muscle (Spannhake et al. , 1981; Piper, 1984), uterine smooth muscle (Bergstrom et al. , 
1968) and gastrointestinal smooth muscle (Wilson and Kaymakcalan, 1981). Moreover, the 
eicosanoids influence gastrointestinal secretion (Wilson and Kaymakcalan, 1981), and play 
an important regulatory role in the kidney (Dunn and Zambraski, 1980). Finally, TXA2, a 
major product of arachidonic acid metabolism in platelets (Hamberg et al. , 1975), causes 
platelet aggregation, and the NSAIDs, in particular, aspirin, may be used for the treatment 
and prevention of thrombotic conditions, because of the anti-aggregatory effects exerted by 
these drugs as a consequence of cyclooxygenase inhibition.
1.4.3.4 A dverse effects of NSAIDs
In 1986, one quarter of all adverse drug reactions reported to the Committee on Safety of 
Medicines in the United Kingdom were due to administration of NSAIDs. Administration of 
these drugs can be associated with a wide range of side effects including renal toxicity, 
gastrointestinal toxicity, hepatotoxicity, prolongation of pregnancy and teratogenicity, 
increased bleeding time, bone marrow depression and blood dyscrasias, skin reactions, 
central nervous system disturbances and hypersensitivity reactions, all of which are related 
to inhibition of eicosanoid production (Rainsford, 1984a; 1984b). The renal and 
gastrointestinal adverse reactions perhaps are 2 of the most serious side effects encountered. 
Prostaglandins are important in the autoregulation of renal blood flow and glomerular 
filtration, and influence tubular transport of ions and water (Dunn and Zambraski, 1980). 
Administration of NSAIDs has been associated with a variety of renal problems in both 
humans and animals, including acute renal failure, papillary necrosis, nephrotic syndrome 
and interstitial nephritis (see Rubin, 1986). The role of the prostaglandins in the 
gastrointestinal tract has been reviewed and includes, inhibition of acid secretion in the 
stomach, inhibition of gastrin and pancreatic secretion, stimulation of salivary and biliary 
secretions, modulation of gastrointestinal blood flow and motility and finally, cytoprotection 
(Highland and Upson, 1986). Therefore, the prostaglandins play an important role in the 
normal physiological processes occurring within the gastrointestinal tract, and administration 
of NSAIDs can induce a variety of effects, including gastric erosion, peptic ulcer formation 
and perforation and changes in the permeability of the bowel (Brooks and Day, 1991).
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1.5 Footrot in sheep
Footrot is a contagious disease of ruminants which is transmitted by Dichelobacter nodosus 
(previously referred to as Bacteroides nodosus), and sheep are very susceptible to the 
disease (Stewart, 1989). Footrot has been recognized for more than 250 years in all 
countries where sheep are reared commercially (Deane and Jenson, 1955), and in addition to 
the important welfare implications, it also can cause large economic losses through decreased 
productivity and labour intensive treatment (Stewart, 1989).
There are 2 main forms of footrot which occur clinically, virulent, or progressive, and 
benign, or non-progressive, and it has been suggested that the severity of the disease 
depends on the invasiveness of the Dichelobacter spp. (Stewart et al. , 1986). Lameness is 
the most prominent clinical sign associated with both forms of the disease (Morgan, 1987; 
Stewart, 1989), and Stewart (1989) describes the pathological and clinical findings changes 
associated with the different forms of the disease. Briefly, virulent footrot is a persistent 
condition, characterised by presence of a necrotic, foul smelling exudate with extensive 
under-running and separation of the horn of the hoof wall and sole in a large number of 
sheep within the flock. However, benign footrot is limited generally to inflammation of the 
interdigital skin, with very little separation of the hoof and little exudation, but again it may 
be present in a large number of sheep within the flock.
Footrot has a seasonal incidence, occurring in warm moist conditions especially when 
pasture is lush underfoot (Beveridge, 1938), and although a wide variety of organisms can 
be isolated from infected feet, the 2 organisms found most commonly are Dichelobacter 
nodosus (Beveridge, 1941) and Fusobacterium necrophorum  (Mohler and Washburn, 
1904). British breeds of sheep, and their crosses, have a greater natural resistance to footrot 
than do the Australian Merino (Emery et al. , 1984), and it has been shown that 
susceptibility to footrot is a heritable characteristic and that natural resistance to footrot may 
be increased by selective breeding (Stewart, 1989). Fortunately, in addition to paring feet, 
there are a variety of treatment options for footrot, including both topical and parenteral 
therapies, and vaccination against infection with Dichelobacter ssp. is possible. Foot care in 
sheep, and treatment options against footrot have been reviewed by Boundy (1979), Morgan 
(1987) and Stewart (1989).
Studies described in this thesis were undertaken to examine the antinociceptive effects of the 
non-steroidal anti-inflammatory drugs in healthy sheep and also in sheep suffering from 
chronic and acute pain. The initial aim of these studies was to develop a test system in sheep 
whereby the antinociceptive properties of the NSAIDs could be detected, and subsequently, 
to evaluate the efficacy and potency of these drugs as antinociceptive agents in this species.
CH A PTER  2 
GENERAL M ATERIALS AND M ETHODS
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2.1 Animals
A group of 8 experimental sheep (Suffolk cross and Border Leicester x Scottish Blackface 
(Greyface)), aged 1 to 2 years, were purchased from either the University farm or from Mr. 
J. Struthers, High Currochtrie Farm, Drummore, U. K. Clinical examination indicated that 
the sheep were healthy and had normal foot conformation. Moreover, the sheep had no 
conformational changes of the feet suggestive of previous bacterial infection. The sheep 
were maintained indoors as a group and fed on hay {ad libitum) and concentrates. Water was 
available ad libitum.
The sheep were treated with a total spectrum wormer, albendazole (Valbazen, 2.5 %, 
Smithkline Beecham Animal Health, Tadworth, U. K.) every 6 months and were vaccinated 
yearly against Clostridium ssp. (Heptavac-P, Hoechst Animal Health, Milton Keynes, U. 
K.). Foot inspection was carried out on a fortnightly basis, and foot trimming was carried 
out as required. The sheep were weighed prior to all experiments (weights ranged between 
45 and 99 kg).
The remaining experimental sheep (study 1 and study 2, chapter 3) were owned by the 
University farm and were all Greyfaces. These sheep were maintained at grass from April to 
December. For the remaining time they were maintained indoors in groups of up to 30 sheep 
and were fed hay (ad libitum) and concentrates. Water was available ad libitum. The sheep 
were weighed prior to all experiments (weights ranged between 45 and 66 kg).
Sheep used for studies of subjective assessment of lameness were owned by Mr. J. Blair, 
Capellie Farm, Barrhead, U. K. (Suffolk cross) (study 1, chapter 7) and Mr. I. Lamont, 
Tandalmuir Farm, Lochwinnoch, U. K. (Scottish Blackface) (study 2, chapter 7).
Sheep used in the study investigating changes in thresholds to noxious stimulation post 
operatively (study 3, chapter 3), were owned by the Institute of Animal Physiology and 
Genetics Research, Roslin, U. K. In addition, a further 4 sheep were purchased from Mr J. 
Struthers. All sheep were Scottish Blackface ewes aged 3 to 4 years and were maintained 
outdoors. Water was available ad libitum. Twelve hours before the experiment the sheep 
were weighed (range 43 to 64 kg), brought indoors, maintained on wood shavings and 
fasted prior to the induction of general anaesthesia. The sheep were returned to the field 24 
hours after surgery or anaesthesia.
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2.2 Drugs and drug administration
The following drugs were used:
Buprenorphine- buprenorphine hydrochloride (Temgesic, 300 |ig/ml, Reckitt and
Colman Pharmaceuticals, Hull, U. K.).
Carprofen- (50 mg/ml, donated by Grampian Pharmaceuticals L td .,
Glasgow, U. K.).
Fentanyl- fentanyl citrate (Sublimaze, 50 (ig/ml, Janssen Pharmaceutical Ltd.
Oxford, U. K.).
Flunixin - flunixin meglumine (Finadyne, 50 mg/ml, Schering-Plough
Animal Health, Mildenhall, U. K.).
Halothane- (Fluothane, Coopers Pitman-Moore, Crewe, U. K.).
Lignocaine- lignocaine hydrochloride (Lignavet, 20 mg/ml, C-Vet L td ., Bury
St Edmunds, U. K.).
Penicillin- procaine penicillin (150 000 iu) and benzathine penicillin (150 000
iu) (Duphamox LA, Duphar Veterinary Ltd. , Southhampton,
U. K.).
Sterile water- (Water for Injections, RMB Animal Health L td ., Dagenham,
U. K.).
Thiopentone- thiopentone sodium (Intraval Sodium, RMB Animal Health Ltd.).
Xylazine- xylazine hydrochloride (Rompun, 20 mg/ml, Bayer UK L td .,
Bury St Edmunds, U. K.).
Ketamine- ketamine hydrochloride (Vetalar, 100 mg/ml, Parke-Davis
Veterinary, Pontypool, U. K.)
Drugs were diluted, if necessary, in sterile 0.9 % saline (Aquapharm 0.9 % w/v sodium 
chloride intravenous infusion BP, Animalcare Ltd. , York, U. K.). Thiopentone sodium (5 
%) was made up from the dried substance by dissolving in water for injection. All drugs 
were administered by intravenous injection (IV), unless otherwise stated, into a jugular or 
cephalic vein v/'a a sterile needle (Microlance, 25 mm long, 0.9 mm or 0.5 mm diameter, 
Becton-Dickenson, Dublin, Ireland).
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2.3 Chemical Materials
All water used in the preparation of standard solutions was distilled in the presence of 
potassium permanganate. 'Analar' or 'Aristar' grade chemicals (BDH Chemicals Ltd. , 
Poole, U. K.) were used in the preparation of all solutions.
Solutions of sodium hydroxide (Koch-Light Ltd. , Haverhill, U. K.), di-sodium hydrogen 
orthophosphate (BDH Chemicals Ltd.) and citric acid (Sigma Chemical Company Ltd. , 
Poole, U. K.) were prepared in water.
Citrate phosphate buffer (pH 3)
Stock citrate phosphate buffer solution (pH 3) was made from 20.5 ml of di-sodium 
hydrogen orthophosphate solution (0.2 M) and 79.5 ml of citric acid (0.1 M). The final pH 
of the solution was adjusted by the addition of sodium hydroxide solution (1 M) or 
orthophosphoric ac id .
Citrate phosphate buffer (pH 5)
Stock citrate phosphate buffer solution (pH 5) was made from 49.3 ml of di-sodium 
hydrogen orthophosphate solution (0.2 M) and 50.7 ml of citric acid (0.1 M). The final pH 
of the solution was adjusted by the addition of sodium hydroxide solution (1 M) or 
orthophosphoric acid.
The pH of the buffer solutions was checked using a digital pH / temperature meter (Fisons 
Scientific Equipment).
Flunixin meglumine and carprofen reference standards were donated by Schering-Plough 
Animal Health and Grampian Pharmaceuticals L td ., respectively.
2.4 Blood sampling techniques and sample preparation
Blood for drug analysis was collected via an intravenous cannula (Vygon Intraflon 2, 80 mm 
long, 2.1 mm diameter, Vet Drug Company pic, Falkirk, U. K.) from a jugular vein. Prior 
to cannulation, wool overlying the jugular furrow was clipped and the area cleaned. Local 
anaesthesia was achieved by the intradermal and subcutaneous injection of 1 ml of lignocaine 
hydrochloride into the area where the cannula was to be inserted. A small skin incision was 
made with a sterile scalpel blade, and the cannula inserted through the skin incision into the 
jugular vein. The cannula was sutured in position, a three-way tap (Vet Drug Company pic) 
attached and the cannula flushed with 3 to 5 ml of heparinized saline (4 units per ml, 0.25 ml 
heparin sodium injection BP (mucous), 1000 units per ml, Evans, Langhurst, U. K. diluted
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in 500 ml sterile saline (Animalcare Ltd.)). Subsequently, the cannula was flushed with the 
same solution as required.
Before blood was collected for analysis, approximately 3 ml of blood was discarded to 
remove any remaining heparinised saline from the cannula. Ten ml blood samples were 
collected into lithium heparin syringes (Li-Heparin LH/10 Monovette®, Sarstedt Ltd. , 
Loughborough, U. K.). Following centrifugation at 1500 g for 10 minutes in a cooled (5- 
15°C) centrifuge (MSE Chilspin, M. S. E. Scientific Instruments, Crawley, U. K.), plasma 
was decanted into 10 ml neutral tubes (Sarstedt Ltd. , Loughborough, U. K.), labelled, and 
stored at -20°C until analysed by high performance liquid chromatography (HPLC) for 
either flunixin or carprofen racemate.
2.5 Preparation of carrageenan (0.0625 %)
A solution of the sodium salt of lambda-rich carrageenan (0.0625 %) (Viscarin, F. M. C. 
Corporation, Springfield, U. S. A.) was prepared by dissolving 0.00625 g of carrageenan 
in 10 ml of 0.9 % saline. The solution was placed in a sonic bath (Sonicleaner, Dawe 
Instruments Ltd. , Coatbridge, U. K.) to aid dissolution of the carrageenan. Aliquots (2 ml) 
of the solution were placed into 5 ml glass tubes, the tubes capped with rubber stoppers and 
a needle (Microlance, 25 mm long, 0.9 mm diameter, Becton-Dickenson) placed through the 
rubber stopper. The tubes were placed in a metal rack and sealed in an autoclave bag 
(Autoclavable Disposal Bag, Guest Medical, Edenbridge, U. K.) prior to autoclaving 
(Sterilin Instruments, Model Number 704-8000-DSE, T. I. S. Services, Alton, U. K.) to 
sterilise the solution. Before removing the tubes from the bag at the end of the autoclave 
cycle, the needles were removed from the rubber stoppers to maintain sterility of the 
carrageenan solution once the bag was opened. The solution was stored for a period of 2 
weeks (but no longer than 3 weeks) prior to the experiments.
2.6. Intradermal injection
The wool, or hair, overlying the site of injection was clipped 24 hours before the 
experiment. Intradermal (ID) injection was made using a sterile needle (Microlance, 10 mm 
long, 0.45 mm diameter, Becton-Dickenson) inserted into the skin parallel to the surface. If 
the needle became dislodged, the site began to bleed, or the solution which was injected was 
seen to ooze from the site, a second injection was made at least 2.5 cm from the first.
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2.7 P rep a ra tio n  of zinc su lphate/sodium  lauryl su lphate  solution (10 %)
A solution of zinc sulphate (10 %) (Golden Hoof, Shep Fair Products, Crickhowell, U. K.) 
was prepared by dissolving 3 kg of compound in 5 1 of warm tap water. The solution was 
placed into a washed sheep footbath and diluted to a final volume of 30 1.
2.8 T o u rn iq u e t
A pneumatic tourniquet was constructed according to the method described by Ibrahim 
(1989). Briefly, a length of rubber tubing, approximately 35 cm, was cut from the inner tube 
of a bicycle tyre, leaving the valve attached. The ends of the tubing were clamped using thin 
metal clamps, to ensure an airtight seal. The inner tube was sewn into a tightly fitting fabric 
sleeve and self-adhesive fabric was stitched in place to hold the tourniquet around the limb. 
A bicycle pump connector was attached to the valve. The distal end of the connector was cut 
off and attached to a three way tap. The inflated tourniquet was tested for leaks by inflating it 
to a pressure >300 mm Hg and submerging it in water.
The tourniquet was applied to the forelimb of the sheep proximal to the carpus and distal to 
the elbow, and was inflated using a sphygmomanometer (Thackray Ltd. , Glasgow, U. K.) 
to a pressure of 300 mm Hg. A photograph of the tourniquet is shown in Fig. 2.1.
2.9 M echanical threshold  testing unit
A device for testing thresholds to noxious mechanical stimulation (Chambers et a l. , 1990) 
was purchased from the Department of Pharmacology, University of Bristol, Bristol, U. K. 
(Fig. 2.2). Briefly, a unit was applied to the leg of the sheep just proximal to the carpus and 
secured by a length of self adhesive fabric which ran through a fulcrum, thus allowing the 
unit to be positioned securely. The leg unit consisted of a pneumatically driven 2 mm 
diameter blunt-ended pin which applied a mechanical noxious stimulus to the leg. The pin 
was attached to a baseplate which acted as a loose piston and which was enclosed fully in a 
small circular box. Above the piston a rubber balloon was positioned and secured to the hub 
section of a 5 ml syringe, which in turn was connected to the 'operate' port on the control 
unit (Fig. 2.3) by a length of polyvinylchloride tubing (internal diameter 3 mm, Portex L td ., 
Hythe, U. K.). The device was driven by compressed oxygen from a size D cylinder (BOC 
Medical Gases, Guildford, U. K.). A reducing valve for oxygen (BOC Medical Gases) was 
attached to the cylinder, and the oxygen passed through a micro-adjustable needle valve. The 
adjustable valve allowed the rate of increase of force applied to the leg to be varied. The rate 
of increase of force was adjusted to achieve a response within 20 to 30 seconds in normal
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Figure 2.1. Photograph of a pneumatic tourniquet (T) and the sphygmomanometer used to 
inflate the tourniquet.
The tourniquet is inflated to a pressure of 300 mm Hg.
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Figure 2.2. Photograph of apparatus for the production of mechanical nociceptive stimuli.
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sheep. A solenoid-operated three way valve diverted the compressed gas either via a 
reservoir and pressure transducer to inflate the balloon, or via an exhaust valve, thus 
removing the stimulus from the leg. The reservoir was connected to a pressure relief valve 
which opened when the pressure within the system rose to 20.7 kPa. A schematic diagram 
of the apparatus for the production of mechanical nociceptive stimuli is shown in figure 2.3.
The pressure transducer was connected to a strain gauge amplifier which was calibrated in 
mm Hg with a mercury manometer (Portable manometer P200, Digitron Instrumentation, 
Hertford, U. K.). Calibration was checked weekly.
2.10 Thermal threshold testing unit
A thermal threshold testing unit, similar to the device described by. Nolan etal. (1987a), was 
constructed (Chemistry Workshop, University of Glasgow). Briefly, the unit comprised of 
an ear clip, a junction box and a control unit (Fig. 2.4). The ear clip was constructed from a 
metal bulldog clip and housed an 8 ohm resistor, as the heating element, covered by a small 
strip of copper to ensure rapid and even heat distribution. A thermocouple, the tip of which 
was located between the copper strip and resistor, was used to detect temperature changes in 
the heating element. The ear clip was attached to the main control unit via a junction box. 
The following modifications were incorporated into the original design for this control unit. 
To improve memory accuracy, a high performance operational amplifier (Bifet™ Op-Amps, 
RS Components, Corby, U. K.) was used to replace the original operational amplifier, 
which removed the need for time consuming off-set nulling techniques. A diode was added 
to the memory board between the input from the manually-operated stop button and the ramp 
reset relay. This facilitated the rapid cooling of the ear clip heating unit when the device was 
in stop mode. A general purpose small signal transistor (NPN, BC108 transistor, RS 
Components) was used to replace the stop mode stabilisation resistor, speeding up data 
acquisition without encountering significant memory creep. Finally, a voltage divider was 
used for the heater ramp control and the over temperature control i. e. the cut-off control, 
allowing a larger range of adjustment with finer control.
The main features of the control unit are shown in Fig. 2.4. The unit was operated by 
pressing a 'run' button, and could be stopped manually . A remote control (ext. control) also 
could be attached to the main control unit and used to switch it on and off. A digital readout 
of temperature was given, and could be used either as a transient read-out of current 
temperature, or in conjunction with a 'peak hold' facility, which recorded the peak 
temperature reached at the resistor in the ear unit at cut-off. A 'reset' button was used in 
conjunction with the peak hold facility, returning the digital temperature readout to a
3 4
Figure 2.4. Photograph of apparatus for the production of thermal nociceptive stimuli. 
C control unit
E ear clip
J  junction box
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preset temperature, which is adjustable from within the unit, and eliminates unnecessary 
inaccuracies in the run time. This feature also was included in the original design. An 
adjustable ramp, and variable cut-off temperature were features of the unit.
Calibration of the thermal unit was achieved using a thermocouple to connect the copper 
tubing encasing the resistor to a multimeter (Multimeter 4055). The unit, which incorporated 
a facility to break the circuit to the ear clip in the event of thermocouple damage, was 
calibrated monthly, or more regularly as required.
2.11 Statistical analysis
All statistical analyses were carried out using Minitab Release 8 (Macintosh® version, 
Clecom, Birmingham, U. K.).
CHAP TER 3
THE ANTINOCICEPTIVE EFFECTS OF NSAIDS IN SHEEP:
1 CLINICAL PAIN
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3.1 Introduction
It is agreed that pain is a subjective phenomenon, and as such it is difficult to provide a 
universally acceptable definition. In 1986, the International Association for the Study of Pain 
defined pain as an unpleasant sensory and emotional experience associated with actual or 
potential tissue damage (Merskey, 1986). Woolf (1989; 1991) divided pain into 2 separate 
and qualitatively different categories, physiological and pathological pain. Physiological pain 
was described as a localised, normal, brief, protective response to a noxious stimulus in a 
normal animal, which resulted in either no, or only localized inflammatory tissue damage. In 
contrast, pathological pain resulted in the following phenomena: pain may be present in the 
absence of a noxious stimulus (persistent pain); responses to noxious stimuli may result in 
an exaggerated response (hyperalgesia); thresholds to noxious stimuli may be lower than in 
normal animals (allodynia); pain may be perceived at a site distant to the original site of 
injury (referred pain) and interactions between the sympathetic and somatosensory systems 
may occur. The development of allodynia and hyperalgesia are the common denominators of 
pathological pain of all origins. The classical example of hyperalgesia frequently quoted in 
review articles (Higgs and Moncada, 1983) is that of sunburned skin. The affected skin may 
not be painful until touched or immersed in warm water, when exaggerated responses occur. 
Indeed, Hardy et al. (1950) demonstrated that the threshold to thermal stimulation in human 
skin was reduced by as much as 50 % after ultra violet irradiation of the skin.
Previously, hyperalgesia had been categorised into primary and secondary hyperalgesia 
(Lewis, 1935; Hardy et al. , 1950). Primary hyperalgesia, is a reduction in the threshold to 
noxious stimulation in the area local to the peripheral site of injury, while secondary 
hyperalgesia is a reduction in the threshold to noxious stimulation in surrounding uninjured 
tissue (Thalhammer and LaMotte, 1982; Raja et al. , 1988). Primary hyperalgesia results in 
an increased sensitivity to both thermal and mechanical stimulation while secondary 
hyperalgesia generally results in increased sensitivity to mechanical stimulation only 
(Campbell et al. , 1979; Raja et al. , 1984), although increased sensitivity to thermal 
stimulation has been recorded (Fitzgerald, 1979). Primary hyperalgesia is assumed to result 
from changes in the sensitivity of nociceptors in the area immediately adjacent to the injury, 
with sensitization of both C- and A-fibre nociceptors having been observed (Raja et al. , 
1988). Secondary hyperalgesia may occur as a result of the antidromic spread of action 
potentials to adjacent peripheral branches of the same nerve with local release of hyperalgesic 
mediators (Lewis, 1935; LaMotte et al. , 1984), or it may involve central mechanisms 
(Hardy e ta l , 1950; Fitzgerald, 1979).
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3.1.1 Peripheral sensitization
Sensitization of peripheral nociceptors adjacent to the site of injury has been recorded (Lynn 
and Carpenter, 1982; Fleischer et al. , 1983), however, this was not a constant feature of all 
units tested and similarly, an increase in spontaneous activity was not observed in every 
case. Fitzgerald (1979) demonstrated that a small skin incision made outside the receptive 
field of an isolated polymodal nociceptor unit with unmyelinated axons, induced the 
development of spontaneous activity and lowered thresholds to thermal stimulation within 
the receptive field of the unit under investigation. This phenomenon is regarded as secondary 
hyperalgesia. Primary hyperalgesia i. e. reduced thresholds to thermal stimulation, also was 
observed on repeated heating within the receptive field of the isolated nociceptor unit. 
Moreover, Fitzgerald (1979) demonstrated that antidromic stimulation of a nerve proximal to 
the site of stimulation also induced the development of sensitization. Although, blockade at 
the site of injury by local anaesthetics prevented the development of secondary hyperalgesia, 
it did not abolish totally the evoked spontaneous activity. Consequently, it was suggested 
that evoked spontaneous activity and the mechanisms by which sensitization occur may be 
different. The peripheral neural mechanisms of primary and secondary hyperalgesia have 
been reviewed (Raja et al. , 1988).
Woolf (1983) demonstrated that pain hypersensitivity following a localized thermal injury in 
decerebrate rats with intact flexor withdrawal reflexes, was shown by alterations in both the 
threshold to stimuli and the responsiveness of the flexion reflex. Electrophysiological studies 
in these rats showed that in ipsilateral flexor efferents, spontaneous activity increased while 
the Von Frey hair threshold fell in both the ipsi and contralateral mechanoreceptive fields. 
The changes evident with electrophysiological studies shadowed the changes observed 
physically, where a bilateral increase in both the response and duration of response to a 
standard pinch (150 g/mm2) was observed. W oolf (1983) commented that nociceptor 
sensitization could account for the ipsilateral changes observed, but that this explanation 
could not account for the hyperalgesia and allodynia seen in association with an expansion of 
receptive fields on the contralateral side. He concluded that pain hypersensitivity following 
thermal injury was related to changes within the central nervous system as well as changes at 
the site of injury, a theory supported by the findings of Coderre and Melzack (1987), who 
demonstrated that spinal anaesthesia, induced immediately following a peripheral thermal 
injury, limited the development of contralateral hyperalgesia.
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3.1.2 Central sensitization
Central sensitization may be regarded as facilitated central responses occurring in response to 
normal afferent input. It has been shown that brief C-fibre input into the spinal cord results 
in heterosynaptic facilitation and a prolonged increase in the excitability of the flexion reflex 
in decerebrate rats, with muscle C-fibre afferents evoking longer lasting changes than 
cutaneous C-fibre afferents (Wall and Woolf, 1984; Woolf and Wall, 1986a). However, 
facilitation was not shown to occur when myelinated A-fibres were activated in a similar 
m anner (Wall and W oolf, 1984). Such changes have been reported following 
experim entally-induced unilateral inflammation in rats (Hylden et al. , 1989). 
Electrophysiological recordings from dorsal hom neurones revealed an increase in receptive 
field, and in ongoing or bursting spontaneous activity, amongst other findings, which 
differed from those recorded in normal rats. Various studies have been conducted in this 
area, most of which draw similar conclusions i. e. increased receptive fields, reduced 
thresholds to mechanical, and or thermal stimulation and an increased responsiveness to 
stimulation. Generally, it can be demonstrated that administration of local anaesthetics after 
injury, or conditioning stimuli, does not alter the progression of sensitization and indicates 
that mechanisms other than those acting peripherally are important i. e. changes in the central 
nervous system are important (Woolf, 1989).
3.1.3 Hyperalgesia and allodynia- chemical mediators
3.1.3.1 Peripheral mechanisms
Both peripheral and central mechanisms contribute to the development and persistence of 
hyperalgesia and allodynia, and in the periphery, sensitization of nociceptors is an important 
component. Endogenous chemical mediators released during tissue damage may cause the 
sensitization of nociceptors, either via a direct, or indirect mechanism. The induction of pain 
by endogenous vasoactive substances including acetylcholine,.5-hydroxytryptamine (5-HT), 
histamine, angiotensin, substance P and bradykinin was demonstrated by Armstrong et al. 
(1952, 1953, 1957) by applying these compounds to blister bases. Noradrenaline, 
adrenaline and isoprenaline were shown to induce mechanical hyperalgesia in the rat paw 
model (Ferreira and Nakamura, 1979b) and subsequently, the role of the sympathetic 
nervous system in the development of inflammatory hyperalgesia was investigated (Levine et 
al. , 1986a; Nakamura and Ferreira, 1987). Although histamine, acetylcholine and 5-HT 
have been demonstrated to cause overt pain and hyperalgesia with associated changes in 
afferent sensitivity (Skouby, 1953; Rosenthal, 1964; Gilfoil and Klavins, 1965; Beck and 
Handwerker, 1974), bradykinin and the prostaglandins have been proposed as the most 
important mediators of pain and hyperalgesia associated with inflammation (Vane, 1983).
4 0
Prostaglandins are released after mechanical or chemical stimulation (Ferreira and Vane, 
1967), and their presence in inflammatory exudates was demonstrated directly by Willis 
(1969), and confirmed in later studies (Greaves et al. , 1971; Velo et al. , 1973). 
Prostaglandins have been shown to induce hyperalgesia under various experimental 
conditions (Horton, 1963; Juhlin and Michaelsson, 1969; Willis, 1969; Karim, 1971; 
Collier and Schneider, 1972; Ferreira, 1972; Ferreira et a l . , 1973; Juan and Lembeck, 1973; 
Moncada e ta l . , 1975; Stazewsba-Barczak e ta l . , 1976; Ferreira ef a l . , 1978a; 1978b).
The study by Ferreira (1972) was pivotal in the development of the popular theory that 
prostaglandins themselves are not mediators of overt pain, but cause hyperalgesia by 
sensitizing nociceptors to the effects of other mediators, resulting in pain. He demonstrated 
that PG Ei, bradykinin and histamine, when infused subdermally into human skin did not 
result in overt pain. However, although the simultaneous, injection of histamine and 
bradykinin did not alter the observed response, when PGEi was injected with either 
compound alone, or both compounds together, a painful response was observed. A similar 
effect has been demonstrated with these mediators using a reflex increase in blood pressure 
as an indicator of pain after bradykinin was injected into the splenic artery (Ferreira et al. , 
1973), the knee joint (Moncada et al. , 1975) or infused over the epicardium (Staszewsba- 
Barczak et al. , 1976). Further studies confirmed these findings (Collier and Schneider, 
1972; Juan and Lembeck, 1973; Ferreira et a l . , 1978b). It should be noted that Collier et al. 
(1977) reported the development of pain after administration of PGE2 , IV, in humans. 
Gilfoil and Klavins (1965) had noted previously that hyperalgesia did not develop 
immediately after injection of bradykinin, 5-HT or histamine, either on their own or in 
combination, in the rat paw, and had suggested that in fact these agents were exerting their 
effects via an indirect mechanism. Using different models, Guzman et al. (1962), Ferreira et 
al. (1973) and Moncada et al. (1975) all had observed similar delays between administration 
of these agents and their subsequent effect. It was not until 1976, that Lembeck and 
colleagues confirmed this hypothesis when they demonstrated that prostaglandins, primarily 
of the PGE group, were released after the infusion of bradykinin in an isolated perfused 
rabbit ear, and concluded that bradykinin augmented its algesic actions by stimulation of 
prostaglandin production.
Bradykinin receptors coupled to a G protein, activate phospholipase A2 (PLA2) to release 
arachidonate, and may be one of the mechanisms by which release of PGE2 occurs (Burch 
and Axelrod, 1987). Studies in which PLA2 paralleled the effects of bradykinin, and a 
specific PLA2 antagonist, mepacrine, inhibited bradykinin-evoked hyperalgesia completely, 
(Taiwo et a l . , 1990) supported the findings of Burch and Axelrod (1987) by demonstrating 
that bradykinin-evoked hyperalgesia resulted from activation of PLA2 , while the 
hyperalgesia seen with noradrenaline was mediated via PLC. However, bradykinin receptors
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have been localized in thin unmyelinated nerve fibres, superficial layers of the dorsal horn of 
the spinal cord and small neuronal cells in sensory ganglia in guinea pigs (Steranka et al. , 
1988), indicating that bradykinin may also exert a direct hyperalgesic effect via these 
receptors.
It is interesting to note that while arachidonic acid injected intradermally evoked a 
hyperalgesic response (Gonzales et al. , 1989), the injection of linoleic acid, also a 
desaturated fatty acid, did not. This suggests that the arachidonic acid exerted its effect 
indirectly, most probably by conversion to prostaglandins, and that the hyperalgesia 
observed is not a non-specific effect of desaturated fatty acids. Although, PGEi, PGE2 and 
PGI2 all induce peripheral hyperalgesia (Ferreira, 1972; Rosenthale et a l . , 1972; Ferreira et 
a l . , 1978a), PGI2 is a more potent hyperalgesic than PGE2 after subplantar injection in the 
rat paw, although of shorter duration (Ferreira et al. , 1978b; Higgs et al. , 1978). la th e  
latter study, PGI2 was 5 times more potent than PGE2 at evoking hyperalgesia while the 
stable metabolite of PGI2 , 6-keto-PG Fia, was not shown to be hyperalgesic. In contrast, 
Taiwo and Levine (1990) concluded that PGD2 and PGF2a  did not evoke hyperalgesia in 
the periphery, although subsequently, PGD2 has been shown to potentiate bradykinin- 
evoked hyperalgesia in guinea pigs pre-treated with a NSAID (Whelan et a l . , 1991). In one 
study PGF2a  reduced the algesic action of bradykinin by antagonising the hyperalgesic
actions of PGE2 (Juan and Lembeck, 1977).
Prostaglandin-induced hyperalgesia may result from a direct action on nociceptors, but 
currently little evidence is available (Chahl and Iggo, 1977; Patermichelakis and Rood, 1982; 
Baccaglini and Hogan, 1983; Taiwo et al. , 1987). Prostaglandin E2 and PGI2 have been 
demonstrated in sympathetic postganglionic neurons (Gonzales et al. , 1989), and 
bradykinin, noradrenaline and leukotrienes (vide infra) have been shown to act indirectly to 
evoke hyperalgesia by stimulating the release of prostanoids from both neural and non- 
neural cells (Juan and Lembeck, 1974; Lembeck et a l . , 1976; Hojvat et a l . , 1983; Levine et 
al. , 1986a; 1986b). Interestingly, it has been suggested that bradykinin and noradrenaline 
induce hyperalgesia via different prostaglandins i. e . bradykinin via PGE2 and noradrenaline 
via PGI2 (Taiwo and Levine, 1988b). Taiwo et al. (1987), in a study designed to 
characterise the onset latencies of 5 different hyperalgesic agents, including PGE2 , 
suggested that the rapid onset of action observed for PGE2 supported the theory that at least 
this prostanoid acts via a direct mechanism of action. In a later study, it was proposed that 
both PGE2 and PGI2 caused hyperalgesia independently o f cyclooxygenase activity, 
peripheral adrenergic transmitters and PMNLs (Taiwo and Levine, 1989), providing further 
support for the theory that prostaglandins exert their effects directly.
The mechanisms by which the prostaglandins induce a cellular response is unclear. Ferreira 
and Nakamura (1979b) demonstrated that intraplantar injection of PGE2, PGI2 , a stable 
analogue of cAMP (di-butryl cyclic adenosine monophosphate (di-butryl cAMP)), a calcium 
ionophore and various catecholamines which stimulate adenylate cyclase, caused a dose 
dependent hyperalgesia in rats pre-treated with a NSAID. Moreover, inhibition of 
phosphodiesterase by administration of methylxanthines, which would lead to a rise in 
intracellular cAMP, potentiated the evoked hyperalgesia. If hyperalgesic mediators such as 
the prostaglandins, induce changes in second messenger systems of afferent nerve terminals 
(Ferreira and Nakamura, 1979b), the sensitivity of the primary afferent may be altered by 
phosphorylation of membrane bound receptors (Rang and Ritchie, 1988). Repeated 
subplantar injection of several hyperalgesic agents, including PGE2, at daily intervals for a 
period of 14 days resulted in the development of a persistent hyperalgesic state, for 
approximately 1 month (Ferreira et al. , 1990). A persistent hyperalgesia was not recorded 
after chronic administration of di-butryl cAMP, but instead resulted in the standard acute 
hyperalgesic response previously demonstrated after each administration (Ferreira and 
Nakamura, 1979b). Cycloheximide, an inhibitor of protein synthesis, attenuated the 
development of the persistent hyperalgesic response and it was suggested that the formation 
of a regulatory protein, controlling adenylate cyclase activation may be involved in the 
development of persistent hyperalgesic states. Consequently, it was proposed that 
prostaglandin-evoked hyperalgesia was a cAMP / calcium dependent process (Ferreira et al.
, 1990).
The role of the leukotrienes, metabolites of the 5-lipoxygenase pathway of arachidonic acid 
metabolism (see chapter 1), in the induction of hyperalgesia is controversial. Originally it 
was thought that they did not to contribute to the hyperalgesia of inflammatory pain 
(Ferreira, 1981), although subsequently, this was shown not to be the case (Levine et al. , 
1984; Bisgaard and Kristensen, 1985; Levine et al. , 1985a; Levine et al. , 1986b). 
Rackman and Ford-Hutchison (1983) demonstrated initially that LTD4 evoked little 
hyperalgesic activity alone, but, as expected, PGE2 augmented the effect. Subsequently, 
Levine et al. (1984; 1985a) showed that LTB4 caused a polymorphonuclear leucocyte- 
(PMNL) dependent hyperalgesia which was not diminished by pre-treatment with a NSAID. 
Moreover, they demonstrated that PMNLs released a small molecular weight lipid factor 
when incubated with LTB4, which itself evoked a maximal hyperalgesia in PMNL depleted 
rats. Using high performance liquid chromatography, this product demonstrated a similar 
retention time to a product of 15-lipoxygenation of arachidonic acid, [8R, 15S]- 
dihydroxyeicosa-(5E-9, 11, 13Z)-tetraenoic acid ([8R, 15S]-diHETE). In a later study, 
Levine et al. (1986b) showed [8R, 15S]-diHETE was hyperalgesic in rats, while the (8S) 
stereoisomer of the compound, [8S, 15S]-diHETE, not only antagonised the effects of [8R,
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15S]-diHETE, but also caused a dose dependent hypoalgesia. In contrast, [8S, 15S]- 
diHETE did not affect PGE2-induced hyperalgesia.
It has been suggested that (8R, 15S)-diHETE may evoke hyperalgesia via a direct, 
cyclooxygenase independent mechanism (Levine e ta l . , 1986b), and it was shown to have a 
similar onset latency to PGE2 (Taiwo et al. , 1987). Bradykinin and noradrenaline-evoked 
hyperalgesia have similar onset latencies (Taiwo et al. , 1987), although both are 
cyclooxygenase dependent (Lembeck et al. , 1976) and rely on intact sympathetic 
innervation (Levine e ta l . , 1986a).
Cytokines, inflammatory proteins, have been demonstrated to induce hyperalgesia (Ferreira 
e ta l . , 1988; Cunha e f tf /., 1991; Cunhae ta l . , 1992). Interleukin-1 releases prostaglandins 
(Bemheim et al. , 1980) which cause a hyperalgesic response (vide supra), and Ferreira et 
al. (1988) demonstrated that IL-lp administered systemically in rats was a potent mechanical 
hyperalgesic itself, approximately 3000 times more potent than IL - la . Moreover, they 
demonstrated that local pre-treatment with a NSAID attenuated the IL -lp  response, 
indicating that the hyperalgesic effect may result from the release of prostaglandins. 
Interleukin-8 also has been demonstrated to cause the development of hyperalgesia in rats 
after intraplantar injection (Cunha et al. , 1991). However, neither NSAIDs, nor a specific 
tripeptide analogue of IL-lp which antagonised the hyperalgesic effects of IL-lp (Ferreira et 
al. , 1988), attenuated IL-8-evoked hyperalgesia. Cunha et al. (1991) concluded that IL-8- 
induced hyperalgesia was independent of both prostaglandin and IL -ip production and that 
hyperalgesia involved the sympathetic nervous system because the hyperalgesic effect of IL- 
8 was attenuated by propranolol and atenolol (p-adrenoreceptor antagonists), a dopamine 
receptor antagonist and guanethidine, a sympathetic neurone-blocking agent. Cunha et al. 
(1992) demonstrated that tumour necrosis factor a  (TNFa) and IL-6 caused a mechanical 
hyperalgesia in rats and they established an order of potency for the known hyperalgesic 
cytokines: IL -ip > T N F a» IL -8» I L - 6. Interleukin-6 was shown to evoke hyperalgesia via 
a common pathway with IL -lp  and prostaglandin production, and indeed IL-6 may induce 
production of IL-lp. Although IL-6-induced production of IL -lp  has not been demonstrated 
to date, interleukins are known to induce their own production and production of other 
cytokines (Dinarello et a l . , 1986; Dinarello et a l . , 1987; Van Damme et a l . , 1987; Streiter 
et al. , 1989). In contrast, TN Fa was found to evoke hyperalgesia via both the IL-lp/IL- 
6/prostaglandin and IL-8/sympathetic mediated hyperalgesic pathways (Cunha et a l . , 1992).
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3.1.3.2 Central mechanisms
The question still remains of how sensitization of the central nervous system occurs, and it 
has been addressed recently by W oolf (1989; 1991). Several neuropeptides including 
substance P (Lembeck et al. , 1977), met- and leu-enkephalin (Huges et al. , 1975), 
somatostatin (Hokfelt et al. , 1976), cholecystokinin (Larsson and Rehfeld, 1979) calcitonin 
gene related peptide (Kuraishi et al. , 1988) and vasoactive intestinal polypeptide (Hokfelt et 
al. , 1983) have been demonstrated in primary sensory neurons both peripherally and 
centrally, and a role for these agents as neurotransmitters or neuromodulators has been 
suggested (Hokfelt e ta l. , 1983). Urban and Randic (1984) showed that substance P and the 
endogenous neurotransmitter for dorsal-root-elicited slow depolarization, act in the same 
manner and subsequently it was demonstrated that such slow potentials could summate, 
producing depolarization (Thompson et al. , 1990). However, these findings in themselves 
would not explain prolonged hypersensitivity states which can occur following injury. It is 
possible that cellular changes including alterations in second messenger systems (cAMP, 
calcium etc.), phosphorylation of membrane receptors or ion channels or alterations in gene 
expression (Hunt et al. , 1987), occur as a result either of depolarization, or by the action of 
neurotransmitters. More recently, Woolf and Thompson (1991) examined the effects of a 
competitive N-methyl-D-aspartate (NMDA) excitatory amino acid receptor antagonist, 3((R)- 
2-carboxypiperazin-4-yl)-propyl-l-phosphonic acid (D-CPP), and a non-competitive 
antagonist, MK-801, on the establishment of both windup, a phenomenon whereby 
progressive increase in action potential discharge occurs after repeated stimulation (Mendell, 
1984), and central sensitization. They showed not only a reduction in the facilitation of the 
flexor reflex in the rat by administration of the antagonists, but also demonstrated that the 
antagonists were capable of abolishing the hypersensitive state once it had become 
established. These findings were confirmed by Ren et al. in 1992, while Malmberg and 
Yaksh in the same year (1992a) used NMDA intrathecally to induce hyperalgesia in rats, and 
reported that pre-treatment with a selective antagonist (MK-801) abolished the response. 
However, administration of the antagonist after the application of NMDA did not modify the 
hyperalgesic response observed in the latter study.
The prostaglandins have been shown to induce hyperalgesia when administered direcdy onto 
the spinal cord. To date, the administration of PGD2 and PGE2 intrathecally in mice has 
resulted in the development of hyperalgesia while injection of PGF2a  did not (Uda et al. ,
1990). How centrally administered prostaglandins evoke peripheral hyperalgesia remains 
unclear, although recent work showed that hyperalgesia induced by intrathecal 
administration of excitatory amino acids, and substance P, was reversed by the 
administration of NSAIDs, suggesting that the prostanoids may play a role in noxious
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information processing at the level of the spinal cord (Malmberg and Yaksh, 1992a). It is 
interesting to note that NMDA receptors can activate the arachidonic acid cascade in primary 
culture of striatal neurons resulting in the release of arachidonic acid and 11- and 12- 
hydroxyeicosatetraenoic acid via a calcium dependent PLA2 (Dumuis et al. , 1992).
3.1.4 Hyperalgesia and clinical pain
There have been many experimental studies investigating the mechanisms and effects of 
primary and secondary hyperalgesia, and extensive clinical studies in humans based on 
patient or observer report of the effect of various analgesic regimes on peri-operative pain. 
However, there are very few studies which have investigated the effect of clinical surgery on 
sensory thresholds to noxious stimulation in humans (Ekblom and Hansson, 1987; Hansson 
et al. , 1988; Lund et al. , 1990; Dahl et al. , 1992). Ekblom and Hansson (1987) 
demonstrated that thresholds to noxious thermal stimulation in humans were not altered in 
the presence of clinical pain (of up to 4 days duration), and a study in the following year 
confirmed these findings (Hansson et al. , 1988). Other workers demonstrated an increase in 
the perception threshold to electrical stimulation in patients after abdominal hysterectomy 
(Lund e ta l . , 1990), in contrast to experimental studies (Woolf, 1983). Lund and colleagues 
(1990) suggested that the analgesia detected post-operatively may have occurred via 
activation of descending inhibitory pathways within the central nervous system. In contrast, 
in patients undergoing gynaecological laparotomy, thresholds to electrical stimulation 
decreased while pain to suprathreshold stimulation increased post-operatively (Dahl et al. , 
1992). In the latter study, fentanyl, a short acting ji-opioid agonist was administered at 
induction of anaesthesia and patients requiring post-operative analgesia were given morphine 
and paracetamol. Post-operative assessments were made at least 12 hours after last 
administration of analgesic. It is interesting that post-operative hyperalgesia was detected 
after administration of post-operative analgesics. There have been no similar studies carried 
out in the domestic species, but Ley et al. (1989) recently demonstrated that thresholds to 
noxious mechanical stimulation in sheep suffering from the chronically painful condition of 
footrot, were significantly lower than those recorded in normal sheep. Even after treatment, 
and clinical resolution of the condition, thresholds were still reduced. Thresholds to noxious 
thermal stimulation were not shown to be reduced in these sheep.
3.1.5 Analgesic testing of NSAIDs
A review of the commonly used laboratory methods for investigation of the analgesic and 
antinociceptive activity of the NSAIDs is given in chapters 1 and 4, and it is clear that in 
order to measure antinociceptive activity of these drugs an inflammatory stimulus must be 
present.
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Although the mode of action of the NSAIDs (reviewed in chapter 1) is well documented, this 
alone does not appear to account for their clinical efficacy as analgesics in the control of 
acute pain (Vernimb and Hennessey, 1977; Milne and Twomey, 1980; Reid and Nolan,
1991). It was considered that either an additional mode, or modes, of action may be 
important. This was supported by the knowledge that carprofen, a NSAID, has been 
demonstrated to be a poor inhibitor of cyclooxyengase in vitro and yet exhibits potent 
antinociceptive actions in vivo (Strub et al. , 1982; Baruth et al. , 1985). It was also 
considered that the prostaglandins may be equally important centrally to the development of 
hyperalgesia, as they were peripherally.
The aim of the work in this chapter was to quantify the action of 2 NSAIDs, flunixin 
meglumine and carprofen, on thermally and mechanically-induced nociceptive responses in 
sheep, and to evaluate the mechanisms by which these drugs exerted their analgesic effects. 
This was approached in 3 ways. Firstly, the analgesic effects of flunixin meglumine and 
carprofen were evaluated in normal sheep using thermally and mechanically-induced 
physiological pain. Secondly, in 1989, Ley and colleagues had demonstrated that exposure 
to chronic pain from footrot (see chapter 1), reduced significantly the thresholds to noxious 
mechanical stimulation in affected sheep. The analgesic and antinociceptive activity of 
NSAIDs is generally difficult to detect in normal animals (see chapter 1 and 4) and the 
antinociceptive, or analgesic, activity of these drugs generally is evaluated after induction of 
an inflammatory focus which causes lowered thresholds to noxious stimuli. Commonly, 
NSAIDs return thresholds towards normal, which is accepted as a demonstration of the 
antinociceptive or analgesic efficacy of the drug. Consequently, it was hypothesized that 
administration of a NSAID, would return thresholds to noxious mechanical stimulation 
towards normal in sheep suffering footrot, indicating an antinociceptive effect of the drug, 
and allowing quantification of drug response. Finally, the mechanical and thermal thresholds 
to noxious stimulation were investigated in a group of sheep undergoing abdominal surgery. 
It was hypothesized that an acute inflammatory response would cause hyperalgesia 
detectable by either or both, mechanical or thermal nociceptive testing. Subsequently, the 
effects of flunixin meglumine and carprofen on the observed responses were investigated.
In addition, in the latter study, buprenorphine, a partial opioid agonist, was used as a drug 
with known analgesic activity in sheep (Nolan et al. , 1987c), and ketamine was 
administered to sheep prior to surgery, in order to 'test' the theories developed in 
experimental models of pain, that an NMDA receptor antagonist could prevent the 
development of hyperalgesia induced by an acute inflammatory stimulus.
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3.2 Materials and Methods
3.2.1 Animals
A total of 90 sheep were used in this series of experiments. Husbandry conditions are 
outlined in section 2.1. Sheep were weighed, either the day prior to the experiment, or 
immediately before the experiment. Sheep undergoing surgery or general anaesthesia 
were fasted for 12 hours (see section 2.1).
Drugs
Five drugs were used during the course of these experiments; flunixin meglumine, 
carprofen, xylazine hydrochloride, ketamine hydrochloride and buprenorphine 
hydrochloride. The drugs were administered as described (see section 2.2).
3.2.2 Threshold testing apparatus
The apparatus used for testing thresholds to noxious mechanical and thermal stimulation 
is described in chapter 2 (section 2.9 and 2.10 respectively).
3.2.2.1 Mechanical nociceptive testing
Sheep were placed in a pen constructed from metal gates (approximately 100 cm wide, 
200 cm long and 130 cm high). The leg unit was secured onto the forelimb, above the 
level of the carpus, and the control unit was placed on a table approximately 1.5 metres 
away from the sheep. When mechanical nociceptive testing was carried out on lame 
sheep, the leg unit was placed on the most severely affected forelimb. The sheep were 
allowed to settle in this environment for 30 to 60 minutes before beginning each 
experiment. The pressure stimulus was applied by activating the solenoid by squeezing 
the foot switch. During this time, the dial on the calibrated strain gauge amplifier indicated 
the rising force which was being applied to the leg of the sheep. When the sheep 
attempted to withdraw the limb from the stimulus by raising the limb from the ground, the 
control unit was switched off by releasing the pressure on the foot switch, and the 
reading on the dial recorded. At least 3 control, or baseline, readings were taken from 
each experimental sheep over a period of approximately 30 minutes, while 6 control, or 
baseline, readings were taken from each 'naive' sheep /. e. sheep which had no previous 
contact with the mechanical nociceptive testing equipment, over a period of approximately 
30 minutes. Only the last 3 readings were used in the 'naive' sheep to calculate the control 
values for each experiment. Drugs were administered IV as a bolus, and the threshold to 
noxious mechanical stimulation was recorded thereafter. A maximum allowed force of 16
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N was used in this series of experiments. At least 2 weeks were allowed to elapse 
between experiments on individual animals.
When mechanical nociceptive testing was carried out on sheep recovering from 
anaesthesia, the leg unit was not placed on the limb until the sheep could stand unaided.
3.2.2.2 Thermal nociceptive testing
Sheep were placed in a pen constructed from metal gates (approximately 100 cm wide, 
200 cm long and 130 cm high). The sheep were allowed to settle in this environment for 
30 to 60 minutes prior to the onset of the experiment. The ear clip of the thermal threshold 
testing apparatus was attached to the untagged ear and the junction box was held 
approximately 1.5 to 2 metres away from the sheep. An ear twitch, head shake or a slow 
blink of the ipsilateral eye were used to indicate a response to the application of the 
noxious thermal stimulus. When this occurred, a remote hand held cut-off switch was 
activated and the response temperature noted. Three or more control readings were taken 
from each sheep over a period of at least 30 minutes. Drugs were administered IV as a 
bolus, and the threshold to noxious thermal stimulation was recorded thereafter. The ear 
clip was removed from the ear between readings and no attempt was made to replace the 
clip in exactly the same position as previously. A ramp rate was selected such that 
automatic cut-off at 65°C was achieved in approximately 45 seconds. The ear was 
checked at intervals throughout the experiment for evidence of hyperaemia or thermal 
burn damage. If at any stage thermal burn damage became evident, the sheep was 
removed from the experiment and was not used in any further experiments until at least 1 
week after the burn had completely healed. At least 2 weeks were allowed to elapse 
between experiments on individual animals.
When thermal nociceptive testing was carried out on sheep recovering from anaesthesia, 
the ear clip was not placed on the pinna until the sheep was in sternal recumbency.
3.2.3 Clinical assessment of sheep with footrot
Sheep suffering from footrot were assessed for lameness by an experienced observer, 
and were awarded a score on a numerical rating scale (NRS). The NRS consisted of 5 
divisions represented by the numbers 0 to 4. The following description of each division 
was used as a guideline when scoring lameness: 0 = clinically sound; 1 = barely 
detectable lameness; 2 = obvious lameness; 3 = severe head nod ± resting affected foot 
when standing; 4 = carrying foot at trot. Lameness was assessed before noxious 
mechanical threshold testing.
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Foot lesions were assessed visually before noxious mechanical threshold evaluation. 
Each foot was awarded a score on a scale of 0 to 4. The following descriptions were used 
in conjunction with the numerical value: 0 = no lesion or healed inactive lesion; 1 = mild 
interdigital dermatitis; 2 = extensive interdigital dermatitis; 3 = severe interdigital 
dermatitis and under-running of the horn of the heel and sole of the foot; 4 = severe 
interdigital dermatitis and under-running of the horn of the heel, sole and under-running 
of the walls of the hoof.
Each sheep suffering from footrot was awarded a total numerical score by adding the 
NRS score for lameness and the total of the scores awarded to each individual foot.
After noxious threshold evaluation, the sheep was turned onto its rump and the feet pared 
of overgrown or dead hom. Areas of infection were exposed and every attempt was made 
to avoid bleeding from the infected areas. All sheep with at least 1 foot given a score of 4, 
were given long acting penicillin intramuscularly (IM). Subsequently, sheep were herded 
into a foot bath containing a 10 % solution of zinc sulphate, and allowed to stand in this 
solution for at least 30 minutes. After this time, the sheep were moved into a concrete 
holding area and allowed to stand for at least 1 hour before being returned to the field or 
pen. Treatment was repeated at weekly intervals until the footrot lesions had healed.
3.2.4 Anaesthesia and surgery
3.2.4.1 Anaesthesia
Induction of general anaesthesia was achieved with either thiopentone sodium, 5 %, IV, 
or ketamine hydrochloride, 10 mg/kg, IV, given as a bolus. A bolus dose of thiopentone, 
800 mg, was injected initially and incremental doses of the drug administered to permit 
endotracheal intubation. Where intubation failed after the administration of ketamine, 
anaesthesia was deepened by the administration of 4 % halothane in a 67 % nitrous oxide 
and 33 % oxygen mixture delivered via a circle system and a Hall's face mask.
Anaesthesia was maintained by the administration of 1.5 % halothane in a 33 % nitrous 
oxide and 67 % oxygen mixture delivered via a circle system with carbon dioxide 
absorption, and a minimum fresh gas flow rate of 3 litres per minute. Immediately after 
induction of anaesthesia, long acting penicillin, 2 ml, was administered IM to each sheep.
3.2.4.2 Surgery
The sheep were placed in dorsal recumbency and the caudal ventral abdominal region was 
clipped and cleansed in preparation for surgery. A ventral midline incision (approximately
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10 cm) was made caudal to the umbilicus and the uterus was located and elevated to the 
wound. Embryo retrieval was accomplished by flushing the left, and subsequently the 
right ovarian duct. The abdominal wound was repaired using a simple continuous suture 
technique (catgut) in the musculature, and the skin edges were opposed by placement of 
surgical clips. The end of anaesthesia was regarded as the time that both halothane and 
nitrous oxide were removed from the inspired mixture. The surgical clips were removed 
10 days post-operatively.
3.2.5 Study design
3.2.5.1 Study 1
A total of 8 experimental sheep were used in these investigations (numbers 1-8).
Five sheep (sheep numbers 1-5) were used to assess any behavioural effects of 
positioning the leg unit of the mechanical threshold testing apparatus, or the ear clip of the 
thermal threshold testing apparatus over a 10 minute period.
The repeatability of both the thermal and mechanical threshold testing apparatus in normal 
sheep was tested over a period of 6 hours using 8 experimental sheep. Recordings were 
made at hourly intervals.
Xylazine, 50 M-g/kg, IV, was administered to 5 of the.se sheep and mechanical and thermal 
testing carried out over a period of up to 75 minutes.
Flunixin, 1.0 and 2.0 mg/kg, IV, carprofen, 0.7 and 4.0 mg/kg, IV, and physiological 
saline, 5 ml, were administered to 8 sheep in a cross-over design to assess the changes in 
thresholds to noxious mechanical and thermal stimulation in normal sheep over a 6 hour 
period. Recordings were made at half hourly intervals after drug or saline administration.
The person assessing the thresholds to noxious mechanical and thermal stimulation in this 
study was aware of which treatment group sheep had been allocated to.
3.2.5.2 Study 2
A total of 47 sheep were used in these investigations (numbers 1-47).
Thresholds to noxious mechanical stimulation were assessed over a 30 minute period in a 
group of 25 normal sheep (numbers 1-25) selected at random from a farm flock. Foot 
trimming was carried out on 10 of these sheep (numbers 16-25), and on the following 2 
days thresholds to noxious mechanical stimulation were recorded again for these animals.
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Thresholds to noxious mechanical stimulation were assessed over a 30 minute period in a 
group of 22 sheep (numbers 26-47) suffering from various degrees of footrot. These 
sheep were selected from the same flock as the 25 normal sheep, and were divided at 
random into 3 groups. Foot trimming was carried out on 8 of the sheep (numbers 26-33) 
and on the following 2 days thresholds to noxious mechanical stimulation were recorded 
again for these animals.
The remaining 2 groups of 7 sheep were administered flunixin meglumine, 1.0 (numbers 
34-40) or 2.0 mg/kg (numbers 41-47) ,IV. Thresholds to noxious mechanical stimulation 
then were assessed in these sheep over a 30 minute period after drug administration. 
Thresholds to noxious mechanical stimulation were assessed in those sheep which 
received flunixin 1.0 mg/kg (numbers 34-40) again on the following 4 days. After 
assessment on day 2 and day 3, these sheep were injected with a repeat dose of the drug.
3.2.5.3 Study 3
Thresholds to noxious mechanical and thermal stimulation were assessed over a 30 
minute period in a group of 35 sheep (numbers 1-35).
Computer generated random numbers were used to allocate 25 of these sheep, which 
were to undergo surgery, to 1 of 4 treatment groups. Group 1 (sheep numbers 7-12), 2 
(sheep numbers 13-18) and 3 (sheep numbers 1-6) were administered the following 
drugs intra-operatively, IV: flunixin (1.0 mg/kg), carprofen (4.0 mg/kg) and 
buprenorphine (10 (ig/kg), respectively. Group 4 received no treatment (sheep numbers 
19-25). In the recovery period, thresholds to noxious mechanical and thermal stimulation 
again were assessed approximately every 30 minutes for a 2 hour period. Treatments 
administered in this group were done so 'blind' /. e. the person assessing the thresholds 
to noxious mechanical and thermal stimulation was unaware to which treatment group 
sheep had been allocated. Drugs were administered IV immediately after embryo retrieval 
was completed.
A further 4 sheep (numbers 26-29) were anaesthetised but did not undergo any surgical 
procedure or receive further treatment. In the recovery period, thresholds to noxious 
mechanical and thermal stimulation were assessed in these sheep over a 2 hour period.
Anaesthesia was induced by the injection of ketamine, 10 mg/kg, IV, in 6 sheep 
(numbers 30-35) which were to undergo surgery. In the recovery period, thresholds to 
noxious mechanical and thermal stimulation were assessed over a 2 hour period.
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The time to sternal recumbency and to standing from the end of general anaesthesia were 
recorded for all sheep.
3.2.6 S ta tis tica l analyses
3.2.6.1 S tudy  1
Initially, distributions for thresholds were investigated for normality, using normal 
probability plots and correlation analysis. Analysis of variance was used to test for 
differences in thresholds to noxious mechanical and thermal stimulation over a 6 hour 
period in a group of normal experimental sheep.
A Kruskal-Wallis test, for non-parametric data, was used to test for differences over time 
after the administration of xylazine. Further analysis was carried out using a Wilcoxon 
signed rank test for non-parametric data.
Initially, distributions for thresholds were investigated for normality, using normal 
probability plots and correlation analysis. To test for differences in thresholds to noxious 
mechanical and thermal stimulation over a 6 hour period in a group of normal sheep 
administered test drugs or saline, a general linear model routine was used. A 3 factor 
nested analysis of variance provided statistical tests for drug treatment, animal and time 
factors and their two-way interactions.
Statistical tests were carried out using a 5% significance level.
3 .2 .6.2 S tudy  2
Initially, distributions for thresholds in all groups and subgroups of sheep were 
investigated for normality, using normal probability plots and correlation analysis. All 
groups and subgroups of sheep were normally distributed except for the group of 25 
normal farm sheep.
Statistical comparisons between groups, and within groups which were normally 
distributed, were made using either an unpaired t test or a paired Student's r test, 
respectively. Comparisons between groups and within groups which were not normally 
distributed, were made using either a Mann-Whitney U test or a Wilcoxon signed rank 
test, respectively. If maximal mechanical threshold was attained by any sheep, 
comparisons for that group were made using tests appropriate for non-parametric data.
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A oneway analysis of variance was used to test for differences between groups for total 
lameness scores, and for differences over time after drug administration. Further analysis 
was carried out using a paired Student's t test.
Statistical tests were carried out using a 5% significance level.
3.2.6.3 Study 3
Initially, oneway analysis of variance was used to assess differences between treatment 
groups for thresholds obtained pre-operatively and also at 120 minutes post-operatively. 
Subsequently, in view of the unbalanced study design, with differing numbers of sheep 
in each group and missing data, statistical analysis was undertaken using a general linear 
model routine. The experimental design was suitable for analysis using a 3 factor analysis 
of variance, previously described (see 3.2.6.1). Further analysis was carried out using a 
Wilcoxon signed rank test.
Statistical tests were carried out using a 5% significance level.
3.3 Results
3.3.1 Study 1
The sheep did not resent the presence of the leg unit of the mechanical threshold testing 
apparatus, and continued to ruminate or eat during the period of application. A similar 
finding occurred when the ear clip of the thermal threshold testing apparatus was attached 
to the sheep. However, 1 sheep immediately dislodged the ear clip by shaking its head. 
When the clip was repositioned, the sheep did not attempt to dislodge the clip again.
Mechanical nociceptive testing
The individual, mean ±SEM for thresholds to noxious mechanical stimulation in a group 
of normal sheep over a 6 hour time period are shown in Table 3.1. The individual values 
have a range from 1.9 N to 6.8 N, with a range of mean values from 2.5 to 3.3 N (Fig. 
3.1). There were no significant changes in the thresholds to noxious mechanical 
stimulation over the 6 hour recording period.
The administration of xylazine caused an elevation of the threshold to noxious mechanical 
stimulation in all sheep (Table 3.2). Sheep numbers 3 and 5 reached maximum force level 
(16 N) by 15 minutes, and sheep number 1 by 30 minutes, after the administration of the 
drug. The remaining 2 sheep (numbers 2 and 4) achieved maximum threshold levels of
15.8 N and 12.5 N respectively, at the 15 minute reading. The time course of drug effect
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N o . N o . N o . N o . N o . N o . N o . N o . Mean ±SEM
1 2 3 4 5 6 7 8
Time (hr) Thermal thresholds
0 55.0 56.2 52.0 57.8 55.7 53.2 52.2 53.9 54.5 0.72
0 .5 53.4 55.6 54.2 57.3 53.5 52.9 53.1 54.7 54.3 0.53
1 54.3 55.8 55.5 54.5 55.5 50.7 51.7 53.7 54.0 0.66
2 54.5 53.7 55.9 56.5 57.0 51.7 52.1 50.5 54.0 0.85
3 56.3 54.9 50.0 52.7 56.5 51.7 54.1 52.9 53.6 0.80
4 54.1 54.1 52.4 56.2 57.4 50.7 52.3 54.8 54.0 0.77
5 55.4 55.4 54.1 55.5 56.4 55.2 52.7 53.7 54.8 0.42
6 54.6 54.9 54.9 56.4 55.7 52.8 50.8 53.4 54.2 0.63
Mechanical thresholds *
0 2.5 3.2 2.9 2.5 2.5 6.8 2.5 2.9 3.2 0.52
0 .5 2.5 2.2 3.2 2.9 1.9 4.5 2.2 2.5 2.6 0.19
1 2.9 2.5 2.9 2.5 2.2 6.5 2.9 3.2 3.2 0.48
2 2.2 2.5 3.2 2.2 3.2 4.5 2.9 2.9 3.0 0.26
3 2.5 2.5 3.9 2.5 2.2 5.8 3.2 2.5 3.1 0.43
4 2.9 3.2 3.9 2.5 2.2 5.8 3.2 2.9 3.3 0.40
5 2.5 2.2 3.2 2.9 2.2 3.2 3.2 2.9 2.8 0.15
6 2.9 2.5 3.5 2.9 3.2 3.9 3.5 2.9 3.2 0.16
Table 3.1. Individual, mean and standard error of the mean (SEM), for thresholds to 
noxious mechanical (Newtons) and thermal (°C) stimulation in a group of 8 normal sheep 
over a period of 6 hours (hr).
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Figure 3.1. Control mechanical threshold responses in sheep recorded over a 6 hour 
(hr) time course.
The response threshold (Newtons) is plotted against time (hr). Each point indicates the 
mean and standard error of the mean for 8 sheep. The first recording was taken at time 0. 
The maximum threshold force (16 N) is indicated.
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No. 1 No. 2 No. 3 No. 4 No. 5 M ean ±SEM
T im e (min) T herm al th resholds
C 52.7 53.4 51.7 53.7 52.2 52.7 0.37
5 62.2 57.8 55.2 62.6 59.2 59.4 1.38
10 65.0 59.4 65.0 65.0 65.0 63.9 *
15 65.0 63.1 65.0 65.0 65.0 64.6 *
20 65.0 63.9 65.0 58.1 65.0 63.4 *
3 0 65.0 63.2 65.0 65.0 59.6 63.6 *
45 58.6 60.4 53.8 53.0 60.2 57.2 1.59
5 0 54.5 56.4 53.5 54.1 55.5 54.8 0.52
55 53.7 54.1 55.2 54.1 55.1 54.4 0.30
60 53.5 53.8 54.0 53.4 54.4 53.8 0.18
65 54.1 53.9 52.4 53.9 53.1 53.5 0.32
M echanical th resho lds
C 2.7 3.7 2.7 3.1 2.3 2.9 0.24
15 8.5 15.8 16 12.5 16 14.3 *
30 16 15.8 15.2 4.5 4.5 10.0 *
45 9.8 6.5 4.5 2.5 2.2 5.1 1.40
6 0 2.5 3.9 3.9 2.5 2.2 3.0 0.50
75 1.9 1.9 2.5 2.2 1.9 2.1 0.10
T ab le  3.2: Thresholds to noxious mechanical and thermal stimulation in sheep 
administered xylazine hydrochloride.
Individual and mean thresholds to noxious mechanical (Newtons) and thermal (°C) 
stimulation, ± standard error of the mean (SEM), in a group of 5 normal sheep
administered xylazine hydrochloride (50 pg/kg), IV. The SEM is not shown where at 
least 1 sheep attained a maximal response at that time.
The control readings (C) are the mean of at least 3 thresholds recorded over a 30 minute 
period prior to drug administration at time 0.
*At least 1 sheep attained the maximum threshold level.
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is demonstrated in Fig. 3.2. Thresholds had returned to baseline values in each sheep 
within 60 minutes of drug administration. Sedation was evident within 2 to 3 minutes of 
injection of xylazine. Two sheep remained standing throughout the study period, but the 
remaining 3 sheep assumed sternal recumbency approximately 5 minutes after drug 
administration. The sheep drooled saliva during the period of sedation and marked 
hyperpnoea was observed. Three of the 5 sheep began to mouth breathe within 10 
minutes of drug injection. Sedation began to wane 25 minutes after xylazine injection and 
all sheep began ruminating between 55 and 65 minutes after drug administration. At the 
end of the experiment when the sheep were removed from the pen there was no evidence 
of ataxic gait.
The individual, mean ±SEM for thresholds to noxious mechanical stimulation in a group 
of normal sheep after the administration of physiological saline, 5 ml, or 1 of 4 drug 
treatments (flunixin 1.0 or 2.0 mg/kg, carprofen 0.7 or 4.0 mg/kg) are shown in Tables 
3.3, 3.4, 3.5, 3.6 and 3.7 respectively. Sheep number 5 was removed from the study 
between the 3rd and 4th crossover because of illness. The administration of saline did not 
change the threshold to noxious mechanical stimulation over a 6 hour recording period 
(Fig. 3.3). Similarly, the administration of flunixin and carprofen had no effect on 
threshold values (Fig. 3.4 and 3.5 respectively). There were no significant differences 
between the 5 different treatment groups and moreover, there were no significant group x 
time interactions.
Thermal nociceptive testing
The individual, mean ±SEM for thresholds to noxious thermal stimulation in a group of 
normal sheep are shown in Table 3.1 The individual values have a range from 50.0 to
57.8 °C over the 6 hour recording period with a range of mean values from 53.6 to 54.8 
°C (Fig. 3.6). There were no significant changes in the thresholds to noxious thermal 
stimulation over the 6 hour recording period.
Xylazine caused an elevation of the threshold to noxious thermal stimulation in all sheep 
(Table 3.2). Sheep numbers 1, 3, 4 and 5 reached maximum threshold level (65 °C) 
within 10 minutes of injection (Table 3.2). Sheep number 2 did not achieve this level at 
any stage after drug administration, but achieved a maximum threshold level of 63.9 °C at 
the 20 minute reading. The time course of drug effect is shown in Fig. 3.7. Thresholds 
had returned to baseline values for each sheep within 65 minutes of drug administration.
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Figure 3.2. Changes in mechanical threshold responses after administration of xylazine 
hydrochloride (50 |ig/kg, IV) in sheep.
The response threshold (Newtons) is plotted against time (min). Each point indicates the 
mean and standard error of the mean for 5 sheep. The SEM is not shown where at least 1 
sheep attained a maximal response at that time. The pre-test reading is the mean of at least 
3 readings for each of 5 sheep over a thirty minute time period before drug administration 
at time 0 , and is shown at time 0.
The maximum threshold force (16 N) is indicated.
*p<0.05, significantly different from pre-test values.
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N o . N o . N o. N o . N o . N o. N o . N o . Mean ±SEM
1 2 3 4 5 6 7 8
Time (hr) Thermal thresholds
C 57.6 51.8 55.9 48.7 57.4 55.1 54.5 50.5 53.9 1.16
0 . 5 56.4 51.5 50.5 49.9 56.9 53.3 53.5 49.1 52.6 1.03
1 51.9 51.1 53.5 52.5 54.9 51.9 51.0 49.1 52.0 0.61
1 .5 57.8 52.9 54:9 50.1 54.8 52.5 55.4 51.0 53.7 0.89
2 54.2 51.0 54.4 46.1 56.2 53.4 55.5 50.8 52.7 1.16
2 . 5 57.4 51.6 56.3 48.3 55.5 52.7 53.5 58.3 54.2 1.18
3 54.9 53.1 55.3 48.5 56.8 53.6 54.5 50.4 53.4 0.96
3 . 5 53.5 54.3 54.1 47.3 57.4 52.2 55.6 48.5 52.9 1.21
4 54.4 51.6 54.2 48.1 55.9 51.6 53.3 57.5 53.3 1.03
4 . 5 53.2 54.1 53.6 46.8 56.4 51.8 55.5 56.8 53.5 1.13
5 53.4 51.9 54.7 48.6 57.9 53.9 54.2 53.6 53.5 0.93
5 . 5 52.3 52.1 52.9 46.6 58.1 52.8 52.0 MD 52.4 1.18
6 53.9 52.8 54.4 48.9 55.7 51.5 53.2 MD 52.9 0.78
Mechanical thresholds
C 2.6 2.0 2.2 2.8 3.3 5.0 2.1 4.2 3.0 0.38
0 . 5 2.5 2.2 1 9 1.5 2.9 5.5 2.5 3.9 3.0 0.43
1 3.2 1.9 1.9 3.2 2.2 5.2 1.9 4.9 3.1 0.48
1 .5 3.2 2.5 3.2 2.2 2.5 3.9 2.5 7.2 3.4 0.58
2 3.5 3.2 MD 2.2 1.9 3.2 1.9 4.5 2.9 0.34
2 . 5 2.9 2.5 3.9 2.9 1.9 3.2 1.9 4.2 2.9 0.30
3 3.9 2.9 2.5 2.5 1.9 4.2 1.9 4.5 3.0 0.36
3 . 5 3.2 1.9 2.9 2.5 1.9 4.5 1.9 4.5 2.9 0.39
4 3.2 3.9 3.2 2.5 1.9 3.2 1.9 4.5 3.0 0.32
4 . 5 3.2 2.5 3.5 2.9 1.9 3.2 2.5 3.9 3.0 0.23
5 3.2 2.9 2.9 2.5 1.9 4.5 1.9 4.2 3.0 0.34
5 . 5 3.2 3.2 3.2 2.5 1.9 3.9 1.9 4.5 3.0 0.32
6 3.2 3.9 2.5 2.2 1.9 4.5 2.5 4.5 3.2 0.37
Table 3.3. Thresholds to noxious mechanical and thermal stimulation in normal sheep 
over 6 hours, after administration of saline, IV.
Individual and mean thresholds to noxious mechanical (Newtons) and thermal (°C) 
stimulation, ± standard error of the mean (SEM), in a group of 8 normal sheep over a 
period of 6 hours (hr) after injection of saline, 5 ml, IV.
The control readings (C) are the mean of at least 3 thresholds recorded over a 30 minute
period prior to drug administration at time 0.
MD= Missing data.
6 0
N o . N o . N o. N o . N o . N o . N o . N o . Mean ±SEM
1 2 3 4 5 6 7 8
Tim e (hr) T herm al thresholds
C 50.8 48.4 56.5 50.4 MD 50.2 50.2 58.9 53.2 0.75
0 .5 58.6 47.1 57.1 50.5 MD 54.9 55.5 56.5 54.1 0.68
1 49.8 50.2 58.1 50.6 MD 54.1 52.3 56.6 54.3 0.54
1 .5 57.5 53.8 55.5 51.5 MD 53.4 53.2 59.4 54.8 0.53
2 MD 54.1 55.8 55.7 MD 53.4 54.6 57.1 53.8 0.67
2 .5 49.9 57.2 58.2 50.1 MD 54.0 53.8 57.6 52.9 0.66
3 50.7 53.2 57.4 49.6 MD 49.1 47.8 56.9 52.8 0.70
3 .5 51.2 51.5 51.9 52.2 MD 50.9 51.2 57.2 53.0 0.74
4 52.1 49.4 58.2 59.9 MD 49.5 52.0 56.4 53.2 0.79
4 .5 50.1 50.1 58.8 53.1 MD 50.5 48.3 59.1 53.0 0.76
5 50.4 49.1 58.0 51.2 MD 53.0 50.9 56.8 53.2 0.67
5 .5 51.1 49.7 59.3 MD MD 55.1 49.5 55.8 53.9 1.59
6 MD 50.3 55.9 55.0 MD 53.4. 49.9 56.9 53.6 1.11
M echanical th resho lds
C 2.5 2.3 3.7 2.5 MD 3.7 2.3 4.5 3.1 0.19
0 .5 4.8 3.2 3.5 1.9 MD 2.9 2.5 4.5 3.3 0.37
1 1.9 2.5 3.5 2.9 MD 3.2 1.9 6.5 3.2 0.56
1 .5 2.5 2.5 3.9 2.5 MD 3.9 2.5 5.8 3.4 0.44
2 3.5 3.2 3.9 3.2 MD 3.2 4.5 5.2 3.8 0.27
2 .5 3.2 2.5 3.9 1.9 MD 2.5 2.2 4.5 3.0 0.34
3 1.9 3.2 2.5 1.9 MD 3.2 2.9 4.5 2.9 0.32
3 .5 2.9 3.5 3.5 1.9 MD 2.9 2.5 3.9 3.0 0.24
4 2.9 2.2 3.2 1.9 MD 3.9 4.5 5.2 3.4 0.43
4 .5 3.9 3.2 2.9 2.5 MD 4.5 3.2 5.2 3.6 0.34
5 2.5 2.5 3.2 1.9 MD 3.2 3.2 5.2 3.1 0.37
5 .5 2.5 2.5 3.5 1.9 MD 3.2 4.5 4.2 3.2 0.34
6 3.2 2.5 3.9 1.9 MD 3.2 3.9 3.9 3.2 0.28
Table 3.4. Thresholds to noxious mechanical and thermal stimulation in normal sheep 
over 6 hours, after administration of flunixin meglumine, 1.0 mg/kg, IV.
Individual and mean thresholds to noxious mechanical (Newtons) and thermal (°C) 
stimulation, ± standard error of the mean (SEM), in a group of 8 normal sheep over a 
period of 6 hours (hr) after injection of flunixin meglumine, 1.0 mg/kg, IV.
The control readings (C) are the mean of at least 3 thresholds recorded over a 30 minute
period prior to drug administration at time 0.
MD= Missing data.
N o . N o . N o . N o . N o . N o . N o. N o . Mean ±SEM
I 2 3 4 5 6 7 8
Time (hr) Thermal thresholds
C 52.3 51.3 46.7 49.8 55.5 53.1 51.0 52.9 53.1 0.75
0 .5 52.7 50.8 45.5 51.6 58.0 52.7 53.1 58.9 54.0 0.82
1 52.8 50.5 55.1 55.7 63.3 52.8 53.2 54.9 54.3 0.84
1 .5 52.1 54.0 58.3 54.5 63.2 51.5 55.2 54.7 53.4 0.80
2 50.8 51.7 50.9 50.9 64.8 53.6 55.6 53.1 53.3 0.83
2 .5 53.9 50.6 47.8 51.6 MD 51.9 53.0 54.5 53.0 0.75
3 52.6 53.7 47.5 50.1 63.7 54.2 55.1 54.9 51.1 2.14
3 . 5 56.4 51.3 45.6 51.3 56.6 54.4 54.9 53.9 50.4 2.12
4 51.0 51.2 48.3 51.2 58.5 49.8 51.6 53.4 50.2 2.10
4 . 5 51.5 52.3 47.9 50.8 57.8 49.8 54.4 MD 52.2 0.66
5 51.9 52.5 47.3 51.4 58.4 54.3 50.5 53.0 52.4 0.67
5 . 5 51.2 50.7 47.1 50.2 59.6 53.4 50.8 53.5 52.2 1.48
6 52.5 53.5 48.1 51.4 59.9 52.2 51.1 54.0 52.9 1.38
Mechanical thresholds
C 2.9 2.6 2.5 3.0 2.6 3.9 2.9 4.9 3.2 0.29
0 .5 2.2 1.9 3.2 3.2 2.2 3.2 2.2 6.5 3.3 0.27
1 3.2 3.9 2.5 2.5 1.9 3.9 1.9 6.8 3.4 0.26
1 .5 5.2 2.9 3.2 2.5 3.9 3.5 3.2 3.9 3.5 0.24
2 4.8 5.2 1.9 2.5 2.2 2.5 MD 4.8 3.2 0.24
2 . 5 2.5 5.8 3.2 1.9 1.9 3.9 3.9 4.5 3.2 0.26
3 2.5 2.5 3.5 1.9 1.9 2.5 3.2 3.9 2.9 0.22
3 .5 5.2 2.5 3.2 1.9 2.9 2.9 2.5 6.5 3.2 0.23
4 2.2 2.5 1.9 2.5 2.5 2.9 2.5 3.2 3.0 0.17
4 .5 5.2 3.9 2.9 2.5 2.9 2.9 3.5 4.8 3.3 0.19
5 4.2 3.2 2.5 2.5 2.2 2.9 2.5 3.9 3.1 0.20
5 .5 3.9 3.9 2.5 1.9 2.2 2.9 3.2 5.2 3.1 0.43
6 4.5 3.5 2.9 2.2 1.9 2.9 1.9 5.2 2.9 0.44
Table 3.5. Thresholds to noxious mechanical and thermal stimulation in normal sheep 
over 6 hours, after administration of flunixin meglumine, 2.0 mg/kg, IV.
Individual and mean thresholds to noxious mechanical (Newtons) and thermal (°C) 
stimulation, ± standard error of the mean (SEM), in a group of 8 normal sheep over a 
period of 6 hours (hr) after injection of flunixin meglumine, 2.0 mg/kg, IV.
The control readings (C) are the mean o f at least 3 thresholds recorded over a 30 minute
period prior to drug administration at time 0.
MD= Missing data.
6 2
N o . N o . N o . N o . N o . N o . N o . N o . M ean ±SEM
1 2 3 4 5 6 7 8
Tim e (hr) T herm al th resholds
C 44.7 59.7 53.6 54.1 48.2 51.1 57.0 52.6 54.0 0.92
0 .5 44.9 60.5 52.6 53.2 54.9 49.2 57.0 55.2 54.4 0.75
1 57.8 61.4 52.2 54.1 59.8 52.9 58.0 50.5 54.8 0.63
1 .5 54.3 56.5 52.1 54.6 54.2 52.7 55.7 51.7 54.5 0.49
2 56.6 MD 53.5 52.3 52.2 50.1 58.4 58.3 55.0 0.62
2 .5 54.0 MD 52.8 58.8 52.1 56.1 56.1 55.5 54.6 0.67
3 59.2 60.5 54.0 55.8 52.1 54.6 56.5 59.6 54.2 0.68
3 .5 50.0 59.9 53.6 52.8 48.1 53.1 56.7 53.6 53.8 0.62
4 51.6 57.9 52.0 53.6 50.2 55.5 56.5 53.8 54.1 0.66
4 .5 52.1 58.1 53.4 54.6 50.1 49.9 58.1 55.3 53.7 0.70
5 MD 60.4 57.3 50.0 49.9 50.9 58.2 54.3 53.4 0.70
5 .5 48.3 57.5 53.8 53.3 50.2 50.2 56.0 53.9 53.6 1.03
6 47.9 58.2 52.1 54.3 51.6 51.6 56.6 52.5 53.8 1.00
M echanical th resho lds
C 3.8 2.3 3.0 2.0 3.0 4.3 9.8 5.9 4.3 0.90
0 .5 2.9 1.9 2.9 2.9 2.5 3.2 5.8 4.5 3.4 0.23
1 3.2 1.9 3.5 1.9 3.5 4.5 3.9 4.8 3.4 0.25
1 .5 3.9 1.9 3.2 2.9 2.2 3.2 3.9 5.8 3.2 0.25
2 5.2 1.9 3.2 MD 2.5 3.5 2.5 6.2 3.1 0.24
2 .5 2.5 1.9 2.2 1.9 2.5 4.5 2.5 2.9 3.0 0.21
3 5.2 2.5 2.5 2.5 2.5 4.2 2.5 3.9 3.4 0.27
3 .5 3.9 1.9 2.5 1.9 1.9 4.5 3.2 4.8 3.4 0.28
4 7.2 2.2 2.9 2.5 2.9 5.2 3.5 3.9 3.4 0.26
4 .5 2.9 1.9 3.9 1.9 2.9 4.8 3.2 5.2 3.2 0.21
5 3.5 1.9 3.9 2.5 2.5 2.5 3.2 4.5 3.1 0.19
5 .5 3.9 2.2 3.9 1.9 2.9 2.5 2.5 5.2 3.0 0.44
6 3.9 1.9 3.5 2.2 2.9 2.9 2.5 4.5 2.9 0.33
Table 3.6. Thresholds to noxious mechanical and thermal stimulation in normal sheep 
over 6 hours, after administration of carprofen, 0.7 mg/kg, IV.
Individual and mean thresholds to noxious mechanical (Newtons) and thermal (°C) 
stimulation, ± standard error of the mean (SEM), in a group of 8 normal sheep over a 
period of 6 hours (hr) after injection of carprofen, 0.7 mg/kg, IV.
The control readings (C) are the mean of at least 3 thresholds recorded over a 30 minute
period prior to drug administration at time 0.
MD= Missing data.
6 3
N o. N o. N o . N o . N o . N o . N o . N o . Mean ±SEM
1 2 3 4 5 - 6 7 8
Tim e (hr) T herm al th resholds
C 52.8 49.9 49.8 57.9 MD 50.2 50.2 44.6 51.8 0.69
0 .5 52.1 55.1 51.9 55.6 MD 54.6 52.5 47.8 52.1 0.65
1 51.6 50.4 55.9 56.0 MD 51.2 51.8 45.8 51.2 0.64
1 .5 55.3 49.5 55.3 55.2 MD 50.1 49.7 46.2 50.9 0.58
2 50.7 49.6 49.2 MD MD 52.9 50.8 46.6 51.3 0.64
2 .5 53.5 50.1 52.3 MD MD 49.4 53.1 46.7 51.7 0.70
3 54.1 48.8 55.1 56.4 MD 57.1 51.9 46.6 52.1 0.74
3 .5 54.2 49.6 51.4 57.1 MD 49.5 50.7 45.9 51.5 0.71
4 54.1 49.4 50.7 58.2 MD 51.6 54.6 46.9 51.5 0.69
4 .5 52.9 50.3 50.3 55.6 MD 47.8 54.3 45.7 51.4 0.58
5 52.4 50.5 51.6 56.2 MD 47.5 53.2 46.6 52.0 0.54
5 .5 50.5 52.0 51.9 54.8 MD 51.2 53.2 51.1 52.4 0.53
6 50.4 51.5 51.5 55.1 MD 56.9 54.6 48.6 53.0 1.15
M echanical th resho lds
C 3.2 3.3 3.1 2.2 MD 3.2 2.0 3.7 3.0 0.23
0 .5 3.2 1.9 2.2 1.9 MD 3.2 3.2 3.9 3.1 0.24
1 2.5 2.5 2.5 2.5 MD 3.2 1.9 6.4 3.2 0.26
1 .5 3.9 2.5 2.5 5.8 MD 2.5 3.2 3.9 3.2 0.23
2 2.5 1.9 3.2 2.9 MD 2.5 5.8 3.2 3.2 0.21
2 .5 3.2 1.9 2.9 1.9 MD 3.2 4.5 3.9 3.2 0.20
3 3.9 3.2 2.9 2.5 MD 2.5 2.5 5.2 3.4 0.21
3 .5 3.2 3.2 4.5 1.9 MD 2.5 2.9 5.2 3.5 0.21
4 3.9 2.9 4.5 2.5 MD 2.9 3.9 5.5 3.4 0.21
4 .5 3.9 2.9 3.5 1.9 MD 3.5 2.5 4.8 3.2 0.18
5 2.9 2.9 3.9 1.2 MD 3.9 3.9 4.5 3.2 0.17
5 .5 3.2 2.9 3.2 1.9 MD 2.5 3.2 3.9 2.9 0.26
6 2.9 3.2 3.2 1.9 MD 3.9 3.9 4.5 3.4 0.34
Table 3.7. Thresholds to noxious mechanical and thermal stimulation in normal sheep 
over 6 hours, after administration of carprofen, 4.0 mg/kg, IV.
Individual and mean thresholds to noxious mechanical (Newtons) and thermal (°C) 
stimulation, ± standard error of the mean (SEM), in a group of 8 normal sheep over a 
period of 6 hours (hr) after injection of carprofen, 4.0 mg/kg, IV.
The control readings (C) are the mean of at least 3 thresholds recorded over a 30 minute
period prior to drug administration at time 0.
MD= Missing data.
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Figure 3.3. Changes in mechanical threshold responses after the administration of 
saline (5 ml, IV) in 8 sheep.
The response threshold (Newtons) is plotted against time (hr). Each point indicates the 
mean and standard error of the mean for 8 sheep. The pre-test reading is the mean of at 
least 3 readings for each sheep over a thirty minute time period before drug administration 
at time 0, and is shown at time 0.
The maximum threshold force (16 N) is indicated.
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Figure 3.4. Changes in mechanical threshold responses after the administration of 
flunixin meglumine, 1.0 (Flu 1) and 2.0 (Flu 2) mg/kg, IV, in sheep.
The response threshold (Newtons) is plotted against time (hr). Each point indicates the 
mean and standard error of the mean for 7 (Flu 1) or 8 (Flu 2) sheep. The pre-test reading 
is the mean of at least 3 readings for each sheep over a thirty minute time period before 
drug administration at time 0, and is shown at time 0.
The maximum threshold force (16 N) is indicated.
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Figure 3.5. Changes in mechanical threshold responses after the administration of 
carprofen, 0.7 (Carp 0.7) and 4.0 (Carp 4) mg/kg, IV, in sheep.
The response threshold (Newtons) is plotted against time (hr). Each point indicates the 
mean and standard error of the mean for 7 (Carp 4) or 8 (Carp 0.7) sheep. The pre-test
reading is the mean of at least 3 readings for each sheep over a thirty minute time period
before drug administration at time 0, and is shown at time 0 .
The maximum threshold force (16 N) is indicated.
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Figure 3.6. Control thermal threshold responses in sheep recorded over a 6 hour (hr) 
time course.
The response threshold (°C) is plotted against time (hours). Each point indicates the mean 
and standard error of the mean for 8 sheep. The first recording was taken at time 0.
The maximum threshold temperature (65°C) is indicated.
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Figure 3.7. Changes in thermal threshold responses after administration of xylazine 
hydrochloride (50 |ig/kg, IV) in sheep.
The response threshold (°C) is plotted against time (min). Each point indicates the mean 
and standard error (SEM) of the mean for 5 sheep. The SEM for each time point is not 
shown where at least 1 sheep attained a maximal response at that time. The pre-test 
reading is the mean of at least 3 readings for each of 5 sheep over a thirty minute time 
period before drug administration and is shown at time 0.
The maximum threshold temperature (65°C) is indicated.
*p<0.05, significantly different from pre-test values.
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The individual, mean ±SEM for thresholds to noxious thermal stimulation in a group of 
normal sheep after the administration of physiological saline, 5 ml, or 1 of 4 drug 
treatments (flunixin 1.0 or 2.0 mg/kg, carprofen 0.7 or 4.0 mg/kg) are shown in Tables 
3.3, 3.4, 3.5, 3.6 and 3.7 respectively. The administration of saline did not change the 
threshold to noxious thermal stimulation over the 6 hour recording period (Fig. 3.8).
Flunixin appeared to raise the mean thermal threshold values slightly, from 0.5 hours 
after administration of 1.0 or 2.0 mg/kg, to 2.0 hours after injection (Fig. 3.9). Similarly, 
carprofen, 0.7 and 4.0 mg/kg, IV, appeared to raise and lower, respectively, the mean 
threshold to noxious thermal stimulation from 0.5 hours after drug injection to 3 hours 
post injection (Fig. 3.10). However, statistical analysis of the thermal threshold data 
indicated no significant differences between the 5 different treatment groups and no 
significant group x time interactions.
3.3.2 Study 2
Thresholds to noxious thermal stimulation were not determined in this study.
M echanical nociceptive testing
Thresholds to noxious mechanical stimulation were recorded for a group of 25 normal 
sheep selected at random from a farm flock. The individual and mean thresholds for each 
of these sheep, taken over a 30 minute period, are shown in Table 3.8. Statistical analysis 
of this data indicated that the thresholds to noxious mechanical stimulation in these 'naive' 
sheep (group mean, 4.9N) were significantly different (p<0.01) from the control 
threshold values obtained in a group of 8 experimental sheep tested routinely (group 
mean, 3.0N) (Table 3.3).
Ten sheep (numbers 16-25) (Table 3.8) were selected at random and after mechanical 
threshold testing on day 1, had their feet pared and were allowed to stand in a foot bath 
for at least 30 minutes. Threshold to noxious mechanical stimulation were re-evaluated on 
the 2 following days over a similar time course (Table 3.9). Statistical analysis of the data 
indicated that there were no significant differences between the readings obtained on day 
1 (group mean, 4.7N) and those obtained on day 2 (group mean, 4.0N), but the values 
recorded on day 1 were significantly greater (p<0.05) than those recorded on day 3 
(group mean, 3 .IN) for the same sheep. Mechanical thresholds for the larger group of 
sheep (n=25) (Table 3.8) on day 1 were also significantly greater (p<0.01) than those 
recorded on day 3 for the smaller group (n=10). Moreover, it is interesting to note that 
there no significant differences between the thresholds recorded on day 3 (group mean,
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Figure 3.8. Changes in thermal threshold responses after administration of saline (5 ml, 
IV) in sheep.
The response threshold (°C) is plotted against time (hr). Each point indicates the mean 
and standard error of the mean for 8 sheep. The pre-test reading is the mean of at least 3 
readings for each sheep over a thirty minute time period before drug administration and is 
shown at time 0.
The maximum threshold temperature (65°C) is indicated.
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Figure 3.9. Changes in thermal threshold responses after administration of flunixin 
meglumine 1.0 (Flu 1) and 2.0 (Flu 2) mg/kg, IV, in sheep.
The response threshold (°C) is plotted against time (hr). Each point indicates the mean 
and standard error of the mean for 8 sheep. The pre-test reading is the mean of at least 3 
readings for each sheep over a thirty minute time period before drug administration and is 
shown at time 0.
The maximum threshold temperature (65°C) is indicated.
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Figure 3.10. Changes in thermal threshold responses after administration of carprofen 
0.7 (Carp 0.7) and 4.0 (Carp 4) mg/kg, IV, in sheep.
The response threshold (°C) is plotted against time (hr). Each point indicates the mean 
and standard error of the mean for 8 sheep. The pre-test reading is the mean of at least 3 
readings for each over a thirty minute time period before drug administration and is 
shown at time 0.
The maximum threshold temperature (65°C) is indicated.
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T1 T2 T3 M ean
S heep N um ber
1 3.2 3.5 5.5 4.1
2 5.2 4.5 5.2 5.0
3 3.9 4.5 4.2 4.2
4 6.8 5.5 5.2 5.8
5 3.5 3.2 3.5 3.4
6 8.5 9.8 8.5 8.9
7 2.5 2.2 4.2 3.0
8 5.2 3.9 3.9 4.3
9 5.2 4.5 4.5 4.7
10 3.2 2.5 2.5 2.7
11 5.8 5.8 5.5 5.7
12 3.5 2.9 2.9 3.1
13 13.2 12.5 11.2 12.3
14 4.5 3.2 4.2 4.0
15 3.9 3.5 4.5 4.0
16 5.8 5.8 5.8 5.8
17 2.9 2.5 2.5 2.6
18 3.5 3.9 3.9 3.8
19 3.9 4.2 3.9 4.0
20 3.9 4.5 3.9 4.6
21 3.2 3.9 3.9 3.7
22 7.8 7.8 7.8 7.8
23 6.5 5.8 6.2 6.2
24 3.2 3.2 3.2 3.2
25 5.2 5.2 4.8 5.1
Table 3.8. Thresholds to noxious mechanical stimulation in farm sheep unaccustomed 
to the testing procedure.
Thresholds to noxious mechanical stimulation (Newtons) in a group of 25 normal sheep 
selected at random from a farm flock. Thresholds (T1 -T3) were recorded over a 30 
minute period.
N o . N o . N o . N o . N o . N o . N o . N o . N o . N o .
16 17 18 19 20  
Day 1
21 22 23 24 25
T 1 5.8 2.9 3.5 3.9 3.9 3.2 7.8 6.5 3.2 5.2
T 2 5.8 2.5 3.9 4.2 4.5 3.9 7.8 5.8 3.2 4.8
T 3 5.8 2.5 3.9 3.9 3.9 3.9 7.8 6.2 3.2 5.2
Mean 5.8 2.6 bo 4.0 4.6
Day 2
3.7 7.8 6.2 3.2 5.1
T 1 3.2 2.5 3.9 3.9 5.5 4.2 4.5 3.9 3.2 3.2
T 2 2.5 1.9 4.2 4.2 10.5 3.9 4.5 3.9 3.2 3.9
T 3 3.2 2.5 3.9 3.9 8.2 3.9 4.5 3.9 3.2 3.2
Mean 3.0 2.3 4.0 4.0 8.1
Day 3
4.0 4.5 3.9 3.2 3.4
T 1 2.9 3.2 3.9 2.5 4.2 2.5 1.5 3.9 4.2 1.5
T 2 2.5 3.5 2.9 2.5 4.5 2.5 1.5 3.9 4.5 1.9
T 3 2.9 3.2 3.5 2.2 4.5 2.5 1.9 3.9 5.2 1.9
Mean 2.8 3.3 3.4 2.4 4.4 2.5 1.6 3.9 4.6 1.8
Table 3.9. Thresholds to noxious mechanical stimulation in farm sheep unaccustomed 
to the testing procedure, over a period of 3 days.
Thresholds to noxious mechanical stimulation (Newtons) in a group of 10 normal sheep 
selected at random from a farm flock. Thresholds (T1 -T3) were recorded over a 30 
minute period on 3 sequential days. The feet of all sheep were pared after threshold 
readings on day 1.
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3 .IN) and those recorded in a group of 8 experimental sheep over a similar time course 
(group mean, 3.ON) (Table 3.3).
Thresholds to noxious mechanical stimulation in 22 sheep suffering varying degrees of 
foot rot (group mean, 5. IN) (Table 3.10) were not significantly different from the control 
thresholds obtained on day 1 for a group of 25 normal sheep from the same farm (group 
mean, 4.7N) (Table 3.8). A summary of the lameness scores and the foot lesion scores 
for the 22 sheep are shown in Table 3.11. There were no significant differences between 
the total scores for lameness (group mean, sheep numbers 26-33, 2.13; 34-40, 1.86; 41- 
47, 2.29) and foot lesions (group mean, sheep numbers 26-33, 4.13; 34-40, 4.14; 41- 
47, 3.86) awarded to the sheep in the 3 groups to which’these animals were allocated.
Eight of these sheep (sheep numbers 26-33) were selected at random and after mechanical 
threshold testing on day 1, had their feet pared and were allowed to stand in a foot bath 
for at least 30 minutes. Subsequently, thresholds to noxious mechanical stimulation in 
these 8 sheep were determined as on day 1 on the 2 following days (Table 3.12). 
Statistical analysis of the data indicated no significant change in the threshold to noxious 
mechanical stimulation over the 3 day test period for these sheep (group mean day 1, 
3.8N; day 2, 4.6N; day 3, 4.6N). In addition, the thresholds recorded on day 3 were not 
significantly different from the thresholds recorded for a group of normal sheep (n=25) 
from the same farm (group mean 4.7N) (Table 3.8), but were still found to be 
significantly different from those thresholds recorded in a group of experimental sheep 
tested routinely (group mean, 3.0N) (Table 3.3).
The individual and mean thresholds to noxious mechanical stimulation in sheep suffering 
from footrot were determined after the administration of flunixin meglumine at 1.0 and
2.0 mg/kg (sheep numbers 34-40 and 41-47 respectively) (Table 3.13a and 3.13b 
respectively). There were no significant treatment x time interactions within each group. 
However, there was a significant difference between the 2 treatment groups. Detailed 
examination of the data shows that the mean pre-treatment threshold values obtained for 
sheep given flunixin, 1.0 mg/kg, (7.6 N) (Table 3.13a) are at least twice those found for 
sheep administered flunixin, 2.0 mg/kg, (3.6 N) (Table 3.13b), thus accounting for the 
recorded differences (Fig. 3.11). Thresholds to noxious mechanical stimulation were 
recorded in 4 of the 7 sheep administered flunixin, 2.0 mg/kg, IV, up to 120 minutes 
after drug administration (data not shown), and no changes from pre-treatment values 
were observed.
7 6
Sheep N um ber T 1 T2 T3 Mean
26 2.2 1.5 2.2 2.0
27 4.5 10.5 5.8 6.9
28 2.5 3.2 2.9 2.9
29 4.8 5.2 4.8 4.9
30 3.2 4.8 3.9 4.1
31 2.9 2.2 2.2 2.4
32 2.5 2.9 3.2 2.9
33 5.2 3.2 4.2 4.2
34 9.5 6.2 6.2 7.3
35 4.5 4.5 4.5 - 4.5
36 7.2 7.2 6.8 7.1
37 6.5 6.8 6.2 6.5
38 11.8 12.2 11.8 11.9
39 5.8 7.2 7.8 6.9
40 9.2 7.2 11.2 9.2
41 2.5 1.9 2.5 2.3
42 5.2 4.5 5.5 5.1
43 2.2 1.9 2.2 2.1
44 2.5 2.5 2.5 2.5
45 3.5 3.2 3.5 3.4
46 6.5 6.5 6.2 6.4
47 3.5 3.9 3.5 3.6
Table 3.10: Thresholds to noxious mechanical stimulation in farm sheep suffering from 
footrot and unaccustomed to the testing procedure.
Thresholds to noxious mechanical stimulation (Newtons) in a group of 22 sheep from a 
farm flock, suffering from varying degrees of footrot. Thresholds (T1 -T3) were 
recorded over a 30 minute period.
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Sheep N um ber N R S F oot T otal
S co re S co re
26 2 4 6
27 3 2 5*
28 3 9 12
29 1 1 2*
30 2 10 12
31 1 1 2*
32 1 2 3
33 4 4 8*
34 3 4 7*
35 3 5 8
36 2 6 8
37 2 2 4*
38 1 5 6
39 1 3 4*
40 1 4 5*
41 1 4 5*
42 3 3 6
43 1 3 4*
44 1 2 3
45 2 7 9
46 4 4 8
47 4 4 8
T able 3.11. Lameness and foot lesion scores in a group of sheep suffering from 
footrot.
Numerical rating scale (NRS) scores (0-4) for lameness, total score for foot lesions (0-4) 
for each foot (maximum possible score of 16) and the total of both scores combined for a 
group of 22 farm sheep suffering from footrot.
*Footrot only present in 1 forefoot.
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N o . N o . N o . N o . N o . N o . N o . N o .
26 27 28 29 
Day 1
30 31 32 33
T 1 2.2 4.5 2.5 4.8 3.9 2.9 3.2 5.2
T 2 1.5 10.5 3.2 5.2 4.8 2.2 2.9 3.2
T 3 2.2 5.8 2.9 4.8 3.2 2.2 2.5 4.2
M ean 2.0 6.9 2.9 4.9
Day 2
4.1 2.4 2.9 4.2
T 1 2.5 6.5 3.2 5.5 6.8 2.2 6.5 5.2
T 2 2.2 6.5 3.5 4.5 5.2 2.2 6.9 5.8
T 3 2.2 4.5 3.2 5.2 5.2 2.9 6.9 5.2
M ean 2.3 5.8 3.3 5.1
Day 3
5.7 2.4 6.8 5.4
T 1 3.5 6.2 6.5 2.9 3.9 4.2 5.2 3.2
T 2 2.9 6.5 7.2 3.2 4.8 3.9 5.2 2.5
T 3 3.5 6.5 9.2 2.9 4.8 3.9 4.8 2.9
M ean 3.3 6.4 7.6 3.0 4.5 4.0 5.1 2.9
Table 3.12. Thresholds to noxious mechanical stimulation in farm sheep suffering from 
footrot and unaccustomed to the testing procedure, over a period of 3 days.
Thresholds to noxious mechanical stimulation (Newtons) in a group of 8 sheep, from a 
farm flock, suffering from varying degrees of footrot. Thresholds (T1 -T3) were 
recorded over a 30 minute period on 3 sequential days. The feet of all sheep were pared 
after threshold readings on day 1.
7 9
Tim e
(min)
N o .
34
N o .
35
N o .
36
N o .
37
N o .
38
N o .
39
N o .
40
Mean ±SEM
C 7.3 4.5 7.1 6.5 11.9 6.9 9.2 7.6 0.88
1 11.8 4.8 12.2 5.2 7.2 9.8 5.8 8.1 1.18
5 8.8 5.8 8.2 5.8 9.8 7.2 11.8 8.2 0.82
9 8.5 3.2 9.2 6.2 15.5 6.8 9.2 8.4 1.43
11 8.2 5.2 9.2 6.8 16.0 7.5 9.5 8.9 *
15 10.5 9.2 6.5 6.8 16.0 8.5 8.5 9.4 *
20 9.5 8.8 6.5 6.2 16.0 9.2 5.8 8.9 *
30 7.8 7.5 9.5 6.5 16.0 9.2 6.5 7.9 *
Table 3.13a. Thresholds to noxious mechanical stimulation in sheep suffering footrot 
after injection of flunixin meglumine, 1.0 mg/kg, IV.
Individual and mean thresholds to noxious mechanical (Newtons) stimulation, ± standard 
error of the mean (SEM), in a group of 7 sheep suffering from varying degrees of footrot 
administered flunixin meglumine, 1.0 mg/kg, IV. The SEM is not shown where at least 1 
sheep attained a maximal response at that time.
The control readings (C) are the mean of at least 3 thresholds recorded over a 30 minute 
period prior to drug administration at time 0.
*At least 1 sheep attained the maximum threshold level.
8 0
T im e
(min)
N o . 
41
N o .
42
No .
43
N o .
44
N o . 
45
N o .
46
N o .
47
M ean ±SEM
C 2.3 5.1 2.1 2.5 3.4 6.4 3.6 3.6 0.60
1 5.2 5.8 3.5 1.9 4.5 7.8 3.4 4.6 0.73
5 5.2 5.8 3.9 2.5 3.9 6.5 6.5 4.9 0.61
9 1.9 5.2 3.9 2.5 3.5 9.8 6.8 4.8 1.05
11 4.5 5.5 3.2 2.9 3.2 8.8 5.2 4.8 0.76
15 4.5 6.5 3.2 2.9 3.2 9.5 5.2 5.0 0.90
20 4.5 5.5 3.2 3.5 3.5 9.8 5.5 5.1 0.87
3 0 5.2 5.5 3.2 3.5 3.2 9.5 4.8 5.0 0.84
Table 3.13b. Thresholds to noxious mechanical stimulation in sheep suffering footrot 
after injection of flunixin meglumine, 2.0 mg/kg, IV.
Individual and mean thresholds to noxious mechanical (Newtons) stimulation, ± standard 
error of the mean (SEM), in a group of 7 sheep suffering from varying degrees of footrot 
administered flunixin meglumine, 1.0 mg/kg, IV.
The control readings (C) are the mean of at least 3 thresholds recorded over a 30 minute 
period prior to drug administration at time 0.
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Figure 3.11. Changes in mechanical threshold responses after administration of 
flunixin meglumine, 1.0 (Flu 1) and 2.0 (Flu 2) mg/kg, IV, in sheep suffering footrot.
The response threshold (Newtons) is plotted against time (min). Each point indicates the 
mean and standard error of the mean (SEM) for 7 sheep. The SEM is not shown where at 
least 1 sheep attained maximal response at that time. The pre-test reading is the mean of at 
least 3 readings for each sheep over a thirty minute time period before drug administration 
at time 0 , and is shown at time 0.
The maximum threshold force (16 N) is indicated.
*p<0.05, significant difference between groups.
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Thresholds to noxious mechanical stimulation in sheep suffering from footrot which 
received flunixin treatment over a period of 3 days were evaluated (Table 3.14). 
Thresholds in this group changed significantly over a 4 day period. Thresholds recorded 
on day 1 prior to drug treatment (group mean, 7.6N) were significantly lower than those 
recorded on day 2 (group mean, 10.7N) (p<().()5), but were significantly greater than 
those recorded on day 3 (group mean, 6.6N) (p<0.01) and day 4 (group mean, 6.0N) 
(p<0.01). There was no significant difference between thresholds recorded on day 2 and 
day 3, or day 3 and day 4. On day 4, all animals except sheep number 40, had lower 
mean thresholds than those recorded on day 1. Thresholds recorded on day 4 were not 
significantly different from those recorded in a group of control sheep from the same farm 
on day 1 (Table 3.9) (group mean, 4.7N), and nor were they significantly different from 
those recorded in the same group of control sheep on day 3 (group mean, 3. IN).
3.3.3 Study 3
There were no significant differences in either the demographic distribution of sheep 
allocated to each treatment group in this study (Table 3.15a and 3.15b), or between 
groups. The mean duration of anaesthesia for each group is shown in Table 3.15a and 
3.15b and was not found to be significantly different. The mean time to assume sternal 
recumbency was significantly longer for sheep which received buprenorphine (sheep 
numbers 1-6) (p<0.01) than for all other groups, and similarly, these sheep also took a 
significantly longer time to stand (p<0.01).
Mechanical nociceptive testing
The changes in threshold to noxious mechanical stimulation were recorded for all sheep in 
the recovery period and are documented in Tables 3.16, 3.17, 3.18, 3.19, 3.20 and 3.21. 
Statistical analysis of the data indicated that there were no significant differences between 
groups pre-operatively. The mean thresholds to noxious mechanical stimulation over a 2 
hour period post-operatively are shown in Fig. 3.12. It is interesting to note that the mean 
thresholds to noxious mechanical stimulation for sheep given no treatment, those which 
did not undergo surgery, and those which received carprofen, buprenorphine or ketamine 
were higher 2 hours post-operatively or post-anaesthesia than control values (6.6 vs. 7.0,
7.1 vs. 9.9, 6.5 vs. 8.0, 5.7 vs. 8.2 and 4.9 vs. 6.5 Newtons respectively). Only those 
sheep which were given flunixin did not show this change (7.6 vs. 6.4N). However, 
there were no significant differences between groups post-operatively and moreover, 
there were no significant group x time interactions. This indicated that neither general 
anaesthesia alone, general anaesthesia and surgery nor general anaesthesia and surgery 
with drug treatment altered thresholds to noxious mechanical stimulation.
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N o . N o . N o . N o . N o . N o . N o .
34 35 36 37  
Day 1
38 39 40
T  1 9.5 4.5 7.2 6.5 11.8 5.8 9.2
T  2 6.2 4.5 7.2 6.9 12.2 7.2 7.2
T  3 6.2 4.5 6.9 6.2 11.8 7.8 11.2
M ean 7.3 4.5 7.1 6.5 
Day 2
11.9 6.9 9.2
T  1 6.5 5.5 11.2 9.8 12.8 14.5 8.2
T  2 7.2 5.5 13.2 11.5 13.2 13.2 15.8
T  3 6.2 5.8 11.2 8:8 13.2 16.0 15.2
M ean 6.6 5.6 11.9 10.0 
Day 3
13.1 14.6 13.1
T 1 6.8 3.9 3.2 5.2 5.8 8.5 12.5
T 2 5.2 3.5 4.5 5.8 5.5 11.2 10.8
T 3 5.8 4.2 2.9 6.2 5.8 10.5 10.5
M ean 5.9 3.9 3.5 5.7 
Day 4
5.7 10.1 11.3
T 1 3.9 3.2 6.5 6.2 3.5 6.5 12.8
T 2 3.9 3.9 5.2 6.2 3.5 6.8 8.5
T 3 3.5 3.5 6.8 6.5 2.9 5.2 14.2
M ean 3.8 3.5 6.2 6.3 3.3 6.2 11.8
Table 3.14. Thresholds to noxious mechanical stimulation in a group of sheep suffering 
footrot. Response to injection of flunixin meglumine (1.0 mg/kg), IV, over a period of 4 
days.
Thresholds to noxious mechanical stimulation (Newtons) in a group of 7 sheep suffering 
from footrot selected from a farm flock. Thresholds (T1 -T3) were recorded over a 30 
minute period on 4 sequential days. The feet of all sheep were pared after threshold 
readings on day 1. Flunixin meglumine, 1.0 mg/kg, was administered IV after threshold 
evaluation on days 1, 2 and 3.
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Sh e ep W eight Dose Thio. Tim e GA S te rn a l S t and i ng
N u m b e r (kg) (mg) (min) (min) (min)
1 53.0 900 25 24 54
2 58.5 1000 24 47 77
3 58.0 900 20 54 79
4 49.0 900 17 51 68
5 56.0 900 21 22 49
6 64.0 1000 15 29 88
M ean 56.4 933.3 20.3 37.8* 69.2*
7 53.0 900 19 30 46
8 52.0 900 24 11 51
9 55.0 900 24 12 59
10 48.0 900 18 24 46
11 63.0 900 22 18 30
12 56.0 900 18 11 25
M ean 54.5 900 20.8 17.7 42.8
13 56.0 900 20 21 28
14 51.0 900 20 26 51
15 44.0 900 22 38 82
16 53.0 900 24 52 MD
17 56.0 900 21 16 31
18 49.0 900 19 21 54
M ean 51.5 900 21.0 29.0 49.2
19 54.0 900 21 18 40
20 54.0 900 23 18 47
21 45.0 800 20 13 23
22 59.0 900 21 14 30
23 55.0 900 15 21 39
24 53.0 900 16 24 29
25 53.0 1000 29 45 69
M ean 53.3 900 19.3 21.9 39.6
T able  3.15a. Demographic and anaesthetic details of a group of sheep undergoing 
general anaesthesia with or without ventral midline laparotomy.
Weight, dose of intravenous anaesthetic agent (thiopentone (Thio)) in milligrams (mg), 
duration of general anaesthesia (Time GA) in minutes (min), time to sternal recumbency 
from the end of anaesthesia (Sternal) and time to standing from the end of anaesthesia in a 
group of sheep undergoing ventral midline laparotomy for embryo retrieval. Group 1 
(sheep numbers 7-12), 2 (sheep numbers 13-18) and 3 (sheep numbers 1-6) were 
administered the following drugs intra-operatively, IV: flunixin meglumine (1.0 mg/kg),
carprofen (4.0 mg/kg) and buprenorphine (10 Jig/kg) respectively. Group 4 (sheep 
numbers 19-25) received no treatment.
MD= Missing data
*p<0.01, significant difference between groups.
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S heep Weight Dose Thio. Tim e GA S te rn a l St and ing
N um b e r (kg) (mg) (min) (min) (min)
26 64.0 1000 20 8 15
27 59.0 1000 20 15 38
28 64.0 1000 20 24 46
29 55.0 1000 20 13 25
M ean 60.5 1000 20.0 15.0 31.0
Dose Ket.
(mg)
3 0 59.0 590 17 30 73
31 51.0 510 18 10 16
32 51.0 510 21 15 17
33 56.0 560 29 8 10
34 43.0 430 21 20 24
35 53.0 530 13 16 26
M ean 52.2 521.7 19.8 16.5 27.7
Table 3.15b. Demographic and anaesthetic details of a group of sheep undergoing 
general anaesthesia with or without ventral midline laparotomy.
Weight, dose of intravenous anaesthetic agent (thiopentone (Thio) or ketamine (Ket)) in 
milligrams (mg), duration of general anaesthesia (Time GA) in minutes (min), time to 
sternal recumbency from the end of anaesthesia (Sternal) and time to standing from the 
end of anaesthesia in a group of sheep undergoing ventral midline laparotomy for embryo 
retrieval (sheep numbers 30-35), or general anaesthesia (sheep numbers 26-29).
MD= Missing data
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No. 1 No. 2 No. 3 No. 4 No. 5 No. 6 M ean ±SEM
Time T herm
(min)
Pre 60.2 46.4 56.6 60.2 57.0 58.7 56.5 2.12
30 55.0 MD MD MD 65.0 56.9 59.0 *
45 54.0 54.0 MD MD 59.8 59.0 56.7 1.57
60 53.0 MD 65.0 60.5 51.0 54.4 56.8 *
90 MD 47.5 60.0 MD 54.7 46.3 52.1 3.2
120 58.0 51.0 55.0 64.5 52.9 56.7 56.4 2.0
Mech
P re 4.8 - 4.8 5.2 7.8 4.4 7.3 5.7 0.59
60 6.2 MD MD MD MD MD 6.2 0
90 7.5 3.9 6.5 8.2 7.8 8.2 7.0 0.67
120 7.8 4.2 9.8 12.8 2.5 12.2 oo to 1.72
Table 3.16. Thresholds to noxious mechanical and thermal stimulation post- 
operatively, for sheep administered buprenorphine (10 fig/kg, IV) intra-operatively.
Individual and mean thresholds to noxious mechanical (Mech) (Newtons) and thermal 
(Therm) (°C) stimulation, ± standard error of the mean (SEM), in a group of 6 normal 
sheep post-operatively. The SEM is not shown where at least 1 sheep attained a maximal
response at that time. Buprenorphine hydrochloride, 10 Jig/kg, IV, was administered 
within 5 minutes of the end of anaesthesia. After surgery, mechanical thresholds were 
evaluated once sheep were standing unaided, while thresholds to noxious thermal 
stimulation were evaluated once sheep were in sternal recumbency.
Pre-readings (Pre) are the mean of at least 3 thresholds recorded over a 30 minute period 
prior to anaesthesia.
MD= Missing data *At least 1 sheep achieved maximum threshold
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No. 7 No. 8 No. 9 No. 10 No. 11 No. 12 M ean ±SEM
Tim e T herm
(min)
Pre 54.0 52.5 59.0 60.0 58.9 61.7 57.7 1.47
30 MD 51.0 58.0 65.0 57.3 62.0 58.7 *
45 55.0 48.0 62.5 59.0 54.2 64.0 57.1 2.42
60 55.0 51.0 57.0 65.0 53.9 65.0 57.8 *
90 54.0 53.0 55.0 62.0 50.9 65.0 56.7 *
120 65.0 65.0 51.0 60.0 60.7 64.0 61.0 *
Mech
P re 13.5 9.2 5.3 6.0 4.0 7.7 7.6 1.39
60 13.2 8.5 11.2 9.2 5.8 7.8 9.2 1.06
90 MD 6.5 6.2 MD 10.8 MD 7.8 1.49
120 7.2 8.2 6.2 6.2 4.5 5.8 6.4 0.51
T ab le  3.17. Thresholds to noxious mechanical and thermal stimulation post- 
operatively, for sheep administered flunixin meglumine (1.0 mg/kg, IV) intra-operatively.
Individual and mean thresholds to noxious mechanical (Mech) (Newtons) and thermal
(Therm) (°C) stimulation, ± standard error of the mean (SEM), in a group of 6 normal 
sheep post-operatively. The SEM is not shown where at least 1 sheep attained a maximal 
response at that time. Flunixin meglumine, 1.0 mg/kg, IV, was administered within 5 
minutes of the end of anaesthesia. After surgery, mechanical thresholds were evaluated 
once sheep were standing unaided, while thresholds to noxious thermal stimulation were 
evaluated once sheep were in sternal recumbency.
Pre-readings (Pre) are the mean of at least 3 thresholds recorded over a 30 minute period 
prior to anaesthesia.
MD= Missing data *At least 1 sheep achieved maximum threshold
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N o . N o . N o . N o . N o . N o . M ean ±SEM
13 14 1 5 16 17 18
Tim e Therm
(min)
Pre 56.5 56.0 58.0 59.0 54.9 57.7 57.0 0.61
3 0 54.0 57.0 MD MD 51.8 65.0 57.0 *
45 61.0 52.0 64.0 MD 65.0 65.0 61.4 *
6 0 63.0 61.0 64.0 65.0 59.4 65.0 62.9 *
90 63.0 64.0 63.0 65.0 65.0 55.4 62.6 *
120 MD 65.0 61.0 65.0 57.1 61.0 61.8 *
Mech
P re 6.8 6.4 7.6 6.2 5.4 6.8 6.5 0.30
60 10.5 8.8 MD 6.8 4.5 12.8 8.7 1.44
90 MD MD 10.5 MD 7.8 5.2 7.8 1.53
120 6.8 9.5 4.5 MD 7.2 11.8 8.0 1.24
Table 3.18. Thresholds to noxious mechanical and thermal stimulation post- 
operatively, for sheep administered carprofen (4.0 mg/kg, IV) intra-operatively.
Individual and mean thresholds to noxious mechanical (Mech) (Newtons) and thermal
(Therm) (°C) stimulation, ± standard error of the mean (SEM), in a group of 6 normal 
sheep post-operatively. The SEM is not shown where at least 1 sheep attained a maximal 
response at that time. Carprofen, 4.0 mg/kg, IV, was administered within 5 minutes of 
the end of anaesthesia. After surgery, mechanical thresholds were evaluated once sheep 
were standing unaided, while thresholds to noxious thermal stimulation were evaluated 
once sheep were in sternal recumbency.
Pre-readings (Pre) are the mean of at least 3 thresholds recorded over a 30 minute period 
prior to anaesthesia.
MD= Missing data *At least 1 sheep achieved maximum threshold
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N o . N o . N o . N o . N o . N o . N o . M ean ±SEM
19 20 2 1 22 23 24 25
Tim e T herm
(min)
Pre 63.7 57.6 62.5 60.5 62.3 53.0 52.4 58.8 1.75
30 45.0 52.6 48.0 62.0 56.0 MD 45.1 51.5 2.75
45 45.5 48.0 55.0 MD 54.0 49.7 45.8 49.7 1.66
60 53.0 51.0 49.0 59.0 54.5 45.6 47.5 51.4 1.72
90 MD 55.0 49.0 60.0 64.0 51.8 47.8 54.6 2.60
120 55.5 57.0 59.0 54.0 65.0 48.1 45.5 54.9 *
Mech *
P re 9.6 7.0 6.2 4.8 6.8 4.0 7.5 6.6 0.69
60 14.8 10.2 11.8 7.8 9.8 3.2 MD 9.6 1.60
90 7.2 11.5 9.2 MD 7.8 4.2 5.5 7.6 1.06
120 5.8 7.8 4.5 16.0 8.2 1.2 5.8 7.0 *
Table 3.19. Thresholds to noxious mechanical and thermal stimulation for sheep post- 
operatively.
Individual and mean thresholds to noxious mechanical (Mech) (Newtons) and thermal
(Therm) (°C) stimulation, ± standard error of the mean (SEM), in a group of 7 normal 
sheep post-operatively. The SEM is not shown where at least 1 sheep attained a maximal 
response at that time. After surgery, mechanical thresholds were evaluated once the sheep 
were standing unaided, while the thresholds to noxious thermal stimulation were 
evaluated once the sheep was in sternal recumbency.
Pre-readings (Pre) are the mean of at least 3 thresholds recorded over a 30 minute period 
prior to anaesthesia.
MD= Missing data *At least 1 sheep achieved maximum threshold
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N o . N o . N o . N o . Mean ±SEM
26 27 28 29
Ti me Therm
(min)
Pre 54.4 51.0 54.0 51.3 52.7 0.89
3 0 55.4 52.4 51.8 55.3 53.7 0.95
45 55.1 58.0 55.7 55.3 56.0 0.67
6 0 54.6 54.0 57.1 51.9 54.4 1.07
90 51.9 57.3 53.5 51.9 53.7 1.27
120 51.6 50.0 50.3 53.4 51.3 0.77
Mech
P re 2.9 9.2 10.6 5.6 7.1 1.75
6 0 3.9 8.5 9.8 10.2 8.1 1.45
90 2.5 8.5 9.2 13.2 8.4 2.21
120 3.9 7.5 12.2 16.0 9.9 *
Table 3.20. Thresholds to noxious mechanical and thermal stimulation for sheep post­
general anaesthesia.
Individual and mean thresholds to noxious mechanical (Mech) (Newtons) and thermal
(Therm) (°C) stimulation, ± standard error of the mean (SEM), in a group of 4 normal 
sheep post-anaesthesia. The SEM is not shown where at least 1 sheep attained a maximal 
response at that time. After anaesthesia, mechanical thresholds were evaluated once sheep 
were standing unaided, while thresholds to noxious thermal stimulation were evaluated 
once sheep were in sternal recumbency.
Pre-readings (Pre) are the mean of at least 3 thresholds recorded over a 30 minute period 
prior to anaesthesia.
*At least 1 sheep achieved maximum threshold
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N o . N o . N o . N o . N o . N o . M ean ±SEM
30 31 32 33 34 35
T im e Therm
(m in)
P re 54.4 57.4 60.1 55.9 57.9 52.1 56.3 1.14
30 57.9 MD 58.0 51.3 61.7 54.0 56.6 1.79
45 56.8 MD 59.3 57.8 61.7 54.0 57.9 1.28
60 53.9 59.3 61.3 59.0 58.9 54.1 57.8 1.24
90 56.7 42.0 56.3 53.8 63.2 56.7 54.6 2.77
120 51.0 57.8 55.5 59.3 61.3 51.3 56.0 1.73
Mech
P re 2.7 6.4 3.6 8.3 5.4 2.9 4.9 0.91
60 6.2 7.8 11.2 15.2 9.2 4.5 9.0 1.56
90 3.5 8.2 MD 4.8 7.8 5.5 6.0 0.89
120 8.8 6.2 4.8 3.5 6.2 9.2 6.5 0.91
Table 3.21. Thresholds to noxious mechanical and thermal stimulation for sheep post- 
operatively.
Individual and mean thresholds to noxious mechanical (Mech) (Newtons) and thermal
(Therm) (°C) stimulation, ± standard error of the mean (SEM), in a group of 6 normal 
sheep post-anaesthesia. Anaesthesia was induced by injection of ketamine hydrochloride, 
10 mg/kg, IV. After surgery mechanical thresholds were evaluated once sheep were 
standing unaided, while thresholds to noxious thermal stimulation were evaluated once 
sheep were in sternal recumbency.
Pre-readings (Pre) are the mean of at least 3 thresholds recorded over a 30 minute period 
prior to anaesthesia.
MD= Missing data
9 2
o
UL
20
18
16
14
12
10
8
6
4
2
0
0
Maximum force
6 0  9 0
Time (min)
1 20
■ No Tx
□ GA
□ Flu
E3 Carp
Bup
□ Ket
Fi gu r e  3.12. Thresholds to noxious mechanical stimulation for sheep either post- 
operatively and post-anaesthesia, and the effect of various intra-operative treatments.
Changes in mechanical threshold responses in 5 groups of sheep post-operatively and 1 
group of sheep post-anaesthesia (n=4) (GA). Sheep which underwent surgery were 
allocated to the following groups: thiopentone induction (n=7) (NoTx); thiopentone 
induction and flunixin meglumine, 1.0 mg/kg, IV, before end of anaesthesia (n=6) (Flu); 
thiopentone induction and carprofen, 4.0 mg/kg, IV, before end of anaesthesia (n=6)
(Carp); thiopentone induction and buprenorphine hydrochloride, 10 Jig/kg, IV, before 
end of anaesthesia (n=6) (Bup); ketamine induction (n=6) (Ket).
The response threshold (Newtons) is plotted against time (min). Each point indicates the 
mean and standard error of the mean (SEM) for readings obtained at each time point. The 
SEM for each time point is not shown where at least 1 sheep attained a maximal response 
at that time. The pre-test reading is the mean of at least 3 readings for each sheep over a 
thirty minute time period before anaesthesia, and is shown at time time 0.
The maximum force (16N) is indicated.
All groups n=6 except No Tx, n=7, GA, n=4, unless stated below.
1- (n=l) 3- (n=3)
5- (n=5) 6- (n=6)
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T herm al nociceptive testing
The changes in threshold to noxious thermal stimulation were recorded for all sheep in the 
recovery period and are documented in Tables 3.16, 3.17, 3.18, 3.19 3.20 and 3.21. 
There were no significant differences between groups pre-operatively. Further analysis 
indicated that there were significant differences between the groups post-operatively.
Thresholds to noxious thermal stimulation in sheep which underwent a surgical 
procedure, but did not receive any drug treatment, were found to be significantly lower 
(p<0.05) 45, 60 and 120 minutes after the end of anaesthesia, than the thresholds 
obtained pre-operatively (Fig. 3.13). Sheep which were anaesthetised but did not 
undergo surgery, were found to have thresholds similar to those obtained pre-anaesthesia 
at all time points (Fig. 3.13). Thresholds to noxious thermal stimulation in sheep which 
underwent surgery and received flunixin prior to the end of general anaesthesia were not 
significantly different from those recorded pre-operatively (Fig. 3.14). Administration of 
carprofen yielded a similar result (Fig. 3.14). However, thresholds to noxious thermal 
stimulation in these sheep were significantly greater than control values for the group 
(p<0.05) 60 minutes post-operatively. Thresholds to noxious thermal stimulation in 
sheep which underwent surgery and received buprenorphine prior to the end of general 
anaesthesia were not significantly different from those recorded pre-operatively (Fig.
3.15) and similarly, thresholds for sheep in which anaesthesia was induced by the 
administration of ketamine did not change significantly in the post-operative period (Fig.
3.16).
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Maximum threshold temperature ■ No Tx
□ GA
Time
6 0  9 0
(min)
Figure 3.13. Changes in thermal threshold responses in 1 group of sheep post- 
operatively (n=7) (No Tx) and a second group of sheep (n=4) after general anaesthesia 
(GA).
The response threshold (°C) is plotted against time (min). Each point indicates the mean 
and standard error of the mean (SEM) for readings obtained at each time point. The SEM 
for each time point is not shown where at least 1 sheep attained a maximal response at that 
time. The pre-test reading is the mean of at least 3 readings for each sheep over a thirty 
minute time period before anaesthesia, and is shown at time time 0.
The maximum threshold temperature (65 °C) is indicated.
*p<0.05, significantly different from pre-test values. 
No Tx, n=7 and GA, n=4, unless stated below.
6- (n=6)
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Figure 3.14. Post-operative changes in thermal threshold responses in 3 groups of 
sheep, 2 of which received different intra-operative treatments.
One group received no treatment (n=7) (No Tx), a second was administered flunixin 
meglumine (n=6) (Flu), 1.0 mg/kg, IV, within 5 minutes of the end of anaesthesia, while 
the third group (n=6) received carprofen, 4 mg/kg, IV.
The response threshold (°C) is plotted against time (min). Each point indicates the mean 
and standard error of the mean (SEM) for readings obtained at each time point. The SEM 
for each time point is not shown where at least 1 sheep attained a maximal response at that 
time. The pre-test reading is the mean of at least 3 readings for each sheep over a thirty 
minute time period before anaesthesia, and is shown at time time 0.
The maximum threshold temperature (65 °C) is indicated.
*p<0.05, significantly different from pre-test values.
All groups n=6 except No Tx, n=7, unless stated below.
4- (n=4) 
6- (n=6)
5 - (n=5)
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Figure 3.15. Post-operative changes in thermal threshold responses in 2 groups of 
sheep, 1 of which received buprenorphine hydrochloride intra-operatively.
One group received no treatment (n=7) (No Tx), the second was administered
buprenorphine hydrochloride (n=6) (Bup), 10 Jig/kg, IV, within 5 minutes of the end of 
anaesthesia.
The response threshold (°C) is plotted against time (min). Each point indicates the mean 
and standard error of the mean (SEM) for readings obtained at each time point. The SEM 
for each time point is not shown where at least 1 sheep attained a maximal response at that 
time. The pre-test reading is the mean of at least 3 readings for each sheep over a thirty 
minute time period before anaesthesia, and is shown at time time 0.
The maximum threshold temperature (65 °C) is indicated.
*p<0.05, significantly different from pre-test values.
No Tx, n=7 and Bup, n=6, unless stated below.
3- (n=3) 4- (n=4)
5- (n=5) 6- (n=6)
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Figure 3.16. Post-operative changes in thermal threshold responses in 2 groups of 
sheep after induction of general anaesthesia using different agents.
Induction of general anaesthesia was achieved by administration of thiopentone, IV, in 
one group (n=7) (No Tx),while in the second group (n=6) (Ket), induction of general 
anaesthesia was achieved by administration of ketamine, IV.
The response threshold (°C) is plotted against time (min). Each point indicates the mean 
and standard error of the mean (SEM) for readings obtained at each time point. The SEM 
for each time point is not shown where at least 1 sheep attained a maximal response at that 
time. The pre-test reading is the mean of at least 3 readings for each sheep over a thirty 
minute time period before anaesthesia, and is shown at time time 0.
The maximum threshold temperature (65 °C) is indicated.
*p<0.05, significantly different from pre-test values.
No Tx, n=7 and Ket, n=6, unless stated below.
5- (n=5) 6- (n=6)
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3.4 Discussion
It has been suggested that it is important to match groups of experimental animals when 
examining the pharmacological effects of drugs (Ley et al. , 1990a), and in all 3 of the 
present studies sheep were matched for both breed and weight. In study 1, a total of 8 
experimental sheep were used. Five of these sheep were Suffolk x Scottish Blackface, and 
the remaining 3 were Border Leicester x Scottish Blackface (Greyface). These sheep were 
closely matched for weight at the time of each experiment, and statistical analysis indicated 
that there were no significant differences between threshold readings obtained for individual 
sheep within each treatment group. There were no breed differences between sheep allocated 
to treatment groups in study 2 or 3, and all sheep were closely matched for weight. Variation 
in the analgesic effect of xylazine hydrochloride, 50 p.g/kg, administered to sheep of 
different breeds has been observed (Ley et al. , 1990a). Variation in the sedative effects of 
this drug also have been noted in different breeds of cattle (Raptopoulos and Weaver, 1984) 
and between individual sheep (Kyles et al. , 1993), although no direct correlation with sheep 
breed was demonstrated in the latter study. Ley et al. (1990a) commented that the differences 
seen in their study may have reflected a breed difference, although further investigations 
indicated that the difference lay in body weight difference.
3.4.1 Study 1
The mechanical threshold testing apparatus used in this study was similar to that which had 
been used successfully to evaluate thresholds to noxious mechanical stimulation in horses 
(Chambers et al. , 1990; Chambers et al. , 1993a), and subsequently in sheep (Muge and 
Livingston, 1992). The thermal threshold testing apparatus was based on an original design 
described by Nolan et al. (1987a). Therefore, it was considered important that the 
repeatability of these 2 units was studied. Results consistent with those found previously in 
sheep (Nolan et al. , 1987a) were recorded, with no significant change in the threshold to 
noxious mechanical and thermal stimulation over a 6 hour period. Thresholds to both 
noxious mechanical and thermal stimulation also were similar to those reported previously 
by Nolan et al. (1987c). It is important that sensitization of the stimulated area does not 
develop over the testing period as this would influence results recorded after drug 
administration. Moreover, the presence of leg and ear units did not appear to alter the 
behaviour of the sheep used in this study. Dummy units, as previously described (Nolan et 
al. , 1987a), were not used.
Results recorded following xylazine injection, a drug with known antinociceptive properties 
in sheep (Nolan et al. , 1987a; 1987b; Ley et al. , 1990a; 1991a; Muge and Livingston, 
1992), significantly elevated thresholds to both mechanical and thermal noxious stimulation.
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Sheep were not moved after administration of xylazine, but those which remained standing 
swayed, and all sheep were sedated heavily. The end-points used for the mechanical and 
thermal threshold testing procedures used in this study are motor responses i. e. leg lift and 
ear flick. Drugs which impair motor ability e. g. xylazine, may therefore influence these test 
systems. The effects of a sedative /  ataractic drug, acetylpromazine, has been investigated on 
the thresholds to noxious mechanical and thermal stimulation in sheep, and was found not to 
change thresholds significantly from pre-treatment values (Nolan et al. , 1987a). Similar 
results have been obtained in the horse (Chambers et al. , 1990; Chambers et al. , 1993a). 
Further investigations on the effects of non-analgesic sedative / ataractic drugs were not 
conducted in the present study because there is no available evidence which suggests that 
NSAIDs impair motor ability.
, Non-steroidal anti-inflammatory drugs may be evaluated in the laboratory using a wide 
variety of models (Otterness and Bliven, 1985). However, laboratory models which induce 
inflammation e. g. Randall Selitto assay (Randall and Selitto, 1957), are used most 
commonly in the assessment of antinociceptive or analgesic efficacy of these drugs. Tests of 
physiological pain in normal animals frequently do not detect antinociceptive activity of 
NSAIDs (Winder, 1959). However, detailed inspection of thresholds to noxious thermal 
stimulation after administration of carprofen, 0.7 mg/kg, IV, indicated an elevation in 
thresholds, although not significant, which persisted for a period of approximately 2 hours, 
that was not evident after administration of placebo. The antinociceptive effects of carprofen 
have been determined in normal horses using thermal threshold testing apparatus 
(Schatzmann et al. , 1990) consisting of a heating element fixed to a girth and tightly 
apposed to a clipped area behind the elbow. Carprofen, 0.7 mg/kg, IV, elevated thresholds 
to noxious thermal stimulation in all horses tested over 24 hours. However, statistical 
analysis was not carried out on the carprofen data and analgesia was defined as an elevation 
in thermal threshold of >1°C at 3 successive determination times for each horse when 
compared with the pre-treatment values obtained for the same horse. Similar criteria applied 
to the data obtained in the present study for normal sheep in the first 2 hours after drug or 
saline administration, indicated that saline caused analgesia in one sheep, while carprofen, 
using either dose rate, caused analgesia in a total of 2 animals in each case. Schatzmann et al. 
(1990) also investigated the relationship between plasma concentration of carprofen and 
analgesia to noxious thermal stimulation. They suggested that plasma levels of carprofen 
>1.5 M-g/ml were required to demonstrate an analgesic effect of the drug. In sheep, similar 
levels of carprofen have been detected in plasma for at least 72 and 48 hours after 
administration of 4.0 and 0.7 mg/kg, IV, respectively (Welsh et al. , 1992). However since 
analgesia was not detected in the present study it is impossible to predict if a similar plasma 
level of carprofen is required in sheep to produce analgesia. Unfortunately, Schatzmann et 
al. (1990) did not record beyond 24 hours and thresholds to noxious thermal stimulation did
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not return to normal. Moreover, in the latter study the standard errors of the mean were 
greater than 1 at every time point after the administration of carprofen, limiting the 
conclusions which may be drawn from the work.
The antinociceptive properties of carprofen have been demonstrated in inflammatory models 
e. g. phenylquinone-induced mouse writhing and rat yeast paw tests (Randall and Baruth, 
1976; Strub et al. , 1982), while the sensitivity of non-inflamed tissue was not affected. The 
present study in sheep confirmed these findings. It is interesting to note that carprofen is a 
relatively weak inhibitor of cyclooxygenase and that effective anti-inflammatory and 
analgesic doses of carprofen in laboratory mammals do not influence the production of 
cyclooxygenase (Strub et al. , 1982; Baruth et al, 1985), suggesting that other mechanisms 
may play a role in the antinociceptive properties of the drug. Although these mechanisms 
have not been elucidated, it appears that carprofen exerts antinociceptive effects only in the 
presence of an inflammatory focus. There is no evidence to date that carprofen acts to inhibit 
lipoxygenase, although it has been shown to be a weak inhibitor of phospholipase A2, one 
of the enzymes involved in the release of arachidonic acid from membrane bound sites 
(Hope and Welton, 1983). Inhibition of release of arachidonic acid would influence 
production, not only of the cyclic endoperoxides such as PGG2, but also the formation of 
the primary prostanoids i. e. PGD2, PGE2, PGF2a  and PGI2- Moreover, substrate for 
lipoxygenase metabolism also would be diminished, limiting production of the leukotrienes. 
Although laboratory models using pain induced by an inflammatory process have shown 
carprofen to be antinociceptive (Strub e ta l . , 1982; Baruth et al, 1985), such models would 
not distinguish between possible modes of action i. e. inhibition of cyclooxygenase or 
inhibition of phospholipase.
Inspection of thresholds to noxious thermal stimulation after administration of flunixin, 1.0 
and 2.0 mg/kg, IV, indicated an elevation in thresholds, which persisted for a period of 
approximately 2 hours. Schatzmann et al. (1990) did not detect an elevation in cutaneous 
thresholds to noxious thermal stimulation after administration of flunixin, 1.1 mg/kg, IV, 
which supported previous findings using similar models in horses at a higher dose rate, 2.2 
mg/kg, IM (Lumb et al. , 1983; Kalpravidh et al. , 1984). The analgesic efficacy of flunixin,
2.2 mg/kg, IM, against experimentally induced visceral pain also was examined in the latter 
2 studies, and it was reported that although flunixin is an effective analgesic for clinical 
visceral pain, it was ineffective in these models (Vernimb and Hennessey, 1977). However, 
recently it has been reported that flunixin, 2.2 mg/kg, IV, in normal sheep caused a 
significant rise in thresholds to noxious mechanical stimulation, for a period of at least 1 
hour, with a maximal effect at 30 minutes after administration (Chambers et al. , 1993b). 
Pre-treatment with the opioid antagonist, naloxone, prevented the hypoalgesic response and 
the authors suggested that flunixin may be acting via a descending system which includes an
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opioidergic link. In the present study, thresholds to noxious thermal and mechanical 
stimulation were recorded every 30 minutes and it is possible that an increase in mechanical 
thresholds may have been obscured between sampling points. However, subsequent 
investigations in normal sheep with more frequent readings taken over 60 minutes (data not 
shown), also failed to detect the hypoalgesic effect of flunixin in normal sheep demonstrated 
by Chambers et al. (1993b). The antinociceptive properties of flunixin were initially 
evaluated using the standard battery of tests for NSAIDs (see chapter 1 and 4), including the 
acetic acid-induced mouse writhing and rat yeast paw tests (Ciafalo et al. , 1975), and it was 
shown that it was either equipotent, or more potent, than pentazocine, a partial opioid 
agonist, and pethidine or codeine, full opioid agonists. Interestingly, Ciofalo et al. (1977) 
also demonstrated that flunixin elevated the tail shock thresholds in normal monkeys, and 
commented that this was an unusual feature for a drug thought to exert its antinociceptive 
effects by inhibiting the enzyme, cyclo'oxygenase. In contrast, flunixin was not effective at 
elevating the threshold to heat-evoked tail flick in mice (Ciofalo e ta l . , 1977). The elevation 
in thresholds to noxious stimulation reported in normal animals after administration of 
flunixin (Ciofalo et al. , 1977; Chambers et al. , 1993b), suggests that this drug may not act 
by inhibiting cyclooxygenase alone, and as proposed by the latter authors, a second, 
possibly central mode of action may be of importance. However, it is apparent that the 
antinociceptive effects of flunixin against physiological pain are very variable, and are not 
detected in every test system.
Inhibition of serum thromboxane production may be used as an indicator of serum 
cyclooxygenase inhibition (Vane, 1971). Flunixin, 1.1 and 2.2 mg/kg, IM, in cattle caused a 
94 and 99 % inhibition of serum thromboxane B2 production (TXB2) respectively, 6 hours 
after drug administration (Lees et al. , 1991a). Similarly, production of PGE2 in 
inflammatory exudate in cattle was inhibited by 94 and 95 % respectively. Serum levels of 
flunixin of approximately 2 jig/ml have been shown to result in >90 % inhibition of serum 
TX B 2 in dogs (McKellar et al. , 1989), while values below this level did not cause 
significant inhibition of serum TXB2 in horses and cats (Lees and Taylor, 1991; Soma et al.
, 1992). Similar studies have not been conducted in sheep, although it is considered likely 
that doses used in the present studies would be sufficient to cause significant inhibition of 
cyclooxygenase in vivo. However, if the antinociceptive activity of flunixin is related to the 
degree of inhibition of cyclooxygenase, it is important that such studies are carried out. 
However, levels of TXB2 in sheep are low (McKellar et al. , 1990a) and accurate 
determination of inhibition would be difficult.
The results of the present study indicate that the prostaglandins are probably not involved in 
mediating nociceptive information processing in physiological pain in sheep.
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3.4.2 Study 2
Thresholds to noxious mechanical stimulation in farm sheep which were not familiar with 
mechanical threshold testing were found to be significantly different from those recorded in 
experimental sheep, familiar with the test system. This occurred despite a 'settling in' period 
in the test area after sheep had been collected from the field, or shed in which they were 
maintained. Moreover, although sheep were penned individually during the period of 
threshold testing, they were not separated visually from their usual flock mates, which were 
held in an adjacent pen. These measures have been recommended to limit stress in 
experimental sheep (Livingston et al. , 1992a). However, exposure of the 'naive' farm 
sheep to the testing procedure over a period of 3 days caused a significant change in the 
thresholds to noxious mechanical stimulation, and by day 3, the thresholds were not 
significantly different from those recorded in experimental sheep (study 1). Thus it appears 
that 'naive' sheep become accustomed to the testing procedure over a period of 3 days, a 
finding supported by studies in laboratory rats (Taiwo et al. , 1989). The latter workers 
studied thresholds in 2 groups of rats over a 4 day period using a mechanical nociceptive 
paw withdrawal reflex, before and after administration of a hyperalgesic agent, bradykinin, 
or saline. They reported that the baseline thresholds recorded on the fourth day of testing 
were significantly lower than those recorded on the first day of the study. There was no 
significant difference between thresholds recorded on the third and fourth day of testing. 
Moreover, they demonstrated that the unexpected hyperalgesia shown after intraplantar 
injection of saline on day 1, was no longer demonstrable after training. This differed from 
the findings after administration of bradykinin, which always caused hyperalgesia after 
injection. Taiwo et al. (1989) suggested that the increase in sensitivity achieved after a 
training period in rats may be crucial where the expected changes in threshold after drug 
treatment are small, and the work presented here supports these findings strongly.
The farm sheep were all Border Leicester x Scottish Blackface (Greyface) and only 3 of the 
experimental sheep were of this breed, but derived from the same flock. Moreover, 5 of the 
experimental sheep were neutered males, whereas all the farm sheep were female. 
Preliminary studies indicated that rams had higher thresholds to noxious mechanical 
stimulation than females. However, this was not true of neutered males. Although 
differences in the extent and duration of xylazine analgesia has been reported between 
different breeds of sheep using mechanical threshold testing apparatus similar to that used in 
the present study (Ley et al. , 1990a), there have been no reports of differences in pre­
treatment thresholds to noxious mechanical stimulation between breeds or sexes. The 
experimental sheep were maintained indoors at all times whereas, the farm sheep were 
maintained either indoors or in a field. Hair was not clipped from the antebrachium of either
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group prior to positioning of the leg unit. It is possible that the differences recorded may be 
related to the density of the hair on the limb, with sheep maintained outdoors having more 
dense hair and possibly less sensitivity to the threshold testing unit. However, the fact that 
thresholds reduced over 3 days to levels similar to those recorded in experimental sheep, 
refutes this. Although sheep in the present study were confined to a small pen, they were not 
physically restrained, and it is interesting to note that they appeared to become less anxious 
over the 3 day testing period when the operator entered the pen to position the leg unit of the 
threshold testing apparatus.
It has been suggested by Hayes et al. (1978) that exposure to pain can activate endogenous 
systems which regulate nociceptive input. However, these workers recognised that pain 
alone may not be the only factor, but that stress associated with noxious stimulation or 
restraint may play an important modulatory role. They demonstrated that although noxious 
stimuli produced either a narcotic or non-narcotic mediated analgesia, stress alone is not 
always sufficient to produce a non-narcotic analgesia. They also commented that stress- 
induced increases in adrenocorticotrophic hormone (ACTH) or endogenous corticosteroids 
were unlikely to mediate either narcotic or non-narcotic mediated stress-induced analgesia. 
Stress-induced increases in ACTH and cortisol have been shown in sheep (Hargreaves and 
Hutson, 1990a; Parrott, 1990; Apple et al. , 1992) although concomitant analgesia has not 
been described.
Various neurotransmitters have been implicated in stress-induced analgesia including 5- 
hydroxytryptamine, dopamine, noradrenaline and endogenous opioids e. g. p-endorphin, 
(Akil et al. , 1986; Curzon et al. , 1986; Ademola and Hart, 1990), but elucidation of the 
characteristics of stress-induced analgesia depend not only of the species under 
investigation, but the type, duration and intensity of the stimulus (Ademola and Hart, 1990) 
making progress in the field slow. Parrott (1990) investigated the physiological responses to 
isolation in sheep and demonstrated elevated levels of cortisol and noradrenaline, a transient 
reduction in vasopressin and very little effect on prolactin, adrenaline or dopamine. In the 
present study, it is important to note that sheep were not visually isolated from their flock 
mates, and in addition limited tactile contact between sheep was possible. Elevations in 
plasma concentrations o f p-endorphin and p-lipotrophin during shearing and 
electroimmobilisation have also been reported (Jephcott et al. , 1987). However, Wood et al.
, (1991) showed that pre-treatment with naloxone did not prevent significant elevations in 
plasma cortisol levels in lambs castrated and tail docked without anaesthesia, and they 
suggested that sheep may have a limited ability to reduce pain and distress by release of 
endogenous opioids. Recently, Rovati et al. (1990) demonstrated that administration of the 
anxiolytic benzodiazepines, diazepam and clonazepam, reduced the analgesia observed after 
inescapable footshock in rats. Moreover, they showed that specific benzodiazepine receptor
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antagonists increased the observed analgesia whereas inverse agonists did not alter the 
response. Although the initial findings of these authors appear encouraging, suggesting that 
anxiety plays an important role in stress-induced analgesia, the other findings are difficult to 
explain. The inverse agonists used in the study were anxiogenic and consequently would be 
expected to elevate thresholds, while the antagonists ought to have no effect on the receptor. 
This is inconsistent with their findings. Jephcott et al. (1988) showed that pre-treatment with 
diazepam did not limit or abolish the increase in plasma cortisol seen in sheep during 
electroimmobilisation.
Stress-induced analgesia may have caused the elevation of thresholds to noxious mechanical 
stimulation found in 'naive' sheep in the present study. However, determination of plasma 
concentration of cortisol or other stress released agents was not carried out, and therefore, it 
is impossible to relate the fall in thresholds over the 3 day test period to a comparable 
alteration in plasma levels of these agents. Pilot studies using experimental sheep 
accustomed to the testing procedure have indicated that physical and visual separation from 
the group caused marked elevations of thresholds to noxious mechanical stimulation. 
Hargreaves and Hutson (1990b) demonstrated that repeated exposure of sheep to sham 
shearing did not change the peak cortisol response, but showed that plasma concentrations 
declined more rapidly to pre-handling values at the end of the training period. The training 
period in the latter study extended over a period of 8 weeks with sheep exposed to the 
stressor only once every 14 days, and so it is difficult to draw comparisons with the present 
study. S im ilarly , Jephcott et al. (1986) found that repeated exposure to 
electroimmobilisation, twice daily for 2 days, did not result in diminution of the measured 
cortisol, prolactin, p-endorphin or p-lipotrophin response in sheep. However, Hargreaves 
and Hutson (1990b) suggested that repetition may be more effective in lowering the stress 
response to less severe stimuli, as the sheep in their study demonstrated a strong conditioned 
aversive response to shearing.
Thresholds to noxious mechanical stimulation in 'naive' farm sheep suffering from footrot, 
were not significantly different from thresholds recorded in normal sheep from the same 
farm. It is interesting to note that when thresholds were evaluated over a period of 3 
consecutive days in these sheep, the thresholds recorded on day 3 were not significantly 
different from those recorded on day 1, unlike the pattern shown in 'naive' farm controls. 
This may indicate that sheep suffering chronic pain have a stress-induced analgesia which 
persists when they are accustomed to the testing procedure. Sheep suffering chronic pain, as 
a result of footrot, have been shown to have significantly lower plasma concentrations of 
cortisol than control sheep, with increased levels of plasma prolactin, and it has been 
demonstrated that plasma levels of these agents return towards normal values with resolution 
of the condition (Ley et al. , 1991b). These findings obviously demonstrate that
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physiological responses to chronic pain in sheep differ from those found in acute pain (vide 
supra). Presently, there are no studies which have evaluated the role of endogenous opioids 
in chronic pain in sheep and it is possible they may play a role.
The present study included 4 sheep with footrot present in both forefeet, and therefore sheep 
were required to weight bear on an affected limb in order to withdraw the contralateral limb 
from the noxious stimulus. This may have contributed to the high threshold values recorded 
over the test period. However, only 4 of the 10 sheep with unilateral lameness tested in 
study 2 were found to have a threshold lower than the mean threshold for control 'naive' 
sheep, and not different from experimental sheep. This lends weight to the finding that in 
fact thresholds to noxious mechanical stimulation were not reduced in sheep suffering from 
footrot in this study. This is contrary to the findings of Ley et al. (1989) who demonstrated 
that sheep infected with footrot for periods of not less than 1 week, had significantly lower 
thresholds to noxious mechanical stimulation than control sheep. M oreover, they 
demonstrated that local anaesthetic block of the affected foot returned thresholds to normal. 
In mildly affected sheep, thresholds to noxious mechanical stimulation returned to normal 
after treatment and resolution of the lesion, whereas in sheep which had been more severely 
affected, resolution of the lesion did not return thresholds to normal. Thresholds to noxious 
thermal stimulation were not changed.
There are a number of differences between the present study and that of Ley et al. (1989). 
Firstly, although the breed of sheep used by Ley et al. (1989) was not mentioned, it is likely 
that they were a different breed to those used in the present study. Secondly, all sheep used 
in the original study were suffering from footrot in only 1 fore foot, whereas <50 % of 
sheep used in the present study had footrot present in only 1 forefoot. Sheep used in the 
present study had been suffering from footrot for a period of at least 1 week, which is 
similar to the duration of infection reported by Ley et al. (1989; 1990b; 1991a). However, it 
was not known for how long sheep had been infected with footrot before that time in the 
present study, and it was not reported by Ley et al. (1989). Moreover, although the farm 
controls were not suffering from footrot at the time of the study, and for at least 1 week prior 
to the study, the history of individual sheep was not known. Ley et al. (1989) demonstrated 
that thresholds to noxious mechanical stimulation were reduced in sheep severely affected 
with footrot for a prolonged period of at least 3 weeks after resolution of the condition. 
Therefore, previous infection with footrot may influence control thresholds to noxious 
mechanical stimulation derived from apparently normal sheep. It is interesting to note that 
data published subsequently by these workers have not demonstrated a significant reduction 
in thresholds to noxious mechanical stimulation in sheep suffering from footrot (Ley et al. , 
1990b; 1991a).
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The finding that flunixin and carprofen did not demonstrate antinociceptive activity in 
noxious mechanical and thermal test systems in normal 'naive' sheep perhaps was not 
surprising (Winder, 1959). Consequently, because a reduction in threshold to noxious 
mechanical stimulation was not found in the present study, it was considered unlikely that 
administration of NSAIDs would alter the thresholds in lame sheep. Indeed, administration 
o f flunixin, 1.0 and 2.0 mg/kg, IV, to sheep suffering from footrot did not change 
thresholds in the 30 minute period after administration. However, there was a significant 
difference between thresholds recorded pre- and post-administration for sheep between the 2 
groups. Sheep were allocated to treatment groups randomly and there were no significant 
differences between total lesion and lameness scores.
In contrast, repeat administration of flunixin, 1.0 mg/kg, IV, over a period of 3 days did 
cause a reduction in mechanical thresholds to noxious stimulation. Unlike control sheep, 
thresholds on day 2 were significantly elevated, although subsequently, on day 3 and 4, 
thresholds were significantly lower than those recorded on the first day. The elevated 
thresholds recorded on day 2 may be linked to paring the feet of the sheep after testing on 
day 1. It is also possible that anticipation of an aversive procedure contributed to the 
development of a stress-induced analgesia (Hargreaves and Hutson, 1990a; 1990b). The 
reduced thresholds recorded on day 3 and 4 may have been related to the administration of 
flunixin meglumine. If this was the case, flunixin was exerting 1 of 2 effects. Firstly, it may 
have caused a hyperalgesia. This would be contrary to available evidence on the mode of 
action of flunixin (Lees et al. , 1991a), in addition to evidence from laboratory studies in 
which flunixin increased thresholds to noxious stimulation in hyperalgesic states (Ciofalo et 
al. , 1975; 1977), and from evidence in normal sheep where flunixin has been shown to 
cause hypoalgesia (Chambers et al. , 1993b). Secondly, flunixin may have exerted an effect 
such that sheep suffering from footrot responded to repeated threshold testing in a manner 
similar to control sheep i. e. over a period of 3 days, thresholds to noxious mechanical 
stimulation fell to a level at which they were no longer significantly different from values 
obtained from experimental sheep. A possible explanation for this is that the anti­
inflammatory, and reported analgesic effects of flunixin (Vernimb and Hennessey, 1977; 
Reid and Nolan, 1991), made the sheep less reluctant to bear weight on the contralateral limb 
which, in most cases also was affected with footrot.
Quantification of clinical pain is difficult for several reasons. Pain is a subjective 
phenomenon and just as in humans, it must be assumed that individual animals will react to 
similar levels of pain by different degrees. However, animals cannot convey what they 
perceive as pain verbally and so the degree of pain must be inferred by observation. 
Currently, in the case of footrot, severity of pain may be assessed by examining the severity
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of lameness or by grading the pathological changes that are present, although evaluation of 
stress hormones may prove useful (Ley et al. , 1991b). This approach is flawed because of 
the difficulty in equating physical changes with severity of pain e. g. personal experience has 
shown that sheep with grade 1 footrot may be severely lame while those with grade 4 
lameness may be virtually sound. Combining the assessment of physical changes and 
observed lameness therefore may help to overcome this problem (Ley et al. , 1989). 
However, when clinical cases are used in the quantification of pain, the history of the sheep 
is not always known, and it is possible that sheep may have suffered recurring bouts of 
footrot which may affect their threshold response to noxious stimulation {vide supra).
3.4.3 Study 3
Because of the limitations of evaluating chronic clinical pain {vide supra), it was decided to 
investigate threshold responses to noxious mechanical and thermal stimulation in a group of 
healthy sheep undergoing identical surgical procedures. Elective surgery of this type 
presents an unique opportunity to limit variation within the test system e. g. exclusion of 
sheep suffering from footrot or any other infectious or non-infectious disease; similar pre-, 
intra- and post-anaesthetic management etc.
There have been conflicting reports in the human literature of changes in sensory thresholds 
in the post-operative period (Ekblom and Hansson, 1987; Hansson et al. , 1988; Lund et al.
, 1990; Dahl et al. , 1992). Most recently, Dahl et al. (1992) demonstrated post-operative 
hyperalgesia in patients which has undergone abdominal surgery. In contrast to the present 
study, Dahl et al. (1992) used electrical stimulation to evaluate pain thresholds, and 
hyperalgesia was recorded for up to 48 hours post-operatively. While an acute surgical 
stimulus did not change thresholds to noxious mechanical stimulation in the present study, 
demonstration of a thermal hyperalgesia in the post-operative period using the ear clip 
method perhaps is puzzling. The sheep in the present study had a caudal ventral midline 
laparotomy. Therefore, it could be anticipated that a primary hyperalgesia may have existed 
in the area local to tissue injury (Raja et al. , 1988), responsive to both thermal and 
mechanical stimulation (Raja et al. , 1984). Because of the nature of the operation, lifting 
and stretching of the wound edges was unavoidable. This potentially could have extended 
the area of secondary hyperalgesia demonstrable on the ventral body surface. However, the 
extent of secondary hyperalgesia was not investigated in the present study. The ear is 
innervated primarily by the facial, trigeminal and vagal nerves which derive from the facial, 
trigeminal and vagal nuclei located within the brainstem (Sissons and Grossman, 1975). 
Innervation of the ventral abdominal wall is from nerves arising from the 8th thoracic to the 
3rd lumbar spinal nerves with afferent fibres terminating in the dorsal horn of the spinal 
cord. Consequently, the detection of thermal hyperalgesia suggests the involvement of a
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central component, not limited to the region of the spinal cord innervating the ventral 
abdominal wall.
Thiopentone is a barbiturate that has been reported to cause development of hyperalgesia 
(Clutton-Brock, 1960; Dundee, 1960), although a recent in vitro study demonstrated that 
barbiturates depressed the nociceptive-related slow ventral root potential, and enhanced the 
antinociceptive dorsal root potential in neonatal rat spinal cord (Jewett et al. , 1992). 
Moreover, in the previous year, an in vivo study in human volunteers showed an analgesic 
effect of thiopentone after subhypnotic doses (Anker-Moller et al. , 1991). Halothane is 
believed to exert very little analgesic effect although nitrous oxide has a recognised analgesic 
effect (Hall and Clarke, 1991). However, thresholds to mechanical and thermal noxious 
stimulation in sheep anaesthetised for a period of 20 minutes using these agents in the 
absence of surgery, were not significantly altered for at least 2 hours post-operatively. This 
indicated that in the present study neither an analgesic, nor a hyperalgesic effect of 
thiopentone was demonstrated. However, it should noted that the first post-operative 
assessment of thresholds to noxious stimulation was made 50 minutes after thiopentone 
administration.
The NSAIDs are being used increasingly in human surgery, either in combination with other 
analgesic agents, or on their own to provide relief of peri-operative pain (Milne and 
Twomey, 1980). There have been many clinical studies comparing both the analgesic effects 
of various NSAIDs and the opioid 'sparing' effects of NSAIDs when administered in 
combination with full or partial opioid agonists (Dahl and Kehlet, 1991). It has been 
demonstrated that pre- and post-operative administration of NSAIDs can reduce pain 
intensity, opioid requirement, or both, in humans which have undergone soft-tissue surgery 
(Owen et al. , 1986; Gillies e ta l . , 1987; Hodsman e ta l . , 1987; Dueholm e ta l . , 1989), and 
similar results have been demonstrated in humans after orthopaedic surgery (Breivik e ta l . , 
1984; Dahl and Kehlet, 1991). It has been suggested that the NSAIDs may exert central as 
well as peripheral analgesic or antinociceptive effects, and a recent electrophysiological study 
in humans demonstrated that analgesia seen after administration of the NSAID, ketoprofen, 
included a central component (Wilier et al. , 1989). It was suggested that a supraspinal 
mechanism was involved since the effect was not demonstrable in paraplegic patients with 
complete spinal transection.
Limited studies have been conducted investigating the analgesic effects of NSAIDs peri- 
operatively in domestic species. In dogs after orthopaedic surgery Mburu et al. (1988), 
Mbugua etal. (1989) and Mburu (1991) demonstrated that phenylbutazone was an effective 
analgesic, but did not reduce post-operative swelling to the same degree as acetylsalicylic 
acid and paracetamol, while indomethacin was toxic. Flunixin meglumine has been reported
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to provide analgesia in horses with non-surgical colic (Vernimb and Hennessey, 1977) and 
recently, it has been shown to provide post-operative analgesia comparable to that achieved 
by papaveretum, an opioid drug, for a period of at least 6 hours after administration to dogs 
undergoing a variety of soft-tissue and orthopaedic surgical procedures (Reid and Nolan, 
1991).
Carprofen is a propionic acid derivative (Baruth et al. , 1985), and the finding that carprofen 
induced a rise in thresholds to noxious thermal stimulation after surgical intervention in 
sheep is interesting. It has been noted previously, that the level of anti nociception observed 
after administration of carprofen is greater than might be expected from the level of inhibition 
of cyclooxygenase achieved at therapeutic doses by this drug (Strub et al. , 1982; Baruth et 
a l , 1985). This suggests that a further mode of action of carprofen may be important. 
Analgesia demonstrated after administration of ketoprofen, also a propionic acid derivative 
(Harris and Vavra, 1985), has been shown to involve a supraspinal mechanism (W ilieretal. 
, 1989), and it is possible that other propionic acid derivatives may have similar actions. 
Flunixin meglumine is a potent inhibitor of cyclooxygenase in a variety of domestic species 
(McKellar et al. , 1991b), and it is of equal interest that administration of flunixin prevented 
a reduction in thresholds to noxious thermal stimulation in the post-operative period. These 
findings suggest that prostaglandins are important in the development of post-operative 
thermal hyperalgesia, either centrally or peripherally, but a further mode of antinociceptive 
action cannot be ruled out for carprofen.
Spinal cyclooxygenase inhibition has been demonstrated to block thermal hyperalgesia in 
rats (Malmberg and Yaksh, 1992a). Interestingly, this effect was maintained when the 
NSAIDs were administered after induction of hyperalgesia. In the present study, treatment 
was administered towards the end of surgery and therefore, after release of endogenous 
hyperalgesic agents and stimulation of small nociceptive afferents (Woolf, 1989). Malmberg 
and Yaksh (1992a) evoked a hyperalgesic response by intrathecal administration of NMDA 
and substance P. Substance P is an excitatory neurotransmitter thought to serve as a pain 
transmitter (Otsuka and Yanagisawa, 1987), and is released from primary afferents (Jessel 
and Iversen, 1977) and recently, a role for substance P in the transmission of thermal 
nociceptive input from the periphery to the central nervous system (CNS) has been 
demonstrated (Lecci eta l. , 1991). The excitatory amino acids, glutamate and aspartate are 
endogenous ligands at the NMDA receptor, and therefore, it would appear that NSAIDs, 
either directly or indirectly, exert a central effect at excitatory synapses. Moreover, the 
NSAID, flurbiprofen, has been demonstrated to act synergistically with an inhibitor (L-NG- 
nitro arginine methyl ester (L-NAME)) of the enzyme nitric oxide synthase, which results in 
the formation of nitric oxide (NO), to enhance the central antinociceptive effect of the 
inhibitor (Morgan et al. , 1992). This is of interest because release of NO in the CNS has
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been demonstrated after NMDA challenge (Garthwaite et al. , 1988), and it has been 
proposed as an intercellular messenger. If NSAIDs act at the level of the NMDA receptor to 
block excitatory transmission, it is possible that they may prevent release of the intercellular 
messenger, NO. Moreover, the NSAIDs may also serve to modulate hyperalgesia centrally 
by limiting production of prostaglandins in the spinal cord, which have a known 
hyperalgesic action (Uda et al. , 1990), or indeed by preventing NMDA receptor activation 
of the arachidonic acid cascade (Dumuis et al. , 1992).
The administration of full and partial opioid agonists is standard for provision of peri­
operative analgesia in both medical and veterinary surgical practice. It is recognised that pre­
emptive analgesia is a more practical goal than attempting to control pain once it has been 
initiated. Suggesting this, McQuay et al. (1988) showed that 56 % of patients, who had not 
received pre-operative analgesia, and who underwent elective orthopaedic surgery requested 
analgesia with 2 hours post-operatively while, only 7 % of patients who had received opioid 
premedication requested supplementary analgesia in the same time period. The 
antinociceptive activity of buprenorphine, 6 ftg/kg, IV, has been investigated in normal 
conscious sheep (Nolan et al. , 1987c). A lag period of approximately 45 minutes occurred 
between administration of the drug and maximal response to noxious thermal stimulation, 
probably due to slow receptor kinetics (Hambrook and Ranee, 1976). In the present study 
buprenorphine, 10 fig/kg, IV, administered after the onset of surgery and before the end of 
anaesthesia did not cause a significant elevation in thresholds to noxious thermal or 
mechanical stimulation. The first measurement of thresholds to noxious thermal stimulation 
was made 30 minutes after termination of anaesthesia, at which time Nolan et al. (1987c) 
observed a non-significant rise in thermal thresholds in normal sheep. It is possible that a 
maximal response was not observed in this study because buprenorphine was administered 
after activation of nociceptive afferents, since it has been demonstrated that the dose of 
morphine, a full opioid agonist, required to prevent C-fibre-induced excitability changes 
from occurring in the spinal cord, is less than that required to elicit a similar response once 
the changes are established (Woolf and Wall, 1986b). However, in the present study 
buprenorphine was given after the start of surgery but before the end of anaesthesia. 
Buprenorphine has a bell shaped dose response curve resulting in antagonistic activity at 
higher dose rates (Dum and Herz, 1981), and it is unclear where the dose given in the 
present study lies on the dose response curve. Fentanyl, a potent short acting full opioid 
agonist, was shown to have a limited extent and duration of analgesia in sheep suffering 
chronic pain when compared to normal sheep (Ley et al. , 1990b). Further studies have 
demonstrated a similar reduction in analgesia after administration of xylazine, an a 2- 
adrenoreceptor agonist, to sheep in chronic pain (Ley et al. , 1991a). Investigations of the 
effect of chronic or acute pain on the analgesia observed after administration of partial opioid 
agonists have not been conducted, but it is possible that the presence of an acutely painful
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stimulus, together with the time of drug administration, may have limited the buprenorphine 
analgesia observed in the present study.
The NMDA receptor appears to play a crucial role in the development of central hyperalgesia 
(Woolf, 1991), and therefore, it was of interest that sheep administered ketamine, a non­
competitive NMDA receptor antagonist, did not develop the thermal hyperalgesia 
demonstrated in control surgical cases. In the present study, ketamine was administered 
before the onset of surgery and concurrent nociceptive afferent activation, but administration 
of an NMDA receptor antagonist, believed to be active at the same site as ketamine (Lodge 
and Johnson, 1990), has been shown to abolish existing hypersensitivity (Woolf and 
Thompson, 1991). However, Malmberg and Yaksh (1992a) found that NMDA receptor 
anatagonists did not attenuate pre-existing thermal hyperalgesia. Currently, ketamine is 
licensed for induction of anaesthesia in sheep and therefore demonstration of an 
antinociceptive effect of this agent in sheep would be invaluable, since use of unlicensed 
agents in food producing species is limited because of residue concerns. Perhaps not 
surprisingly, subanaesthetic doses of ketamine have proved analgesic in humans (Owen et 
al. , 1987; Maurset et al. , 1989).
The discovery that laparotomy in sheep, with gentle manipulation of the uterus causes a 
reduction in thresholds to noxious thermal stimulation over a period of at least 2 hours is 
exciting. While many other workers have demonstrated hyperalgesia experimentally 
following administration of hyperalgesic agents, controlled studies in clinical cases have 
been limited. Such studies are hindered by variation in the degree of pain or extent of 
pathology present prior to testing (Ley et al. , 1989), or variation in surgical procedure and 
lack of appropriate controls (McQuay et al. , 1988), and these factors limit interpretation of 
data. Duration of surgery, surgical technique and peri-operative management was identical in 
the sheep used in the present study, and further investigations under the same conditions in 
larger numbers of sheep would be invaluable to further quantify the findings which have 
been presented.
CHAP T E R 4
TH E A N TIN O C IC EPTIV E EFFECTS OF NSAIDS IN SH EEP: 
2 EX PERIM EN TA L PAIN
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4.1 Introduction
4.1.1 Tourniquet-induced ischaemic effects
A tourniquet is an instrument applied around an extremity for compression of blood 
vessels in order to control or prevent circulation distal to the tourniquet (Blass and Moore, 
1984). These workers trace the history of the tourniquet back to the Romans, but it was 
not until 1864 that the tourniquet was used for procedures other than amputation of a 
limb. In 1904, Cushing described a pneumatic tourniquet suitable to allow extremity 
surgery. The use of a tourniquet limits blood loss during surgery and perhaps most 
importantly, provides a bloodless surgical field allowing surgeons to operate quickly. 
Application of a tourniquet also may be used to facilitate intravenous regional anaesthesia 
(Weaver, 1972; Bogan and Weaver, 1978).
Application of a tourniquet is not a benign procedure (Blass and Moore, 1984; Ibrahim, 
1989), and arrest of circulation must be regarded as unphysiological. In humans, 
occlusion of blood by application of a tourniquet causes the extremity distal to the 
tourniquet to become pale, peripheral pulses cannot be detected and the temperature of the 
soft tissues declines (Mullick, 1978). Various local and systemic biochemical and 
physiological changes have been observed during ischaemia in both humans and animals, 
including reduction in venous pH (Chin et al. , 1976; Scott et al. , 1979; Singh et al. , 
1982); changes in venous and muscle partial pressures of oxygen and carbon dioxide 
(Heppenstall et al. , 1979; Scott et al. , 1979; Rorabeck, 1980; Singh et al. , 1982); 
elevation in creatinine phosphokinase, an enzyme found primarily in skeletal muscle 
(Chin et al. , 1976; Heppenstall et al. , 1979) and alterations in blood levels of glucose, 
potassium and lactic acid (Heppenstall et al. , 1979; Scott e ta l . , 1979; Rorabeck, 1980). 
Shortly after reperfusion of the ischaemic extremity, systemic and local concentration of 
these agents have been found to return to control levels (Blass and Moore, 1984).
Muscle and nerve damage are frequent complications after use of a tourniquet (Eckhoff, 
1931; Moldaver, 1954; Mullick, 1978; Patterson and Klenerman, 1979; Rorabeck, 
1980). Muscular damage has been shown to be more severe directly under the area of 
tourniquet compression than more distally (Patterson and Klenerman, 1979). There has 
been much debate about the cause of nerve damage after tourniquet application. It is not 
known whether the damage results from mechanical compression or from ischaemic 
damage (Blass and Moore, 1984), but slowing of conduction velocity of affected nerves 
has been shown to vary with the duration and pressure o f tourniquet application 
(Rorabeck, 1980).
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Hypertension may occur due to the presence of an inflated tourniquet during surgery 
(Kaufman and Walts, 1982; Abrahamsen etal. , 1989; Copland et al. , 1989). Kaufman 
and Walts (1982) defined hypertension as a 30 % increase in either the systolic or 
diastolic pressure from baseline values recorded at first incision, and showed a mean 
latency to the development of hypertension of approximately 1 hour. This equated closely 
to the latency period reported by Cole (1952) before development of tourniquet pain in 
human patients. Similarly, Valli and Rosenberg (1985) demonstrated a hypertensive 
response to inflation of a tourniquet in people under general anaesthesia, but showed that 
a similar response did not occur after epidural or spinal anaesthetic techniques. Copland et 
al. (1989) reported that inflation of a tourniquet in anaesthetised horses increased mean 
arterial blood pressure (MABP) during the period of inflation. The rise in MABP was 
observed with the tourniquet positioned both on the forelimb and on the hindlimb, and 
with the tourniquet positioned on the uppermost and the dependent limb, and was greatest 
with the tourniquet positioned on a dependent forelimb. Interestingly, Abrahamsen et al. 
(1989) found that an increase in MABP occurred only on the first of 2 occasions when 
the same horse was anaesthetised twice, and in which an inflated tourniquet was used 
during surgery on each occasion. In all studies deflation of the tourniquet caused a rapid 
decline in MABP towards baseline levels. However, hypotension was not observed in 
horses after deflation of the tourniquet, as previously described in humans (Valli and 
Rosenberg, 1985). Hyperaemia and increased blood flow in the limb observed after 
ischaemia in humans (Larsson and Bergstom, 1978), may be sufficient to cause such a 
fall in MABP.
Cole (1952) reported that inflation of a tourniquet in the presence of full spinal 
anaesthesia resulted in the development of pain in the ischaemic limb approximately 45 to 
60 minutes after application of the tourniquet. Prior to this report, only mention of 
discomfort in the presence of a tourniquet had been made (Allen, 1938). Cole (1952) 
suggested that pain resulted from compression of nerves or from ischaemic damage to 
nerves, and commented that tourniquet pain could be controlled by administration of the 
opioid analgesic, morphine. Immediate relief from tourniquet pain can be achieved by 
release of the tourniquet, allowing reperfusion of the ischaemic extremity (de Jong and 
Cullen, 1963). These workers compared both the sensation, and time to onset of 
tourniquet pain in human patients under spinal anaesthesia and experimental subjects. 
They reported few differences between the 2 groups, and suggested firstly, that 
tourniquet pain was transmitted via unmyelinated C-fibres, and secondly, that at the time 
of onset of tourniquet pain, larger diameter myelinated nerve fibres (A(3) would have 
reduced conduction due to the effect of compression and, consequently, would not inhibit 
impulses carried in the smaller unmyelinated C-fibres. M oreover, it has been
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demonstrated that conduction in larger afferent fibres (A5 and A(3) within the compressed 
area ceases completely after approximately 30 minutes and therefore, it is unlikely that 
these fibres conduct noxious information from the periphery to the central nervous system 
during ischaemia (Bentley and Schlapp, 1943).
The tourniquet method, or exercise and ischaemia, has been used to evoke experimental 
pain in both man and laboratory animals (Hewer and Keele, 1948; Hilgard, 1978). In 
man, a limb is made ischaemic by application of a tourniquet and exercised until no 
further work can be carried out. Time to termination, or work accomplished may be 
measured. Similarly, the time to first reported pain (threshold time) may be recorded and 
the subject asked to continue until no further work is possible (tolerance time). Smith et 
al. (1966) described the 'submaximum effort tourniquet technique' which examined 
magnitude of pain rather than tolerance times. This technique involved removing blood 
from the extremity by applying an elastic bandage, then positioning a tourniquet above the 
elastic bandage before removing the bandage. The subject was asked to complete a 
defined amount of work using the ischaemic extremity, which did not cause the 
development of pain, and finally the ischaemic extremity was rested until pain developed. 
Termination using the submaximum effort tourniquet method occurred after a longer 
period of time (20-30 minutes) than when the original methods were used (3-4 minutes) 
(Hilgard, 1978). Beecher (1957) commended tourniquet-induced pain as an experimental 
tool because the resultant pain was not sudden fleeting pain, but developed over a period 
of time, and persisted during the application of the tourniquet, features that more 
accurately reflect most clinical pain.
The use of tourniquet-induced ischaemic pain in animals is limited because animals cannot 
communicate pain verbally and investigators must rely on behavioural, motor or 
physiological indicators to assess painful stimuli in these animals (see chapter 1). 
Moreover, it is difficult to impose defined levels of work on these animals. Gelgor etal. 
(1986a) have described a model of ischaemic pain in rats. Ischaemia of the tail was 
induced by application of an inflatable cuff to the base of the rat's tail, and the cuff 
inflated to a pressure of 200 mm Hg. When the rat demonstrated escape behaviour, 
observed as grooming vigorously, jumping forward or attempting to turn round, the cuff 
was deflated. These workers suggested that standardizing the duration of ischaemia 
would lead to ethical problems because response latencies differed between animals, and 
they concluded that using a defined end-point i. e. coordinated escape behaviour, was 
most suited to this technique.
The tail flick reflex is used widely in rats for the study of analgesic agents (Chapman et 
al. , 1985), and Gelgor et al. (1986a) have used the tail flick reflex to detect post-
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ischaemic hyperalgesia in rats. After a period of ischaemia, they demonstrated a reduction 
in tail flick latency at temperatures above 39°C which was not apparent in rats after 
application of a sham tourniquet. The authors of the latter study suggested that the release 
of endogenous mediators such as hydrogen ions, lactate and other hyperalgesic mediators 
(see chapter 3) may have caused sensitization of peripheral nociceptors, or that changes in 
neuronal excitability may have been involved, as previously proposed by Woolf (1983). 
Subsequently, it was shown that post-ischaemic hyperalgesia could be abolished by the 
pre-treatment of rats with lysine acetylsalicylate, a non-steroidal anti-inflammatory drug 
(NSAID) (see chapter 1), or mepyramine maleate, an antihistamine (Gelgor et al. , 
1986b). These findings indicated that both histamine and the prostaglandins played an 
important role in the development of post-ischaemic hyperalgesia. It is interesting to note 
that although a variety of NSAIDs did not alter the latency to coordinated escape 
behaviour, they prevented reperfusion hyperalgesia in rats. The authors concluded that 
the mechanisms of tourniquet-induced pain and those of reperfusion hyperalgesia were 
not the same. Recently, intracerebroventricular (ICV) micro-injections of NSAIDs have 
been shown to abolish the phenomenon of post-ischaemic reperfusion hyperalgesia in rats 
(Gelgor et al. , 1992a), without altering the latency to coordinated escape behaviour. This 
work suggested a central role for either the NSAIDs directly or prostaglandins indirectly.
Neurones, which respond to noxious thermal stimulation of the tail, have been located in 
the ventrobasal complex of the thalamus in the rat (Guilbaud e ta l . , 1980; Gelgor e ta l . ,
1988). During post-ischaemic noxious thermal stimulation of the rat tail, a reduction in 
threshold temperature, and temperature at peak firing rate, has been described which 
parallels the behavioural changes seen both during and after ischaemia of the tail (Gelgor 
et al. , 1988). A recent study by Sher et al. (1992) demonstrated that administration of 2 
different N-methyl-D-aspartate (NMDA) receptor antagonists inhibited the development of 
post-ischaemic reperfusion hyperalgesia in rats, in a similar manner to the opioid receptor 
agonists, morphine and pethidine, but without the motor impairment recorded after 
administration of morphine and pethidine. The NMDA receptor has been implicated in the 
development of central sensitization and the amplification, prolongation and enhancement 
of noxious information received from the periphery (see chapter 3), and consequently, it 
would appear that central sensitization may be important in the development of 
reperfusion hyperalgesia. However, peripheral involvement cannot be excluded. It is 
important to note that a positive link between tourniquet-induced pain, and post-ischaemic 
reperfusion hyperalgesia has not been demonstrated.
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4.1.2 Laboratory models for testing NSAIDs
Laboratory techniques used for assessing the effects of drugs on nociceptive responses 
have been reviewed (see chapter 1). The development of such models was essential to 
allow potential analgesic agents to be screened to identify products which were truly 
analgesic, and therefore, worthy of further development. The variety of different 
techniques reflects the difficulty that research workers have in evaluating analgesic agents 
because of the difficulty in defining pain and adequate relief of pain. Consequently, there 
is no single model which is used for the evaluation of novel analgesic compounds and 
instead a variety of different models are used in combination (Franklin and Abbott,
1989). The NSAIDs are anti-inflammatory, anti-pyretic and analgesic agents and their 
actions appear to be primarily related to inhibition of prostaglandin synthesis (Vane, 
1971). However, many of the standard laboratory tests fail to detect NSAID analgesia in 
normal animals (Woolfe and McDonald, 1944; Winder, 1959; Gilfoil e ta l.  , 1963; 
Romer, 1980; Otterness and Bliven, 1985), and the presence of an inflammatory focus 
appears to be essential. Randall and Selitto (1957) evaluated the antinociceptive effects of 
various NSAIDs using a modification of a rat paw pressure test which had been described 
by Green and Young (1951). They recorded a reduction in the threshold to mechanical 
pressure after injection of a 20 % suspension of brewer's yeast, 0.1 ml, into the paw, and 
noted that the administration of NSAIDs reduced the observed hyperalgesia, whereas the 
threshold for the uninflammed paw was unchanged. Various other irritants have been 
described for this model including carrageenan, trypsin, kaolin, elastase, dextran, 
hyaluronidase, serotonin and acid phosphatase (Vinegar et al, 1976; Otterness and 
Bliven, 1985). Maximum hyperalgesia after carrageenan injection has been shown to 
occur 2 to 3 hours after injection (Vinegar et al. , 1987; Yamamoto et al. , 1993). 
Originally, test drugs were administered at the same time as subplantar injection of irritant 
(Randall and Selitto, 1957), but later work suggested that the test drug should be 
administered 2 hours after irritant injection to maximise the analgesic rather than the anti­
inflammatory effects of the test drugs (Winter and Flataker, 1965).
Turpentine injected into the paw of cats was shown to induce a long lasting inflammation 
(Frankstein et al. , 1965), and a modification of the technique was described by 
Dubuisson and Dennis (1977) where formalin, 0.05 ml of a 5 % solution, was injected 
into cats and rats. The pain response which was observed was biphasic (Dubuisson and 
Dennis, 1977). An early, brief period of intense pain was observed within the first 5 
minutes; the pain then subsided for a period and finally a tonic phase of moderate pain 
was observed up to 60 minutes after injection. Dubuisson and Dennis (1977) suggested 
that the early pain phase was a result of direct stimulation of nociceptors, whereas the
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tonic pain phase occurred after release of endogenous inflammatory mediators. Non­
steroidal anti-inflammatory agents and steroids do not influence the early phase of the 
formalin response but have been shown to modify the late phase (Hunskaar et al. , 
1986b; Hunskaar and Hole, 1987; Shibata et al. , 1989). In contrast, the 'classic' 
centrally acting analgesic agents, such as the opioids, have been demonstrated to be 
analgesic in both the early and late phase of formalin-induced pain (Hunskaar et al. , 
1986b; Hunskaar and Hole, 1987; Shibata et al. , 1989).
In the 1950s it was observed that intraperitoneal injection of various irritants caused 
marked abdominal writhing in rodents (Vander Wende and Margolin, 1956; Siegmund et 
al. , 1957). More than 40 different irritants have been described for use in this assay 
(Otterness and Bliven, 1985), but phenylbenzoquinone (Siegmund et al., 1957), 
acetylcholine (Collier e ta l . , 1964), acetic acid (Koster et al. , 1959) and sodium chloride 
(Collier and Schneider, 1969) are the most frequently employed. Vander Wende and 
Margolin (1956) injected an iodinated contrast medium intraperitoneally, and although the 
writhing response was blocked by local anaesthetic agents and opioids, administration of 
NSAIDs did not block the response. However, later studies, using weaker irritants, were 
able to detect NSAID analgesia (Collier et al. , 1968) and the assay is used widely in the 
evaluation of NSAIDs (Vinegar et al. , 1976). The writhing assays were not specific for 
analgesics (Whittle, 1964; Chernov etal. , 1967), but it was suggested that non-analgesic 
agents could be detected by the presence of various side effects including sedation and 
motor dysfunction (Whittle, 1964). Arachidonic acid and the prostanoids were reported to 
cause a writhing response after intraperitoneal injection, and administration of NSAIDs 
only limited the response to arachidonic acid (Collier and Schneider, 1972). In addition, 
prostaglandin E2 (PGEj), and the stable product of prostacyclin hydrolysis, 6-keto- 
PGFjcx, have been detected in the peritoneal cavity after administration of the irritant,
zymosan (Doherty et al. , 1987). The pain response in the writhing test has not been fully 
evaluated, but it will certainly be multi-factorial in origin, with release of prostaglandins 
playing an important role in sensitizing nociceptors to the effects of other endogenous, 
and exogenous, algesic agents (see chapter 3).
Experimentally-induced arthritis in rats has been used widely as a model of chronic 
inflammatory pain (reviewed by Otterness and Bliven, 1985). Various other models 
including the cross-perfused spleen preparation and intra-articular injection, also have 
been used to investigate the analgesic effects of the NSAIDs (Guzman et al. , 1962; 
Ferreira et al. , 1973; Moncada et al. , 1975), but those mentioned above are the most 
frequently employed.
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Models of physiological pain were shown to be incapable of detecting NSAID-induced 
antinociception in sheep (see chapter 3). Consequently, it was decided to assess 2 
different methods of experimentally-induced allodynia or hyperalgesia in sheep and to 
investigate the effect of 2 non-steroidal anti-inflammatory drugs on the evoked responses. 
The tourniquet method was chosen as a model in which the sheep would have a degree of 
control over the duration of the noxious stimulus, and moreover, thresholds to noxious 
stimulation had not been investigated during the period of ischaemia previously. In 
addition, intradermal injection of carrageenan was investigated to establish whether 
mechanical or thermal hyperalgesia developed after injection of the irritant in sheep, in 
which case the response to injection of NSAID could be evaluated.
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4.2 Materials and Methods
4.2.1 A nim als
A total of 6 sheep were used in this series of experiments. Husbandry conditions are 
outlined in section 2.1. Sheep were not fasted, and were weighed immediately before the 
experiment. A period of at least 7 days elapsed between successive experiments.
Drugs
Four drugs were used during the course of these experiments; flunixin meglumine, 
carprofen, fentanyl citrate and lignocaine hydrochloride. Drugs were administered as 
described (see section 2 .2).
4.2.2 Threshold testing apparatus
The apparatus used for testing thresholds to noxious mechanical and thermal stimulation 
is described in sections 2.9 and 2.10 respectively, and testing procedures are described in 
sections 3.2.2.1 and 3.2.2.2 respectively.
4.2.3 Tourniquet
The tourniquet is described in section 2.8. The tourniquet was positioned on the forelimb 
proximal to the carpus and distal to the elbow after control mechanical threshold values 
were obtained. The leg unit was positioned proximal to the carpus but distal to the 
tourniquet. The tourniquet was inflated to a pressure of 300 mm Hg for a maximum 
period of 30 minutes, however, the tourniquet was deflated when the sheep showed signs 
of aversion. Preliminary studies indicated that for approximately 5 minutes following 
inflation of the tourniquet, sheep flexed the limb to which it was attached at regular 
intervals, but continued to eat or ruminate. Aversion was defined as the point at which 
sheep lifted the limb, on which the tourniquet was positioned, purposefully, more than 3 
times in a 15 second period. The tourniquet was deflated at aversion.
4.2.4 Carrageenan
Twenty-four hours before the experiment, the site of intradermal injection was clipped. 
The preparation of the carrageenan solution is described in section 2.5, and the technique 
for intradermal (ID) injection described in section 2.6. Carrageenan or saline, 100 |il, was 
injected intradermally immediately distal to the carpus on the lateral aspect of the leg after 
control mechanical and thermal threshold values were obtained. Injections were made on 
alternating forelimbs on successive cross-overs. The diameter of the resulting wheal was
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measured on each occasion, 120 minutes after injection of carrageenan or saline, using 
electronic digital calipers (Max-Cal, CP Instruments, Bishop Storford, U. K.).
4.2.5 Study design
4.2.5.1 Study 1
Five experimental sheep (sheep numbers 1-5) were used to assess behavioural effects of 
positioning the leg unit of the mechanical threshold testing apparatus in the presence of 
the uninflated tourniquet. In addition, changes in threshold to noxious mechanical 
srimulation were evaluated after the uninflated tourniquet had been in position for a period 
of 15 minutes, and again, 15 and 30 minutes after removal of the tourniquet. Lignocaine 
2 %, 5 ml, IV, was injected distal to the tourniquet after inflation in 2 sheep in order to 
assess the effectiveness of the tourniquet. Thresholds to noxious mechanical stimulation 
were recorded at 5 minute intervals during inflation of the tourniquet and until thresholds 
returned to normal after deflation.
Mechanical thresholds were recorded from the ipsilateral limb during tourniquet inflation, 
and following tourniquet deflation for 30 minutes. A similar investigation was conducted 
with the leg unit attached to the contralateral limb.
Flunixin, 1.0 mg/kg, carprofen, 0.7 mg/kg, or saline (0.9 %), 5 ml, was administered IV 
after control thresholds to noxious mechanical stimulation had been recorded, and 1 hour 
before positioning and inflation of the tourniquet. Fentanyl, 5 Jig/kg, IV, was 
administered 55 minutes after control thresholds to noxious mechanical stimulation had 
been recorded, and 5 minutes before positioning and inflation of the tourniquet. The 
drugs were administered in a cross-over design and the operator was not 'blind' to the 
drug administered. Mechanical thresholds were determined during the period of 
tourniquet inflation and until thresholds returned to normal after deflation.
Time to aversion was recorded in all investigations.
4.2.5.2 Study 2
Six experimental sheep (sheep numbers 1-6) were used in this study. The following 
treatments were investigated:
Group 1- saline 0.9 %, 100 |il, ID
Group 2- carrageenan 0.0625 %, 100 fil, ID/saline 0.9 %, 5 ml, IV
Group 3- carrageenan 0.0625 %, 100 jil, ID/flunixin, 2.0 mg/kg, IV
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Group 4- carrageenan 0.0625 %, 100 jil, ID/carprofen, 4.0 mg/kg, IV
Treatments were administered in a cross-over design and the operator was not 'blind' to 
the drug administered. Thresholds were assessed on the ipsilateral side to intradermal 
injection. Control thresholds to noxious mechanical and thermal stimulation were 
determined before injection of saline or carrageenan, ID. Afterwards, thresholds were 
recorded at 30 minute intervals for 2 hours before injection of test drug or saline, IV, and 
thereafter for a further 4 hours. Twenty-three hours after injection of saline or 
carrageenan, ID, a series of thresholds was recorded over 60 minutes.
Ambient temperature was maintained between 8 and 12°C.
4.2.6 S ta tis tica l analyses
4.2.6.1 S tudy  1
The data were investigated for normality, using normal probability plots and correlation 
analysis. Oneway analysis of variance was used to determine variation between treatment 
groups. Statistical significance of differences within groups was evaluated by the 
Student's t test.
A Kruskal-Wallis test, for non-parametric data, was used to test for differences between 
time to aversion after drug or saline treatment. Statistical tests were carried out using a 5 
% significance level.
4 .2 .6.2 S tudy 2
The data were investigated for normality, using normal probability plots and correlation 
analysis. Initially, oneway analysis of variance was used to assess differences between 
treatment groups for control thresholds and also thresholds recorded 24 hours later. 
Subsequently, the data was examined in 2 stages. Firstly, the response to intradermal 
injection was examined and secondly, the response to intravenous treatment was 
investigated. Statistical analysis was undertaken using a general linear model routine in 
each case. The experimental design was suitable for analysis using a 3 factor nested 
analysis of variance. This provided statistical tests for treatment groups, animal and time 
factors and their two-way interactions. Statistical significance of differences within 
groups was evaluated by the Student's t test.
Finally, the thermal data was analysed again after grouping the sheep according to the 
sequence in which they were injected with carrageenan i. e . 1st, 2nd and 3rd occasion. 
Oneway analysis of variance was used to assess differences between control thresholds to
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noxious thermal and mechanical stimulation, and also to assess differences between 
thresholds recorded 120 minutes after injection of the irritant. Further analysis was 
carried out using a paired Student's t test. Statistical tests were carried out using a 5 % 
significance level.
4.3 Results
4.3.1 Study 1
The presence of the uninflated tourniquet above the leg unit was not resented by sheep 
and did not cause a significant change in threshold to noxious mechanical stimulation after 
a period of 15 minutes. After the tourniquet was removed, thresholds remained similar to 
control values for at least 30 minutes.
Thresholds to mechanical stimulation after injection of lignocaine, IV, distal to the 
tourniquet after inflation resulted in maximal elevation of thresholds (16N) in 2 sheep for 
the period of tourniquet inflation (30 min). Maximal thresholds were achieved in both 
sheep at the first recording after injection (10 min) and neither sheep demonstrated signs 
of aversion during the period of tourniquet inflation. Thresholds returned to control levels 
within 5 minutes of tourniquet deflation.
Figure 4.1 shows the change in threshold to noxious mechanical stimulation during and 
after a period of limb ischaemia, with the leg unit attached either to the contralateral or 
ipsilateral limb. Thresholds to mechanical stimulation, when the leg unit was attached to 
the ipsilateral limb, fell during ischaemia in all sheep examined (Table 4.1). Thresholds to 
noxious mechanical stimulation 15 minutes after tourniquet inflation (group mean, 1.7N) 
were significantly different (p<0.01) from control thresholds (group mean, 3 .IN). In 
addition, the last thresholds to noxious mechanical stimulation recorded before tourniquet 
deflation (group mean, 1.7N), were significantly lower than control values (p<0.01). The 
mean time to aversion was 20.6 minutes. Thresholds returned to control levels within 5 
minutes of deflating the tourniquet. In contrast, thresholds to mechanical stimulation did 
not fall when measurements of threshold were recorded from the contralateral limb (group 
mean pre-inflation, 3.6N vs. group mean before deflation, 3.4N) (Table 4.2), while the 
mean time to aversion, 19 minutes, was not significantly different from that recorded for 
the ipsilateral limb.
Thresholds to mechanical stimulation, when the leg unit was attached to the ipsilateral 
limb, fell during ischaemia in all sheep which received saline, IV (Table 4.3). Statistical 
analysis indicated that the last thresholds recorded before aversion were significantly
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Figure 4.1. Thresholds to noxious mechanical stimulation before, during and after 
inflation of a pneumatic tourniquet on the forelimb of sheep.
Thresholds to noxious mechanical stimulation before (Pre), during (5 to 20 min) and after 
(+5 to +15 min) inflation of a pneumatic tourniquet at time 0 proximal to the leg unit of 
the mechanical threshold testing apparatus in a group of sheep (n=5, except when n=2 
(2)) are shown. The tourniquet was positioned on either the ipsilateral (ipsi) or 
contralateral (contra) limb.
The response threshold (Newtons) is plotted against time (min). Control values (Pre) are 
the mean of at least 3 reading taken over a 30 minute period. Each point indicates the 
mean and standard error of the mean for recorded values at each time point.
The maximum threshold force (16 N) is indicated.
*p<0.01 statistically different from control values.
■ ■ Ipsi
Maximum force □ Contra
1 2 5
T im e
(m in)
No. 1 No. 2 No. 3 No. 4 No. 5 M ean ± S E \1
C 3.3 2.3 2.7 3.1 3.9 3.1 0.27
5 3.2 1.2 2.9 3.5 2.5 2.7 0.40
10 1.9 1.9 3.2 2.2 1.9 2.2 0.25
1 5 1.5 0.9 1.9 1.9 2.5 1.7* 0.26
20 2.2 1.9 2.1
TA 20.0 19.0 18.0 24.0 22.0 20.6 1.08
+ 5 2.5 1.9 4.2 3.5 3.2 3.1 0.40
+ 15 3.2 1.9 3.2 2.9 2.9 2.8 0.24
+ 30 2.9 2.2 3.9 2.9 3.9 3.2 0.34
Table 4.1. Thresholds to noxious mechanical stimulation before, during and after 
inflation of a pneumatic tourniquet on the ipsilateral forelimb of sheep.
Individual and mean thresholds to noxious mechanical stimulation (Newtons), ± standard 
error of the mean (SEM), in a group of 5 sheep during and after application of an inflated 
tourniquet on the same limb as the threshold testing leg unit at time 0. The time to 
aversion (TA, min) was recorded as the tourniquet was removed and thresholds to 
noxious mechanical stimulation were recorded for a further 30 minutes. Control values 
(C) are the mean of at least 3 readings taken over a 30 minute period.
*p<0.01 statistically different from control values.
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T im e
(m in )
No. 1 No. 2 No. 3 No. 4 No. 5 M ean ±SEM
C 5.7 4.0 2.9 2.3 3.1 3.6 0.59
5 4.2 3.5 3.4 2.2 6.0 3.9 0.62
10 4.5 2.4 3.4 2.1 5.6 3.6 0.65
15 6.4 3.1 3.4 1.6 2.7 3.4 0.80
20 6.2 6.2
TA 22.0 19.0 17.0 20.0 17.0 19.0 0.95
+ 5 6.5 3.2 3.5 2.2 5.6 4.2 0.80
+ 15 5.9 2.4 3.2 1.7 3.2 3.3 0.71
+ 30 5.8 2.9 3.2 2.3 2.7 3.4 0.62
T able 4.2. Thresholds to noxious mechanical stimulation before, during and after 
inflation of a pneumatic tourniquet on the contralateral forelimb of sheep.
Individual and mean thresholds to noxious mechanical stimulation (Newtons), ± standard 
error of the mean (SEM), in a group of 5 sheep during and after application of an inflated 
tourniquet on the contralateral limb to the threshold testing leg unit at time 0. The time to 
aversion (TA, min) was recorded as the tourniquet was removed and thresholds to 
noxious mechanical stimulation were recorded for a further 30 minutes. Control values 
(C) are the mean of at least 3 readings taken over a 30 minute period.
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Tim e No. 1 No. 2 No. 3 No. 4 No. 5 Mean ±SE M
(m in)
C 2.8 3.0 2.8 3.3 2.1 2.8 0.20
5 1.4 1.7 3.1 2.4 1.7 2.1 0.31
10 1.3 1.9 2.6 1.6 1.4 1.8* 0.23
15 1.2 1.0 1.9 1.9 1.4 1.5** 0.18
20 1.2 1.1 2.0 1.6 1.3 1.4** 0.16
TA 24.0 23.0 21.0 22.0 23.0 22.6 0.51
+ 5 1.8 3.3 3.1 3.0 2.0 2.6 0.31
+ 15 1.8 3.0 3.0 2.7 2.1 2.5 0.24
+ 30 1.9 3.1 2.7 3.4 2.1 2.6 0.29
+ 45 1.8 3.1 3.0 3.1 2.0 2.6 0.29
Table 4.3. The effect of saline, IV, on thresholds to noxious mechanical stimulation 
during and after inflation of a pneumatic tourniquet on the ipsilateral forelimb of sheep.
Individual and mean thresholds to noxious mechanical stimulation (Newtons), ± standard 
error of the mean (SEM), in a group of 5 sheep during and after application of an inflated 
tourniquet on the same limb as the threshold testing leg unit at time 0. The time to 
aversion (TA, min) was recorded as the tourniquet was removed and thresholds to 
noxious mechanical stimulation were recorded for a further 45 minutes. Control values 
(C) are the mean of at least 3 readings taken over a 30 minute period, and were recorded 
before administration of saline (0.9 %), 5 ml, IV, 1 hour before the tourniquet was 
inflated.
* p<0.05 / **p <0.01 statistically different from control values.
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different from control values (p<0.05) as described previously (vide supra). For all 
remaining treatments, fentanyl (Table 4.4), flunixin (Table 4.5) and carprofen (Table 
4.6), there were no significant differences between the last thresholds recorded before 
aversion and control values.
Fentanyl evoked marked behavioural changes in all sheep immediately after 
administration. Sheep chewed frantically at ropes and bars and snatched at hay. 
Nystagmus was observed in some sheep, as was ataxia, while others paced back and 
forth within the available space. One sheep (number 3) head pressed. Thresholds to 
mechanical stimulation were elevated in all sheep throughout the period of ischaemia at all 
time points except for the Final reading obtained from sheep number 3. Thresholds were 
significantly greater than control readings (mean, 3.4N), 5 (p<0.01) and 10 minutes 
(p<0.05) after tourniquet inflation (means, 6.6N and 5.5N, respectively) /. e. 10 and 15 
minutes after drug administration. Final thresholds obtained during ischaemia for these 
sheep were higher than control values (p<0.07), but were not significantly different from 
control values. Three sheep (numbers 1, 4 and 5) did not show signs of aversion before 
maximum cut-off time was reached. Sheep number 3 showed signs of aversion at 16 
minutes. This sheep was the most agitated of all after administration of fentanyl. 
Thresholds in all sheep 5 minutes after deflation of the tourniquet were the same or 
greater than control values although these differences were not significant.
No behavioural changes were noted after administration of flunixin. Threshold to 
mechanical stimulation were maintained in one sheep (number 2) which did not 
demonstrate signs of aversion within the 30 minute test period (Table 4.5). Reduction in 
thresholds were observed in the remaining 4 sheep during the period of ischaemia. 
However, there were no significant changes between control thresholds and the final 
thresholds obtained during ischaemia (means, 2.8N and 1.9N, respectively).
Similarly, no behavioural changes were noted after administration of carprofen. 
Thresholds to mechanical stimulation were maintained in 2 of the 5 sheep investigated 
(numbers 1 and 2) during ischaemia (Table 4.6). Moreover, sheep numbers 1 and 2 did 
not demonstrate signs of aversion within the 30 minute test period. Thresholds during 
ischaemia in the remaining 3 sheep fell during the period o f ischaemia, although sheep 
number 4 did not show signs of aversion before maximum cut-off time was reached. 
There were no significant changes between control thresholds and the final thresholds 
obtained during ischaemia (means, 2.6N and 3.6N, respectively). There were no 
significant differences between time to aversion demonstrated by the different treatment 
groups.
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Tim e No. 1 No. 2 No. 3 No. 4 No. 5 M ean ±SE M
(m in)
C 2.7 3.0 3.7 3.2 4.4 3.4 0.30
5 4.1 6.7 5.4 7.7 9.2 6.6** 0.88
10 5.6 6.6 4.1 4.8 6.5 5.5* 0.48
15 7.8 7.5 3.1 5.4 6.7 6.1 0.86
20 4.1 8.6 6.5 4.2 5.9 0.53
25 3.6 6.2 5.8 6.1 5.4 0.61
3 0 4.3 5.1 5.8 5.1 0.43
TA 30.0 29.0 16.0 30.0 30.0 27.0 2.75
+ 5 10.8 4.0 3.7 3.6 5.2 5.5 1.36
+ 15 3.0 6.1 2.9 3.7 5.0 4.2 0.63
+ 30 2.9 3.3 3.5 3.0 3.8 3.3 0.16
+ 45 2.7 2.7 3.2 2.9 3.6 3.0 0.17
Table 4.4. The effect of fentanyl, IV, on thresholds to noxious mechanical stimulation 
during and after inflation of a pneumatic tourniquet on the ipsilateral forelimb of sheep.
Individual and mean thresholds to noxious mechanical stimulation (Newtons), ±  standard 
error of the mean (SEM), in a group of 5 sheep during and after application of an inflated 
tourniquet on the same limb as the threshold testing leg unit at time 0. The time to 
aversion (TA, min) was recorded as the tourniquet was removed and thresholds to 
noxious mechanical stimulation were recorded for a further 45 minutes. Control values 
(C) are the mean of at least 3 readings taken over a 30 minute period, and were recorded
at least 55 minutes before administration of fentanyl, 5 M-g/kg, IV. Fentanyl was 
administered 5 minutes before the tourniquet was inflated.
* p<0.05 /  **p<0.01 statistically different from control values.
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Tim e No. 1 No. 2 No. 3 No. 4 No. 5 M ean ±SE M
(m in)
C 3.2 2.4 2.8 3.2 2.4 2.8 0.18
5 2.0 3.5 2.7 3.5 2.5 2.8 0.29
10 1.6 4.4 2.4 2.3 1.9 2.5 0.49
15 1.5 5.6 2.9 0.7 2.0 2.5 0.84
20 1.7 4.5 2.0 0.7 1.6 2.1 0.63
25 2.8 2.8
30 3.6 3.6
TA 25 30 24 23 24 25.2 1.24
+ 5 3.6 5.0 2.9 3.0 2.7 3.4 0.41
+ 15 3.5 6.3 2.6 2.9 3.1 3.7 0.67
+ 30 3.2 6.4 2.9 2.9 3.2 3.7 0.67
+ 45 3.2 5.3 2.7 3.0 2.6 3.4 0.52
Table 4.5. The effect of flunixin meglumine, IV, on thresholds to noxious mechanical 
stimulation during and after inflation of a pneumatic tourniquet on the ipsilateral forelimb 
of sheep.
Individual and mean thresholds to noxious mechanical stimulation (Newtons), ± standard 
error of the mean (SEM), in a group of 5 sheep during and after application of an inflated 
tourniquet on the same limb as the threshold testing leg unit at time 0. The time to 
aversion (TA, min) was recorded as the tourniquet was removed and thresholds to 
noxious mechanical stimulation were recorded for a further 45 minutes. Control values 
(C) are the mean of at least 3 readings taken over a 30 minute period, and were recorded 
before administration of of flunixin meglumine, 1.0 mg/kg, IV, 1 hour before the 
tourniquet was inflated.
T im e No. 1 No. 2 No. 3 No. 4 No. 5 M ean ±SE M
(m in )
C 2.7 2.8 2.8 2.2 2.6 2.6 0.11
5 3.0 2.0 2.1 L4 3.1 2.3 0.32
10 2.9 2.0 2.3 1.4 2.9 2.3 0.28
15 3.3 2.9 2.4 1.5 1.5 2.3 0.36
20 3.1 3.5 2.3 1.3 2.6 0.49
25 3.1 3.5 1.5 1.6 2.4 0.46
3 0 3.1 3.3 1.4 2.6 0.47
TA 30 30 26 30 18 26.8 2.33
+ 5 3.4 2.7 2.6 2.4 2.4 2.7 0.18
+ 15 3.2 3.3 2.4 2.0 2.9 2.8 0.25
+ 30 3.3 3.2 2.9 1.4 2.7 2.7 0.34
+ 45 3.3 2.9 2.3 1.9 2.6 2.6 0.24
Table 4.6. The effect of carprofen, IV, on thresholds to noxious mechanical stimulation 
during and after inflation of a pneumatic tourniquet on the ipsilateral forelimb of sheep.
Individual and mean thresholds to noxious mechanical stimulation (Newtons), ± standard 
error of the mean (SEM), in a group of 5 sheep during and after application of an inflated 
tourniquet on the same limb as the threshold testing leg unit at time 0. The time to 
aversion (TA, min) was recorded as the tourniquet was removed and thresholds to 
noxious mechanical stimulation were recorded for a further 45 minutes. Control values 
(C) are the mean of at least 3 readings taken over a 30 minute period, and were recorded 
before administration of carprofen, 0.7 mg/kg, IV, 1 hour before the tourniquet was 
inflated.
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4.3.2 Study 2
Intradermal injection of normal saline, 100 fil, caused a small intradermal bleb 
immediately after injection. This lesion was not apparent within 30 minutes of injection. 
Intradermal injection of carrageenan, 0.0625 %, 100 (il, also caused a small intradermal 
bleb immediately after injection. However, within 60 minutes of administration, a 
cutaneous wheal was present at the site of the original injection. The size of the wheal, 
approximately 1.5 to 2.0 cm x 1.5 to 2 cm, was consistent between sheep and between 
cross-overs. In most sheep, the wheal was not apparent 24 hours after injection, and if 
detected there were no distinct edges to the lesion.
Mechanical thresholds
Intradermal injection of saline did not alter thresholds to noxious mechanical stimulation 
over a 24 hour period (Table 4.7). However, administration of carrageenan ID, caused a 
significant reduction of the thresholds to noxious mechanical stimulation (p<0.01) in 
group 3 (carrageenan ID, flunixin IV) (Table 4.8) compared with the other treatment 
groups during the first 120 minutes. Post-hoc tests did not locate the site of this 
significance. Statistical analysis also indicated a significant difference between sheep 
within treatment groups (p<0.01). Sheep number 6 consistently responded to noxious 
mechanical stimulation at a greater force than the remaining sheep.
Statistical analysis of the data after administration of IV treatments (150-360 min) 
indicated that there was a significant difference between treatments (p<0 .01), and 
between sheep within treatment groups (p<0.01). After administration of flunixin (Table 
4.8), carprofen (Table 4.9) and saline (Table 4.10), IV, thresholds to noxious mechanical 
stimulation were significantly lower than those recorded in sheep which were 
administered saline ID, but received no subsequent treatment IV (Table 4.7). However, 
again, post-hoc tests failed to locate the site of this significance. Sheep number 6 had 
thresholds significantly greater, and sheep number 4 had thresholds significantly lower, 
than other sheep examined over the course of the study.
Thermal thresholds
Thresholds to noxious thermal stimulation after injection of saline (0.9 %), ED, were not 
significantly different from control thresholds for the same group of sheep over a 24 hour 
period (Table 4.7). However, injection of carrageenan (Table 4.8, 4.9 and 4.10), 0.0625 
%, ID, significantly reduced thresholds to thermal stimulation when compared with saline 
(ID) controls (p<0.01) (Fig. 4.2). Thresholds to noxious thermal stimulation were 
significantly lower 120 minutes after carrageenan injection in groups 2, 3 and 4 (group
1 3 3
Tim e No. 1 No. 2 No. 3 No. 4 No. 5 No. 6 M ean ±SE M
(m in)
T herm al th resho lds
C 52.4 52.0 49.7 51.4 51.8 51.7 51.5 0.39
30 50.4 52.2 51.5 51.8 53.5 50.3 51.6 0.49
60 55.7 53.5 51.9 51.2 52.8 52.1 52.9 0.65
90 53.6 53.4 49.6 51.5 51.7 52.9 52.1 0.62
120 53.7 52.0 53.8 52.8 54.6 50.8 53.0 0.56
150 52.5 53.2 50.1 50.6 51.0 51.9 51.6 0.49
180 50.0 54.0 52.1 52.4 50.4 50.2 51.5 0.65
210 52.5 55.6 51.2 53.0 51.5 52.7 52.8 0.64
240 53.0 53.9 51.5 MD 51.7 51.0 52.2 0.53
300 51.6 51.6 51.7 53.6 51.8 51.0 51.8 0.36
3 6 0 53.4 54.2 51.9 53.8 51.8 50.9 52.7 0.54
1440 49.9 52.5 50.8 52.7 51.4 50.8 51.4 0.44
M echanical th resho lds
C 3.6 4.7 3.3 2.4 3.6 2.2 3.3 0.37
3 0 2.5 4.7 2.5 2.6 3.4 2.5 3.0 0.36
60 2.7 4.8 3.0 3.5 3.9 3.0 3.5 0.32
90 2.6 4.3 2.6 3.0 3.3 2.5 3.1 0.28
120 3.5 4.8 2.6 2.2 3.5 2.9 3.3 0.37
150 3.1 4.8 2.5 2.5 3.3 3.0 3.2 0.35
180 1.9 6.2 3.0 2.1 2.9 2.2 3.1 0.66
210 1.6 5.2 3.0 2.4 2.9 3.0 3.0 0.49
240 1.6 5.4 4.5 1.9 2.7 3.2 3.2 0.61
300 3.4 5.6 3.4 2.1 3.0 4.3 3.6 0.49
360 2.6 5.9 2.9 2.1 .3 .3 2.9 3.3 0.55
1440 2.6 3.4 2.9 2.4 3.5 2.9 3.0 0.18
Table 4.7. The effect of intradermal injection o f saline on thresholds to noxious 
mechanical and thermal stimulation in sheep.
Individual and mean thresholds to noxious mechanical (Newtons) and thermal (°C) 
stimulation, ± standard error of the mean (SEM), in a group of 6 sheep. Control values 
(C) are the mean of at least 3 readings taken over a 30 minute period before injection of
100 jixl saline (0.9 %) intradermally in the forelimb, at time 0.
MD= missing data
1 3 4
Time No. 1 No. 2 No. 3 No. 4 No. 5 No. 6 Mean ±SE \1
(min)
Thermal thresholds
C 49.4 54.2 50.5 51.3 51.1 52.5 51.5 0.68
30 44.6 52.6 44.4 53.9 47.2 49.5 48.7 1.64
6 0 48.0 55.1 44.0 47.3 50.2 47.1 48.6 1.53
90 48.0 54.3 48.6 49.6 45.4 49.6 49.3 1.19
120 46.5 52.8 46.6 50.6 45.9 47.1 48.3** 1.14
150 50.0 55.2 47.1 51.7 51.1 52.9 51.3 1.12
180 47.3 54.9 53.2 54.0 52.6 52.4 52.4 1.09
2 1 0 49.8 57.2 52.1 49.8 50.1 52.7 52.0 1.17
2 4 0 50.0 47.7 55.4 47.7 51.9 53.5 51.2 1.28
3 0 0 50.0 55.5 52.2 52.7 53.2 52.5 52.7 0.72
3 6 0 52.6 52.7 48.3 51.6 51.1 50.7 51.2 0.67
1 4 4 0 51.4 52.9 51.1 53.2 50.8 51.8 51.9 0.40
Mechanical thresholds
C 3.9 2.5 3.5 1.5 2.9 3.4 . 3.0 0.35
30 2.5 2.2 2.7 1.7 1.5 3.9 2.4 0.35
60 2.5 1.6 2.7 1.7 1.2 3.9 2.3 0.40
90 2.2 2.1 3.9 1.4 2.9 3.9 2.7 0.42
120 1.7 3.2 2.5 2.1 1.9 3.4 2.5 0.29
150 3.5 2.4 3.3 2.0 3.2 2.5 2.8 0.24
180 5.5 2.7 1.9 1.5 1.7 3.1 2.7 0.61
2 1 0 5.3 2.6 1.9 2.3 2.9 3.9 3.2 0.51
2 4 0 6.5 3.0 2.5 2.0 1.6 3.1 3.1 0.72
3 0 0 5.4 3.5 1.9 2.4 4.5 3.5 3.5 0.53
3 6 0 3.4 2.4 2.0 1.4 3.0 2.9 2.5 0.30
1440 4.9 2.6 3.4 1.6 2.3 2.7 2.9 0.46
Table 4.8. The effect of intradermal injection of carrageenan on thresholds to noxious 
mechanical and thermal stimulation in sheep, and the response to injection of flunixin 
meglumine intravenously.
Individual and mean thresholds to noxious mechanical (Newtons) and thermal (°C) 
stimulation, ± standard error of the mean (SEM), in a group of 6 sheep. Control values 
(C) are the mean of at least 3 readings taken over a 30 minute period before injection of
100 p.1 carrageenan (0.0625 %) intradermally in the forelimb, at time 0. Flunixin 
meglumine, 2.0 mgAg, was injected intravenously at 120 minutes.
**p<0.01 statistically different from control values.
1 3 5
Tim e No. 1 No. 2 No. 3 No. 4 No. 5 No. 6 M ean ±SE M
(m in)
T herm al th resho lds
C 51.4 52.5 53.5 53.5 52.1 51.8 52.4 0.36
30 50.6 47.6 51.2 46.6 49.7 51.6 49.6* 0.83
60 49.1 45.0 52.0 47.9 49.1 50.3 48.6* 0.96
90 44.6 48.2 51.2 47.2 49.8 48.1 48.2** 0.92
120 46.2 46.9 50.9 47.6 51.4 48.1 48.5** 0.86
150 52.4 53.3 MD 54.5 49.1 53.2 52.5 0.91
180 53.1 53.8 51.6 48.0 53.3 47.3 51.2 1.16
210 52.1 56.3 56.3 50.8 54.5 52.6 53.8 1.93
240 4 7 .1 ' 54.9 54.5 54.2 54.6 52.9 53.0 1.22
300 48.9 56.2 54.7 53.0 50.7 53.1 52.8 1.10
360 46.6 54.9 55.5 51.1 51.2 53.3 52.1 1.32
1440 50.3 55.5 53.4 51.8 50.9 54.0 52.7 0.81
M echanical th resho lds
C 3.2 3.5 3.3 2.8 4.1 3.1 3.3 0.18
30 2.3 3.3 2.9 2.3 3.3 3.5 2.9 0.22
60 3.0 2.9 3.3 2.1 2.9 2.3 2.8 0.19
90 2.2 2.3 3.7 2.5 3.1 3.1 2.8 0.24
120 3.2 3.2 2.5 2.1 3.9 2.6 2.9 0.26
150 2.9 2.2 2.4 2.2 1.6 3.4 2.5 0.26
180 3.9 2.0 3.3 1.9 3.6 2.6 2.9 0.34
210 3.3 3.2 2.3 2.0 2.3 3.1 2.7 0.23
240 4.1 3.0 2.3 2.0 2.7 3.9 3.0 0.35
300 3.0 1.7 3.1 1.9 3.1 4.3 2.9 0.39
360 2.5 2.9 3.1 2.4 2.3 2.1 2.6 0.15
1440 2.5 2.9 3.3 2.3 2.9 2.9 2.8 0.14
Table 4.9. The effect of intradermal injection of carrageenan on thresholds to noxious 
mechanical and thermal stimulation in sheep, and the response to injection of carprofen 
intravenously.
Individual and mean thresholds to noxious mechanical (Newtons) and thermal (°C) 
stimulation, ± standard error of the mean (SEM), in a group of 6 sheep. Control values 
(C) are the mean of at least 3 readings taken over a 30 minute period before injection of
100 |il carrageenan (0.0625 %) intradermally in the forelimb, at time 0. Carprofen, 4.0 
mg/kg, was injected intravenously at 120 minutes.
*p<0.05 / **p<0.01 statistically different from control values. MD= missing data
1 3 6
Tim e No. 1 No. 2 No. 3 No. 4 No. 5 No. 6 M ean ±SE M
(m in)
T herm al th resho lds
C 52.9 53.0 53.5 50.6 54.6 50.0 52.4 0.72
30 46.8 53.8 53.8 46.2 51.1 49.3 50.2 1.35
60 50.1 52.3 49.1 43.4 48.7 52.2 49.3 1.33
90 47.0 50.8 48.6 45.2 50.0 48.3 48.3** 0.83
120 47.8 54.9 50.1 44.6 50.9 47.6 49.3* 1.44
150 45.1 50.2 52.3 44.9 54.8 46.4 49.0* 1.68
180 47.1 50.6 52.1 44.8 49.8 46.2 48.4** 1.15
210 48.1 54.6 51.5 44.2 52.5 50.9 50.3 1.50
240 48.3 54.5 53.6 44.6 50.1 47.3 49.7 1.55
300 48.3 54.0 50.1 46.4 49.7 51.0 49.9 1.05
360 50.1 50.1 53.5 48.5 54.1 48.3 50.8 1.01
1440 48.1 54.4 50.1 52.9 53.8 52.2 51.9 0.98
M echanical th resho lds
C 2.4 2.1 3.3 2.0 2.0 3.5 2.6 0.28
30 2.4 3.1 2.2 1.7 2.2 5.5 2.9 0.56
60 2.0 2.1 2.7 1.7 1.4 6.8 2.8 0.82
90 2.2 3.2 1.9 2.1 2.1 6.2 3.0 0.68
120 3.0 2.4 2.6 2.0 1.7 7.9 3.3 0.95
150 2.0 1.5 3.4 1.9 2.1 5.8 2.8 0.66
180 1.2 1.4 2.6 1.7 3.4 7.2 2.9 0.92
210 2.2 1.2 2.9 1.2 2.2 6.2 2.7 0.76
240 2.2 1.2 2.4 2.3 1.9 6.5 2.8 0.77
300 3.2 1.2 1.6 1.7 1.7 4.8 2.4 0.56
360 3.2 1.0 1.9 1.7 2.4 5.2 2.6 0.61
1440 1.9 2.5 3.1 1.8 2.3 5.5 2.9 0.56
Table 4.10. The effect of intradermal injection of carrageenan on thresholds to noxious 
mechanical and thermal stimulation in sheep, and the response to injection of saline, 
intravenously.
Individual and mean thresholds to noxious mechanical (Newtons) and thermal (°C) 
stimulation, ± standard error of the. mean (SEM), in a group of 6 sheep. Control values 
(C) are the mean of at least 3 readings taken over a 30 minute period before injection of
100 |il carrageenan (0.0625 %) intradermally in the forelimb, at time 0. Saline (0.9 %), 5 
ml, was injected intravenously at 120 minutes.
*p<0.05 / **p<0.01 statistically different from control values.
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Figure 4.2. Response to injection of saline (0.9 %) (sal), 100 |il, and carrageenan 
(carra), 100 fil of 0.0625 %, intradermally on the lateral aspect of a forelimb in sheep.
Thresholds to noxious thermal stimulation (°C) are plotted against time (min) after 
intradermal injection. Each point indicates the mean and standard error of the mean for 6 
sheep. The pre-test reading (pre) is the mean of at least 3 readings for each sheep over a 
30 minute time period prior to intradermal injection at time 0. Sheep given carrageenan 
also were administered saline (0.9 %), 5 ml, intravenously, at 120 minutes.
The maximum threshold temperature (65°C) is indicated.
*p<0.05 /  **p<0.01 statistically different from control values.
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means, 49.3; 48.3; 48.5°C, respectively), than control values for those groups (group 
means, 52.4, 51.5, 52.4, respectively). There was a significant difference between sheep 
within treatment groups (p<0.01).
Statistical analysis of the data after administration of IV treatments indicated that there was 
a significant difference between treatments (p<0.01), and between sheep within treatment 
groups (p<0.01). Thresholds to thermal stimulation for group 2 (carrageenan ID, saline 
IV) were significantly lower than thresholds recorded for the remaining 3 groups until 
180 minutes.
It is interesting to note that the mean thresholds to noxious thermal stimulation after 
injection of carrageenan, ID, did not fall to the same extent after each occasion on which 
the irritant was injected (Table 4.11). There were significant differences between control 
thresholds to noxious thermal stimulation, and thresholds recorded 120 minutes after 
injection of carrageenan on the first 2 occasions only (p<0.01) (Fig. 4.3). Unfortunately, 
there was not a standard period between injections of carrageenan because the study was 
designed as a cross-over, and not all treatments involved injection of carrageenan. 
Therefore, there was at least a 7 day period between successive injections of carrageenan, 
with a maximum period of 14 days.
1 3 9
C arrageenan  1 C arrageenan  2 C arrag een an  3
C 120 C 120 C 120
No. 1 52.9 47.8 51.4 46.2 49.4 46.5
No. 2 52.5 46.9 54.2 52.8 53.0 54.9
No. 3 50.5 46.6 53.5 50.1 53.5 50.9
No. 4 50.6 44.6 53.5 47.6 51.3 50.6
No. 5 51.1 45.9 54.6 50.9 52.1 51.4
No. 6 52.5 47.1 50.0 47.6 51.8 48.1
M ean 51.7 46.5* 52.9 49.2* 51.9 50.4
±SE M 0.44 1.45 0.73 1.01 0.59 1.22
Table 4.11. Changes in thresholds to noxious thermal stimulation after intradermal 
injection of carrageenan, on 3 different occasions in sheep.
Individual and mean thresholds to noxious thermal (°C) stimulation, ± standard error of
the mean (SEM), in a group of 6 sheep. Responses to injection of carrageenan, 100 |il of 
0.0625 %, intradermally on the lateral aspect of a forelimb in a group of 6 sheep on 3 
occasions, 7 days to 14 days, apart, are shown.
Control values (C) are the mean of at least 3 reading taken over a 30 minute period and 
were recorded before administration of carrageenan at time 0. Thresholds were recorded 
subsequently 120 minutes after injection (120).
*p<0.01 statistically different from control values.
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F igure  4.3. Response to injection of carrageenan (carra), 100 |il of 0.0625 %, 
intradermally on the lateral aspect of a forelimb in a group of 6 sheep on 3 occasions, 7 to 
14 days, apart.
Thresholds to noxious thermal stimulation (°C) are plotted against time (min) after 
intradermal injection. Each point indicates the mean and standard error of the mean for 6 
sheep. The pre-test reading (shown at time 0) is the mean of at leiast 3 readings for each 
sheep over a 30 minute time period prior to intradermal injection at time 0.
The maximum threshold temperature (65°C) is indicated.
*p<0.01 statistically different from pre-test values.
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4.4 D iscussion 
4.4.1. S tudy  1
Evaluation of tourniquet-induced pain in sheep was achieved by observing the number of 
times sheep lifted their leg from the ground in a purposeful manner. Therefore, it was 
important to demonstrate that the presence of an uninflated tourniquet did not change the 
normal behaviour of the sheep. Moreover, it was important to establish that the presence 
o f the tourniquet alone did not change thresholds to noxious mechanical stimulation. 
Preliminary studies demonstrated that sheep did not object to the presence o f the 
tourniquet and thresholds were not affected.
It has been recommended that surgical tourniquets should be inflated to the lowest 
pressure that will produce a bloodless field (Patterson and Klenerman, 1979) and 
pressures of approximately 100 mm Hg greater than systolic pressure are adequate for 
this purpose (Blass and Moore, 1984; Hagenouw et al. , 1986). Although, much higher 
pressures are occasionally employed (Hagenouw et al. , 1986), they do not cause greater 
occlusion of blood supply but may cause greater damage to the extremity (Bolton and 
McFarlane, 1978). In the present study, the systolic blood pressure of the sheep was not 
measured before each experiment and an occlusion pressure of 300 mm Hg was used in 
each case. This pressure was of a similar level to that used in human volunteer studies of 
tourniquet pain (Posner, 1984; Hagenouw et al. , 1986). By using local intravenous 
injection of lignocaine, 300 mm Hg was shown to be sufficient to occlude venous 
drainage of the sheep limb for a period of at least 30 minutes. However, it would be 
preferable to establish the systolic pressure for each sheep individually prior to tourniquet 
inflation, in order to limit unnecessary damage (Bolton and McFarlane, 1978).
Gelgor et al. (1986a) demonstrated thermal hyperalgesia, for periods of up to 90 minutes, 
following tourniquet-induced ischaemia of the rats tail, using a modified tail flick test, but 
did not record thresholds to noxious thermal stimulation during the period of tourniquet 
inflation (Gelgor et al. , 1986a; 1986b; 1992a; 1992b). In addition, hindlimb ischaemia 
induced by acute occlusion of the femoral artery, has been shown to act as a conditioning 
stimulus leading to the development of mechanical hyperalgesia in the ipsilateral rat hind 
paw (Sher and Mitchell, 1990). In the present study, tourniquet inflation decreased the 
thresholds to noxious mechanical stimulation during the period of inflation on the 
ipsilateral limb, but not the contralateral limb of sheep, indicating that the mechanical 
hyperalgesia observed was a local peripheral effect. However, reperfusion hyperalgesia 
was not detected, and mechanical thresholds returned to normal values immediately upon 
release of the tourniquet. Mechanical threshold testing apparatus similar to the equipment
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used in the present study, did not detect analgesia after administration of a partial opioid 
agonist, buprenorphine, and a full opioid agonist, pethidine, in sheep (Nolan et al. , 
1987c; Nolan et al. , 1988), that was detected by a thermal device. Similarly, post­
operative hyperalgesia, not detected by mechanical threshold testing apparatus, was 
detected using thermal threshold testing apparatus (study 3, chapter 3). The differential 
sensitivity of noxious threshold testing procedures is well recognized for the opioid drugs 
e. g. pain induced by noxious thermal stimulation is modulated primarily by mu receptor 
agonists, whereas pain produced by chemical irritants is modulated by both mu and kappa 
agonists (Franklin and Abbott, 1989). Thus, while noxious mechanical stimulation 
detects hyperalgesia during ischaemia, it may not be sensitive enough to detect 
reperfusion hyperalgesia. Thresholds to noxious thermal stimulation were not recorded in 
the present study, however, it would be interesting to investigate if thermal hyperalgesia 
' could be detected in the sheep model. This could be achieved either using the thermal ear 
clip described in chapter 2 , or preferably, by a modification of the clip such that the 
heating resistor could be applied to the limb both during and after ischaemia.
It has been suggested that hypertension observed in anaesthetised animals that had an 
inflated tourniquet positioned around a limb, occurred as a result of tourniquet-induced 
pain (Abrahamsen et al. , 1989; Copland et al. , 1989). Consequently, it would be of 
interest to evaluate any change in mean arterial blood pressure which occurred during 
tourniquet inflation in conscious sheep. This could be achieved by either direct or indirect 
methods of measurement. Pilot studies in experimental sheep using an indirect 
measurement of blood pressure via a cuff positioned on the contralateral forelimb, were 
unsuccessful. The sheep were alarmed by the cyclic inflation and deflation of the cuff and 
the cuff became dislodged easily. Direct measurement of arterial blood pressure would 
probably provide more detailed information, and be most easily achieved in sheep in 
which the carotid artery had been relocated to a subcutaneous position.
Cole (1952), reporting on tourniquet pain, observed that administration of morphine 
before the onset of pain, frequently prevented the subsequent development of pain. 
Moreover, it was demonstrated recently that morphine administered intrathecally at the 
same time as bupivacaine resulted in fewer complaints o f tourniquet pain in humans 
undergoing surgery of the lower extremities (Tuominen et al. , 1988). The authors 
suggested that binding of morphine to opioid receptors in the spinal cord inhibited 
transmission of tourniquet-induced noxious information. Fentanyl, a potent short acting p. 
opioid agonist, with known analgesic properties in sheep (Ley et al. , 1990b), elevated 
thresholds to noxious mechanical stimulation significantly after tourniquet inflation. 
Thresholds for all sheep during the period of ischaemia were greater than control values, 
although thresholds prior to tourniquet release were not significantly different from
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control readings. The dose of fentanyl given to sheep in the present study was 3 times 
less than that used by Ley et al. (1990b), and may explain the differences in maximal 
threshold responses seen between the 2 studies i. e. in the present study the mean 
maximal response was almost half that reported by Ley et al. (1990b). Interestingly, Ley 
et al. (1990b) demonstrated that the extent and duration of fentanyl analgesia in sheep 
suffering chronic pain was less than that recorded in normal sheep. Thus, tourniquet pain 
may parallel clinical pain, as suggested by Beecher (1957), and limit the extent of fentanyl 
analgesia. It is possible that the motor and excitatory reactions observed in sheep after 
administration of fentanyl caused the increased time to aversion. This theory was 
proposed by Sher et al. (1992) to explain the increased escape latencies observed in rats 
after administration of pethidine and morphine, which prevented the development of 
reperfusion hyperalgesia. However, since it has been demonstrated that morphine can 
abolish C-fibre-induced excitability changes in flexor alpha-motoneurones at the level of 
the spinal cord (Woolf and Wall, 1986b), it is probable that |i selective opioids exert 
some degree of antinociceptive activity in the tourniquet model.
Pre-treatment of sheep with the NSAIDs, flunixin meglumine and carprofen, did not alter 
the time to aversion after inflation of the tourniquet, confirming similar findings in the rat 
(Gelgor et al. , 1986b; 1992a; 1992b). However, although thresholds to noxious 
mechanical stimulation fell during ischaemia in most sheep given flunixin and carprofen, 
overall, the reduction in recorded thresholds was not significantly different from control 
thresholds. This suggests an antinociceptive action of these 2 agents during tourniquet- 
induced pain. Pre-treatment of rats using a variety of NSAIDs, including lysine 
acetylsalicylate, indomethacin, ibuprofen and paracetamol has been shown to attenuate 
reperfusion hyperalgesia in a dose-dependent manner in the rat tail ischaemia model 
(Gelgor et al. , 1986b; 1992b). This indicated that the mechanisms of tourniquet-induced 
pain and reperfusion hyperalgesia differed, because administration of a NSAID did not 
prolong the escape latency in the same model, and administration of NSAIDs did not alter 
tail flick latency in the absence of ischaemia. Although the latter experiment demonstrated 
a well recognized phenomenon i. e. that generally NSAIDs do not exert antinociceptive 
activity in the normal animal, it does not preclude an antinociceptive action of these drugs 
during ischaemia when many local metabolites, including prostaglandins are released 
(Staszweska-Barczak et al. , 1976; Longhurst and Dittman, 1987). Prostaglandins 
released during ischaemia may act to increase activity in afferent nociceptive pathways 
(Staszweska-Barczak et al. , 1976; Longhurst and Dittman, 1987), and it has been 
demonstrated that peripheral A5 and C-fibres are activated under such conditions (Chabel 
et al. , 1990; Maclver and Tanelian, 1992). Humans describe tourniquet pain as poorly 
localized, aching, dull and burning (de Jong and Cullen, 1963; Gelgor et al. , 1992b; 
Maclver and Tanelian, 1992) which may correspond to activation of C-fibres, and Chabel
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and colleagues (1990) showed that in a rat model of tourniquet ischaemia, while 
spontaneous activity decreased in myelinated fibres, previously inactive C-fibres began to 
discharge spontaneously. Therefore, C-fibre activation may have a pivotal role in 
tourniquet pain. However, Gelgor et al. (1992b) proposed that hyperalgesia was 
observed during reperfusion, because it was at this stage that accumulated arachidonate 
was metabolized, since it was known that prostaglandin synthesis depends on a high local 
oxygen concentration (Lands, 1979). Results from the present study tend to contradict 
this theory since administration of NSAIDs attenuated the fall in thresholds to noxious 
mechanical stimulation during ischaemia, and also caused an increase in the time to 
aversion in some sheep. It is possible that these differences were noted because of the 
different test systems involved. However, it is important to note that the development of 
hyperalgesia during ischaemia has not been investigated in the rat model.
Recently NSAIDs injected intracerebroventricularly were shown to abolish reperfusion 
hyperalgesia in the rat tail ischaemia model (Gelgor et al. , 1992a), suggesting a central 
mode of action of the NSAIDs. This is supported by the findings of many other workers, 
including Malmberg and Yaksh (1992a) who demonstrated an antinociceptive effect of 
NSAIDs administered intrathecally in rats. Thermal hyperalgesia was evoked in the latter 
study by intrathecal administration of glutamate receptor agonists, including NMDA, and 
both pre- and post-treatment with NSAIDs attenuated the resulting hyperalgesic response. 
Sher et al. (1992) have demonstrated that systemic administration of 2 NMDA receptor 
antagonists, ketamine and D-2-amino-5-phosphonovalerate, inhibits reperfusion 
hyperalgesia. However, although Malmberg and Yaksh (1992a) showed that pre­
treatment with an NMDA receptor antagonist, MK-801, attenuated the development of 
hyperalgesia in a non-ischaemic model, administration of the antagonist after induction of 
hyperalgesia, in contrast to the NSAIDs, did not. In the present study it has been 
demonstrated that the development of mechanical hyperalgesia during ischaemia is a local 
peripheral effect. However, it is possible that flunixin and carprofen may be exerting a 
central effect in addition to local inhibition of prostaglandin production. Therefore, it 
would be interesting to investigate the effects of intrathecally administered NSAIDs in 
sheep using the tourniquet model.
In conclusion, tourniquet-induced pain or hyperalgesia may prove to be a useful model 
for the investigation of the antinociceptive affects of the NSAIDs in larger domestic 
species. The animals have a degree of control over the duration of ischaemia, and there 
appears to be no residual effects after tourniquet release. The sheep in the present study 
were not observed to be lame afterwards. It would be valuable to establish whether 
thermal reperfusion hyperalgesia occurs in sheep, and if so to what extent, since this 
would provide a longer test period when assessing the antinociceptive or analgesic
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properties of test drugs. Moreover, it may provide a model for investigation of the spinal 
antinociceptive effects of the NSAIDs.
4.4.2 S tudy  2
It was demonstrated in chapter 3 that investigation of clinical pain frequently is hampered 
by a variety of factors which are difficult to control or limit, such as pre-existing or 
concurrent disease, lack of information on the exact duration of disease or of previous 
episodes of the disease. Footrot in sheep has been used as a model of chronic clinical pain 
in sheep (Ley et al. , 1989) and has yielded some interesting results. However, it has 
proved difficult to repeat the initial findings of the latter study (study 2, chapter 3). 
Artificial infection of sheep with the organisms responsible for the development of footrot 
(see chapter 1) has been described (Egerton et al. , 1969), and induction of footrot in 
experimental sheep would allow closer control of experimental conditions. However, 
such experiments are difficult to justify ethically. Footrot is prevalent in the sheep flock in 
the United Kingdom, and presents a major welfare problem. Although, the infection 
responds readily to appropriate treatment, sheep can remain lame for prolonged periods of 
time, and sheep which have apparently recovered from infection continue to respond to 
noxious stimuli at a lower threshold than normal sheep for a period of weeks (Ley et al. , 
1989).
The present study was designed to investigate the effects of intradermal injection of a mild 
irritant in sheep, in an attempt to mimic the inflammatory response of grade 1 footrot in 
this species. Carrageenan is a mucopolysaccharide extract of Irish marine algae, and is 
used widely in experimental models of non-immune inflammation such as the carrageenan 
foot oedema test, Randall-Selitto test and exudative models of inflammation. Carrageenan 
was selected as the irritant in the present study for several reasons. It induces a mild 
inflammatory reaction, of short duration (Higgins et al. , 1987), and it was considered 
important that the duration of the inflammatory response was limited for 2 reasons. 
Firstly, the response of the sheep to intradermal injection of an irritant was unknown, and 
therefore, initially it was important to ensure that any adverse effects were of limited 
duration. Secondly, it was considered important that if changes in thresholds to noxious 
stimulation were observed, that a return to control values could be documented. In 
addition, it has been demonstrated that carrageenan not only provides a useful animal 
model of acute inflammation, characterised by swelling and hyperalgesia (Winter et al. , 
1962), but it also stimulates leukocyte migration, oedema and the formation of 
endogenous chemical mediators of inflammation (Ottemess and Bliven, 1985; Vinegar ef 
al. , 1987). Grade 1 footrot is generally limited to the interdigital space with little or no 
under-running of the hoof wall or sole. Where there is disruption of the epithelium, an
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accumulation of exudate in the intercellular spaces and leukocyte infiltration occurs 
(Stewart, 1989). Therefore, it was considered that the carrageenan-evoked inflammatory 
response would parallel that which might be observed in the initial stages of footrot. 
Further support for the choice of irritant was provided by Vinegar et al. (1979). These 
workers categorised the oedema and hyperalgesia produced by a variety of irritants used 
experimentally according to their response to anti-inflammatory agents and serotonin 
antagonists, and they demonstrated that the response to carrageenan was responsive to 
anti-inflammatory agents and not to serotonin antagonists.
Intraplantar injection of carrageenan in rats is known to cause a reduction in the threshold 
to noxious mechanical stimulation using the Randall-Selitto test (Otterness and Bliven, 
1985). In the present study, reduction in thresholds to noxious mechanical stimulation in 
sheep were not recorded after injection of saline, ID, and there was no consistent 
response to injection of carrageenan, ID, over a 120 minute period after injection. Only 1 
of the 3 groups (Table 4.8) which received carrageenan demonstrated a significant 
reduction in thresholds to noxious mechanical stimulation after injection, and before drug 
treatment, compared to the other treatment groups. The reasons for these findings are 
unclear, because thresholds to noxious mechanical stimulation within group 3 were not 
significantly different from control values for that group. Experimental variation was kept 
to a minimum during the period of the study. The degree of swelling observed in the rat 
foot after injection of carrageenan has been shown to vary with environmental 
temperature (Green et al. , 1971), and consequently, the ambient temperature during 
recording was maintained between 8 and 12°C. Moreover, the carrageenan used in the 
present study had been prepared at least 2 weeks in advance of each experiment to 
improve the uniformity of wheal formation (Otterness and Bliven, 1985), and finally, all 
experiments were conducted at the same time of day, 0830 start time, in order to limit any 
circadian effects on lesional size (Labrecque et al. , 1981). Thus, it is unlikely that the fall 
in thresholds to noxious mechanical stimulation occurred as a consequence of 
experimental variation. Secondary hyperalgesia, whereby non-damaged tissues in the area 
local to the site of injury demonstrate reduced thresholds to noxious stimulation, is a well 
recognised phenomenon (Thalhammer and LaMotte, 1982; Raja et al. , 1988), and it is 
perhaps surprising that a definitive mechanical hyperalgesia was not recorded in the 
present study. However, Kocher et al. (1987) reported that mechanical sensitization of 
unmyelinated skin nociceptors in the rat did not occur after subcutaneous injection of 
carrageenan, although it has been shown to occur after thermal injury (Raja et al. , 1984). 
The leg unit of the mechanical threshold testing apparatus was positioned such that the 
blunt ended pin was pushed out against the medial aspect of the limb, and in retrospect, it 
would have been perhaps more appropriate, when using this model, to position the pin 
towards the lateral aspect of the limb because the irritant was injected laterally.
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Oedema formation after intraplantar injection of carrageenan occurs in 2 phases (Vinegar 
et al. , 1968), and similarly, Vinegar et al. (1987) demonstrated that intraplantar injection 
of carrageenan in rats caused a biphasic hyperalgesic response. Within 2 minutes of 
injection, a short-lived hyperalgesia was recorded, which also was apparent after 
intraplantar saline injection. This was followed by a more prolonged period of 
hypoalgesia, peaking at 60 minutes post-injection. This was superceeded by a 
hyperalgesic phase, which reached maximum intensity by 180 minutes. It is interesting to 
note that from 150 to 360 minutes after administration of carrageenan or saline, ID, 
thresholds to noxious mechanical stimulation were lower in those sheep which had 
received carrageenan than in those which had received saline, ID, although the differences 
within groups were not significant. This suggested that a mechanical hyperalgesia was 
present after administration of carrageenan, ID, from 150 to 360 minutes after injection, 
which would correlate with the second phase of hyperalgesia demonstrated by Vinegar et 
al. (1987). The reduction in thresholds to noxious mechanical stimulation in the present 
study occurred despite administration of flunixin and carprofen, both NSAIDs, 2 hours 
after injection of carrageenan.
Hyperalgesia recorded after intraplantar administration of carrageenan may be detected 
using noxious thermal stimulation as well as noxious mechanical stimulation (Ren e ta l . , 
1992; Yamamoto et al. , 1993). Intradermal administration of saline did not change 
thresholds to noxious thermal stimulation in sheep, but in contrast, administration of 
carrageenan, ID, induced hyperalgesia in all groups examined within 120 minutes of 
injection. Significant thermal hyperalgesia was observed after injection of saline, IV, for 
at least 180 minutes after intradermal injection of carrageenan. The presence of thermal 
hyperalgesia in this model, using an ear clip thermal device, suggests the development of 
central changes in response to peripheral injection of the irritant, carrageenan. In support 
of these findings, Ferreira et al. (1978a) reported that intraplantar injection of carrageenan 
in the rat, 120 minutes before a second intraplantar injection into the contralateral paw, 
reduced the time to maximal mechanical hyperalgesia in the contralateral paw, and 
suggested that carrageenan-evoked central changes induced this change. However, these 
workers did not record a decrease in response latency to noxious mechanical stimulation 
in the contralateral paw during the period between the 2 injections of carrageenan. In 
contrast, hyperalgesia after intraplantar injection of carrageenan in the rat hind paw has 
been demonstrated in paws distant to the injected paw, including the ipsilateral fore paw, 
over a similar period of time to the injected paw (Kayser and Guilbaud, 1987), and repeat 
intraplantar injection of saline was reported to cause a similar effect (Levine et al. , 
1985b). In both of these studies, injection of a local anaesthetic in the inflamed area, 
suppressed the development of distant hyperalgesia, suggesting that afferent input from
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the injured area was involved in the development of distant hyperalgesia. Both groups 
suggested that crossed-spinal reflexes were involved, although heterosegmental 
connections must be involved also to explain the expansion in neuronal receptive fields 
ipsilaterally (Guilbaud et al. , 1986). Carrageenan-induced oedema and hyperalgesia is 
initiated by histamine, bradykinin and serotonin, but by the third hour after injection the 
products of the arachidonic acid cascade play an important role (Di Rosa et al. , 1971; 
Holsapple et al. , 1980), and may enhance the sensitivity of cutaneous afferent fibres 
(Chahl and Iggo, 1977). Administration of flunixin and carprofen, IV, restored 
thresholds to noxious thermal stimulation back to control values within 30 minutes of 
drug administration, while injection of saline, IV, did not. These results suggest that the 
NSAIDs exerted an antinociceptive action in this model of inflammatory pain, possibly by 
inhibiting the development of prostaglandins peripherally. However, a central 
antinociceptive action of these agents is likely and cannot be excluded based on the 
present results.
Concentrations of 1 % carrageenan are used frequently to evoke hyperalgesia in rat paw 
models, using 50 to 100 pi injection volumes (Winter and Flataker, 1965; Vinegar e ta l . , 
1976; Vinegar ei al. , 1987; Wheeler-Aceto et al. , 1990). However, in a recent study by 
Yamamoto et al. (1993), 2 mg of carrageenan was injected into the rat paw to evoke a 
hyperalgesic response, approximately 32 times more than was used in the present study. 
While it would be of interest to repeat the control experiments in this study using higher 
concentrations of carrageenan, it is important to remember that the sheep cannot limit the 
effects of the injection of the irritant, and thus, a balance between experimental effect and 
limiting the pain and distress suffered by experimental animals must be made. Vinegar et 
al. (1987) commented that after subcutaneous injection of 1 % carrageenan in the rat paw, 
the dermis did not appear normal histologically until day 15 after injection. Moreover, 
after intraplantar injection of carrageenan, epidermal tissues did not return to normal until 
at least 21 days. A period of 14 days elapsed before intradermal injection was made on 
the same limb for a second time in the present study, and consequently residual tissue 
damage may have been evident. However, it is unlikely that carrageenan was injected into 
exactly the same site on the second occasion in sheep, while it would be difficult to avoid 
this possiblity if injecting carrageenan into the rat paw. Moreover, the concentration of 
carrageenan used in the present study was much lower than that shown to induced 
prolonged pathological changes.
Thermal hyperalgesia, which was evident 120 minutes after injection of carrageenan on 
the first occasion, was diminished, although still significantly reduced from control 
values, on the second occasion. However, thresholds to noxious thermal stimulation 
were not significantly reduced after injection of carrageenan on the third occasion,
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suggesting tachyphylaxis. Thresholds to noxious mechanical stimulation did not show a 
similar trend. It is interesting to note that Ferreira et al. (1978a) reported a diminished 
oedema response after injection of carrageenan into the rat paw, 2 hours after intraplantar 
injection of the irritant in the contralateral paw. However, the authors did not observe a 
reduction in the intensity of the hyperalgesia which developed, and moreover, these 
findings were acute, whereas, the findings in the present study occurred over a period of 
weeks. The reasons for the diminished response to injection of carrageenan, ID, in sheep 
are not clear, however, tachyphylaxis has been observed after repeat administration of 
bradykinin, histamine and formylmethionyl-leucylphenylalanine, where reduced vascular 
permeability was observed when an intradermal site was injected on a second occasion, 
and compared with a new site in the same animal (Colditz, 1985). It is important to note 
that the alteration in response to injection of carrageenan over the study period would 
influence the results obtained. However, because the hyperalgesic response was 
diminished rather than increased after repeat administration, the observed changes do not 
weaken the conclusions drawn from the study.
In conclusion, these preliminary studies suggest that intradermal injection of carrageenan 
may be a suitable model for the investigation of the antinociceptive effects of the 
NSAIDs. The low concentration of carrageenan used in this study was not physically 
resented by the sheep, and they continued to eat and ruminate throughout the 24 hour 
study period. Gentle digital pressure over the site of the wheal generally caused the sheep 
to flex their leg in the first 6 hours after injection, but they did not flex their leg 
spontaneously in response to the presence of the wheal. Injection of the irritant did not 
affect locomotion and they were able to lie and rise without difficulty. Thus it appears that 
the concentration of carrageenan used in this study presents a mild stimulus, which 
causes a significant thermal hyperalgesia, although the mechanical response is more 
variable. If tachyphylaxis to carrageenan occurs, this would limit the number of studies 
which could be carried out on any given group of sheep. However, it is possible that a 
longer 'rest' period between cross-overs may resolve the problem.
The 2 models described here have provided some interesting results. Tourniquet pain, or 
hyperalgesia, has been demonstrated using a noxious mechanical stimulus, and appears to 
be a local effect, hyperalgesia during ischaemia not being evident on the contralateral 
limb. In contrast, the carrageenan model appears to involve a central mechanism, with 
thermal hyperalgesia evident at a site distant to the inflammatory stimulus.
CHAP TE R 5
TH E PH A RM A CO K IN ETICS OF FLUNIXIN M EG LU M IN E AND 
CA RPRO FEN  (RACEM ATE)
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5.1 Introduction
5.1.1 Chrom atography
Chromatography is a process by which separation of a mixture of agents can be achieved. 
This process involves 2 immiscible phases, 1 of which is moving (mobile phase: gas or 
liquid) while the other is stationary (stationary phase: liquid or solid). Separation of the 
mixture is achieved by adsorption or differential partition of molecules between the 
mobile and the stationary phase. Thin layer chromatography (TLC), gas liquid 
chromatography (GLC) and column chromatography are all examples of this technique: 
TLC utilises a liquid mobile phase and a solid adsorbant (silica gel or alumina), applied 
either to a glass plate or other suitable base; GLC utilises a gaseous mobile phase and a 
liquid adsorbed onto an inert materialfcolumn chromatography generally uses a liquid 
mobile phase and a solid stationary phase. High performance (pressure) liquid 
chromatography (HPLC) is a refinement of the basic column chromatographic technique. 
Molecules within the sample may be separated by different techniques using HPLC, such 
as varying the mobile and stationary phases e. g. steric exclusion, where the molecular 
size restricts the diffusion of the solute through the column; adsorption, where solutes 
bind with differing affinities to the stationary phase; partition, where solutes dissolve in a 
liquid stationary phase which both coats, and is present within, a porous inert packing 
material; ion-exchange, where charged solutes are attracted to ionic sites bonded, or 
coated on a packing material.
Samples are injected onto the HPLC column via an injection valve. These valves 
comprise fixed-volume sample loops which control the volume of injection and minimise 
the dead space within the system. Moreover, the valve ensures the time over which the 
sample is injected remains constant between samples, and is independent of the viscosity 
of the liquid. Liquid mobile phases carry the sample through the system and must be 
degassed prior to use. Pre-columns are occasionally employed, and are positioned in 
front of the injection valve to prolong column life. Similarly, guard-columns may be 
positioned between the injection port and the HPLC column. These columns are packed 
with the same material as the main column and again act to prolong the life of the main 
column, in this case by removing impurities from the sample. HPLC columns are made 
of stainless steel or compounds such as glass, and are available in different lengths and 
internal diameters. The function of the HPLC column is to separate compounds within a 
mixture. These columns may be packed with either solid or liquid stationary phases (vide 
supra), and require high pressures to pump the mobile phase through the column. Smaller 
packing material particle sizes have led to the introduction of shorter HPLC columns, 
resulting in shorter analysis time.
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The compounds which are separated are detected by various means. The output from the 
detector is quantifiable allowing the amount of compound in the mixture to be calculated. 
Various detectors can be used with HPLC. Ultra violet (uv) detectors measure the degree 
to which the solute absorbs uv light, while fluorescence detectors may be used to detect 
solutes, or derivatives of solutes, which fluoresce. The sensitivity of the latter system is 
greater than that achieved with the uv detector. These 2 methods, together with 
electrochemical detection are solute specific detectors, whereas refractive index (RI) 
detectors record the presence of all molecules which have a refractive index different to 
that of the mobile phase used in the system. The RI detector is less sensitive than the uv 
detector and there must be very little temperature fluctuation within the system as this can 
vary the refractive index of liquids.
5.1.2 Pharm acokinetics of NSAIDs
Flunixin meglumine is a potent NSAID used widely in clinical veterinary practice for both 
its anti-inflammatory and analgesic properties (see chapter 1). In the United Kingdom, it 
is currently licensed for use in the horse, dog and cow at dose rates of 1.1, 1.0 and 2.2 
mg/kg respectively. Reports of the pharmacokinetics of flunixin in the ruminant have 
been limited to the bovine (Benitz, 1984; Hardee et al., 1985; Anderson et al., 1990), 
although they also have been investigated in the dog (Hardie et al., 1985b), cat (Lees and 
Taylor, 1991) and horse (Chay et a l . , 1982; Soma et a l . , 1988).
Carprofen (±-6-chloro-a-methyl carbazole-2-acetic acid) is a novel NSAED (see chapter 
1) presented in solution as a racemic mixture. In the United Kingdom, it is currently 
licensed for use in the horse and dog at dose rates of 0.7 and 4.0 mg/kg respectively. In 
the domestic species, descriptions of the pharmacokinetics of the racemate have been 
limited to the dog (McKellar et a l . , 1990b), horse (McKellar et a l . , 1991c) and lactating 
cow (Ludwig et al. , 1989) and recently, Lees et al. (1991c) described the 
pharmacokinetics of carprofen enantiomers in the horse. They showed that there were 
marked differences in the pharmacokinetic disposition of the individual enantiomers, 
although the reasons for this were not established. At all time points after administration 
of carprofen, the R(-)-isomer predominated and 24 hours after injection the ratio of R(-) 
to S(+) was approximatley 9:1. In the same year, Graser et al. (1991) reported a similar 
disposition of carprofen enantiomers, not only in horses, but also in cattle. However, in 
contrast to horses, the R(-):S(+) ratio showed no time dependent change over 24 hours in 
cattle. Limited in vitro investigations by the same authors indicated that incubation of the 
S(+)- and R(-)- isomers of carprofen in cattle and horse liver homogenates did not result 
in chiral inversion of either the eutomer or the distomer.
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Pharmacokinetic studies are necessary to identify differences in absorption and 
disposition processes that may contribute to species variation in drug response. This is of 
particular importance where drugs are known to have a narrow therapeutic index. The 
NSAIDs have known toxic effects in the domestic species (Snow and Bogan, 1979; 
Mathews et al., 1990; McKellar et al., 1991b; McNeil, 1992) and consequently, it was of 
interest to investigate the pharmacokinetics of both flunixin meglumine and carprofen 
when administered IV to sheep.
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5.2 M aterials and Methods
5.2.1 Anim als
A total of 9 Suffolk and Suffolk-cross rams and wethers, weighing 52 to 87 kg and aged 
1 to 4 years were used in this study. All were free from clinical signs of systemic disease 
at the time of the study. Sheep numbers 1 to 5 were maintained indoors as a group. Sheep 
numbers 6 to 9 were maintained outdoors as part of a larger group. The entire group were 
brought to a holding area prior to the onset of the experiment to allow the sheep to settle. 
Hay and water were available ad libitum throughout the trial period.
Drugs
Flunixin meglumine, 1.0 mg/kg, as a 5 % solution, was injected IV in sheep numbers 1 
to 9, and after an interval of not less than 14 days, the drug was administered IV to sheep 
numbers 1 to 5, at a dose rate of 2.0 mg/kg.
Carprofen, 0.7 mg/kg, as a 5 % mixed micelle solution, was injected IV in sheep 
numbers 1 to 5, and after an interval of not less than 14 days, the drug was administered 
IV to the same sheep, at a dose rate of 4.0 mg/kg
The test drug (flunixin, 1.0 or 2.0 mg/kg and carprofen, 0.7 or 4.0 mg/kg) was injected 
into a jugular vein as a bolus. Venous blood samples were collected serially from the 
contralateral jugular vein in the manner previously described (see section 2.4). Control 
samples were collected from all sheep in the period prior to injection of the test drug. 
Blood samples were collected at 0.03, 0.08, 0.17, 0.25, 0.33, 0.50, 0.67, 0.75, 1, 2, 4, 
6, 8, 23, 24 and 32 hours after administration of flunixin, while samples after carprofen 
injection were collected at 0.08, 0.50, 1, 2, 4, 6, 8, 12, 24, 32, 48, 56 and 72 hours.
5.2.2 Assay for flunixin meglumine in plasma
The assay method used to determine the concentration of flunixin in plasma was the 
method described by McKellar etal. (1989).
Extraction procedure
Plasma samples were defrosted at room temperature on the day of analysis. To extract 
flunixin from plasma, a 2 ml sample of plasma was placed in a 60 ml conical glass- 
stoppered tube, and 0.6 ml of citrate phosphate buffer (pH 5) and 20 ml of diethylether 
were added. The stoppered tubes were shaken on a slow rotating mixer for 10 minutes
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and then 15 ml of the supernatant ether was decanted into a clean 60 ml glass test tube and 
a further 20 ml of ether added to the tube. The stoppered tube was shaken for a further 10 
minutes and then 20 ml of the supernatant ether removed and placed in the second test 
tube as before. Using a heating block, the 35 ml of organic solvent was evaporated under 
air at 50°C until approximately 7 ml remained. The remaining solvent was decanted into 
10 ml conical glass tubes and the 60 ml tube was washed down with 1 ml of ether, 3 
times, and the ether collected into the 10 ml tube. The remaining organic solvent was 
evaporated to dryness under air at 50°C. The tube was washed down with 1 ml of ether 
and evaporated to dryness once more. Prior to injection into an HPLC system (vide 
infra), samples were reconstituted in at least 150 pi methanol.
Quantification procedure
Stock solutions of flunixin meglumine in methanol (10, 20 and 100 pg/ml) were prepared 
from pure compound. These solutions were used to 'spike' blank plasma samples (2 ml) 
at different concentration levels, 0, 0.1, 0.5, 1.0, 2.0 and 5.0 pg/m l. These were 
included in each assay in order to calculate mean recovery. The expected recovery of 
flunixin extracted in ether was 95 % (75 % in the first 15 ml of supernatant and 20 % in 
the second 20 ml harvest of supernatant). The remaining 5 % of drug was discarded with 
the plasma and remaining ether. A standard injection (2 pg/ml) was run after every 2 
sample injections in order to assess detector variability.
Chromatograph details
The mobile phase was an 80:20 mix of methanol : water containing 50 pi of a 1 in 55 
dilution of a 70 % solution of perchloric acid. Prior to use, the solvent was degassed 
using a sonic bath and vacuum pump (Millipore U. K. , Watford, U. K.). A solvent 
delivery pump and manometric module (Gilson Model 302 and 802, Scotlab, Coatbridge, 
U. K.) were used to pump the mobile phase at 1.1 ml per minute through a Shandon 
column, 100 mm x 5 mm (Shandon Southern, Runcorn, U. K.), with 5 pM  
octadecylsilica Hypersil packing and a variable wavelength (A.) ultraviolet detector 
(Spectra Physics Model SP8450, Burke Electronics, Glasgow, U. K.). The uv X was set 
at 287 nm and the absorbance was set at 0.005 aufs. The samples, or standards, were 
injected using a glass syringe into an injection port with a valve attached (Negretti and 
Zambra Aviation Ltd. , Southampton, U. K.). The valve had a 20 pi loop and the 
injection volume was 15 pi. The output from the uv detector was connected to a variable 
speed chart recorder (Vitatron, M. S. E. Scientific Instruments) set at a speed of 5 mm 
per minute.
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The limit of detection achieved using this method was 10 ng/ml or better. This was based 
on twice background noise on the chromatogram.
Measurement of the chromatogram
The concentration of flunixin in ovine plasma was calculated from the peak height of the 
chromatogram. The ratio of test drug peak height and peak height of the closest standard 
injection, was multiplied by the concentration of the standard injection (2 fig/ml). This 
figure was adjusted for volume, expected drug recovery and finally multiplied by a 
conversion factor calculated from expected recovery from spiked samples and actual 
recovery of spiked samples on the day of injection.
*5.2.3 Assay of carprofen racemate in plasma
Carprofen racemate was extracted from the plasma using a method developed from that 
described by Iwakawa etal. (1989).
Extraction procedure
Plasma samples were defrosted at room temperature on the day of the analysis. To extract 
carprofen racemate from plasma, a 0.25 ml sample of plasma was placed in a 10 ml 
conical glass-stoppered tube along with 62.5 |il of citrate phosphate buffer (pH 3) and 6 
ml of ethyl acetate. The stoppered tube was shaken on a slow rotating mixer for 10 
minutes and then 4 ml of the supernatant ethyl acetate decanted into a 10 ml glass tube. A 
further 4 ml of ethyl acetate was added to the residue of the first tube and the procedure 
repeated. Using a heating block, the 8 ml of organic solvent was evaporated under 
nitrogen gas (BOC Medical Gases) at 50°C. When the organic layer had completely 
dried, the tube was washed down using approximately 1 ml of ethyl acetate, and again 
evaporated to dryness under nitrogen gas at 50°C. Prior to injection into an HPLC 
system, the sample was reconstituted in at least 150 jil of methanol.
Quantification procedure
Stock solutions of carprofen racemate in methanol (5, 10, 20, 40, 100 Jig/ml) were 
prepared from the racemic compound, and were used to 'spike' blank plasma samples 
(0.25 ml) as previously described, to give final concentrations of 0.25, 0.5, 1.0, 2.0 and
5.0 p.g/ml. These standards were included in each assay in order to calculate mean 
recovery. The expected recovery of carprofen extracted in ethyl acetate was 88.67 % 
(66.67 % in the first 4 ml of supernatant and 22 % in the second 4 ml harvest of 
supernatant). The remaining drug was discarded with the plasma and remaining ethyl
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acetate. A standard injection (5 |ig/ml) was run after every 2 sample injections in order to 
assess detector variability.
Chromatograph details
The mobile phase was a 75:25 mix of methanol : water containing 50 p.1 of a 1 in 55 
dilution of a 70 % solution of perchloric acid. The solvent was prepared by degassing, 
and delivered as described above through an identical HPLC system. The uv X was set at 
254 nm and the absorbance was set at 0.02 aufs.
The limit of detection was based on twice background noise on the chromatogram and 
was 100 ng/ml or better using this method.
Measurement of the chromatogram
The recovery of racemic carprofen from ovine plasma was calculated from the peak height 
of the chromatogram using the same system as described for flunixin meglumine (vide 
supra).
5.2.4 Pharm acokinetic analysis
The decline in plasma concentration of flunixin and carprofen with time following a single 
bolus IV injection were analysed for each animal using a nonlinear regression Fortran IV 
curve stripping computer programme, CSTRIP (Sedman and Wagner, 1976). Akaike's 
information criterion (AIC) (Yamaoka et a l . , 1978) was used to confirm the number of 
exponents best describing each data set.
The CSTRIP program is based on standard equations describing bi- and tri-exponential 
decay (Baggot, 1977).
Bi-exponential- Crp = Ae" 061 + Be" & 1
Tri-exponential- Cfp = Pe" K 1 + Ae" 001 + Be" ® 1
Where Cfp is the plasma concentration of drug at time t.
P, A and B are the zero-time plasma drug concentration intercepts of the biphasic or 
triphasic disposition curve i. e. the maximum drug concentration for each exponential.
7t, a  and 6 are the rate constants for a given exponential process.
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The time taken (in hours or minutes) for the plasma concentration of drug to fall by 50 %, 
is constant at any part of the curve and is referred to as the half-life of the drug. It may be 
estimated as tj/2 = 0.693/rate constant.
Other terms used in the description of the pharmacokinetic analysis are defined as 
follows:
h/2% or l i/2oe" distribution half-lives (min or hr).
t]/2p- elimination half-life (min or hr).
Vd(iirca)- apparent volume of drug distribution (ml/kg).
Dose/AUC.(3
Vc- volume of the central compartment (ml/kg).
Dose/C°p
Vd(ss)- apparent volume of distribution at steady state (ml/kg).
AUMC/AUC2 
CI5- body clearance rate (ml/kg.min).
Dose/A UC
Kel- first-order elimination rate constant.
calculated from the ratio of CI5 to Vc
The area under the plasma concentration-time curve for observed values (AUC(0bS)) 
(jig.hr/ml), or zero moment curve, was calculated using the trapezoidal rule. The area 
under the first moment curve (AUMC(0bs)) (p.g.hr2/ml), or the plasma concentration-time 
versus time curve for observed values was calculated using the equation AUMC = P/(7t)2 
+ A /(a )2 -1- B/(p)2. The ratio of AUMC to AUC for any drug is the mean residence time 
(MRT) (hr or min). The MRT is the average time that a drug will persist in the body after 
administration, and the time it takes for 63.2 % of the administered dose to be eliminated 
from the body (Rowland and Tozer, 1989).
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5.2.5 Statistical analyses
Results are quoted as mean values ± standard error of the mean (SEM). Values for half- 
lives are given as the harmonic mean. Derived kinetic parameters were tested with a 
Mann-Whitney U Test. Interdose comparisons within a group were made and statistical 
tests were carried out using a 5 % significance level.
5.3 Results
5.3.1 Assay o f flunixin meglumine in plasma
Figure 5.1 illustrates a typical chromatograph of a plasma sample collected after 
administration of flunixin 1.0 mg/kg, IV. No coextracted endogenous compounds from 
ovine plasma interfered with the flunixin peak, nor was there evidence that any 
metabolites of flunixin were detected in this system.
The precision of the extraction procedure was moderate as can be seen from the between- 
day coefficients of variation (Table 5.1). The mean between-day coefficient of variation 
was 17.6 %. No flunixin meglumine was detected in the drug free plasma.
The mean plasma concentration of flunixin v.y time following injection of 1.0 mg/kg of 
drug, IV, to 9 sheep is shown in Fig. 5.2. The mean plasma levels showed an initial 
rapid distribution phase (k phase), followed by a slower second distribution phase (a  
phase) and a slow elimination phase ((3 phase). Plots of the plasma flunixin decay curve 
for each individual sheep were best fitted to a tri-exponential decline and this was 
confirmed by applying the AIC. The individual values for the rate constants are shown in 
Table 5.2. The pharmacokinetic parameters calculated from the tri-exponential equations 
used to describe the plasma concentration vs time data for individual sheep are shown in 
Table 5.3. These indicate an initial rapid distribution half life (tj/2n) of 2.3 minutes, 
followed by a slower second distribution phase (tj/2a ) of 101 minutes. The mean 
elimination half-life (t]/2|j) was 221.7 minutes. Sheep number 2 had slow initial and 
second distribution phases and a slow elimination half-life, 16.1, 222.5 and 728.7 
minutes, respectively.
The mean apparent volume of distribution, Vd(arca), was small, 248.6 ± 57.3 ml/kg, 
although a higher value was calculated for sheep number 2. Similarly, the mean apparent 
volume of distribution at steady state, Vd(ss), and the mean apparent volume of the central 
compartment, Vc were small, 166.2 ± 37.23 ml/kg and 36.3 ± 4.9 ml/kg respectively.
160
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Figure 5.1. Typical chromatogram of flunixin meglumine in ovine plasma.
Key- a and b- unknown ovine plasma samples
c- 2 yug/ml flunixin meglumine in ovine plasma (standard injection)
direction of flow
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C o n cen tra tio n M ean recovery S tan d a rd C oefficient of
(p.g/ml) (% ) dev ia tion V ariation (% )
0.1 82.1 17.3 21.1
0 .5 91.7 14.7 16.1
1.0 97.0 16.8 17.2
2 .0 89.3 19.0 21.2
5 .0 94.0 11.6 12.4
Mean 90.7 15.9 17.6
T able 5.1. Mean recovery and coefficient of variation (%) of flunixin meglumine in 
ovine plasma (n=14).
100
•  1 mg/kg (n=9) 
□  2 mg/kg (n=5)
x c
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Figure 5.2. A semilogarithmic plot of the decline of mean concentration of flunixin 
meglumine in plasma (±SEM) of sheep plotted against time in minutes (min) after the IV 
administration of either 1.0 mg/kg or 2.0 mg/kg of drug.
1 6 2
S h eep P A B K a P
N u m b er (pg /m l) (pg/m l) (pg /m l) (m in '1) (m in*1) (m in*1)
1 23.2 13.9 5.77 0.54 0.05 0.006
2 14.7 0.92 0.76 0.04 0.003 0.001
3 17.2 10.1 3.09 0.25 0.01 0.002
4 55.4 13.8 4.78 1.11 0.05 0.003
5 18.3 5.18 2.93 0.05 0.01 0.003
6 16.5 7.21 3.82 0.19 0.009 0.003
7 25.6 7.91 5.11 0.31 0.03 0.004
8 13.6 3.35 2.57 0.08 0.01 0.003
9 11.8 6.84 3.58 0.12 0.01 0.002
M ean 21.8 7.69 3.6 0.30 0.02 0.003
±SEM 4.45 1.46 0.50 0.11 0.006 0.0005
T able 5.2. Individual and mean pharmacokinetic constants, ± standard error of the 
mean (SEM), for 9 sheep determined after injection of flunixin meglumine, 1.0 mg/kg, 
IV.
S h eep 1 1/2 K t M ia 1 l/2p Vd (area) Vc Vd(ss) kel C ib
N u m b er (min) (min) (min) (ml/kg) (ml/kg) (ml/kg) (min’1) (ml/kg.min)
1 1.3 13.6 126.3 123.6 23.3 106.5 0.03 0.7
2 16.1 222.5 728.7 695.4 61.1 457.4 0.01 0.7
3 2.8 60.6 284.6 225.3 32.9 121.5 0.01 0.5
4 0.6 15.3 213.9 182.2 13.5 138.1 0.04 0.5
5 15.1 50.0 222.5 194.6 37.8 114.9 0.02 0.6
6 3.6 76.0 207.2 165.0 36.3 105.3 0.02 0.5
7 2.2 20.9 158.1 168.1 25.9 123.7 0.03 0.7
8 9.0 67.1 226.6 248.8 51.2 171.5 0.02 0.7
9 5.7 48.2 301.6 234.7 44.9 156.8 0.01 0.5
M ean 2.3* 101.0* 221.7* 248.6 36.3 166.2 0.02 0.6
±SEM 57.3 4.9 37.2 0.004 0.03
Table 5.3. The individual and mean plasma pharmacokinetic parameters, ±  standard 
error of the mean (SEM), for 9 sheep given flunixin meglumine, 1.0 mg/kg, IV.
* Harmonic mean.
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Whole body clearance, (Cl^), was slow in all sheep, mean 0.6 ± 0.03 ml/kg.min. The 
mean residence time of flunixin, 1.0 mg/kg, in plasma for observed values, MRT(obs), 
was calculated as 189.8 ± 22.3 minutes (Table 5.4).
The mean plasma concentration of flunixin following injection of 2.0 mg/kg of drug, IV, 
to 5 sheep is shown also in Fig. 5.2. The mean plasma levels showed an initial rapid 
distribution phase (k phase), followed by a slower second distribution phase (a  phase) 
and a slow elimination phase ((3 phase). Plots of the plasma flunixin decay curve for each 
individual sheep were best Fitted to a tri-exponential decline and this was confirmed by 
applying the AIC. Individual values for the rate constants are shown in Table. 5.5. The 
pharmacokinetic parameters calculated from the tri-exponential equations used to describe 
the plasma concentration versus time data for individual sheep are shown in Table. 5.6. 
These indicate an initial rapid distribution half life ( t ] ^ )  of 1.9 minutes followed by a 
slower second distribution phase (tj/2a) of 40.2 minutes. The mean elimination half-life 
(ti/2B) was 205.8 minutes. Sheep number 5 had slow initial and second distribution 
phases and a slow elimination half-life, 13.6, 81.1 and 302.8 minutes, respectively.
The mean Vd(arca) was small, 310.1 ± 54.4 ml/kg, and similarly, the mean values for 
Vd(ss) and Vc were small, 151.8 ± 26.3ml/kg and 40.9 ±11.1 ml/kg respectively.
Whole body clearance was slow in all sheep, mean CI5 was calculated as 0.7 ± 0.01 
ml/kg.min. The MRT(obs) of flunixin, 2.0 mg/kg, in plasma was calculated as 201.7 ±
21.7 minutes (Table 5.3).
The mean area under the plasma concentration time curve for observed values (AUC0bs) 
for animals given flunixin, 2.0 mg/kg, IV was approximately 1.95 times greater than the 
AUC0bs for those animals administered 1.0 mg/kg IV, indicating that, between these two 
dose rates, plasma levels are proportional to the dose rate.
Statistical analysis revealed no significant difference (p>0.05) between the kinetic 
parameters observed at the two different dose rates used in this study.
5.3.2 Assay of carp ro fen  in plasm a
Figure 5.3 illustrates a typical chromatograph of a plasma sample collected after 
administration of carprofen, 0.7 mg/kg, IV. No coextracted endogenous compounds 
from ovine plasma interfered with the carprofen peak nor was there evidence that any 
metabolites of carprofen were detected in this system.
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S h eep M R T  (obs) M R T (0bs)
N um ber (min) (min)
1.0 mg/kg 2.0 mg/kg
1 141.0 157.2
2 117.0 146.4
3 208.2 226.2
4 207.0 217.8
5 182.4 261.0
6 108.0
7 209.4
8 204.0
9 331.8
M ean 189.8 201.7
±SEM 22.3 21.7
T ab le  5.4. The individual and mean, mean residence time for observed values
(MRT(obs))* ± standard error of the mean (SEM), for sheep given flunixin meglumine,
1.0 or 2.0 mg/kg, IV.
S h eep P A B K a P
N u m b er (pg /m l) (pg /m l) (pg /m l) (m in -1) (m in*1) (m in*1)
1 123.6 26.3 3.89 1.09 0.02 0.003
2 12.6 21.8 11.7 0.26 0.03 0.006
3 11.2 18.0 3.31 0.10 0.01 0.002
4 31.27 14.2 8.09 0.30 0.02 0.004
5 16.0 4.84 4.05 0.05 0.009 0.002
M ean 38.9 17.0 6.21 0.36 0.02 0.003
±SEM 21.4 3.70 1.61 0.19 0.003 0.0008
Table 5.5. Individual and mean pharmacokinetic constants, ± standard error of the 
mean (SEM), for 5 sheep determined after injection of flunixin meglumine, 2.0 mg/kg, 
IV.
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S heep 1 1/27C 1 l / 2 a 1 1/2(3 V d  (area) Vc V d (ss) kel C lb
N um ber ( mi n) ( mi n) (mi n) ( ml / kg ) ( ml / kg ) ( ml / k g ) (min**) ( ml / k g . mi n )
1 0.6 42.9 201.5 232.2 13.0 104.3 0.05 0.7
2 2.6 21.6 125.8 467.8 43.3 100.1 0.02 0.7
3 6.8 55.8 334.3 317.0 30.8 178.4 0.01 0.6
4 2.3 39.5 196.7 155.9 37.3 135.6 0.02 0.6
5 13.6 81.1 302.8 377.4 80.3 240.7 0.01 0.8
Mean 1.9* 40.2* 205.8* 310.1 40.9 151.8 0.02 0.7
±SEM 54.4 11.1 26.3 0.007 0.01
Table 5.6. The individual and mean plasma pharmacokinetic parameters, ± standard 
error of the mean (SEM), for 5 sheep given flunixin meglumine, 2.0 mg/kg, IV.
* Harmonic mean.
Figure 5.3. Typical chromatogram of carprofen in ovine plasma.
Key- a- 5yug/ml carprofen in ovine plasma (standard injection)
b and c- unknown ovine plasma samples
- direction of flow
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The precision of the extraction procedure was good as can be seen from the between-day 
coefficients of variation (Table 5.7). The mean between-day coefficient of variation was
11.7 %. No carprofen was detected in the drug free plasma.
The mean plasma concentration of carprofen, 0.7 mg/kg, following IV injection to 5 
sheep plotted against time (min), is shown in Fig. 5.4. The mean plasma levels showed 
an initial rapid decline (a  phase) and a slower elimination phase ((3 phase). Plots of the 
plasma concentration decay curve for each individual sheep were best fitted to a bi­
exponential decline and this was confirmed by applying the AIC. The individual values 
for the rate constants are shown in Table. 5.8. The pharmacokinetic parameters calculated 
from the bi-exponential equations used to describe the plasma concentration versus time 
data for individual sheep are shown in Table. 5.9. The mean elimination half-life (tj^g) 
was 25.8 hours with a range from 21.9 to 28.5 hours.
The mean plasma disposition and pharmacokinetic characteristics indicate a small volume 
of distribution, V d ^ ^ ,  95.5 ± 5.95 ml/kg, a small volume of distribution at steady state, 
Vd(ss), 92.7 ml/kg and a slow whole body clearance, Cl^, 2.5 ± 0.1 ml/kg.hr. The 
specific volume of the central compartment, Vc, ranged from 44.6 to 64.7 ml/kg. The 
mean residence time of carprofen, 0.7 mg/kg, in plasma for observed values, MRT(0bs), 
was calculated as 17.4 ± 2.06 hours (Table 5.10).
The mean plasma concentration of carprofen, 4.0 mg/kg, following IV injection in 5 
sheep plotted against time (min), is shown in Fig. 5.4. The mean plasma levels showed 
an initial rapid decline (a  phase) and a slower elimination phase ((3 phase). Plots of the 
plasma concentration decay curve for each individual sheep were best fitted to a bi­
exponential decline and this was confirmed by applying the AIC. The individual values 
for the rate constants are shown in Table. 5.11. The pharmacokinetic parameters 
calculated from the bi-exponential equations used to describe the plasma concentration 
versus time data for individual sheep are shown in Table. 5.12. The mean elimination 
half-life ( t^ g )  w^s 32.3 hours with a range from 24.6 to 43.5 hours.
The mean plasma disposition and pharmacokinetic parameters indicate a small V d ^ ^ ) ,
117.3 ± 3.53 ml/kg, small Vd(ss), 117.3 ml/kg and a slow CI5, 2.5 ± 0.3 ml/kg.hr. The 
Vc ranged from 52.5 to 67.9 ml/kg. The MTR(obs), (Table 5.8) of carprofen, 4.0 mg/kg, 
in plasma was calculated as 27.2 ± 1.66 hours. Statistical analysis indicated that the 
MTR(obs) for carprofen, 4.0 mg/kg, IV, was significantly longer than for carprofen, 0.7 
mg/kg, IV (p<0.()5) (Table 5.10).
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C on cen tra tio n M ean recovery S tan d a rd C oeffic ien t of
(|ig /m l) (% ) dev ia tion V ariation (% )
0 .2 5 80.9 16.2 20.0
0 .5 98.1 12.3 12.5
1 .0 92.6 6.1 6.6
2 .0 105.8 13.2 12.5
5 .0 97.7 6.7 6.9
Mean 95.0 10.9 11.7
Table 5.7: Mean recovery and coefficient of variation (%) of carprofen in ovine plasma 
(n=10) .
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F igure 5.4. A semilogarithmic plot of the decline of mean plasma concentration 
(±SEM ) of carprofen racemate, in sheep, with time in hours (hr), after the IV 
administration of either 0.7 mg/kg or 4.0 mg/kg of drug.
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S heep A B a P
N um ber (|ig /m l) (|ig /m l) ( h r '1) ( h r '1)
1 5.91 4.91 0.57 0.03
2 8.55 5.35 0.50 0.03
3 7.77 7.58 1.28 0.02
4 8.38 7.33 0.74 0.03
5 7.77 6.66 1.21 0.03
M ean 7.8 6.37 0.86 0.03
±SEM 0.47 0.53 0.16 0.002
Table 5.8. Individual and mean, ± standard error of the mean (SEM), pharmacokinetic 
constants for 5 sheep determined after IV injection of carprofen, 0.7 mg/kg.
S heep 1 1/2(3 V d  (area) Vc V d („ ) kel C ib
N um ber (hr) (ml/kg) (ml/kg) (m 1/kg) ( hr ' 1) (ml/kg.hr)
1 26.3 114.0 64.7 110.0 0.05 3.0
2 21.9 78.8 50.4 76.0 0.05 2.5
3 28.5 90.6 45.6 88.9 0.05 2.2
4 26.0 91.7 44.6 88.2 0.06 2.4
5 27.7 102.6 48.5 100.2 0.05 2.6
Mean 25.8* 95.5 50.8 92.7 0.05 2.5
±SEM 5.95 3.63 5.77 0.002 0.1
Table 5.9. The individual and mean, ± standard error o f the mean (SEM), plasma 
pharmacokinetic parameters for 5 sheep given carprofen, 0.7 mg/kg, IV.
* Harmonic mean.
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S heep M R T (obs) M RT (obs)
N um ber (hr) (hr)
0.7 m g/kg 4.0 m g/kg
1 16.3 25.0
2 12.0 29.0
3 14.4 23.0
4 22.8 26.4
5 21.5 32.6
M ean 17.4 27.2*
±SEM 2.06 1.66
Table 5.10. The individual, mean, ± standard error of the mean (SEM) mean residence 
times for observed values (MRT(obs)) for sheep given carprofen, 0.7 or 4.0 mg/kg, IV.
*p<0.05 significantly different from 0.7 mg/kg treatment group.
S heep A B a P
N um ber (jag/ml) (M-g/ml) ( h r -1) (h r -1)
1 34.9 34.6 7.56 0.02
2 31.4 27.5 2.19 0.03
3 34.8 30.9 1.50 0.02
4 34.8 30.5 1.63 0.02
5 39.8 36.3 2.92 0.02
M ean 35.1 32.0 3.16 0.02
±SEM 1.34 1.56 1.13 0.002
Table 5.11. Individual and mean, ± standard error of the mean (SEM), pharmacokinetic 
constants for 5 sheep determined after injection of carprofen, 4.0 mg/kg, IV.
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S heep 1 1/2(3 Vd (area) Vc ^ ( s s ) kel C l b
N u m ber (hr) ( m l / k g ) (m l / kg ) ( m l / k g ) ( h r ' 1) ( m l / k g . h r )
1 30.3 115.4 57.6 115.0 0.05 2.6
2 24.6 125.9 67.9 124.5 0.05 3.5
3 33.8 127.4 62.7 125.6 0.04 2.6
4 36.4 113.7 61.2 112.6 0.04 2.2
5 43.5 109.4 52.5 108.8 0.03 1.7
M ean 32.3* 118.4 60.4 117.3 0.04 2.5
±SEM 3.53 2.57 3.31 0.004 0.3
Table 5.12. The individual and mean, ± standard error of the mean (SEM), plasma 
pharmacokinetic parameters for 5 sheep given carprofen, 4.0 mg/kg, IV.
* Harmonic mean.
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The mean area under the plasma concentration time curve for observed values (AUC(obs)) 
for sheep given carprofen, 4.0 mg/kg, IV, was approximately 5.7 times greater than the 
AUC(0bS) for those animals administered 0.7 mg/kg, IV, indicating that, between these 
two dose rates, plasma levels are proportional to the dose rate.
With the exception of the MRT^obs), statistical analysis revealed no significant difference 
(p>0.05) between the kinetic parameters observed at the two different dose rates used IV 
in this study. It is interesting to note that an increase in plasma carprofen concentration 
occurred between 6 and 8 hours after drug administration at both dose rates.
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5.4 Discussion
5.4.1 Assay of flunixin meglumine in plasma
The decline in the plasma concentration of flunixin meglumine with time, after a single IV 
injection of either 1.0 or 2.0 mg/kg body weight, was best described by a triexponential 
equation in all sheep. This differs from the kinetic studies in cattle, 1.1 mg/kg (Benitz, 
1984; Hardee, et al. , 1985; Anderson et al. , 1990) horses, 1.0 mg/kg (Chay et al. , 
1982) and dogs, 1.1 mg/kg (Hardie et al., 1985b), where the plasma concentration decay 
curve of flunixin was best fitted by a two compartment model, although Chay et al. 
(1982), suggested a possible third compartment for flunixin in horses. Soma et al. (1988) 
confirmed the presence of a third compartment in the horse after administration of a 
higher dose rate of 2.2 mg/kg'Compartmental modelling was not carried out on the data 
from the present study, but it is likely that the third exponent detected in this study 
represents transfer of drug out of a third compartment. The detection of a third exponent 
in this study, at both dose rates, is probably related to the frequency and duration of 
sampling and to assay sensitivity. Residue studies on flunixin meglumine in sheep have 
not been carried out to date, and consequently, this may have implications for the use of 
flunixin in the sheep, a food producing animal, although the terminal elimination half-life 
of the drug in sheep was not prolonged. However, it is interesting to note that the 
administration of flunixin, 1.1 mg/kg, intramuscularly every 8 hours, over a period of 60 
hours, to lactating cattle did not lead to accumulation of the drug in plasma (Anderson et 
al. , 1990).
There were no significant differences between the kinetic parameters for flunixin, 1.0 and
2.0 mg/kg, administered IV. The mean initial distribution half-lives of flunixin in sheep,
2.3 and 1.9 minutes, are less than those reported by Anderson et al. (1990) in lactating 
adult cattle (9.6 min), and also less than those reported in the horse, 12 minutes (Chay et 
al. , 1982) and dog, 33 minutes (Hardee et al. ,1985b). In these previous studies, plasma 
concentration decay curves of flunixin were best fitted by a two compartment model and it 
is possible that the distribution half-lives quoted lie between the values found in the 
present study for the initial and second distribution half-lives /. e. 2.3 and 1.9, and 101.0 
and 40.2 minutes respectively. The mean elimination half-lives (tj/2[j) of flunixin in this 
study, 229.8 and 205.8 minutes, are similar to those reported for lactating cattle, 188.4 
minutes (Anderson et al., 1990) and also dogs, 220.2 minutes (Hardie et al., 1985b). 
However, Hardee et al. (1985), reported a t^ B  in cattle of considerably longer duration 
than those already mentioned, 487.2 minutes. The assay for flunixin used by the latter 
authors was less sensitive than the assay used in this study, resulting in a five fold 
decrease in the limit of detection achieved (50 ng/ml v.y 10 ng/ml). Although Hardee etal.
1 7 4
(1985) sampled for 72 hours after the administration of flunixin, plasma concentrations of 
the drug fell below the limit of detection by 12 hours. The differences between the 
sensitivities of the assays, limiting the time over which the drug could be detected may 
explain the differences seen in t^ u -  In comparison the reported for horses (Chay et 
al., 1982) is of much shorter duration, in the order of 96 minutes, which is comparable 
with that proposed for the cat (Taylor et a/., 1991). However, in the latter study 
insufficient data points precluded the accurate calculation of this parameter. The half-life 
values obtained in the present study have been expressed as the harmonic mean, while the 
authors cited above refer to the arithmetic mean. The harmonic mean is the most 
appropriate average to use when dealing with rates (Moroney, 1963). It is worth noting 
that sheep number 2, after the administration of 1.0 mg/kg of flunixin, had a particularly 
long t]/2B> 728.7 minutes. This was a consequence of a large volume of distribution, 
Vd(area)> 695.4 ml/kg.
The small value for the volume of distribution of flunixin, at both dose rates, illustrated 
that the drug was not widely distributed throughout the body. This is perhaps 
unsurprising since NSAIDs are all highly protein bound in plasma (Lees et al. , 1991a).
The mean body clearance rates of flunixin in sheep were 0.6 and 0.7 ml/kg.min, less than 
those previously reported in cattle (Hardee et al., 1985; Anderson et al., 1990), horses 
(Soma et al., 1988) and dogs (Hardie et al., 1985b). This suggests that sheep may clear 
flunixin at a slower rate than other species.
The estimation of cyclooxygenase inhibition by flunixin in sheep would have provided 
further information on the duration of action of the drug in this species. The generation of 
the stable breakdown product of platelet thromboxane (TX) A2 in serum, TXB2 , has 
been used to investigate the level of cyclooxygenase inhibition after the administration of 
NSAIDs (Vane, 1971; Lees et al. , 1987a and b). Serum levels of flunixin >2 }ig/ml in 
dogs have been shown to inhibit serum thromboxane synthesis by more than 98% in 
vivo, and in dogs and horses by more than 99% in vitro (McKellar et al. , 1989). Soma et 
al. (1992) demonstrated that plasma levels of flunixin of approximately 0.12 Jig/ml were 
not associated with the inhibition of serum thromboxane synthesis in the horse, while 
Semrad et al. (1985) demonstrated that plasma levels of >75 Jig/ml were associated with 
100 % inhibition of serum TXEh, in this species. Similarly, Lees and Taylor (1991) 
found the inhibition of serum TXB2 could only be demonstrated for approximately 5 
hours after the administration of 1.0 mg/kg, IV, in the cat. The mean plasma level of 
flunixin at 5 hours in this latter study was approximately 0.2 jig/ml. A fter IV 
administration of flunixin, 1.0 or 2.0 mg/kg, the drug was only detected in ovine plasma 
in the present study at levels >2 fig/ml, for approximately 120 minutes, while the mean
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plasma concentration persisted between 0.12 and 0.2 |ig/ml for up to 720 minutes. 
McKellar et al. (1990a) reported that sheep have low baseline values of TXB2 and 
consequently, neither the extent or the duration of cyclooxygenase inhibition were 
measured in this study.
Lees and Higgins (1984) showed, in a tissue model of equine inflammation, that flunixin 
meglumine will suppress prostaglandin E2-like activity for at least 24 hours, longer than 
flunixin can be detected in the plasma. These findings were supported by further studies 
from the same laboratory in both the horse and the cow (Lees et al. , 1987a; Lees, 1989). 
These findings highlighted that information on the penetration into, and the persistence of 
the NSAIDs in inflammatory exudate is perhaps more valuable with regard to establishing 
dosage regimes, than is pharmacokinetic data (Lees, 1992).
5.4.2 Assay of carprofen in plasma
The decline in plasma concentration of carprofen racemate with time, after a single IV 
injection of either 0.7 mg/kg or 4.0 mg/kg bodyweight, was best described by a bi­
exponential equation in all sheep. However, the decline in plasma concentration of 
carprofen, 100 mg, IV, with time, in humans (Crevoisier, 1982), and after the IV 
injection of 1.0 mg/kg in dogs (Rubio et al. , 1980), was best described by a three 
compartment kinetic model. It is possible that a second phase of distribution also occurred 
in sheep but infrequency of sampling in the immediate post-injection period precluded the 
detection of this phase. The high drug concentration of carprofen in ovine plasma, at both 
0.7 and 4.0 mg/kg, may be explained by the small volume of distribution, 95.5 ±5.95 
and 118.4 ±3.5 ml/kg, respectively, illustrating that the drug was not widely distributed 
throughout the body. These results are consistent with those reported in the horse 
(McKellar et al., 1991c), dog (McKellar et al., 1990b) and cow (Ludwig et al., 1989), 
and are probably related to the high degree of protein binding of carprofen, which can be 
as great as 99.9 % at therapeutic concentrations (Crevoisier, 1982; Baruth et al., 1985), 
as with most other NSAIDs.
There were no significant differences between the kinetic parameters for 0.7 and 4.0 
mg/kg carprofen racemate administered IV. The distribution half-life o f carprofen in 
plasma was not calculated in the present study because of the small number of samples 
that were taken in the first hour after drug administration. Calculation of this parameter 
from the available information therefore would be inaccurate, and indeed the quoted 
values for calculated pharmacokinetic parameters which use the a  rate constant or A, the 
zero-time plasma drug concentration intercept, may be inaccurate. The elimination half- 
life of carprofen in sheep was 25.8 and 32.3 hours after the administration of 0.7 and 4.0 
mg/kg, IV, respectively. These values were similar to those observed in the horse and
1 7 6
pony administered 3.5 mg/kg, IV, (21.9 ± 2.3 hr) (McKellar et al., 1991c). In the 
lactating cow the plasma elimination half-life ranged from 44.5 to 64.6 hours (Ludwig et 
al., 1989), considerably longer than that observed in sheep in the present study, and over 
three times greater than that observed by McKellar et al. (1990b) in dogs administered 
carprofen, 0.7 mg/kg, IV, (8.0 ± 1.2 hr). It is possible that the existence, or differences 
in the degree of enterohepatic circulation of carprofen between species could account for 
the wide range of values seen.
It appears likely that enterohepatic recycling occurs between 6 and 8 hours in sheep (Fig. 
5.4). An increase in plasma carprofen concentration occurred in four of the five sheep 
sampled. Enterohepatic circulation of carprofen has been described both in humans (Ray 
and Wade, 1982) and the dog (McKellar et al. , 1990b), although Rubio et al. (1980) did 
not detect any evidence of enterohepatic circulation of carprofen in the dog in an earlier 
study.
Whole body clearance of carprofen, 2.5 ml/kg.hr, was slower than reported in cattle 
(Ludwig et a l , 1989), dogs (McKellar et al., 1990b) and horses (McKellar et al., 1991c). 
This may be because sheep clear NSAIDs at a slower rate than do other species, as was 
reported in an earlier study by this laboratory (Welsh et al., 1993). However, 
enterohepatic recycling also may influence the rate at which carprofen is cleared in sheep 
and this is supported by the prolonged mean residence time of observed values of 
carprofen in the body.
Carprofen is presented in solution as a 50:50 racemic mixture, and in general, 
enantiomers have similar physical and chemical properties although their physiological 
effects may differ. When racemic compounds are used therapeutically, the more active 
isomer is referred to as the eutomer and the less active isomer as the distomer (Ariens,
1986). Therapeutic agents which are marketed as the racemate, including carprofen, 
ketamine and ketoprofen, may contain up to 50 % of the inactive enantiomer. Ariens
(1986) pointed out that the presence of the distomer in therapeutic agents could be 
disadvantageous for several reasons e. g. the distomer may act as a competitive 
antagonist, or partial agonist, at the drug receptor; the isomers may be physiological 
antagonists, resulting in opposite biological effects and finally, the distomer may cause 
side effects not shown by the eutomer. However, it should be noted that distomers may 
be equipotent with the eutomer, or the distomer may contribute to the efficacy of the 
eutomer e. g. the distomer may reduce the metabolic degradation of the eutomer such as 
occurs with the analgesic levomethorphan, with co-administration of the distomer 
dextromethorphan (Cooper and Anders, 1974). The physiological effects of the carprofen 
enantiomers differ markedly, and the S(+)-isomer is a more potent anti-inflammatory
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agent than the R ( - ) - i s o m e r .  However, the distomer of carprofen is not inactive and has 
been shown to have greater anti-inflammatory activity than phenylbutazone and aspirin 
(Gaut et al. , 1975; Randall and Baruth, 1976). Currently, there is no evidence to suggest 
that the activity of the S(+)-isomer of carprofen relies on the presence of the distomer, nor 
that the distomer of carprofen acts as an antagonist to the more active S(+)-isomer.
It is apparent that enantiomers can exert different effects on biological systems and 
therefore, it is not unreasonable to assume that enantiomers may be handled differendy by 
biological systems during absorption, distribution, m etabolism and excretion. 
Stereoselectivity appears to be of greatest importance in relation to protein binding and 
hepatic metabolism of isomers, with drug absorption and renal excretion being affected to 
a lesser degree (Williams and Lee, 1985). Obviously, such differences may alter 
calculated pharmacokinetic parameters for the 2 isomers. Moreover, it is important to 
establish whether chiral inversion of the eutomer or the distomer occurs within the body. 
Although, chiral inversion of the 2-arylpropionic acids, including carprofen, has been 
demonstrated (Hutt and Caldwell, 1984), chiral inversion of carprofen enantiomers did 
not occur in dogs despite differing pharmacokinetic profiles (McKellar, personal 
communication), and similarly, negligible inversion R(-) to S(+), or vice versa, occurred 
in humans (Stoltenberg et al. , 1981; Iwakawa et al. , 1989). Consequently, when a 
therapeutic agent is administered to an animal as the racemate, the pharmacokinetics of the 
2 isomers should be examined. Chromatographic separation of enantiomers may be 
achieved either by using a chiral chromatographic system (Graser et al. , 1991) or by 
derivitisation of the compound prior to separation by standard chromatographic 
techniques (Sallustio e ta l . , 1986). In the present study the pharmacokinetics of racemic 
carprofen only are presented, however, further analysis of is being undertaken currently 
to elucidate the disposition of the individual enantiomers of carprofen in sheep plasma 
using the method described by Sallustio etal. (1986).
In conclusion, the results of the present study indicate that accumulation of flunixin 
meglumine, 1.0 or 2.0 mg/kg, IV, should not occur if the drug is administered at 12 or 
24 hour intervals, and that a dose rate of 1.0 mg/kg would be appropriate for further 
investigation in sheep. Similarly, a dose rate of flunixin meglumine, 1.1 mg/kg, 
intramuscularly, has been recommended in sheep (Welsh et al. , 1993), and it was shown 
that accumulation of flunixin meglumine, 2.2 mg/kg, intramuscularly, did not occur after 
repeat injection at 24 hour intervals in the same study. The authors in the latter study 
demonstrated that absorption of flunixin from the intramuscular injection site occurred 
rapidly, and that bioavailability of the drug was high. In addition, the results of the 
present study also indicate that carprofen, 0.7 mg/kg, IV, would be an appropriate dose 
rate for further studies in sheep. Further investigations of the bioavailability and
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pharmacokinetics after intramuscular injection of carprofen in sheep would be valuable 
because this route of administration is used frequently in the larger domestic species.
C H A PTER  6 
M ETHODS OF LAM ENESS M EASUREM ENT
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6.1 In tro d u ctio n
Lameness in animals occurs when there is a disturbance of the normal gait pattern during 
locomotion. The animal may be lame either as a result of pain in one of the body systems 
involved in locomotion, or as a result of mechanical interference with normal motion 
(Stashak, 1987; Scott, 1989). Frequently, however, both of these factors play a role in 
lameness e. g. interdigital fibroma in rams (Bulgin, 1986).
Normal gait and lameness can be assessed both subjectively and objectively. One of the 
simplest ways of evaluating lameness clinically is subjective assessment based on 
observation of factors such as alterations in stride length, duration of weight bearing on 
affected and unaffected limbs, carriage of the limb, head and tail position and joint 
movement (Leach et al. ,1977). Such details may be recorded to allow comparison not 
only between animals, but also of the same animal on subsequent occasions. However, 
there are also various methods of objective assessment of both normal and abnormal gait 
although these are used more commonly experimentally because of the high costs of 
many of these techniques (Nunamaker and Blauner, 1985).
6.1.1 Subjective rating scales
Rating scales are used frequently in scoring subjective phenomena. Pain and signs of 
pain are some of the most difficult subjective clinical parameters for both medical (Banos 
et al. , 1989) and veterinary clinicians (Taylor, 1982) to quantify. Pain is a subjective 
multidimensional experience with both sensory and affective considerations (Prieto and 
Geisinger, 1983) and medical clinicians must rely upon observation and patient report to 
evaluate it (Revill et al., 1976). Similarly, in veterinary medicine the clinician must rely 
upon their own evaluation of the animal and on owners reports of signs in the animal in 
order to assess pain. Consequently, many subjective rating scales have been designed for 
use in the assessment of pain and have undergone extensive evaluation. Indeed, 
subjective rating scales are used widely where objective assessments of the problem 
under consideration are difficult or impossible to obtain. However they have been used in 
situations where quantitative analysis of the condition may also be available e. g. airway 
obstruction (Swinburn et al. , 1984) and post-operative swelling (Berge, 1988).
6.1.1.1 Simple descriptive scale
The simple descriptive scale (SDS) or verbal rating scale (VRS) as it is also known, 
provides a choice of verbal descriptions, often between 4 and 5, of the problem under 
consideration e. g. pain (Downie et al., 1978a), and thus it forces the translation of 
feeling into words (Ohnhaus and Adler, 1975). Keele (1948), for example selected
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words commonly used by patients to describe their own pain to construct the following 
scale; nil, slight, moderate, severe and agonising. The SDS treats change as a unit step 
(Keele, 1948; Lasagna, 1964) and as such is simple to use for scoring pain subjectively 
(Keele 1948; Huskisson, 1974). However, it has been demonstrated that there are 
unequal distances between verbal descriptions of pain, which frequently are considered to 
be equidistant (Sriwatanakul et al. , 1982), and as many as 39 different levels of pain 
have been perceived between the point when pain is first detected i. e. the pain threshold, 
and that point at which pain can no longer be tolerated /. e. the pain tolerance (Hardy et 
al. , 1952, Grossi et al. , 1983). Consequently, the SDS lacks sensitivity, not only 
because an assumption is made that the differences between each term used are equal 
(Huskisson, 1974; Ohnhaus and Adler, 1975; Scott and Huskisson, 1976; Downie et al. 
, 1978a), but also because a very limited number of words are used to describe pain in 
the scale. In practice, this assumption does not allow for small changes in scoring and 
Ohnhaus and Adler (1975) showed that the use of a SDS artificially increased the 
analgesic effect of a drug. The SDS is usually transformed by applying numbers to each 
term, thus nil = 0, slight = 1, etc. in order to quantify the scale and to convert it from a 
nominal to an ordinal scale (Deschamps et al. , 1988). However, in doing this, the 
assumption that the differences between each term are equal is compounded, and as such 
the variations seen in scores cannot be expressed mathematically (Aitken, 1969).
6.1.1.2 Numerical rating scale
Numerical rating scales (NRS) are perhaps the most frequently used rating scales for 
subjective assessment in veterinary medicine. The NRS consists of divisions which are 
represented by numerical values e. g. 0 to 10 or 0 to 100. Those using the scale assign a 
numerical value to the condition under investigation e. g lameness or pain, that they feel 
represents the level of severity of that condition (Fordyce et a l . , 1984). Numerical rating 
scales have been used to record body condition scores in a variety of species (Henneke et 
a l . , 1983; Braun et a l . , 1986), as well as carcase fat thickness (Lee et a l . , 1984). These 
scales also have been used to rate lameness in many large animal species including, sheep 
(Ley et al. , 1989), cattle (Braun et al. , 1987) and horses (Stashak, 1987; Wyn-Jones, 
1988). In addition, signs of pain in dogs have been scored using an NRS by many 
workers (Taylor and Houlton, 1984; Taylor and Herrtage, 1986; Waterman and 
Kalthum, 1988; Thompson and Johnson, 1991). Numerical rating scales provide an 
improvement of discrimination when compared to the SDS (Downie et al. , 1978a; 
Downie et al. , 1978b), but still lack sensitivity when compared to other methods such as 
the visual analogue scale (Huskisson, 1983). However, Downie et al. (1978a) found that 
the NRS provided the best balance between the SDS, which limits choice, and the visual 
analogue scale {vide infra) which is confusing due to the lack of limitations. Again, the
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assumption is made that the numerical divisions represent an equal increase, or decrease 
in the condition under investigation.
6.1.1.3 Visual analogue scale
The visual analogue scale (VAS) (Hayes and Paterson, 1921; Freyd, 1923), uses a 
straight line, usually 100 mm long, the extreme limits of which are marked with 
perpendicular lines. The VAS may be vertical or horizontal (Huskisson, 1974; Revill et 
al. , 1976; Scott and Huskisson, 1979; Langley and Sheppeard, 1984). Both ends of the 
scale have a verbal description of each extreme of the clinical sign or symptom to be 
evaluated, and the observer is asked to mark the line at a position that represents the 
severity of the sign or symptom under investigation. The verbal descriptions at the 
extremes of the scale are intended to anchor the ends of the scale so that the intermediate 
points may be assigned more easily (Joyce et al. ,1975). Data are generally converted to 
numerical form by measurement of the distance to where the mark is made. Visual 
analogue scales have proved particularly satisfactory for subjective measurement of pain 
(Scott and Huskisson, 1976), or relief of pain in human beings (Huskisson, 1974) and 
they are used extensively for this purpose (Carlsson, 1983). The VAS also has been 
applied for measurement of feelings (Aitken, 1969), thirst (Thompson et al. , 1987; 
Thompson et al. , 1991) and certain psychiatric disorders such as anxiety (McClelland et 
al. , 1977; Ansseau and Von Frenckell, 1991) and depression (McClelland et al. , 1979; 
Faravelli et al. , 1986). Clinical parameters that can be assessed easily using objective 
techniques, such as breathlessness (Swinburn et al., 1984) and post-operative facial 
swelling (Berge, 1988), also have been evaluated using the VAS. The VAS has been 
found to increase the sensitivity of measurement of pain over other rating scales 
(Huskisson, 1974; Joyce et al. , 1975; Ohnhaus and Adler, 1975; Scott and Huskisson, 
1976; Seymour, 1982).
There has been much discussion as to whether trained observers should be used to score 
pain in human patients, rather than allowing patients to record their own pain scores using 
a VAS (Parkhouse and Holmes, 1963). The luxury of such choice is not available to 
veterinary surgeons, and all assessments of pain, discomfort, lameness or any subjective 
measurement in animals must be made by clinicians or trained observers. The use of the 
VAS in veterinary medicine has been limited to date (Mburu, 1991; Reid and Nolan, 
1991). Reid and Nolan (1991) recently reported the use of the VAS for scoring post­
operative signs of pain and sedation in dogs, and commented that previously, verbal 
descriptive scales have been most commonly used for this purpose in veterinary 
medicine. Pain is a composite measurement and one that is very difficult to quantify. 
Given that the application of the VAS for this purpose has been suggested to be superior
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to other methods of subjective measurement (Joyce et al. , 1975; Ohnhaus and Adler,
1975), it might be expected that use of a VAS for measurement of other composite 
subjective responses, such as lameness could be equally advantageous in increasing the 
sensitivity of measurement.
6.1.1.4 Graphic rating scale
Graphic rating scales (GRS) are an amalgam formed from the simple descriptive scale 
and the visual analogue scale (Freyd, 1923). The GRS consists of a VAS with 
descriptive terms placed at intervals along the length of the scale (Scott and Huskisson,
1976). Assigning descriptive terms along the length of the VAS, thus converting it to a 
GRS, has been found to make the scale easier to use, especially if those people scoring 
are unfamiliar with rating scales in general (Scott and Huskisson, 1976; Heft and Parker, 
1984; Reid and Nolan, 1991). As with the VAS, there are an infinite number of points 
which can be assigned along the length of the scale (Huskisson 1974). However, the 
responses recorded by those using the GRS are frequently clustered near the descriptive 
terms on the scale (Huskisson 1974; Heft and Parker, 1984), effectively limiting the 
sensitivity of the GRS to that of the SDS (Huskisson 1974; Scott and Huskisson, 1976). 
Huskisson and Scott (1977) found that this particular problem of clustering of results 
rendered the GRS unsatisfactory when used to rate pain relief. Freyd (1923) commented 
on the possibility of changing the interval between descriptive phrases to compensate for 
abnormal distribution of scores in a study on personality traits. Similarly, Heft and 
Parker (1974) suggested that the intervals between the words on the GRS should reflect 
the intervals between the words as those scoring perceived them, with moderate being 
rated as 0 and responses below that rated as negative and responses above moderate rated 
as positive. Moderate would be rated as 0 because the distance between the lowest 
description and no pain cannot be evaluated. A further problem which they noted, was 
that some patients used points beyond the extremes of the scale, and in conclusion, the 
authors proposed that uneven intervals between the descriptive terms employed along the 
GRS should be used to overcome the problem of clustering.
6.1.2 Objective gait analysis
The study of gait in man and animals is well established although it remains difficult to 
gain useful diagnostic or therapeutic benefit from the data (Nunamaker and Blauner, 
1985). Gait analysis can provide not only information about the geometry of movement 
(kinematics), and the timing of movement (temporal information), but also about the 
forces that initiate, maintain and alter movement (kinetics). Recent work has concentrated 
on the horse because locomotive disorders are a major source of economic loss to the
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racing industry (Fredricson et al. , 1980). A brief review of objective methods of 
lameness assessment will be given.
In the late 19th century, Eadweard Muybridge was accredited with pioneering the use of 
moving pictures, using stroboscopic photography, to record the gait of animals such as 
the horse and greyhound, and subsequently, many workers have contributed to this field. 
Leach and Dagg (1983) provide an excellent review of this work. Currently, high speed 
cinematography provides a method of gait analysis which allows both temporal and 
kinematic aspects of locomotion to be evaluated (Fredricson et al. , 1970; 1972; 1974; 
1976; 1980; Fredricson and Drevemo, 1971; 1972a; 1972b; 1972c). This technique 
documents movement accurately and in a standardized manner to provide a visual record 
of motion (Leach, 1987). Although an extremely expensive method of analysis, high 
speed cinematography can provide a vast array of information with each frame, and this 
can be stored easily for later analysis (Fredricson et al. , 1980; Leach, 1987). Although 
most research in this field has been directed towards the characterisation of normal gaits, 
some studies have used the technique to characterise gait patterns in lame animals 
(Clayton, 1986a; 1986b; 1988; Ratzlaff et a l . , 1989).
Force plates measure ground reaction forces (Fackelman and Seeherman, 1983), and are 
manufactured with strain gauges, or piezoelectric quartz transducers at each comer 
(Fackelman and Seeherman, 1983; Leach, 1987). They record the magnitude, direction, 
duration and position of the foot as it is placed on the plate (Leach, 1987), thus allowing 
evaluation of temporal and kinetic aspects of movement, and they have been used in man 
(Cavagna, 1975), horses (Pratt and O'Connor, 1976; Steis et al , 1982), cattle (Scott, 
1988; 1989), cats (Coulmance et al. , 1979) and dogs (Dueland et al. , 1977; Budsberg, 
1987; Budsberg et al. , 1987; 1988). Analysis of force plate data has been used as a 
reliable method of quantifying limb dysfunction and response to medical and surgical 
intervention, not only in horses (Gingerich et al. , 1979; 1981; Auer et al. , 1980; 
Merkens and Schamhardt 1988a; 1988b; Dow et a l . , 1991), but also in dogs (Dueland et 
al. , 1977, Budsberg et al. , 1987, Person, 1989, McLaughlin et al. , 1991) and cattle 
(Scott 1989).
Goniometry is the objective measurement of joint motion or joint position (Nicol, 1989), 
and Smith (1982) has reviewed the development of goniometry in human medicine. 
Using electrogoniometry, joint characteristics such as range and amplitude of motion can 
be recorded (Leach, 1987), and studies have been made not only of normal joint motion 
in dogs and horses (Adrian et al. , 1966; Taylor et al. , 1966), but also in animals 
suffering lameness (Adrian et a l . , 1977; Ratzlaff et a l . , 1982; Ratzlaff and Grant, 1986).
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They also have been used for quantitative evaluation of drug treatment on locomotion 
(Ratzlaff et al. , 1981).
Although cinematography, force plate analysis and electrogoniometry are perhaps the 
most frequently reported techniques of objective lameness assessment, there are other 
techniques which provide objective data and have proven useful either in their own right, 
or in association with other techniques. These methods include, pedobarographs (Scott, 
1988), force shoes (Leach, 1987), electromyography (Nunamaker and Blauner, 1985; 
Seeherman et al. , 1981), thermography (Purohit and McCoy, 1980; Vaden et al. , 1980) 
and the evaluation of energy expenditure through oxygen consumption (Fedak and 
Seeherman, 1979).
Although subjective assessment of lameness in domestic animals provides a rapid method 
of recording the degree of gait abnormality, the value of a reliable, rapid objective 
assessment method cannot be underestimated (Fackelman and Seeherman, 1983; Leach
1987). Not only would such a system be of diagnostic and prognostic value, but it would 
allow accurate evaluation of the effects of conservative treatment, surgical intervention 
and drug therapy. Further, it would provide an opportunity to evaluate fully the reliability 
and precision of subjective rating scales used for lameness assessment.
For the purpose of clinical measurement, it is important to compare a new measurement 
technique with an established one to ensure sufficient agreement (Bland and Altman,
1976). Perfect agreement between two methods of measurement would result if the two 
methods gave exactly the same reading each time a measurement was made. If this were 
the case, and the results from one of the methods were plotted against the results from the 
second method, all points would lie along a straight line which is referred to as the line of 
equality. It is also important to have an indication of measurement errors in both 
techniques before replacing the old method with the new (Krebs et al. , 1985). It was 
considered that the application of the VAS to the measurement of lameness might increase 
the degree of sensitivity over the commonly used NRS. Consequently, it was decided to 
compare the reproducibility, repeatability and sensitivity of a VAS and an NRS when 
used to score lameness, using sheep as a model. Reproducibility is a measure of between- 
observer variability, which can be defined as the closeness of agreement between scores 
obtained by the use of the same scoring system on the same animal by different observers 
(British Standards Institution, 1979). Repeatability is a measure of within-observer 
variability, which can be defined as the closeness of agreement between 2 mutually 
independent score results obtained under conditions when the results are obtained by use 
of the same scoring system, on the same animal, by the same observer within short time 
intervals (British Standards Institution, 1979).
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The importance of ensuring that the person using a subjective rating scale receives a full 
explanation of its use, and becomes familiar with the scale prior to assessment is 
generally recognised (Huskisson, 1974; Seymour, 1982). In order to investigate this 
finding, an untrained observer was used to score lameness in sheep to compare the 
reproducibility and repeatability of scores awarded by an untrained observer with those of 
2 trained observers.
Experimental models of pain in the domestic species frequently fail to detect the analgesic 
activity of non-steroidal anti-inflammatory drugs (NSAIDs), which are found to be potent 
analgesics when used clinically (see chapter 1 and chapter 4). The VAS has been widely 
used in the field of rheumatology for evaluation of analgesic efficacy (Downie et al. , 
1978b) and also it is used frequently in clinical trials (Huskisson, 1982; 1983). Footrot 
(see chapter 1) is an extremely painful naturally occurring condition of the epidermal 
tissues of the ruminant foot (Egerton, 1989; Stewart, 1989). Consequently, it was 
decided to investigate the power of the VAS as a method of detecting changes in 
lameness, induced by footrot, in sheep after administration of a NSAID.
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6.2 Materials and Methods
6.2.1 Animals
6.2.1.1 Study 1
Sixty-two adult non-pregnant females were used. They were aged from 2 to 4 years and 
were of mixed breed. These sheep were selected from the flock by a shepherd as sheep 
believed to be suffering from forelimb lameness. All were free from clinical signs of 
systemic disease at the time of the study. They were maintained on grass as a group 
separate from the main flock. No supplementary feeding was provided and water was 
available ad libitum. These sheep were brought from the field to a holding area 1 hour 
prior to the onset of the experimental procedure to allow the sheep to settle.
6.2.1.2 Study 2
A total of 25 sheep were used. Sheep numbers 1 to 8 were Scottish Blackface lambs aged 
approximately 8 to 10 weeks and sheep numbers 9 to 25 were non-pregnant females, also 
Scottish Blackface, aged from 2 to 4 years. These sheep were selected from a different 
flock by a shepherd as sheep believed to be suffering from footrot. All were free from 
clinical signs of systemic disease at the time of the experiment. They were maintained on 
grass as a group with the main flock. No supplementary feeding was provided and water 
was available ad libitum. These sheep were separated from the main flock and brought to 
the holding area prior to the onset of the experimental procedure to allow the sheep to 
settle.
Drug treatment
Flunixin meglumine was administered by intravenous (IV) bolus injection at a dose rate 
of 1.0 mg per kg to sheep numbers 1 to 6 and at a dose rate of 2.0 mg per kg to sheep 
numbers 9 to 23. Sheep numbers 7, 8, 24 and 25 received no treatment.
6.2.2 Subjective lameness assessment  
Observers
6.2.2.1 Study 1
A total of three observers were used. All 3 observers were veterinary surgeons and were 
familiar with lameness assessment in domestic animals. Observer 1 and 2 were 
experienced in scoring sheep lameness specifically and were experienced in the use of the
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VAS, both for scoring lameness and also for scoring signs of pain in dogs. Observers 1 
and 2 were also experienced in the use of NRS to score lameness. Observer number 3 
was unfamiliar with the use of VAS although she was familiar with the NRS method of 
subjective scoring.
To assess reproducibility (between-observer variability), sheep numbers 1 to 45 were 
scored for lameness on 1 occasion by observer 1 and also by observer 2. Sheep numbers 
1 to 25 were similarly scored for lameness on 1 occasion by observer 3. The third 
observer scored sheep numbers 1 to 25 at the same time as observers 1 and 2. The 
observers viewed the sheep at the trot, both to the left and to the right and also when 
turning. No restriction was placed on the time taken to reach a decision on the degree of 
lameness shown by an individual sheep, although a score was generally awarded within 
3 minutes. The observers did not collaborate over the score awarded to individual sheep 
although they initially agreed on which fore limb the sheep was lame.
To assess repeatability (within-observer variability), sheep numbers 46 to 62 were scored 
for lameness on two occasions, one hour apart, by observer 1 and also by observer 2. 
Observers 1 and 2 did not have access to the first score awarded when scoring sheep 
numbers 46 to 62 on the second occasion 1 hour later. Sheep numbers 46 to 55 were 
similarly scored for lameness on 2 occasions by observer 3. The third observer scored 
sheep numbers 46 to 55 at the same time as observers 1 and 2. Lameness was scored as 
described (vide supra).
6.2.2.2 Study 2
Observers 1 and 2 (vide supra) were used. Sheep numbers 1 to 25 were scored for 
lameness by both observers on 5 occasions. The sheep were initially scored for lameness 
before drug administration and subsequently at 1, 2, 4 and 6 hours after drug injection. 
Lameness was scored as described previously. The sheep were assessed for overall 
lameness rather than lameness on 1 specific limb as frequently more than one limb was 
affected.
6.2.3 Lameness rating scales 
Numerical rating scale
In study 1, an NRS was completed by each observer on each occasion that they scored a 
sheep for lameness. The NRS consisted of five divisions represented by the numbers 0, 
1, 2, 3 and 4. Only four of these divisions characterised lameness. The observers had the 
following descriptions of each division provided and were able to refer to them as 
required; 0 = clinically sound/no evidence of lameness; 1 = barely detectable lameness; 2
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= obvious lameness: 3 = severe head nod and possibly resting the affected foot when 
standing; 4 = carrying foot at the trot.
Visual Analogue Scale
In both studies a VAS was completed by each observer on each occasion that lameness 
was scored. A new score sheet was used for each sheep each time it was assessed for 
lameness. The VAS was a straight horizontal line, 100 mm long, whose extreme limits 
were marked with perpendicular lines. Both ends of the scale carried a verbal description. 
The descriptions used were as follows; 0 mm = clinically sound, 100 mm = could not be 
more lame (Fig. 6.1). The observer marked the line at a position which represented to 
them, the severity of lameness exhibited by the sheep under investigation.
6.2.4 Study Design
6.2.4.1 Study 1
Forty-five sheep were selected at random (sheep numbers 1-45) and in order to assess 
reproducibility (between-observer variability), observers 1 and 2 scored these sheep for 
lameness using a VAS. In addition, each observer completed an NRS score for the same 
45 sheep.
The remaining 17 sheep were scored on 2 occasions, 1 hour apart, to investigate the 
repeatability (within-observer variability) of both the VAS and the NRS. The sheep were 
not identified by number (sheep numbers 46-62) to the observers until after the second 
scoring period was completed.
In order to evaluate how familiarity with use of VAS and NRS could affect the 
reproducibility and repeatability of the two scales, observer 3 scored sheep numbers 1 to 
25 for lameness on 1 occasion using both a VAS and an NRS, and sheep numbers 46 to 
55 for lameness on 2 occasions 1 hour apart.
6 .2.4 .2 S tudy  2
Twenty-five sheep were scored for lameness by 2 observers using a VAS. The effect of a 
potent NSAID, flunixin meglumine on the severity of lameness was evaluated. The drug 
was administered at one of two dose rates. Sheep numbers 1 to 6 (group A), received 1.0 
mg/kg, IV, and sheep number 9 to 23 (group B), received 2.0 mg/kg, IV. The remaining 
4 sheep, numbers 7, 8, 24 and 25 were not treated. The 2 observers scoring lameness 
were unaware of the number of sheep which did not receive treatment. They were
1 9 0
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MORE LAME
Figure 6.1. Format of the visual analogue scale (VAS) used in the assessment of 
lameness.
The VAS was a 10 cm line (not drawn to scale) and observers were asked to mark the 
line at the position which represented the severity of lameness.
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informed that one of two different dose rates would be administered. All sheep were 
scored for lameness on 4 occasions after drug administration at 1,2, 4, and 6 hours. The 
observers were not given access to previously recorded scores for individual sheep when 
scoring post-treatment lameness, and the sheep were not identified by number to the 
observers.
6.2.5 Statistical analyses 
Study 1
The VAS data were expressed to the nearest 0.5 mm, whereas the individual discrete 
values awarded for the NRS were used in the results. The distributions for scores were 
investigated for normality, using normal probability plots and correlation analysis. 
Statistical significance of differences between observers when scoring lameness by the 
VAS was determined by use of a paired Student's t test on the differences obtained 
between the 2 observers for the same sheep. Differences within observer, when scoring 
the same sheep on 2 occasions were similarly analyzed. When scoring lameness by the 
NRS, differences were more appropriately analyzed using the Wilcoxin signed rank test.
Statistical tests were carried out using a 5% significance level.
Study 2
There were four control sheep in this study. These sheep were not included in the 
statistical evaluation of the study.
The VAS data were expressed to the nearest 0.5 mm. In view of the unbalanced study 
design, with 6 sheep in group A and 15 sheep in group B, statistical analysis was 
undertaken using a general linear model routine. The experimental design was suitable for 
analysis using a 3 and 2 factor nested analyses of variance. The 3 factor nested design 
provided statistical tests for treatment, observer and time factors and their two-way 
interactions. The 2 factor design was applied at individual time points and provided tests 
for differences between treatments, differences between observers and treatment x 
observer interaction. Animals were regarded as a random factor whereas treatments, 
observers and time were regarded as fixed factors.
Statistical tests were carried out using a 5% significance level.
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6.3 Resul ts
6.3.1 Study 1
6.3.1.1 Reproducibility (between-observer variability)
The VAS and NRS scores assigned by observer 1 and observer 2 to sheep numbers 1 to 
45 are shown in Table 6.1.
The distribution of VAS scores obtained for observers 1 and 2 did not indicate normal 
distributions, and this was confirmed by statistical analysis, using the correlation test for 
normality. Instead, most VAS values were close to the extremes and a few values were in 
the middle of the scale. Differences between the scores of the 2 observers for the same 
sheep had a mean value of -0.46 and a range from -25.5 to 23.5. These differences did 
appear to have a normal distribution. Five sheep were awarded VAS scores which 
resulted in a difference between observers of >20 mm (sheep numbers 2, 8, 13, 21 and 
23). The observers were in full agreement on 7 occasions, and as might be expected, 6 of 
these 7 sheep were observed to be sound. Observer 1 awarded a higher score than did 
observer 2 for 18 sheep, and observer 2 awarded a higher score than did observer 1 for 
20 sheep. However, for most sheep the 2 observers were in close agreement, and 64% of 
the scores for the same sheep were within ± 10 mm. Statistical analysis indicated that the 
differences between the 2 observers when scoring lameness by use of a VAS were not 
significant.
The distribution of NRS scores obtained for observers 1 and 2 indicated normal 
distributions, and this was confirmed by statistical analysis, using the correlation test for 
normality. The distribution of NRS scores for each observer were remarkably similar, 
each observer mostly recording a score of 0 or 1. The observers awarded the same 
lameness score to 20 of the sheep and awarded scores that differed by 1 discrete scoring 
unit to a further 23 sheep. The remaining 2 sheep were awarded scores that differed by 2 
units. Six of the sheep scored for lameness were found to be sound by both observers, as 
was the case when they were scored by VAS. Statistical analysis of the data indicated that 
the differences between observers, using the NRS, were not significant.
6.3.1.2 Repeatability (within-observer variability)
The results for scoring 17 sheep for lameness using a VAS and an NRS on 2 occasions,
1 hour apart are shown in Table 6.2.
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Obs 1
VAS 
Obs 2 D iff Obs 1
NRS  
Obs 2 D iff
Sheepl 1 10.0 1 1.0 -1 1 1 0
2 12.0 32.0 -20.0 1 2 -1
3 0 0 0 0 0 0
4 4.0 0 4.0 1 0 1
5 0 4.0 -4.0 0 1 -1
6 5.5 0 5.5 1 0 1
7 0 0 0 0 0 0
8 6.5 32.0 -25.5 1 2 -1
9 32.0 48.0 -16.0 2 2 0
10 0 9.0 -9.0 0 1 -1
11 27.5 24.5 3.0 2 2 0
12 11.0 15.5 -4.5 1 1 0
13 23.5 0 23.5 2 0 2
X 4 7.0 0 7.0 1 0 1
15 0 0 0 0 0 0
16 23.0 11.0 12.0 2 1 1
17 14.0 1.5 12.5 1 1 0
18 3.0 0 3.0 1 0 1
19 12.5 4.5 8.0 1 1 0
20 7.0 0 7.0 1 0 1
21 20.5 0 20.5 2 0 2
22 0 16.0 -16 0 1 -1
23 6.0 30.0 -24.0 1 2 -1
24 0 0 0 0 0 0
25 0 0 0 0 0 0
26 79.0 89.0 - 10.0 4 4 0
27 69.0 72.0 -3.0 4 3 1
28 29.0 11.0 18.0 2 1 1
29 45.0 31.0 14.0 3 2 1
30 15.0 16.0 - 1.0 2 1 1
31 0 15.0 -15.0 0 1 -1
32 0 0 0 0 0 0
33 4.0 4.0 0 1 1 0
34 17.0 0 17.0 1 0 1
35 7.0 3.0 4.0 1 1 0
36 69.0 88.0 -19.0 3 3 0
37 85.0 98.0 -13.0 3 4 -1
38 67.0 53.0 14.0 3 2 1
39 0 2.0 -2.0 0 I -1
40 96.0 97.0 - 1.0 4 4 0
41 87.0 92.0 -5.0 4 4 0
42 8.0 6.0 2.0 1 1 0
43 0 5.0 -5.0 0 1 -1
44 18.0 19.0 - 1.0 1 1 0
45 68.0 65.0 3.0 4 3 1
Table 6.1. Scores assigned by observers 1 and 2 when a group of 45 sheep were rated 
for lameness, using a continuous scoring system (visual analogue scale; VAS) and a 
discrete scoring system (numerical rating scale; NRS) on the same occasion.
Differences (Diff) between scores of the observers (obs) are also shown.
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VAS N R S
Obs 1 Obs 2 O bs 1 O bs 2
T 1 T 2 D iff T 1 T 2 D iff T 1 T 2 D iff T 1 T 2 D iff
Sheep 46 35.0 0 35.0 33.0 0 33.0 2 0 2 2 0 2
47 26.0 7.0 19.0 0 7.0 -7.0 2 1 1 0 1 -1
48 32.5 22.0 10.5 32.5 22.0 10.5 2 2 0 2 2 0
49 53.0 34.5 18.5 15.0 32.0 -17.0 3 2 1 1 2 -1
50 0 9.0 -9.0 14.0 0 14.0 0 1 -1 1 0 1
51 14.0 15.5 -1.5 0 2.0 -2.0 1 1 0 0 1 -1
52 28.0 10.0 18.0 42.0 27.0 15.0 2 1 1 2 2 0
53 14.0 31.0 -17.0 3.5 4.0 -0.5 1 2 -1 1 1 0
54 0 12.0 - 12.0 18.0 5.5 12.5 0 1 -1 1 1 0
5 5 0 4.5 -4.5 0 0 0 0 1 -1 0 0 0
56 38.0 34.0 4.0 0 23.0 -23.0 2 2 0 0 2 -2
57 0 0 0 0 0 0 0 0 0 0 0 0
58 40.0 34.0 6.0 20.0 31.0 - 11.0 2 2 0 2 2 0
59 35.0 46.0 - 11.0 56.0 62.0 -6.0 2 2 0 2 3 -1
60 0 0 0 0 6.0 -6.0 0 0 0 0 1 -1
61 54.0 36.0 18.0 5.0 10.0 -5.0 3 2 1 1 1 0
62 57.0 10.0 47.0 30.0 14.0 16.0 3 1 2 2 1 1
Table 6.2. Scores assigned by observers 1 and 2 when a group of 17 sheep were rated 
for lameness, using the visual analogue scale (VAS) and the numerical rating scale 
(NRS), on 2 occasions (T1 and T2), 1 hour apart.
The differences (Diff) between the scores of the observers (obs) are also shown.
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For time 1 and time 2, the mean VAS scores (± SEM) for observer 1 were 25 (± 5.0) and 
18 (± 3.6), respectively. For observer 2 at time 1 and time 2, the mean VAS scores (± 
SEM ) were 15.8 (± 4.2) and 14.4 (± 4.0), respectively. The difference between the 
scores awarded to each individual sheep on each occasion was also determined. 
Agreement between the 2 scores should result in a difference of zero. This was only 
achieved by observer 1 for sheep 57 and 60 and by observer 2 for sheep 55 and 57. 
Observer 1 judged 4 sheep to be lame on only 1 occasion, whereas observer 2 judged 6 
sheep to be lame on only 1 occasion. Both observers scored most of the sheep within 20 
mm of the previous score. Statistical analysis of the data indicated that the differences 
were not significant.
Using the NRS, there were no differences between the scores awarded at the first and 
second assessment times by observer 1 for sheep 48, 51, 56, 57, 58, 59 and 60 and by 
observer 2 for sheep 48, 52, 53, 54, 55, 57, 58 and 60. Observer 1 judged 4 sheep to be 
lame on only 1 occasion, whereas observer 2 judged 6 sheep lame on only 1 occasion. Of 
sheep not achieving the same score on both occasions, most were scored within 1 discrete 
unit of their previous score. Statistical analysis of the data indicated that the differences 
were not significant.
6.3.1.3 Comparison of VAS and NRS
To compare the precision of the VAS and the NRS when used to score lameness, a 
precise objective measurement of lameness would be required with which to compare the 
subjective rating scales. No objective measurement of lameness was made during this 
study, therefore, the VAS and the NRS were evaluated by comparing one with the other 
directly. The degree of linear correlation (r) between the 2 measurement methods for 
observers 1 and 2 was 0.94 and 0.95, respectively. Despite a similar degree of correlation 
between methods for both observers, agreement between the methods was not perfect, 
because all points did not lie on the theoretical line of equality (Fig. 6.2a and 6.2b). The 
line of equality is that line on which all points would lie if the VAS and NRS were in 
perfect agreement. Consequently a line of best-fit was constructed by plotting a curved 
line through the median VAS values for each of the NRS scores (Fig. 6.2a and 6.2b). 
For small VAS values, the best-fit line for both observers was convex and was clearly 
above the theoretical line of equality, whereas for large VAS values, the best-fit line was 
concave.
For each observer, a score of 1 on the NRS was associated with the range 0 to 20 mm on 
the VAS, and the values tended to lie above the theoretical line of equality. Similarly, 
when observer 1 awarded a score of 2 on the NRS, the equivalent VAS value was <40
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Figure 6.2a . The scores awarded to 45 sheep for lameness by observer 1 using the 
visual analogue scale (VAS), plotted against the scores awarded to the same 45 sheep 
using the numerical rating scale (NRS).
The curved line of best-fit is plotted through the median of the VAS values awarded at
each NRS score. The theoretical line of equality is shown.
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Figure 6.2b . The scores awarded to 45 sheep for lameness by observer 2 using the 
visual analogue scale (VAS), plotted against the scores awarded to the same 45 sheep 
using the numerical rating scale (NRS).
The curved line o f best-fit is plotted through the median o f the VAS values awarded at
each NRS score. The theoretical line of equality is shown.
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mm. However, observer 2 hud u wider range of VAS values, <60 mm associated with the 
NRS score of 2, and these values crossed the theoretical line of equality. The same trend 
was seen for sheep awarded an NRS score of 3 by both observers, the VAS values that 
lie in the range 45 to 85 mm again crossed the theoretical line of equality. Apart from one 
sheep awarded a score of 45 mm on the VAS with an NRS score of 3 by observer 1, all 
other sheep awarded an NRS score of 3 by observer 1 or 2, had VAS values >65 and 
>68 mm, respectively. For both observers, an NRS score of 4 was associated with VAS 
values >68 and these again tended to lie above the theoretical line of equality. Fewer 
visual analogue scores were located in the region of 40 to 70 mm by both observers.
6.3.1.4 Influence of learning on the use of subjective rating scales
Reproducibil ity
The scores for observers 1, 2 and 3 when scoring sheep numbers 1 to 25 for lameness 
using a VAS and an NRS are shown in Table 6.3. The distribution of VAS scores for 
observer 3 suggested a normal distribution, and this was confirmed by statistical analysis 
using the correlation test for normality. The VAS scores awarded by observers 1, 2 and 3 
to the same 25 sheep were in full agreement on only 1 occasion when sheep number 24 
was observed to be sound by all 3 observers (Table 6.3). Observer 3 awarded a higher 
VAS score than either observer 1 or observer 2 to 21 of the 25 sheep. Four sheep scored 
as sound by observers 1 and 2 were judged to be lame by observer 3. Again, for most 
sheep, observers 1 and 2 were in close agreement, and 64% of the scores for the same 
sheep were within ± 1 0  mm. This was the same percentage as shown for the same two 
observers scoring a total of 45 sheep for lameness. Observer 3 scored only 36% of sheep 
within ± 10 mm of observer 1 and 40% of sheep within ± 10 mm of observer 2. 
Statistical analysis indicated that there was a highly significant difference between the 
VAS values awarded to the same animal by observer 1 and observer 3, p<0.0001, and 
similarly between observer 2 and observer 3, p<0.001.
The distribution of NRS scores for observer 3 also suggested a normal distribution, and 
again this was confirmed by statistical analysis using the correlation test for normality. 
Observers 1, 2 and 3 only awarded three sheep (1,17 and 24) the same NRS score. For 
10 animals, observer 3 was in agreement with only 1 of the other 2 observers. Statistical 
analysis indicated that there was a significant difference between the NRS values awarded 
to the same animal by observer 1 and observer 3, p<0.01, and observer 2 and observer 3,
p<0.01.
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VAS 
Obs 1 Obs 2 Obs 3
N R S 
Obs 1 Obs 2 Obs 3
Sheep No. 1 10.0 11.0 12.0 1 1 1
2 12.0 32.0 24.0 1 2 2
3 0 0 12.0 0 0 1
4 4.0 0 8.0 1 0 1
5 0 4.0 12.5 0 1 1
6 5.5 0 17.0 1 0 2
7 0 0 1.5 0 0 1
8 6.5 32.0 32.5 1 2 2
9 32.0 48.0 63.0 2 2 3
10 0 9.0 0 0 1 0
1 1 27.5 24.5 61.0 2 2 3
12 11.0 15.5 0 1 1 0
13 23.5 0 37.0 2 0 2
14 7.0 0 8.0 1 0 1
1 5 0 0 43.0 0 0 2
16 23.0 11.0 43.5 2 1 2
17 14.0 1.5 16.5 1 1 1
18 3.0 0 18.0 1 0 1
19 12.5 4.5 57.0 1 1 2
20 7.0 0 46.0 1 0 2
21 20.5 0 21.5 2 0 1
22 0 16.0 40.0 0 1 2
23 6.0 30.0 49.0 1 2 2
24 0 0 0 0 0 0
25 0 0 5.0 0 0 1
Table 6.3. Scores assigned by 2 observers (Obs), 1 and 2, familiar with the use of a 
visual analogue rating scale (VAS) and an numerical rating scale (NRS), and 1 untrained 
observer, observer 3 where 25 sheep were rated for lameness on 1 occasion.
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Repeatability
The scores assigned to a group of 10 sheep (sheep numbers 46-55), on two occasions 
one hour apart, by observers 1, 2 and 3 using both a VAS and an NRS are shown in 
Table 6.4.
For time 1 and time 2, the mean VAS scores (± SEM) for observers 1, 2 and 3 were 20.3 
(± 5.6), 15.8 (± 4.9), 41.0 (± 8.2) and 14.6 (± 5.6), 10.0 (± 3.9) and 39.3 (± 3.9) 
respectively. Observer 3 awarded scores within 20 mm of the previous score to 50% of 
sheep. Statistical analysis of the data indicated that the differences between the VAS 
scores awarded by observer 3 at time 1 and the VAS scores awarded by the same 
observer at time 2 were not significant.
Observer 3 awarded the same NRS score at each recording interval to five sheep (sheep 
numbers 1, 2, 4, 7 and 10). Statistical analysis of the data indicated that the differences 
between the scores awarded at time 1 and the scores awarded at time 2 were not 
significant.
Comparison of VAS and NRS
The degree of linear correlation between the two scoring methods when used to score 25 
sheep on 1 occasion by observer 3 was 0.9. Although there was a good degree of 
correlation between the two methods, clearly agreement between the methods was not 
perfect, because all points did not lie on the theoretical line of equality. A line of best-fit 
was constructed by plotting a curved line through the median VAS values for each of the 
NRS scores (Fig. 6.3). For small VAS values, the best-fit line was convex and clearly 
above the theoretical line of equality, whereas for larger VAS values, the best-fit line 
tended towards concavity, but remained above the theoretical line of equality. A score of 
1 on the NRS was associated with the range 5 to 21.5 mm on the VAS. Similarly when 
observer 3 awarded a score of 2 on the NRS the equivalent VAS value was <57 mm. 
Observer 3 awarded an NRS score of 3 to only 2 sheep where the equivalent VAS values 
were 61 and 63. No sheep were awarded a maximum NRS score of 4. Most visual 
analogue scores were located in the region between 12 and 49 mm.
6.3.2 Study 2
6.3.2.1 Differences between observers
Table 6.5a shows the VAS scores, and the mean and SEM of the scores, awarded by 
observer 1 and observer 2 to sheep in group A. Table 6.5b shows the VAS scores, and
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Obs 1 Obs 2 Obs 3
T 1 T 2 D iff T 1 T 2 D iff T 1 T 2 D iff
Sheep 46 35.0 0 35.0 33.0 0 33.0 50.0 47.5 2.5
47 26.0 7.0 19.0 0 7.0 -7.0 47.0 45.0 2.0
48 32.5 22.0 10.5 32.5 22.0 10.5 62.0 20.0 42.0
49 53.0 34.5 18.5 15.0 32.0 -17.0 60.5 56.0 4.5
50 0 9.0 -9.0 14.0 0 14.0 0 45.0 -45.0
51 14.0 15.5 -1.5 0 2.0 -2.0 60.0 22.0 38.0
52 28.0 10.0 18.0 42.0 27.0 15.0 48.0 47.0 1.0
53 14.0 31.0 -17.0 3.5 4.0 -0.5 6.5 43.0 -36.5
54 0 12.0 -12.0 18.0 5.5 12.5 67.5 43.0 24.5
55 0 4.5 -4.5 0 0 0 8.5 24.5 -16.0
Obs 1 Obs 2 Obs 3
T 1 T 2 D iff T 1 T 2 D iff T 1 T 2 D iff
Sheep 46 2 0 2 2 0 2 2 2 0
47 2 1 1 0 1 -1 2 2 0
48 2 2 0 2 2 0 3 1 2
4 9 3 2 1 1 2 -1 3 3 0
50 0 1 -1 1 0 1 0 2 -2
51 1 1 0 0 1 -1 2 1 1
52 2 1 1 2 2 0 2 2 0
53 1 2 -1 1 1 0 1 2 -1
54 0 1 -1 1 1 0 3 2 1
5 5 0 1 -1 0 0 0 1 1 0
T able 6.4. Scores assigned by observers (obs) 1, 2 and 3 when a group of 10 sheep 
were rated for lameness, using a visual analogue scale (VAS) and an numerical rating 
scale (NRS) on 2 occasions (T1 and T2), 1 hour apart.
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Figure 6.3. The scores awarded to 25 sheep by observer 3 using the visual analogue 
scale (VAS), plotted against the score awarded to the same 25 sheep using the numerical 
rating scale (NRS).
The curved line of best-fit is plotted through the median o f the VAS values awarded at
each NRS score. The theoretical line of equality is shown.
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Obs 1
Sheep N o .
T im e(h r) 1 2 3 4 5 6 7 8 Mean ±SEM
0 46.5 30.5 21.0 8.0 89.0 84.0 68.0 79.0 46.5 13.7
1 35.5 18.0 8.0 13.0 60.5 25.0 100 26.5 26.7 10.9
2 7.5 33.0 20.0 0 19.5 20.0 25.0 29.0 16.7 4.5
4 0 46.0 14.0 6.0 35.0 16.0 85.5 67.0 19.5 7.2
6 5.0 17.0 23.5 5.0 21.0 0 78.0 71.5 11.9 4.0
Obs 2
S heep N o .
T im e(h r) 1 2 * 3 4 5 6 7 8 M ean ±SEM
0 24.5 22.0 2.5 15.5 83.0 63.0 53.0 77.5 35.1 12.7
1 5.5 13.0 3.0 0 9.5 2.5 58.0 0 5.6 2.0
2 0 14.0 0 6.0 7.0 14.0 47.0 8.5 6.8 2.6
4 0 34.0 0 0 0 0 62.0 38.5 5.7 5.7
6 0 38.5 4.5 1.5 27.5 0 66.0 38.5 12.0 6.8
Table 6.5a. Scores assigned by observers (Obs) 1 and 2 when a group of 8 sheep were 
rated for lameness using a visual analogue scale before and after the administration of 
flunixin meglumine, 1.0 mg/kg, IV, at time 0.
The drug was administered at time 0. The mean and standard error of the mean (SEM) of 
the VAS scores at each time point are shown.
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Obs 1
S heep N o .
T im e (hr) 9 10 1 1 12 13 14 1 5 16 17 18
0 34.0 25.0 71.5 100 47.0 24.5 42.0 13.5 100 11
1 32.0 33.5 44.0 100 7.0 13.5 38.0 20.0 62 14
2 34.0 17.5 29.0 100 0.0 14.0 5.5 22.0 75 5
4 18.0 14.5 51.0 100 8.0 9.0 0 31.0 63.5 13
6 0 48.0 45.5 100 3.0 22.0 10.0 34.5 79.5 22
Tim e (hr) 19 20 21 22 23 24 25 M ean ± SE M
0 52 43.5 58 41 37.5 '46 .5 37.0 46.2 10.9
1 30 48.5 25.5 9.5 49.5 64.0 0 35.1 9.9
2 11.5 0 18.5 8.5 22 69.0 27.5 24.2 11.4
4 14 12 44.5 32.5 41.5 50.0 12.0 30.2 10.9
6 25.5 7.5 18 28 0 56.0 45.0 29.6 11.8
Obs 2
S heep N o .
Tim e (hr) 9 10 11 12 13 14 15 16 17 18
0 14.0 17.5 93.0 35.0 24.0 12.0 37.5 44.0 70.0 15.5
1 7.0 6.0 20.5 MD 88.0 11.0 13.5 21.0 13.0 3.5
2 5.0 5.0 14.0 94.0 0 15.0 8.5 4.0 31.0 0
4 8.5 70.0 20.0 68.0 7.0 12.5 10.0 22.0 43.0 3.5
6 16.5 14.0 25.0 76.0 9.5 11.5 32.0 22.0 25.0 6.5
Tim e (hr) 19 20 21 22 23 24 25 M ean ± S E M
0 28.5 11.0 12.5 5.0 18.5 35.0 19.0 28.7 10.0
1 8.5 15.0 6.0 0 16.0 29.5 18.0 21.5 8.8
2 2.0 2.5 9.5 5.0 8.0 25.0 17.0 23.6 9.6
4 10.5 10.5 19.5 14.0 8.0 41.0 7.0 16.9 6.9
6 22.0 3.5 13.5 11.0 6.0 28.0 20.0 17.3 7.1
Table 6.5b. Scores assigned by observers (Obs) 1 and 2 when a group of 17 sheep 
were rated for lameness using a visual analogue scale (VAS) before and after the 
administration of flunixin meglumine, 2.0 mg/kg, IV, at time 0.
The drug was administered at time 0. The mean and standard error of the mean (SEM) of 
the VAS scores at each time point are shown. MD = Missing data.
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the mean and SEM of the scores, recorded by observer 1 and observer 2 to sheep in 
group B. Comparison of the scores awarded by observers 1 and 2 at time 0 i. e. prior to 
drug treatment, to animals in group A and B, indicated that there was a significant 
difference, p<0.01, in the scores awarded to individual sheep at that time. The mean of 
the VAS scores awarded pre-treatment to group A and B by observer 1 was 46.5 and 
46.6 mm respectively, while the mean of the VAS scores for the 2 groups recorded by 
observer 2 was 35.1 and 28.7 mm respectively. At time 0, and for the remaining time 
points observer 1 tended to award higher VAS scores to the sheep in both groups than did 
observer 2. Consequently, the absolute change in VAS scores /. e. the difference between 
pre- and post-treatment scores, was used to examine the between treatment data further.
6.3.2.2 Differences between treatments
Group A
No sheep in group A were found to be sound on initial lameness assessment by either 
observer (Table 6.5a). However, observer 1 recorded a VAS score of 0 post-treatment 
for 3 sheep (sheep numbers 1, 4, and 6). Similarly, observer 2 recorded a VAS score of 
0 for 6 sheep (sheep numbers 1, 3, 4, 5, 6 and 8) post-treatment.
Table 6.6a shows the percentage decrease in lameness after drug administration recorded 
by observer 1 and observer 2 for group A. Both observers recorded at least 50% decrease 
in lameness on 1 or more occasions over the 6 hour post-treatment recording period for 
sheep numbers 1, 3, 4, 5 and 6. The remaining sheep in group A, sheep number 2, was 
shown to have at least a 40% decrease in lameness by both observers at 1 hour post­
treatment. At 6 hours post-treatment, observer 1 scored 2 sheep more severely lame than 
at initial assessment (sheep numbers 3 and 7), while observer 2 scored 3 sheep more 
severely lame than at initial assessment (sheep numbers 2, 3 and 7). All of the remaining 
sheep were found by both observers to be less lame at 6 hours post-treatment than pre­
treatment.
Group B
No sheep in group B were found to be sound on initial lameness assessment by either 
observer (Table 6.5b). However, observer 1 recorded a VAS score of 0 post-treatment 
for 6 sheep (sheep numbers 9, 13, 15, 20, 23 and 25). Similarly, observer 2 recorded a 
VAS score of 0 for 3 sheep (sheep numbers 13, 18 and 22) post-treatment.
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Obs 1
Sheep N o .
Time (hr) 1 2 3 4 5 6 Mean ±SEM
1 23.6 41.0 61.9 -62.9 32.0 70.6 27.8 19.5
2 83.9 -8.2 4.8 100 78.1 76.5 55.9 18.6
4 100 -50.8 33.3 25.0 60.7 81.2 41.6 21.8
6 89.3 44.3 11.9 37.5 76.4 100 59.9 13.9
Obs 2
S heep N o .
Time (hr) 1 2 3 4 5 6 M ean ±SEM
1 77.6 40.9 -20.0 100 88.6 96.0 63.9 18.9
2 100 36.4 100 61.3 91.6 77.8 78.9 10.3
4 100 -54.5 100 100 100 100 74.3 25.7
6 100 -75.0 -80.0 90.3 66.9 100 33.7 35.5
Table 6.6a. The decrease in the level of lameness, recorded as a percentage of the pre­
treatment visual analogue scores awarded to 6 sheep by observers (Obs) 1 and 2. 
Flunixin meglumine was administered at 1.0 mg/kg, IV, at time 0.
The mean and standard error of the mean (SEM) for each time point are also shown.
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Table 6.6b shows the percentage decrease in lameness after drug administration recorded 
by observer 1 and observer 2. Observer 1 recorded at least a 50% decrease in lameness 
for >70% of sheep on 1 or more occasions after drug treatment, and observer 2 found a 
similar decrease in lameness in >80% of sheep. Six hours after drug administration, 3 
sheep, numbers 10, 16 and 18 were assessed as more severely lame than at initial 
assessment by observer 1. Observer 2 scored 6 different sheep, numbers 2, 3, 9, 12, 21 
and 22 more severely lame than at initial assessment at the same time point. All except 1 
of the remaining sheep (sheep number 12) were found by both observers to be less lame 
at 6 hours post-treatment, than pre-treatment. Observer 1 consistently scored sheep 
number 16 as more severely lame than initially. Observer 1 also scored sheep number 12 
at 100 mm on the VAS scale on each occasion. Statistical analysis revealed no significant 
difference between the 2 treatment groups at any time point post-treatment.
Further statistical analysis of the data revealed that there were no significant interactions 
between treatments, observers and time.
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Obs 1 
S heep N o .
Tim e (hr) 9 10 1 1 12 13 14 1 5 16 17
1 5.9 -3.4 38.5 0 85.1 44.9 9.5 -48.2 38.0
2 0 30.0 59.4 0 100 42.9 86.9 -63.0 25.0
4 47.1 42.0 28.7 0 83.0 63.3 100 -130 36.5
6 100 -92.0 36.4 0 93.6 10.2 76.2 -156 20.5
Tim e (hr) 18 19 20 21 22 23 M ean ±SE M
1 -27.3 42.3 -11.5 56.0 76.8 -32 16.3 10.8
2 54.6 77.9 100 68.1 79.3 41.3 46.8 11.4
4 -18.2 73.1 72.4 23.3 20.7 -10.7 28.8 14.4
6 -100 60.0 82.8 69.0 31.7 100 21.6 20.4
Obs 2
S h eep N o .
Tim e (hr) 9 10 1 1 12 13 14 15 16 17
1 50 65.7 78.0 MD -227 8.3 64.0 52.3 81.4
2 64.3 71.4 85.0 -169 100 -25.0 77.3 90.9 55.7
4 39.3 60.0 78.5 -94.3 70.8 -4.2 73.3 50.0 38.6
6 -17.9 20.0 73.1 -117 60.4 4.2 14.7 50.0 64.3
Tim e (hr) 18 19 20 21 22 23 M ean ±SE M
1 77.4 70.2 -36.4 52.0 100 13.5 29.3 24.7
2 100 93.0 22.7 24.0 0 56.8 43.2 18.0
4 77.4 63.2 4.5 -56.0 -180 56.8 18.5 19.3
6 58.1 22.8 68.2 -8 -120 67.6 16.0 16.1
T able 6.6b. The decrease in the level of lameness, recorded as a percentage of the pre- 
treatment visual analogue scores awarded to 15 sheep by observers (Obs) 1 and 2. 
Flunixin meglumine was administered at 2.0 mgAg, IV, at time 0.
The mean and standard error of the mean (SEM) for each time point are also shown.
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6.4 D iscussion
6.4.1 S tudy 1
There is a wealth of published data available on gait analysis in horses and dogs, but little 
has been published on the use or reliability and sensitivity of subjective rating scales such 
as SDS, GRS, NRS, or VAS in scoring lameness in domestic animals. A subjective 
response, such as pain intensity, requires an accurate, reliable and sensitive method of 
measurement (Joyce et al. , 1975). The same must be true for other subjective responses, 
such as lameness. Indeed, in sheep with footrot, signs of pain and lameness are likely to 
be intimately linked with each other. The early stages of footrot are associated with severe 
interdigital inflammation, with little or no physical deformation of the foot, and therefore, 
one must assume that at least initially, the lameness often seen in these animals is a result 
of the pain experienced when bearing weight.
Precise and objective measurement of lameness in domestic animals, that could be easily 
used in the clinic or in the experimental situation, would provide an ideal starting point on 
which to base investigations of the effects of various therapeutic interventions. The 
precision of other more subjective measurements e. g. NRS, VAS, then also could be 
assessed. Unfortunately, such measurements tire not as yet available, although techniques 
such as electrogoniometry (Adrian et al., 1977; Rowe et al., 1989) may, in time, yield 
such information.
Normal probability plots of the VAS data for observer 1 and 2 indicated that the 
population of sheep investigated for lameness were not normally distributed. A similar 
examination of the NRS data, however, revealed a normal distribution. The 62 sheep in 
this study were selected from a flock of 300 animals because they were considered by the 
shepherd to be lame. This group of lame sheep represented <20 % of the entire flock. 
Within the flock, it can be assumed that most sheep were not markedly lame, and 
therefore, a normal distribution curve would not be seen. However, we were in effect, 
looking at a separate population of sheep; they were all specifically chosen because they 
were believed to be lame. Despite this, we would not expect the data from this group of 
sheep to have a normal distribution. In any group of sheep with footrot, most will be only 
mildly lame, with minor interdigital or digital lesions. There will also be a small 
percentage of sheep with a severe form of the condition, which often will persist 
chronically (Stewart, 1989), and therefore, a normal distribution curve would not be 
obtained.
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Visual analogue scales provide a continuous method of subjective measurement, and 
remove the constraints placed on observers by the NRS, which groups information in 
discrete units. The differences seen in the results may therefore, be explained by virtue of 
the ability of the VAS to allow more accurate interpretation of the data, because it does not 
force observers to group unlike data. However, normal probability plots of both the VAS 
and the NRS data for the 25 sheep scored by observer 3 indicated normal distribution. It 
is important to note that for this smaller sample of sheep the normal probability plot for 
the VAS data for both observer 1 and 2 also indicated normal distribution. This may be 
related to the differences in sample size between the two groups.
If the results for reproducibility, or between-observer variability, of the VAS and the 
NRS are examined it is clear that both methods, when used for assessment of lameness, 
provide suitably reproducible results between 2 trained observers. However there were 
highly significant differences between the untrained observer, observer 3, and the two 
trained observers when using the VAS and NRS. The untrained observer tended to award 
sheep a higher score using the VAS than the trained observers, and also recorded 4 sheep 
lame which both trained observers had scored as sound. Some variation between 
observers is inevitable, but it is interesting to note that the error in scoring due to visual 
motor performance alone, is ± 8 mm when using a VAS (Revill et al. , 1976). Observers 
1 and 2 scored 64% of sheep within ± 10 mm of each other, and it is possible that a 
portion of this error may be accounted for because of visual motor limitations. However, 
when the 2 trained observers were compared to the untrained observer, <40% of sheep 
were awarded scores within ± 10 mm, emphasising the differences between the trained 
and untrained observers.
Dixon and Bird (1981) reported that reproducibility of the VAS can vary along the length 
of the line, with the greatest reproducibility at the ends of the line and at the centre point. 
They also indicated that the region ± 20 mm of the centre point of the line causes the most 
difficulty when allocating scores. It was not possible to test this hypothesis in the present 
study because of the apparent distribution of lameness present in the study group i. e. few 
sheep were awarded VAS scores in the centre region of the scale (from 30 to 70 mm). 
However, it is interesting to note that all scores which resulted in differences between 
observers of >20 mm (n=5), involved sheep which were awarded a lameness score of 23 
to 32 mm by one observer and 0 to 12 mm by the second observer (Table 6.1). Further, 
in each case the sheep were awarded a corresponding NRS value of 2 by one of the 
observers and a value of 1 or 0 by the other observer. To fully evaluate this, a larger 
group of sheep would be required to ensure that a full range of lamenesses were included 
within the group.
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It is essential to establish that any subjective method used for clinical measurements is 
repeatable. This allows comparisons to be made, for example, to assess improvement in 
lameness over a period of days or weeks after treatment has been initiated. Analysis of 
this data is complex. Within each recording period, each sheep is awarded a subjective 
score for lameness, and within each recording period this score is assumed not to change. 
However, it cannot be assumed that the degree of lameness will not alter in the time 
period between recordings. Because there is no reliable objective method of lameness 
scoring, there is no way in which any such change can be quantified. Factors that may 
contribute to alteration in the degree of lameness manifested by sheep include exercise and 
standing on concrete in the interval between recordings. It has been demonstrated that 
within-observer comparisons are more sensitive than between-observer comparisons 
(Maxwell, 1978), and in this study the differences that were seen between measurements 
made at a one hour interval, were not judged to be statistically significant for either 
observers 1, 2 or 3 when using either method. Therefore, although observer 3, scored 
lameness in sheep in a different manner to the trained observers, she demonstrated 
repeatability using both scoring methods. This indicates that although an observer may be 
unfamiliar with using an NRS or a VAS for scoring lameness, they would be able to take 
sequential measurements, and to gauge from these whether or not there had been any 
improvement or deterioration in lameness.
Perhaps the most important variable to consider when a comparison of the VAS and NRS 
is made, is the sensitivity of the scoring method. It was not appropriate to evaluate the 
accuracy of the 2 methods in this study, because that would require a precise 
measurement of lameness with which the VAS and NRS could be compared. Such a 
technique in sheep is not available currently. Consequently, the data were examined by 
evaluating the 2 subjective measurement methods against each other. Correlation 
measures the strength of relation between 2 variables, and not the agreement between 
them. The degree of correlation between the VAS and NRS methods was good for all 
observers. However, assigning significance to these correlation values in this instance, is 
inappropriate for several reasons. It is the agreement between 2 methods and not the 
correlation that allows us to assess by how much one method differs from another (Bland 
and Altman. 1986). Moreover, perfect correlation will exist between two methods of 
measurement if the points lie along any straight line, whereas perfect agreement is 
obtainable only if the points lie along the line of equality. The use of 2 interchangeable 
methods for measuring a clinical variable necessitates close agreement. Finally, any 
change in the scale of measurement will not affect correlation, but will affect agreement 
between 2 methods.
The VAS alters the method of measurement from a discrete to a continuous scale and, 
therefore, can be expected to alter agreement. Perfect agreement between the VAS and 
NRS, however, cannot be achieved. By design, if a sheep is awarded a score of 0 by 1 
method it must also be awarded a score of 0 by the second method. However the same 
does not apply to the maximal scores. A maximal score (100 mm) by the VAS ('could not 
be more lame') must correspond to a maximal score of 4 by the NRS, but in this instance, 
the reverse does not apply as indicated by the results. Sheep may be given a score of 4 
(NRS) without achieving a maximal 100 mm score by the VAS. Therefore, the line of 
equality which is represented on Fig. 6.2a, 6.2b and 6.3, is referred to as the theoretical 
line o f equality. Consequently, use of these scales interchangeably cannot be 
recommended, because agreement at the upper limits cannot be evaluated. In addition, it 
can be seen from the data that the 4 lameness categories measured by the NRS do not 
reflect equal divisions on the VAS. If this were the case, a straight line of best-fit would 
have resulted.
The verbal descriptions placed at either end of a VAS anchor the scale and should 
correspond to the absolute maximum and absolute minimum of the parameter being 
measured (Joyce et al. , 1975; Maxwell, 1978). The agreement between the VAS and the 
NRS could perhaps be altered if the verbal descriptions at the end of the scale were 
changed. Freyd (1923) stated that the end phrases used should not be so extremely 
worded as never to be employed. In lameness assessment, one of the extremes is easy to 
place as an animal can never be less lame than when it is sound on all four limbs. 
However, the other extreme of the absolute scale is less easy to place. In this study, the 
statement of'could not be more lame' was used which might imply that the sheep would 
score a maximal 100 mm on that scale only if recumbent. A phrase such as 'not touching 
limb to ground' might be more appropriate because there would be less disagreement 
between observers as to the meaning of the statement.
It is interesting to note that the line of best-fit for each observer is curvilinear. The point 
of inflection occurs at approximately 60 and 78 mm for observer 1 and 2, respectively. 
For observer 1, this correspond to the 'golden section', which is that point on a line 
which divides it into 2 segments such that the smaller is to the larger as the larger is to the 
whole line (Benjafield and Adams-Webster, 1976). This point occurs at 62% of the way 
along the length of a line which in the case of the VAS used in this experiment would be 
62 mm. Dixon and Bird (1981) found in an experiment designed to investigate 
reproducibility along a vertical VAS, that subjects under estimated above the 'golden 
section' and over estimated below the 'golden section'. If this is true for observer 1 it
2 1 3
would suggest that they tend to over-estimate lameness below 60 and conversely, under­
estimate lameness above those values.
Ohnhaus and Adler (1975) indicated that a verbal rating scale produced an artificial 
augmentation of analgesic drug effect. They concluded that this feature was seen because 
the data were 'discretised', and that the VAS reflected more precisely what the patient 
actually felt. Similarly, if a sheep is not completely sound, the observer is obliged to 
record a NRS score of at least 1 for that animal, although it may, in fact, be perceived to 
be clinically less lame than the average sheep assigned to that group. It has been 
demonstrated that both the VAS and the NRS are reproducible and repeatable when used 
to score lameness in sheep. However, it has been shown that there is not perfect 
agreement between the VAS and the NRS. Each NRS value had a range of VAS values 
associated with it which spanned the line of best-fit. This demonstrates an increase in-the 
sensitivity of the VAS when used to score lameness when compared to the NRS. This 
increase in sensitivity is particularly important at the lower end of a lameness scale where 
small improvements in lameness may be of great value e. g . in detecting the therapeutic 
effect of a novel analgesic or anti-inflammatory drug.
6.4.2 S tudy  2
The VAS is a simple, robust, sensitive and reproducible subjective rating scale which is 
frequently used in clinical trials of analgesic drugs (Huskisson, 1982). In study 1 the 
VAS was used to assess lameness in sheep, and was found to be simple, reproducible, 
repeatable and more sensitive than the NRS, with which it was compared. Consequently, 
it was decided to apply the VAS to the measurement of lameness in sheep which were 
treated with an analgesic drug to test the power of the VAS as an instrument for the 
assessment of therapeutic effect.
In order to evaluate the VAS as a tool to detect changes in lameness, it would be 
preferable to treat the sheep with an analgesic drug with a proven effect in sheep. 
Unfortunately the drugs which have been demonstrated as effective analgesics in sheep, 
such as the ct2-adrenoreceptor agonists or the opioids (Livingston et al. , 1992b), can 
result in marked ataxia. Therefore, a NSAID, flunixin meglumine, was chosen to treat the 
sheep. Flunixin meglumine is a potent NSAID (see chapter 1), and it has been 
demonstrated as an effective analgesic in laboratory animals (Ciofalo etaL , 1975, 1977), 
humans (Zederfeldt et al. , 1977; Sunshine et al. , 1984), horses (Houdeshell and 
Hennessey, 1977; Vernimb and Hennessey, 1977) and more recently in dogs (Reid and 
Nolan, 1991).
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In a study designed to examine the effects of an analgesic drug the tendency of the 
observers might be to award lower scores post-treatment than pre-treatment with the 
assumption that an improvement in lameness would occur. To minimise this effect the 
observers were not allowed access to original lameness scores for sheep. Moreover, 
when scoring post-treatment lameness they were a) unaware that younger animals had all 
been assigned to group A and had received only 1.0 mg/kg of flunixin meglumine and b) 
that an unspecified number of sheep were left untreated. These untreated sheep were not 
included in the statistical analyses of the data because of the unbalanced design of the 
study and the small numbers of animals involved.
The 2 observers used in this study were both experienced at using the VAS to record the 
severity of lameness in sheep. However, statistical analysis indicated that there were 
significant differences between the scores awarded by observer 1 and the scores awarded 
by observer 2 pre-treatment. The mean scores for each observer indicated that observer 1 
tended to award sheep a higher VAS score than did observer 2, and this remained a 
constant feature throughout the study period. It is interesting to note that in study 1 there 
were no significant differences found between the VAS scores awarded by the same 2 
observers i. e. there was good reproducibility. Prior to the onset of study 1, both 
observers were scoring sheep for lameness on a regular basis (twice weekly) using the 
VAS and the NRS. However, at the of time study 2, observer 2 had not scored sheep for 
lameness using either the VAS or the NRS for approximately 5 months, while observer 1 
was using the VAS regularly throughout that period. This indicates that, not only is it 
important that an observer is familiarised with the VAS prior to the onset of a study, but 
also that regular use of the system, or a period of retraining using the system is required 
to maintain a high degree of reproducibility within a study. However, there were no 
significant observer x time interactions, which confirmed that although the 2 observers 
were scoring sheep at a different level, they continued to score in a similar manner relative 
to each other throughout the study period. Therefore, the differences between observers 
should not have adversely affected the results obtained in study 2. However, to eliminate 
any differences that did exist due to the way in which the observers recorded lameness, 
the post-treatment scores were all converted to absolute changes in the VAS score, prior 
to statistical analysis. This manoeuvre effectively convened the absolute values from the 
VAS to the difference in lameness intensity values I. e. the change in lameness from the 
original score awarded.
Although there were no significant differences between the drug treatments at any time 
point after administration of flunixin meglumine, at either dose rate, it was apparent that 
most sheep in group A (>80%) and group B (>70%) showed a decrease in degree of
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lameness after treatment. The sheep included in this study were selected because they 
were observed to be lame. No animals were excluded because of the degree of severity of 
lameness and consequently, sheep which were both extremely lame e. g. sheep number 
12, and sheep that were suffering only a mild degree of lameness e. g sheep number 18, 
were included in the study. Therefore, failure to detect significant changes in lameness 
post-treatment, may have resulted from the wide spread of values which were recorded 
from a small number of animals (25) (Quiding and Haggquist, 1983). In order to detect 
small differences between treatment groups, and scores awarded post-treatment within 
groups, a larger sample size would have been necessary.
It is possible to obtain an estimate of the number of sheep that should be included in each 
treatment group to afford the optimum opportunity of detecting a significant change, 
should one exist, from the data provided by this preliminary study (Lipsey, 1990). The 
estimate may be derived from a power chan appropriate for a 5% significance level with a 
power of 80% (Lipsey, 1990). There are 2 pieces of information which are required to 
operate this chart. Firstly, the order of difference which is sought within the test system 
must be known. From study 1, when 2 observers score a group of lame sheep on 2 
occasions, they award scores within 20 mm of the previous score to most sheep. 
Therefore, a change of >20 mm could be considered as the most appropriate order of 
difference to indicate change within the system. Secondly, the normal variation within the 
population, should be indicated /. e. the standard deviation. This information allows the 
calculation of the effect size value (ES). The ES is calculated by dividing the order of 
difference required within the system, in this case 20 mm, by the standard deviation of 
the population of animals which is to be investigated. The power chart then uses this 
calculated value to estimate the optimal number of animals to include in the study. To 
detect whether or not there was a significant improvement in the degree of lameness 
exhibited by the sheep in study 2, approximately 26 sheep would have been required in 
each treatment group. It is interesting to note, that with the degree of variation within the 
population of lame sheep which were examined in study 2, in order to detect an 
improvement of 10 mm on the VAS scale, should one occur, that it would have been 
necessary to score approximately 130 sheep in each group. Langley and Sheppeard 
(1984) suggested that when assessing the effect of different drug treatments on pain, the 
groups used should be matched with care to ensure similar initial pain severity scores, 
and it has been demonstrated that imbalance in the initial pain severity scores of 2 groups 
undergoing treatment can affect the outcome of an analgesic trial adversely (Huskisson, 
1974). From study 2, it is apparent that it would be appropriate to group sheep, prior to 
the onset of the study, to ensure similar pre-treatment lameness scores. This would 
reduce the background variation within the test system thus allowing a reduction in the 
number of sheep in each treatment group. Moreover, it would allow the introduction of a
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more stringent test of improvement without the requirement for a large number of animals 
e. g. an improvement of 10 mm in the VAS lameness score.
The VAS has been used extensively in the field of human rheumatology (Downie et al. , 
1978b) to evaluate drug efficacy. When assessing the therapeutic effect of an analgesic 
agent for use in rheumatology, the patients receiving treatment are generally asked to 
either record their pain relief or the severity of their pain (Langley and Sheppeard, 1984), 
rather than the clinician assessing the improvement in joint or limb mobility. However a 
veterinary surgeon prescribing an analgesic in similar circumstances, must rely on the 
improvement in lameness or joint mobility as an indicator of the analgesic effect of the 
drug treatment. The VAS used in this study recorded the severity of the lameness 
exhibited by the sheep at each time point rather than the improvement in lameness from 
the pre-treatment level. Therefore the VAS used in this study rated absolute values. An 
absolute VAS utilises the 2 extremes of the condition under investigation at either end of 
the scale e. g. 'sound' and ’could not be more lame’. A comparative VAS however, 
measures the improvement from the original state recorded e. g. one end of the scale 
might be marked ’no improvement’ and the other ’sound’. In this study the observers 
were rating lameness in sheep, and the sheep were not identified to the observers until 
after a score had been assigned. Therefore, the observers could not be expected to recall 
the original score for any particular sheep. One possible solution to such a problem would 
be to allow the observers access to the original VAS score for each individual sheep. 
There has been conflicting evidence over the issue of access to previous scores. Several 
studies found that access to previous scores had deleterious effects on subsequent scores 
(Jacobsen, 1965; Hart and Huskisson, 1972; Carlsson, 1983) while Huskisson and Scott 
(1977) argued that although subsequent scores might be influenced by access to previous 
scores, this led to an increase in precision. The latter authors also suggested that an over- 
estimation of severity would occur if access was not allowed. In general, the reliability of 
the comparative scale is poor as it requires recollection of the initial state and further, it 
does not allow for a deterioration in the condition which can result in bias towards the 
treatment (Langley and Sheppeard, 1984). However, over a short term, Scott and 
Huskisson (1979) have shown that patients recording pain can recollect their initial score 
quite accurately when using a VAS. Consequently, an absolute VAS, measuring severity, 
probably represents the best choice of linear analogue scale for use in veterinary medicine 
when assessing lameness.
In conclusion, the VAS and the NRS have been shown to be reproducible and repeatable 
methods of scoring lameness in sheep, but should not be used interchangeably. Trained 
observers have greater reproducibility than untrained observers when using both systems, 
but repeatability remains high. A distinct advantage of the VAS is the improvement in the
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degree of sensitivity achieved. In clinical medicine, where the technology for objective 
measurement frequently is not available, as when measuring lameness, signs of pain or 
sedation, the use of a reliable and sensitive method of subjective scoring is essential. The 
VAS provides the opportunity for such a scale to become an integral part of scoring 
systems. Moreover, from preliminary studies it is apparent that the VAS may provide a 
useful tool to gauge change in lameness after the administration of therapeutic agents e. g. 
NSAIDs. However it would be important to group animals appropriately in order to 
ensure a similar initial lameness severity score and to reduce the background variation 
within the system.
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Current knowledge of the mechanisms and consequences of both acute and chronic pain 
derive primarily from experimental pain studies, where smaller mammals, including rats , 
mice and cats, have been used for many years as models for human pain, although 
occasionally, humans themselves have been employed. In veterinary science, in addition 
to the smaller mammals, a variety of domestic species, including, dogs, cats and horses 
have been used as models of experimental pain. Valuable information may be drawn from 
these studies, not only on the basic mechanisms of pain, analgesia and antinociception 
which may be applied to mammals in general, but more specifically to the species from 
which the information was derived. There are a wide range of techniques used to evoke 
experimental pain, and to assess analgesia and antinociception in humans and animals, 
but in the domestic species radiant and conducted heat, mechanically-induced pain and 
balloon models of visceral pain are used most commonly. Recently, sheep were 
introduced as a model for experimental pain (Nolan et al. , 1987a; Livingston et al. , 
1992a), and these animals have proved useful models for the evaluation of the analgesic 
effects of the opioids and co-adrenoreceptor agonists. In addition, hyperalgesia to 
mechanical stimulation has been reported in sheep suffering from the naturally occurring 
infectious disease, footrot, thus these animals may be used as a model of chronic pain, in 
which the effects of various analgesic agents may be evaluated (Ley et al. , 1989; 1990b; 
1991a). Importantly, using sheep as an experimental model of pain has encouraged 
research into the mechanisms of pain and its control in this species, and in food- 
producing animals generally, a much neglected area. The requirement for effective control 
of pain in this group of animals is beyond doubt, but unfortunately, this requirement 
often is counterbalanced by the economic constraints imposed when an unlicensed drug is 
administered to food-producing animals, rendering the carcase unmarketable.
There is much subjective anecdotal clinical evidence, and little objective experimental 
evidence, suggesting marked improvement in acute pain in domestic species after 
administration of certain NSAIDs, including flunixin meglumine and carprofen. To date, 
failure to demonstrate the antinociceptive effects of the NSAIDs experimentally in the 
domestic species, probably has been related to the models in which these drugs have been 
assessed. Generally, to detect an antinociceptive effect of a NSAID, it is accepted that an 
inflammatory focus, which tends to reduce thresholds to noxious stimulation, must be 
present. Therefore, attempting to assess the antinociceptive effects of these agents in such 
models as the balloon model of visceral pain are unlikely to succeed, and consequently, 
failure to detect an antinociceptive effect of flunixin and carprofen using thermally- and 
mechanically-induced physiological pain in sheep was not unexpected. It was 
hypothesized that it would be possible to assess the antinociceptive effects of the NSAIDs
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in sheep suffering from the inflammatory condition of footrot. Unfortunately, failure to 
detect mechanical hyperalgesia in these sheep prevented such an investigation.
Laboratory animals frequently are acclimatized to the environment in which experiments 
are to be carried out, in order to reduce the stress associated with removing the animal 
from its companions and familiar surroundings on the day of the experiment. Similarly, 
because sheep are highly social animals and prone to isolation stress, it has been 
recommended that they are maintained with at least one other companion during 
experimental procedures (Livingston et al. , 1992a). Despite such precautions, and 
assessment of control thresholds for each sheep over a period of time, it was found that 
sheep unaccustomed to the experimental procedures used in these studies had 
significantly higher thresholds to noxious mechanical stimulation than sheep familiar with 
experimental procedures. However, repeated exposure to threshold testing over a period 
of 3 days reduced thresholds to a level comparable to experimental sheep. This raises the 
possibility that had sheep suffering from footrot been familiarized with testing procedures 
for a longer period, mechanical hyperalgesia may have been detected. However, it must 
be questioned whether or not it would be ethical to handle and test sheep with this 
condition over a period of days without initiating treatment, which may affect the outcome 
of the experiment. Conversely, it has been reported that mechanical hyperalgesia was 
detected in sheep which were severely affected with footrot, after clinical resolution of the 
problem (Ley etal. , 1989). Thus, it might be possible to 'train' sheep with footrot to the 
testing procedure, and also initiate treatment, then subsequently assess thresholds to 
noxious mechanical hyperalgesia. However, in contrast to normal sheep, thresholds to 
noxious mechanical stimulation in sheep suffering from footrot, and unaccustomed to 
experimental threshold testing, did not fall over a period of 3 days, but remained 
significantly different from experimental sheep. It would be of interest to investigate the 
mechanisms which caused this finding, although these sheep may simply require a longer 
period of acclimatization, than normal sheep. Sheep in these studies were selected at 
random, which should limit the effects of individual variation, however, they were not 
matched for severity of footrot,which is difficult to achieve, and this may have affected 
the outcome. Moreover, it would be of interest to monitor changes in plasma levels of 
'stress hormones' in sheep with footrot, compared with control animals, during the 
period of habituation.
Repeat injection of flunixin over the period of acclimatization, caused sheep suffering 
from footrot to behave in a similar manner to normal sheep i. e. after 3 days, mean 
thresholds to noxious mechanical stimulation, in these sheep, were not significantly 
different to experimental sheep. It was suggested that the anti-inflammatory and / or the 
antinociceptive effects of the drug over 3 days, reduced pain in the contralateral forelimb,
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frequently also affected with footrot, thus reducing reluctance to bear weight on that limb. 
If this were the case, it should have been possible to detect an improvement in the degree 
of lameness over the period of 4 days on which the sheep were tested. Unfortunately, 
although an assessment of lameness was made on the first day, this was not carried out 
subsequently. However, the effect of flunixin meglumine on lameness in sheep was 
evaluated in a later study, and although injection of the drug did not cause a significant 
improvement in lameness in a 6 hour period after administration, this was probably 
caused by the experimental design, rather than a lack of efficacy of the drug. Closer 
matching of sheep in the latter study for level of lameness, or alternatively, including a 
larger number of sheep in the study, may have allowed more significant conclusions to 
have been drawn. However, because of the diversity of the pathological changes which 
occur with footrot, and frequently, the lack of correlation with clinically evident 
lameness, close matching of groups is difficult.
Rating scales are frequently used to evaluate the antinociceptive activity of the NSAIDs, 
and other analgesics, in human clinical trials. Such scales should be easy to use and 
understand, allow accurate interpretation of data, be reproducible and repeatable and 
perhaps of greatest importance, the scales should be sensitive enough to'allow small 
changes in the test system to be detected (Huskisson, 1974). It is difficult to categorise 
subjective phenomena, such as pain and relief of pain, distress, anxiety and lameness into 
a discrete number of equal units, which is a criticism of a number of subjective rating 
scales currently in use. However, the visual analogue scale (VAS) is a popular tool for 
assessment of pain and related problems in man, and is gaining favour in veterinary 
medicine. The VAS has been described for assessment of signs of pain in animals and 
has been shown to be a reproducible, repeatable and sensitive measure of lameness in 
sheep. The VAS is regarded as a unidimensional scale and it may be argued that 
lameness, in a similar manner to pain, should not be considered to be unidimensional. 
Multidimensional scales such as the McGill Pain Questionnaire (Melzack, 1975), 
constructed from words used by patients to describe their pain, considers both sensory, 
affective and evaluative components of pain, and fulfils the criteria for rating scales 
mentioned above. A similar system for evaluation of animal pain or lameness could be 
used, however, subjective evaluation of an animal's condition relies on observation of 
signs, or registration of symptoms, by an observer. Consequently, when evaluating 
lameness factors including clinical lameness, pain on manipulation, gross pathological 
change and radiographic changes could be considered. However, it is important to 
consider the situation in which the scale is to be used, and in many cases in clinical 
veterinary practice, a scale which is rapid and easy to use would be of primary 
importance. Presently, the numerical rating scale, verbal rating scale and VAS match this
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need and all are reproducible and repeatable. However, the VAS has been shown to 
provide an in increase sensitivity for no extra time costs.
In 1957, Beecher commented that when evaluating the effectiveness of analgesic agents, 
the results of studies using experimental pain often were not comparable with those 
obtained in the clinical situation, as mentioned above for the NSAIDs. To overcome some 
of the limitations of experimentally-induced pain, he suggested using a tourniquet to 
induce pain of longer duration, and which in addition produced many of the sympathetic 
responses associated with pathological pain. These features generally are not associated 
with physiological pain, such as that produced by noxious mechanical and thermal stimuli 
in normal animals. Tourniquet-induced pain has been used successfully in man to 
investigate the analgesic properties of various drugs and reperfusion hyperalgesia has 
been investigated in rats. In sheep application of an inflated limb tourniquet produced 
signs of aversion after approximately 20 minutes. Previously, it had been shown that 
application of a tail tourniquet in rats produced signs of aversion at approximately 12.5 (± 
0.2) minutes (Gelgor et al. , 1986a), while it was reported that the pain tolerance 
threshold was reached after 36.2 (± 11.3) minutes in a volunteer study of tourniquet pain 
in humans (Benzon et al. , 1988). Unfortunately, the differences between these studies 
preclude accurate comparison. Limb tourniquets were used in sheep and humans, 
whereas a tail tourniquet was used in rats. Moreover, in humans the limb was 
exsanguinated prior to testing, and this was not carried out in sheep or rats. In human 
studies of tourniquet pain, the subject is asked to perform certain muscular tasks during 
ischaemia, and the amount of work done can influence the time to maximum pain. 
Although the sheep used in the studies of tourniquet pain were restrained in a small pen, it 
was impossible to regulate the number of times an individual sheep would pace back and 
forth or indeed lift the limb on which the tourniquet was placed. This must have 
introduced a degree of error into the subsequent recordings, and may explain why not all 
sheep underwent the same reduction in thresholds to noxious mechanical stimulation on 
each occasion. However, tourniquet-induced pain, or hyperalgesia, afforded detection of 
NSAID antinociception, and also opioid analgesia. Moreover, although application of a 
tourniquet is undoubtedly a more noxious procedure than inducing physiological pain 
alone, the sheep retained a degree of control over the duration of the applied stimulus. It 
would be interesting in the future to correlate physiological changes with signs of 
aversion in sheep, which perhaps would allow refinement of the method by which 
aversion is assessed, thus improving the experimental procedure.
Thus, it becomes more obvious that some degree of inflammatory change, or at least 
release of biochemical mediators of inflammation, is required in order to detect the 
antinociceptive effects of the NSAIDs. Injection of the mild irritant carrageenan has been
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used for many years to evaluate not only the antinociceptive properties of the NSAIDs, 
but also the anti-inflammatory, or anti-oedema, effects. Intradermal injection of a very 
low percentage of carrageenan in sheep caused a thermal hyperalgesia of approximately 
180 minutes duration, which was reversed by injection of flunixin and carprofen. 
Curiously, over a period of weeks the response to injection of the irritant in sheep was 
either lost, or at least limited. This was very surprising, because it appeared that 
peripheral injection of carrageenan evoked central changes, and such changes are 
considered usually to persist for some time after the original insult (Woolf, 1989). This 
finding may have been related to the very low percentage of carrageenan used in the 
study, 0.0625 %, and it would be of interest to assess the severity of this stimulus in 
sheep. Injection of carrageenan, 1 %, has been shown to induce oedema but not 
hyperalgesia in rats, and it was reported that a rise in plasma corticosterone accounted for 
this finding (Haworth et al. , 1989). Increasing the concentration of the irritant by 100 %, 
also caused an increase in plasma glucocorticoid levels, but hyperalgesia was detected. 
Thus, evaluation of plasma levels of the 'stress hormones', such as cortisol, may provide 
such insight.
It is difficult to achieve a perfect balance between ideal experimental conditions and 
animal welfare. The provision of accurate controls and well matched treatment groups, 2 
of the main benefits of using experimental animals, frequently is difficult to achieve in the 
clinical situation. However, matching the experimental procedure with the situation of an 
animal which is experiencing acute or chronic clinical pain, may be fraught with 
inaccuracies, because of differences between the affective components of the pain 
experience as well as other factors. Clinically healthy sheep of the same sex, breed and 
age group were anaesthetised with thiopentone and halothane, underwent ventral midline 
laparotomy, and were used in an investigation of the pain response of sheep to an acute 
surgical stimulus. This was achieved by assessing thresholds to noxious mechanical and 
thermal stimulation both pre- and post-operatively. It was shown that such animals 
developed a significant thermal hyperalgesia in the post-operative period and that intra­
operative administration of flunixin and carprofen, NSAIDs, and buprenorphine, a partial 
opioid agonist, prevented the development of post-operative hyperalgesia. Changes 
detected in a pain test system, such as that described, are easier to qualify if a return to 
control thresholds is demonstrated. Unfortunately, thresholds to noxious stimulation 
were evaluated for only 2 hours after the end of anaesthesia in sheep, and consequently, 
the time course of the observed hyperalgesia was not determined accurately. In addition, 
the duration of drug effect could not be determined. All drugs were administered to sheep 
after the onset of surgery, and although this did not prevent the detection of an 
antinociceptive effect of the drugs, it would be of interest to compare the extent and 
duration of antinociception or analgesia achieved if the drugs were injected pre-
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operatively. Although many experimental studies have investigated the neuroanatomical, 
neurophysiological and neuropharmacological consequences of acute injury, only a 
limited number of clinical studies have been conducted (Dahl and Kehlet, 1993), and 
currently more work is required in this area.
The pharmacokinetics of flunixin and carprofen were investigated in a group of healthy 
sheep, but no correlation between plasma levels of either agent and antinociceptive effect 
could be made, because changes in thresholds to noxious mechanical or thermal 
stimulation were not detected in healthy animals. To compare the relative potencies of the 
agents used in this series of experiments, a wider range of dose rates should be 
investigated, and it would be of interest to try and correlate drug effect with the level of 
drug in plasma. After injection of NSAIDs, inhibition of serum thromboxane production 
is used frequently as an indicator of drug effect. However, not all NSAIDs are potent 
inhibitors of the enzyme cyclooxygenase, which is required for the production of 
thromboxane, limiting the value of this procedure in some situations, and measurement of 
prostaglandin production would face the same problem. Using test systems in which the 
antinociceptive effect of the NSAIDs can be detected, it should be possible to correlate 
this effect with plasma drug concentration, regardless of the potency of cyclooxygenase 
inhibition. However, it has been suggested that it may be more appropriate, in the case of 
the NSAIDs, to correlate drug effect with the concentration o f the NSAID in 
inflammatory exudate (Lees, 1992). Intradermal injection of carrageenan has been shown 
to cause thermal hyperalgesia in sheep, and therefore it would be interesting to investigate 
whether injection of this irritant into a tissue cage (Higgins et al. , 1984) would provoke 
the same response. If so, correlation of NSAID effect, and local concentration of the drug 
in the tissue cage could be established. However, if the NSAIDs exert central 
antinociceptive actions, there may be little value in establishing such a relationship.
In addition to the central and peripheral sites of action which have been proposed for the 
NSAIDs, some workers have claimed a direct antagonistic action at the level of the 
prostaglandin receptors (Collier and Sweatman, 1968; Rees et al. , 1988; Lopez-Bernal et 
al. , 1990), and it was hypothesized that flunixin may exert a similar effect. Preliminary 
studies in the rat kidney have indicated that this drug does not displace PGE2 from its 
binding sites within the kidney, and the effects of flunixin on prostaglandin binding in the 
spinal cord are being investigated presently.
In conclusion, the antinociceptive effects of the NSAIDs, classically considered for the 
control of mild to moderate severity, chronic pain, may have been undervalued. It is 
apparent that pharmacological modulation of the arachidonic acid cascade, is an important 
method by which acute pain may be attenuated in humans (Dahl and Kehlet, 1991) and
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animals (Reid and Nolan, 1991). However, although the role of the NSAIDs as inhibitors 
of the metabolism of arachidonic acid has been researched widely, and undoubtedly 
explain many of the anti-inflammatory and anti-pyretic actions of this group of drugs, 
many avenues remain to be explored before the puzzle of NSAID-induced antinociception 
can be answered in full. Recent laboratory studies in rats have presented a strong case in 
favour of a central antinociceptive action of the NSAIDs (Malmberg and Yaksh, 1992a; 
1992b), which has been supported by limited clinical evidence in humans. Direct spinal 
administration of the NSAIDs in sheep using either appropriate experimental models, or 
clinically in animals undergoing surgery, would provide further valuable information on 
the mode of antinociceptive action of these agents in farm and other animals.
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